
<html lang="en"     class="pb-page"  data-request-id="35046dc5-b093-4a81-b78f-8bdde2a71ae6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b01469;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-9"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update" /></meta><meta name="dc.Creator" content="Solomon  Tadesse" /></meta><meta name="dc.Creator" content="Elizabeth C.  Caldon" /></meta><meta name="dc.Creator" content="Wayne  Tilley" /></meta><meta name="dc.Creator" content="Shudong  Wang" /></meta><meta name="dc.Description" content="Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associ..." /></meta><meta name="Description" content="Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 13, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01469" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01469" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01469" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01469" /></link>
        
    
    

<title>Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01469" /></meta><meta property="og:title" content="Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0011.jpeg" /></meta><meta property="og:description" content="Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01469"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01469">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01469&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01469&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01469&amp;href=/doi/10.1021/acs.jmedchem.8b01469" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4233-4251</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01530" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Solomon Tadesse</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Solomon Tadesse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Discovery and Development, University of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Solomon++Tadesse">Solomon Tadesse</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9966-2236" title="Orcid link">http://orcid.org/0000-0002-9966-2236</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth C. Caldon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth C. Caldon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia</div><div class="loa-info-affiliations-info">St Vincent’s Clinical School, UNSW Medicine, UNSW Sydney, Darlinghurst, NSW 2010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+C.++Caldon">Elizabeth C. Caldon</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wayne Tilley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wayne Tilley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wayne++Tilley">Wayne Tilley</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shudong Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shudong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Drug Discovery and Development, University of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +61 8 8302 2372; E-mail: <a href="/cdn-cgi/l/email-protection#8edde6fbeae1e0e9a0d9efe0e9cefbe0e7fdefa0ebeafba0effb"><span class="__cf_email__" data-cfemail="b3e0dbc6d7dcddd49de4d2ddd4f3c6dddac0d29dd6d7c69dd2c6">[email protected]</span></a> (S.W.)</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shudong++Wang">Shudong Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link">http://orcid.org/0000-0001-6225-5525</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01469&amp;href=/doi/10.1021%2Facs.jmedchem.8b01469" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4233–4251</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 13, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 September 2018</li><li><span class="item_label"><b>Published</b> online</span>13 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01469" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01469</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4233%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSolomon%2BTadesse%252C%2BElizabeth%2BC.%2BCaldon%252C%2BWayne%2BTilley%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D9%26contentID%3Dacs.jmedchem.8b01469%26title%3DCyclin-Dependent%2BKinase%2B2%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BAn%2BUpdate%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4251%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01469"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6700</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">54</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01469" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Solomon&quot;,&quot;last_name&quot;:&quot;Tadesse&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;C. Caldon&quot;},{&quot;first_name&quot;:&quot;Wayne&quot;,&quot;last_name&quot;:&quot;Tilley&quot;},{&quot;first_name&quot;:&quot;Shudong&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4233-4251&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01469&quot;},&quot;abstract&quot;:&quot;Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01469&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01469" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01469&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01469" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01469&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01469" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01469&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01469&amp;href=/doi/10.1021/acs.jmedchem.8b01469" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01469" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01469" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01469%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DTadesse%26date%3D2019%26atitle%3DCyclin-Dependent%2BKinase%2B2%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BAn%2BUpdate%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D9%26spage%3D4233%26epage%3D4251%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/jmcmar.2019.62.issue-9/20190509/jmcmar.2019.62.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Background</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cell division cycle is a fundamental process in life where series of events occur in a cell resulting in the formation of two identical daughter cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It governs the transition from quiescence or cytokinesis to cell proliferation and through its checkpoints, ensures genome stability.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The cell division cycle involves four sequential phases (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The S-phase, when DNA replication occurs, and the M-phase, when the cell divides into two daughter cells, are separated by gaps known as G1 and G2. In G1, cells undertake most of their growth and synthesize proteins, RNAs, and organelles needed for DNA synthesis, whereas in G2, the microtubules that will be used to mobilize the chromosomes in the M-phase are assembled. Quiescence (G0) represents an exit from the cell cycle either because of deprivation of mitogen or full differentiation of the cell (e.g., heart muscle cells and neurons).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. An overview of the cell division cycle, and the role of CDKs and checkpoints. In cells, DNA replicates in the S-phase, and chromosome segregation occurs at the M-phase. Two gap phases separate the S-phase and M-phase: G1, when cells grow and synthesize proteins, and G2, when cells prepare for mitosis. CDK3–cyclin C stimulates Rb phosphorylation to affect the G0/G1 transition. CDK4/6–cyclin D and CDK2–cyclin-E-mediated sequential phosphorylation of Rb relieves suppression of the activity of the E2Fs allowing the G1/S transition through the restriction point. As cells prepare to exit from the S-phase, CDK2–cyclin A directly phosphorylates E2F to deactivate its function, preventing apoptosis that might be triggered by persistent E2F activity. CDK1 in complex with cyclin A or B has defined roles in regulating the G2/M checkpoint and progression through mitosis. The cell cycle is controlled by checkpoints. The integrity of the DNA is assessed at the G1/S checkpoint. Proper chromosome replication is checked at the S and G2/M checkpoints. Attachment of each sister chromatid to a spindle fiber is evaluated at the spindle assembly checkpoint (SAC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most adult cells are at G0 and the transcriptional activity of E2F transcription factors (E2Fs) is repressed by the retinoblastoma proteins (hereafter called Rb).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> When needed, these cells can go back into the cell division cycle.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Briefly, cells at G0 enter G1 because of mitogenic stimuli. This requires CDK3–cyclin C, which phosphorylates Rb at Ser807/811.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> During G1, D-type cyclins bind and activate CDK4 and/or CDK6, also resulting in partial phosphorylation of Rb, leading to the activation of E2Fs. At this stage, E2Fs remain bound to Rb but are able to transcribe genes such as <i>CCNE1</i>, <i>CCNA2</i>, <i>CCNB1</i>, <i>CDK2</i>, and <i>CDK1</i>. In late G1 (after the restriction point), cyclin E binds to CDK2 to further phosphorylate Rb, releasing and fully activating the E2Fs.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> E2Fs then trigger the transcription of S-phase proteins such as cyclins A and E.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> CDK2–cyclin A, CDK1–cyclin A, and CDK1–cyclin B then sustain the phosphorylation of Rb ensuring cell-cycle progression. CDK2–cyclin A facilitates S/G2 transition, and CDK1–cyclin A and CDK1–cyclin B enable the commencement of mitosis and the progression through the M-phase, respectively (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Finally, cyclin B is degraded, and Rb is dephosphorylated by two phosphatases, PP1 and PP2A, returning the cell to the G1 state.<a onclick="showRef(event, 'ref5 ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref8">(5,6,8)</a> Intriguingly, animal models have demonstrated that CDK2, CDK4, and CDK6 (interphase CDKs) or their cyclin counterparts are not essential for proliferation of nontransformed cells and development of most tissues.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> On the other hand, deregulation of CDKs has been reported to cause unscheduled proliferation as well as genomic and chromosomal instability resulting in human cancer and to contribute to both cancer progression and aggressiveness.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Additionally, many cancers are uniquely dependent on CDKs and hence are selectively sensitive to their inhibition.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In this regard, the most successful clinical approach to date has involved targeting CDK4 and CDK6, where three CDK4/6-selective inhibitors, namely palbociclib, abemaciclib, and ribociclib, are approved for treatment of breast cancer.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p last">There are several excellent reviews on the CDK area that include some aspects of CDK2.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a> However, an updated review comprising the biology of CDK2 and the medicinal chemistry of its inhibitors in conjunction with approaches for designing of CDK2-selective inhibitors is lacking. Thus, this review focuses on the role of CDK2 in nontransformed and cancer cells, the rationale for developing CDK2-targeted cancer therapy, as well as the design and future therapeutic potential of CDK2-selective inhibitors in cancer treatment.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structure and Regulation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Constituting a major part of phosphotransferases in the human genome, kinases catalyze the reversible transfer of the γ-phosphate group of ATP onto a target substrate, mediate signal transductions, and regulate most aspects of cell life.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Currently, about 518 human protein and 20 lipid kinases have been identified. Protein kinases are enzymes that play key regulatory roles in nearly every aspect of cell biology, and on the basis of the nature of the target amino acid in their substrates, they are classified as tyrosine kinases, serine/threonine kinases, dual specificity kinases (act as both tyrosine and serine/threonine kinases), and histidine kinases. The phosphorylation of Ser, Thr, or Tyr residues of proteins by kinases results in conformational change altering the activity of the protein substrates.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">CDKs belong to the serine/threonine protein kinase family, and their kinase activity requires binding to a cyclin protein.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> They are involved in various aspects of cell biology, notably in cell-cycle control (CDKs 1, 2, 3, 4, and 6, see above), transcription (CDKs 7, 8, 9, 12, and 13), regulation through phosphorylation of the C-terminal tail of RNA polymerase II, metabolism (CDKs 1, 2, 3, 4, and 6),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and, in certain cell types, differentiation (CDKs 1, 2, and 4).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Although CDKs are commonly grouped into cell-cycle or transcriptional CDKs, these roles are frequently combined in many CDKs.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> CDK7 indirectly regulates the cell cycle by activating CDKs 1, 2, 4, and 6. CDKs 5, 10, 11, 14–18, and 20 have heterogeneous and unique functions that are frequently tissue-specific. For example, CDK5 has a pivotal role in modulating the migration of postmitotic neurons.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> CDK10 is implicated in regulating gene transcription by steroid hormones by promoting the interaction between heat-shock proteins and the ecdysone receptor EcRB1.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> CDK11–cyclin L regulates RNA splicing.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">Among CDKs, sequence and structure similarity is high (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). For instance, there is 74% sequence identity between CDK2 and CDK3, while root-mean-square deviation of Cα atoms ranges from 1.7 Å for CDK4 to 0.9 Å for CDK5.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In addition, their convergence to a conserved structure upon activation has presented challenges for the design of selective inhibitors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Yet, the available structural diversity and conformational plasticity of the CDK fold have been successfully exploited to fine-tune potency and selectivity and to identify the first CDK inhibitors to be registered for clinical use targeting CDK4 and CDK6. However, most inhibitors still exhibit substantial activity for a subset of the family.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Percent (%) Sequence Similarity between CDK2 and Other CDKs<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CDK</th><th class="colsep0 rowsep0" align="center">% sequence identity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 3</td><td class="colsep0 rowsep0" align="center">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 1</td><td class="colsep0 rowsep0" align="center">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 5</td><td class="colsep0 rowsep0" align="center">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 6</td><td class="colsep0 rowsep0" align="center">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 4</td><td class="colsep0 rowsep0" align="center">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 7</td><td class="colsep0 rowsep0" align="center">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 20</td><td class="colsep0 rowsep0" align="center">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 10</td><td class="colsep0 rowsep0" align="center">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 18</td><td class="colsep0 rowsep0" align="center">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDKs 9, 14, 15, and 16</td><td class="colsep0 rowsep0" align="center">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 17</td><td class="colsep0 rowsep0" align="center">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 8</td><td class="colsep0 rowsep0" align="center">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 19</td><td class="colsep0 rowsep0" align="center">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDK 11</td><td class="colsep0 rowsep0" align="center">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">CDKs 12 and 13</td><td class="colsep0 rowsep0" align="center">9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Sequence alignments were performed and % sequence similarity determined by using the UniPort database (<a href="http://www.uniprot.org/align/" class="extLink">http://www.uniprot.org/align/</a>).</p></div></div></div><div class="NLM_p">CDK2, similar to other protein kinases, has the classic bilobal architecture, an N-terminal lobe (residues 1–82) and the C-terminal domain (residues 83–297) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).<a onclick="showRef(event, 'ref18 ref19 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref28 ref29">(18,19,28,29)</a> The smaller N-terminal lobe is mainly made up of β-sheets (five antiparallel β-strands) with one αC-helix (PSTAIRE). The αC-helix contains the sequence PSTAIRE and is essential for cyclin binding (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The larger C-terminal lobe is rich in α-helices and contains the activation segment (also known as the T-loop (residues 145(Asp)-172(Glu)) and the activating phosphorylation site Thr160. The T-loop is the platform for binding of the Ser/Thr (phosphor-acceptor) region of substrates for phosphorylation. The N-terminal and C-terminal lobes are connected by the flexible hinge region (residues 81(Glu)–84(His)), which lines a deep cleft, the ATP binding site. ATP recognition involves residues from both lobes. CDK2 offers adjacent binding sites for ATP and the phosphor-acceptor protein substrate so that the γ-phosphate of ATP faces the hydroxylated side chain of Ser/Thr on the substrate surface.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural basis of CDK2 activation and inhibition. (A) Nonactivated monomeric CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EK3">4EK3</a>). The N-lobe β-sheets and the αC-helix (PSTAIRE) are shown in pink and blue, respectively; the C-lobe is indicated in purple, and the hinge region and the T-loop are indicated in green. (B) Fully active (phosphorylated CDK2–cyclin A complex, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JST">1JST</a>). Cyclin A and the activating phosphorylation site Thr160 are depicted in cyan and yellow, respectively; ATP is displayed in orange sticks bound in the deep cleft between the two domains. CDK2 apoenzyme is inactive, and full activation entails complex formation with cyclins E or A and phosphorylation of the Thr160 residue. During the activation, the T-loop moves toward the C-terminal domain, where it forms a binding area for the substrate protein, and the αC-helix moves into the binding cleft and is rotated. (C) Inhibited p27-Thr160 phosphorylated CDK2–cyclin A complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JSU">1JSU</a>). The N-terminal of p27-peptide (shown in yellow) binds with cyclin A, and its C-terminal binds to the N-terminal domain of CDK2 to induce structural changes rendering the CDK2–cyclin complex inactive. (D) Mechanisms of CDK2 regulation. The activity of CDK2 is regulated by four mechanisms. The first level of regulation involves the binding of CDK2 to cyclin E or A, resulting in partially activated CDK2–cyclin E or CDK2–cyclin A complex. Second, the full activation of CDK2–cyclin E or A complexes necessitates the phosphorylation of Thr160 by CAK. The third mechanism includes inhibitory phosphorylation of Thr14 and Tyr15 by Wee1 and Myt1 kinases, respectively. Dephosphorylation of these residues by members of the Cdc25 family of protein phosphatases reactivates CDK2. Fourth, CDK2 is deactivated by the binding of CDK inhibitory protein families Cip and Kip. Cyclins E and A are destroyed by the Skp/Cullin/F-box-containing complex (SCF) and the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligases. (E) During the S-phase, CDK2 can follow a distinct path to activation, in which T-loop phosphorylation precedes cyclin binding. Dephosphorylation of CDK2 Thr160 by the cyclin-dependent kinase-interacting phosphatase (KAP) occurs in the absence of cyclin A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Extensive biochemical and structural studies have established a clear picture of the activation and regulatory mechanisms that determine the activity of CDK2.<a onclick="showRef(event, 'ref18 ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref29">(18,19,29)</a> In the absence of mitogenic signals, CDK2 is in an inactive form. During late G1-phase, CDK2 activity increases as a result of (1) E2F-mediated transcription of <i>CCNE</i> genes, the protein product of which binds and activates CDK2; (2) CDK4/6–cyclin-D-mediated sequestration of the CDK-interacting protein/kinase inhibitory protein (Cip/Kip) class of CDK inhibitors, p21Cip1, p27Kip1, and p57Kip2, which bind to CDK2–cyclin complexes and render them inactive; and (3) ubiquitin-mediated proteolysis of Cip/Kip following their phosphorylation by CDK2.<a onclick="showRef(event, 'ref18 ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref29">(18,19,29)</a> The Cip/Kip family of inhibitors change the shape of the catalytic cleft of CDK2 to completely deactivate the enzyme by inserting a small helix inside the catalytic unit in a way similar to ATP (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). Cyclins E and A regulate CDK2 activity by being synthesized and destroyed in a cell-cycle phase-specific manner.<a onclick="showRef(event, 'ref18 ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref29">(18,19,29)</a> The Skp/Cullin/F-box-containing complex (SCF) mediates the rapid proteasomal degradation of cyclin E during the S-phase, and CDK2 associates with newly synthesized cyclin A to form active CDK2–cyclin A complexes. Cyclin A is stable throughout the interphase and is degraded by the anaphase-promoting complex/cyclosome (APC/C) ubiquitination just before the metaphase to anaphase transition.<a onclick="showRef(event, 'ref18 ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref29">(18,19,29)</a> Once cyclin A is disassociated or degraded, dephosphorylation of Thr160 (see below) is executed by a Ser/Thr-directed phosphatase, CDK-interacting phosphatase (KAP).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p last">Cyclins E and A in concert with phosphorylation by CDK-activating kinase (CAK, CDK7-cyclin H-MAT1 complex) play a critical role in the regulation of CDK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Although cyclin binding alone confers enzymatic activity on an intrinsically inert CDK2 monomer, T-loop phosphorylation results in an ∼300-fold increase of activity toward a substrate.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Upon binding to its cyclin partner, CDK2 changes its conformation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Extensive hydrophobic interactions between CDK2 and its cyclin partner move the αC-helix on the N-lobe toward the catalytic cleft. This conformational change moves the side chain of Glu51 of the αC-helix into an inside position favoring a hydrogen bond between Glu51 and Lys33, allowing Lys33 to bind to the α- and β-phosphates of ATP and align them to enable the phospho-transfer reaction of the γ-phosphate to substrate proteins.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Additionally, cyclin binding relieves the obstruction at the entrance of the active site by moving the T-loop by 20 Å toward the cyclin and displacing onto the C-terminal lobe, leaving the ATP binding site accessible to substrates.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Moreover, cyclin binding was previously thought to be required to expose the buried Thr160 of monomeric CDK2 for phosphorylation by CAK, and this phosphorylation was believed to lead to further conformational changes in the substrate binding site of CDK2 for the full activation of the CDK2–cyclin complex.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> However, CAK efficiently phosphorylates monomeric CDK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E).<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> During the S-phase of the cell cycle, in order to surpass the competition for cyclin A from the more abundant CDK1, Thr160 phosphorylation of CDK2 precedes cyclin A binding. This is because of CAK’s inability to phosphorylate monomeric CDK1, contributing to a kinetic barrier preventing CDK1–cyclin A assembly. Phosphorylation of the glycine-rich loop (residues 11(Glu)–18(Tyr)), residues Thr14 and Tyr15 by Wee1 and Myt1 kinases, respectively, which can be reversed by the cell division cycle 25 (Cdc25) phosphatases (Cdc25A, Cdc25B, and Cdc25C), turns off CDK2 activity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D,E).<a onclick="showRef(event, 'ref17 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref17 ref28 ref29">(17,28,29)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Biological Roles and Substrates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Most normal tissues have low expression of CDK2.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Such an observation is supported by the fact that, with the exception of a few tissues that have a functional need for constant proliferation, the majority of normal cells are found in a state of quiescence.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Among the exceptions to this is the high CDK2 activity observed in the testes, where CDK2 is thought to play a unique role in meiotic cell division mirroring the essential meiotic functions of CDK2 in mice.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> CDK2-deficient mice are unable to undergo meiotic division of gametes and are thus sterile. Since kinase-dead CDK2 protein was not capable to drive normal meiotic cell division in vivo, CDK2 is proposed to regulate meiosis by phosphorylating the yet to be determined protein substrates.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In dividing cells, CDK2 is a core cell-cycle component that is essentially active from the late G1-phase and throughout the S-phase. Among the key CDK2 substrates during G1/S progression is the Rb (see above). Rb contains 16 sites for phosphorylation by the CDKs that have been characterized as either specific for CDK4/6 or CDK2 or as able to be phosphorylated by combinations of these kinases.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In actively cycling cells, the initial monophosphorylation of Rb in early G1-phase is catalyzed by CDK4/6 and occurs on any of 14 sites. Subsequently, CDK2 activation leads to hyperphosphorylation and complete inactivation of the Rb protein.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Beyond Rb, CDK2 governs the phosphorylation of a wide range of transcription factors including mothers against decapentaplegic homologue 3 (SMAD3),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> forkhead box protein M1 (FOXM1),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> forkhead box protein O1 (FOXO1),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> the helix–loop–helix protein inhibitor of DNA binding 2 (ID2),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> as well as upstream binding factor (UBF),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> nuclear factor Y (NFY),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Myb-related protein B (B-MYB),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and Myc proto-oncogene protein (MYC),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> which contribute to cell-cycle progression at different levels. Besides these cell-cycle targets, it is understood that CDK2 plays a role in mammalian DNA replication,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> adaptive immune response,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> cell differentiation,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and apoptosis.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Rationale for Targeting CDK2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CDK2 is a critical modulator of various oncogenic signaling pathways, and its activity is vital for loss of proliferative control during oncogenesis.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In addition, the overexpression of CDK2 binding partners cyclin A and/or E is a key oncogenic process in several cancers.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> It has also been shown that cyclin-E-deficient cells are resistant to oncogenic transformation.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Cyclin E overexpression promotes tumor formation in mice, and it correlates with poor prognosis in patients with several tumor types.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> Developing small molecules that can directly target cyclins is implausible, because these cyclins act as regulatory subunits rather than as an enzyme or receptor. Thus, given the relative specificity of cyclin E for CDK2 and its deregulation in certain types of cancer, CDK2 is an attractive target in treating tumors of specific genotypes.</div><div class="NLM_p">Initial interest for CDK2 as a cancer therapeutic target was tempered to some extent by the knowledge that CDK2 inhibition using anti-CDK2 shRNA, antisense oligonucleotides, a dominant-negative CDK2, or overexpression of p27Kip1 failed to arrest the proliferation of colon cancer cells.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In addition, genetic ablation of CDK2 did not appear to have a negative effect on cellular proliferation during early murine development.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These methods, however, result in ablation of CDK2 protein expression, possibly allowing for compensation by other CDKs, and they are therefore likely to have different effects than acute inhibition of CDK2 kinase activity using small molecules. Besides, as these studies have been carried out in vitro and in mice, the requirement of CDK2 for humans cannot be completely ruled out.</div><div class="NLM_p">Examination of different kinds of human cancers, with defined molecular features, for their susceptibility to CDK2 inhibition has unveiled the scope in which CDK2 might represent a good therapeutic target. For example, in ovarian cancer with amplified <i>CCNE1</i> expression,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> in <i>MYCN</i>-amplified neuroblastoma cells,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><i>KRAS</i> mutant lung cancers,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and several cancers with <i>FBW7</i> mutation and cyclin E1 overexpression,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> CDK2 is a therapeutic target. In glioblastoma<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and B-cell lymphoma,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> CDK2 is highly expressed and is functionally required for cell proliferation. In prostate cancer, CDK2 is significantly associated with metastasis.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> CDK2 contributes to breast cancer progression by phosphorylating and activating hormone receptors,<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62−64)</a> and it is a target in hepatocellular carcinoma.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> In acute myeloid leukemia, CDK2 inhibition drives differentiation in cell lines and patient-derived primary samples.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> CDK2 is a transcriptional target of melanocyte lineage transcription factor (MITF), and it is critical for growth of melanoma cells. Expression levels of MITF and CDK2 are tightly correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibition.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Taken together, CDK2 plays an essential role in tumor growth, and CDK2 inhibitors have the potential to induce growth arrest and apoptosis in cancer cells. In line with these observations, CDK2 knockout mice are viable without apparent abnormalities suggesting that CDK2 inhibitors might preferentially target cancer cells while sparing normal tissues.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p last">Compelling evidence to support a therapeutic role for pharmacological CDK2 inhibition in cancer has also been presented by several recent findings through combination strategies. A combination of CDK2 and PI3K inhibitors induced apoptosis in glioma and colorectal cancer xenografts.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> A synergistic effect of concurrent inhibition of bromodomain-containing protein 4 (BRD4) and CDK2 in MYC-amplified medulloblastoma was observed.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Enhanced sensitivity of apoptotic-resistant cells was shown by combined inhibition of CDK2 and BCL-2 family proteins.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> Besides a synergistic role, CDK2 inhibition also attenuates the development of resistance. Pharmacological or molecular targeting of CDK2 sensitizes BRAF and HSP90 inhibition-resistant melanoma cell lines.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Inhibition of CDK2 gives an opportunity to revert acquired resistance to CDK4/6 inhibitors.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In Rb-deficient cancer cells, the E2Fs are constitutively active, and CDK4/6 signaling is redundant. In Rb-positive cells, overexpression of cyclin E or loss of the CIP/KIP proteins might bypass CDK4/6 inhibition by activating CDK2.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Thus, CDK2 inhibition is a potential therapeutic strategy for treatment of tumors that are considered as poor candidates for CDK4/6 inhibitor therapy. One such example is triple-negative breast cancer (TNBC), where tumors often demonstrate loss of expression of the RB protein or high expression of cyclin E—both of which would be expected to confer resistance to treatment with CDK4/6 inhibitors. In addition, in TNBC, CDK2 inhibition is synergistic with chemotherapeutic agents and radiotherapy, and restores chemo and radiosensitivity in resistant cases.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> CDK2 inhibition, either using an inhibitor or through cyclin E knockdown, inhibits the growth of trastuzumab-<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and tamoxifen-resistant<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> breast cancer cells both in vitro and in vivo. Beyond oncology, the potential applications of CDK2 inhibitors are also expanding into other clinical settings including hearing loss<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> as well as neurodegenerative<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and infectious diseases.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">CDK2 Inhibitors in Drug Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While the main incentive behind the development of CDK2 inhibitors lies in their potential application as anticancer drugs, small-molecule CDK2-selective inhibitors would be vital chemical probes to dissect the underpinnings of a cellular process or disease.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Since the currently available CDK2 inhibitors are not selective, phenotypic responses (both cellular and at organism level) to them are defined by all the on- and off-targets. As such, it is difficult to associate the observed responses to CDK2 inhibition only.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibitors in Clinical Trials</h3><div class="NLM_p">A few pharmacologic inhibitors of CDK2 are in clinical development as anticancer agents (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2-1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2-2" href="#tbl2-2">2-2</a>). Some have already been discontinued from clinical development because of promiscuity leading to off-target kinase inhibition and associated side effects (e.g., SNS-032, AZD5438, and R547) as well as failure to achieve an acceptable clinical end point (e.g., AG-024322).<a onclick="showRef(event, 'ref13 ref84'); return false;" href="javascript:void(0);" class="ref ref13 ref84">(13,84)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2-1. CDK2 Inhibitors under Clinical Evaluation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0009.gif" alt="" id="gr9" /></img><div></div></div><div class="NLM_p">Alvocidib (flavopiridol),<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> the first CDK inhibitor in clinical trials, is a flavone alkaloid ATP-antagonistic broad spectrum kinase inhibitor. It induces G1 as well as G2 cell-cycle arrest due to inhibition of CDK2/4 and CDK1 activity, respectively. Alvocidib has been studied in numerous clinical trials, as a single agent or in combinations with other drugs, but demonstrated unsatisfactory efficacy and high toxicity. Despite these setbacks, clinical efficacy was confirmed in hematological malignancies, and it received orphan drug designation for the treatment of patients with acute myeloid leukemia. Seliciclib (roscovitine, CYC202),<a onclick="showRef(event, 'ref85 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref87">(85,87)</a> a purine analogue and the second CDK inhibitor to enter clinical trials, is a pan-CDK inhibitor that exhibited some CDK more selectively when compared with alvocidib. However, despite many successful preclinical studies, results from several clinical trials are not promising. It seems that combination therapies may possibly be more encouraging than monotherapy. Thus, both alvocidib and seliciclib are currently in Phase I and Phase II clinical trials in combination with other anticancer agents. A number of other compounds targeting CDK2 are also in various stages of drug development. <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2-1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2-2" href="#tbl2-2">2-2</a> provide a summary of the preclinical and clinical data of the second-generation CDK inhibitors that have shown potent CDK2 inhibition and are currently in clinical trials.<a onclick="showRef(event, 'ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106 ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104 ref105 ref106 ref107 ref108 ref109">(88−109)</a></div><div class="NLM_table-wrap" id="tbl2-2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2-2. CDK2 Inhibitors under Clinical Evaluation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0010.gif" alt="" id="GRAPHIC-d7e803-autogenerated" /></img><div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibitors in Preclinical Development Pipeline</h3><div class="NLM_p">A large number of inhibitors of CDK2 have been identified based on a structurally diverse range of scaffolds and are at the preclinical development stage. The majority of these inhibitors are ATP-competitive, interacting with the catalytic ATP binding site of the enzyme, which has a high level of sequence homology among protein kinases.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Hence, akin to the clinical compounds, almost all of the reported preclinical inhibitors suffer from specificity problems. Of the preclinical CDK2 inhibitors, the purine derivatives developed by a group at Newcastle University, UK, over a span of almost two decades, appears promising in terms of addressing the selectivity issue.<a onclick="showRef(event, 'ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120">(111−120)</a> Indeed, purine is a privileged scaffold, which is ubiquitously expressed in the chemical architecture of a number of bioactive compounds including ATP and several kinase inhibitors. 2,6,9-Trisubstituted purines were among the earliest CDK2 inhibitors to be developed as anticancer agents. For instance, olomucine,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> roscovitine,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> and purvalanol B<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> are 2,6,9-trisubstituted purine CDK2 inhibitors that also target other CDKs. Despite being purine derivatives like ATP, these molecules, however, do not reproduce the orientation of the purine ring of ATP at the binding site (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). While ATP forms two hydrogen bonds with the backbone amide of Leu83 and the carbonyl oxygen of Glu81 of CDK2 through the N1 and C6 amino group of the purine ring,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> respectively, the substituted purines interact with CDK2’s hinge region via N7 and the hydrogen of the NH of C6 with Leu83, enabling the larger C6 substituent on the purine ring to be accommodated away from the deep pocket unlike the ATP.<a onclick="showRef(event, 'ref121 ref123 ref125'); return false;" href="javascript:void(0);" class="ref ref121 ref123 ref125">(121,123,125)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of ATP and CDK2 inhibitors to CDK2 structure. (A) ATP (PDB = 1JST), (B) roscovitine (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DDQ">3DDQ</a>), (C) NU2058 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIP">1HIP</a>), (D) NU6102 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIS">1HIS</a>), (E) compound <b>4</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LQE">5LQE</a>). (F) The allosteric inhibitor ANS (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PYL">3PYL</a>). Hydrogen bonds are shown in red dashed lines. The figures were prepared using PyMOL1.3 (Schrödinger Inc., 2013).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Building upon the 2,6,9-trisubstituted purine benchmark compounds, more optimized purine CDK2 inhibitors have been described by several groups. Among these are the potent 2-amino-6-oxypurine (guanine) derivatives (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120">(111−120)</a> The first compound identified to be promising was the O<sup>6</sup>-cyclohexylmethylguanine NU2058.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> The crystal structure of NU2058 in complex with the active form of CDK2 revealed that O<sup>6</sup>-cyclohexylmethyl optimally occupies the CDK2 ribose binding site by tightly packing against the hydrophobic patch presented by the G-loop (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Moreover, the X-ray crystallography suggested that substitution at the C2-position might modulate both potency and selectivity. Subsequent SAR studies exploring C2-substitutions revealed the requirement for a hydrogen bonding C2-NH, and an aromatic substituent at its 4-position culminated in the identification of NU6102, a highly potent CDK1 and CDK2 inhibitor, more so than NU2058.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> NU6102 forms two additional hydrogen bonds to Asp86 of CDK2 via its sulfonamide moiety facilitating the hydrophobic packing of the arylamino group toward the solvent exposed region of the ATP binding pocket of CDK2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). The sulfonamido oxygen accepts a hydrogen bond from the backbone NH of Asp86, while a sulfonamido NH donates a hydrogen bond to the side chain carboxylate of Asp86. However, alkyl substitutions at the C8-position in order to induce interaction with the gate keeper Phe80 were poorly tolerated within this series. Because of the intramolecular hydrogen bond between the adjacent 5-nitroso and 4-amino groups, NU6027 and the first three derivatives (<b>1</b>, <b>2</b>, and <b>3</b>) were suggested to adopt a purine ring mimicking geometry and were synthesized during the SAR exploration of the purine derivatives leading to a pyrimidine series with a similar mode of binding to CDK2.<a onclick="showRef(event, 'ref113 ref115 ref116 ref119'); return false;" href="javascript:void(0);" class="ref ref113 ref115 ref116 ref119">(113,115,116,119)</a> Further SAR studies to establish the nature of the interaction between the C6 substituents and the ribose binding pocket within the CDK2 binding site resulted in the identification of a fourth derivative (compound <b>4</b>), a very potent CDK2 inhibitor with very high selectivity against CDK1 (2000-fold) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> However, compound <b>4</b> was inactive in cancer cell proliferation assays. This unexpected lack of cellular activity may result from poor physicochemical properties including cell membrane permeability, stability, intracellular accumulation, and metabolism.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Thus, to further develop <b>4,</b> additional optimization of potency, cellular penetration, and SAR studies are required.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Identification and optimization of 2-amino-6-oxypurine core as CDK2 inhibitors. * represents inhibition at 100 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SAR studies of the same series have also resulted in the discovery of NU6300, the first irreversible CDK2 inhibitor with reasonable selectivity over 131 protein kinases.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The vinyl sulfone of NU6300 forms a covalent bond to the ε-amino group of Lys89. NU6300 decreases the phosphorylation of Thr821 on Rb, confirming its cellular activity. However, caution should be exercised when comparing the activity of NU6300 with its reversible ATP-competitive analogues, as irreversible inhibitors generally become more potent through time.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> 4-Hydroxy-2-nonenal has also been described as a covalent modifier of CDK2.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><div class="NLM_p">Besides, several compounds with a variety of heterocyclic cores (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) were identified as potent inhibitors of CDK2 by using bioisosterism as a rational tool to design new scaffolds from the purine core. These includes pyrazolo[3,4-<i>d</i>]pyrimidines,<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> pyrazolo[1,5-<i>a</i>]pyrimidines,<a onclick="showRef(event, 'ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref131 ref132">(131,132)</a> pyrazolo[1,5-<i>a</i>]-1,3,5-triazines,<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> pyrazolo[3,4-<i>b</i>]pyridines,<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> imidazo[2,1-<i>f</i>]-1,2,4-triazines,<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> imidazo[1,2-<i>a</i>]pyrazines,<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> imidazo[4,5-<i>b</i>]pyridines,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> imidazo[1,2-<i>a</i>]pyridine,<a onclick="showRef(event, 'ref138 ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref138 ref139 ref140">(138−140)</a> imidazo[1,2-<i>b</i>]pyridazine,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and triazolo[1,5-<i>a</i>]pyrimidines.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Development of CDK2 inhibitors using purine bioisosters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Indole (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>)<a onclick="showRef(event, 'ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152">(143−152)</a> and thiazole (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>)<a onclick="showRef(event, 'ref153 ref154 ref155 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref153 ref154 ref155 ref156 ref157">(153−157)</a> cores have also been explored in the development of CDK2 inhibitors. Inspired by the CDK inhibitory activity of indole containing natural products indirubin (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A)<a onclick="showRef(event, 'ref143 ref144 ref145 ref146 ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145 ref146 ref147 ref148 ref149">(143−149)</a> as well as meridianins and variolins<a onclick="showRef(event, 'ref150 ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152">(150−152)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B), researchers have prepared indirubin analogues as well as hybrid molecules (meriolins) from the marine products meridianins and variolins. The earlier derivatives of these natural products had poor pharmacokinetic (PK) properties (e.g., <b>15</b> and <b>18</b>), and therefore, medicinal chemistry efforts mainly focused on enhancing PK while maintaining potency.<a onclick="showRef(event, 'ref145 ref152'); return false;" href="javascript:void(0);" class="ref ref145 ref152">(145,152)</a> This effort has been realized by the latest molecules (e.g., <b>17</b> and <b>19</b>) which demonstrated improved aqueous solubility.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Optimization of indole based natural products as CDK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Identification and optimization of the thiazole core as CDK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">High throughput screening campaign by three independent research groups identified three hits (<b>20</b>, <b>22</b>, and <b>25,</b><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A–C) containing the thiazole nucleus.<a onclick="showRef(event, 'ref153 ref154 ref155 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref153 ref154 ref155 ref156 ref157">(153−157)</a> Compound <b>20</b> was a potent inhibitor of CDK2, but it was not active in cells and unstable in plasma. Medicinal chemistry efforts to overcome this hurdle resulted in the discovery of SNS-032 (BMS-387032) and its subsequent entry to the clinical trials.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a><b>24</b> and <b>27</b> are among the most potent CDK2 inhibitors of the thiazole series.<a onclick="showRef(event, 'ref156 ref158'); return false;" href="javascript:void(0);" class="ref ref156 ref158">(156,158)</a> A thiazole urea, CDKi 277, has also been previously reported as a potent and ATP-competitive inhibitor of CDK2, CDK1, and CDK5 activity with an IC<sub>50</sub> less than 10 nM.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div><div class="NLM_p">Allosteric modulators of kinases generally act by inducing conformational changes to modulate activity.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> They do not compete with ATP for binding to the catalytic domain. As they bind to unique regions of the kinase (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), they are likely to be more selective than ATP-competitive inhibitors and may be useful in overcoming resistance to ATP-competitive inhibitors. A noncatalytic pocket near the interface of the CDK2–cyclin complex and a large allosteric pocket adjacent to the ATP binding pocket were identified by using peptides<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> and 8-anilino-1-naphthalene sulfonate (ANS),<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). ANS specifically interacts with CDK2 by binding to the hydrophobic allosteric pocket and stabilizes a CDK2 conformation that is unsuitable to interact with its cyclin partners. However, it is readily displaced from CDK2 upon cyclin binding, as its affinity for CDK2 (<i>K</i><sub>d</sub> = 37 μM) is significantly lower than that of cyclin A (<i>K</i><sub>d</sub> = 0.6 μM). Yet, its discovery has enabled the development of a high throughput ANS-displacement assay to identify small-molecule ligands of CDK2 with a potential allosteric mode of action.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Compounds that displace ANS from CDK2 are classified as allosteric ligands through the use of staurosporine, which occupies the ATP binding pocket without displacing ANS. This assay in combination with modeling was used to identify allosteric ligands from commercially available compounds through virtual screening using the allosteric pocket of the CDK2–ANS complex.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. ATP and allosteric binding sites of CDK2. (A) The catalytic ATP binding site, the two noncatalytic pockets, and the cyclin binding groove are circled and labeled. (B) Type II inhibitor K03861 bound to CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A14">5A14</a>) and the four core structural components of type II inhibitors: a heterocyclic hinge binding core, a linker, hydrogen bonding structure, and a hydrophobic moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Small-molecule CDK2 inhibitors that bind into a pocket made of Arg126, Arg150, and Tyr180 near the interface of the CDK2–cyclin A3 complex have been reported (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The molecules disrupt the interaction between CDK2 and cyclin A3. Pentapeptides (e.g., TAALS) having a similar mechanism of action have also been described.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> In addition, drug design strategies have been used to identify peptidomimetic inhibitors (e.g., HAKRRLIF based on a sequence found in the endogenous CDK inhibitor, p27) that act at the cyclin groove substrate recruitment site identified on the cyclin subunit<a onclick="showRef(event, 'ref167 ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169 ref170">(167−170)</a> or the protein–protein interaction interface of CDK2 and its regulatory cyclin partners (C4, derived from amino acids 285–306 in the α5-helix of cyclin A)<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> to develop non-ATP-competitive CDK2 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). However, the use of these peptides is limited by their poor pharmacokinetic properties. Unnatural amino acids are being incorporated into the peptides to improve the penetration ability and their stability.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> However, given the weak CDK2 inhibitory and poor pharmacokinetic properties of the allosteric molecules, the discovery of tighter allosteric binders with drug-like properties is an avenue of research that should be investigated further and actively pursued.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Approaches toward Selective Inhibition of CDK2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the last three decades, a large number of crystal structures of CDK2 in different activation states have been solved.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Though the degree to which these snapshots are an accurate reflection of the dynamic intracellular CDK2 conformations remains unclear, this wealth of structural information is extremely valuable when designing selective inhibitors of CDK2 for therapies.</div><div class="NLM_p">The vast majority of CDK2 inhibitors that have been developed so far are known as type I inhibitors and target the conserved ATP binding site of the kinase in its active conformation where the activation loop assumes an Asp–Phe–Gly-in (DFG-in) conformation conducive to phosphate-transfer.<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173,174)</a> Typically, the inhibitors exploit the hydrophobic adenine binding pocket via a heterocyclic structure. They form one to three hydrogen bonds to the hinge residues, mimicking those formed by the exocyclic amino functional group of the adenine of ATP (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). While the adenine region is universally engaged by every type I inhibitor, substitutions on the core heterocyclic structure present various functional groups for interaction to other less conserved regions such as (1) the solvent exposed region outside of the active site cleft on the surface of the C-terminal lobe, (2) the hydrophobic cavity behind the Phe80 gate keeper residue directly adjacent to the ATP binding site, and (3) the G-loop, which can form the basis for inhibitor selectivity toward CDK2. For instance, unlike CDK1, Tyr15 of the G-loop in several CDK2–cyclin A inhibitor complex structures is folded into the active site contacting residues of the αC-helix, suggesting that optimal steric bulk in the ribose binding pocket would stabilize a G-loop (which forms part of the ribose pocket) conformation that is favored in CDK2 but not in CDK1.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Nevertheless, introducing hydrogen bonds between CDK2 and an inhibitor in the G-loop to enhance binding is believed to be problematic. The highly hydrated and dynamic nature of the pocket leads to entropic penalty and unpredictable interaction geometries.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Four key residue differences within the ATP binding pocket among CDK2 (Phe82, Leu83, Lys89, and Gln131) and CDK4 (His95, Val96, Thr102, and Glu144, respectively) can be effectively used to discriminate between these two closely related kinases.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Indeed, several of the reported CDK2 inhibitors possess optimal selectivity for CDK2 over CDK4/6. Targeting CDK2’s relatively less extended and more rigid pocket rather than the formation of specific polar contacts has also been suggested as a means to achieve selectivity over CDK9.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Besides, since Lys89 in CDK2 aligns with Thr, Val, and Gly in CDK4/6, CDK7, and CDK9, respectively,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> small and nucleophilic substituents near the positively charged Lys89 favor CDK2 selectivity, whereas large electrophilic groups and more hydrophobic substituents favor CDK4/6 and CDK7/9 selectivity, respectively. For example, CDK4/6-selective inhibitors with piperazine substituents are capable of making favorable polar interactions with the hydroxyl side chain of Thr, but they are repulsed by CDK2 Lys89.</div><div class="NLM_p">Compounds that preferentially bind to the DFG-out conformation that is characteristic of an inactive CDK2 conformation are called type II inhibitors (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).<a onclick="showRef(event, 'ref172 ref174'); return false;" href="javascript:void(0);" class="ref ref172 ref174">(172,174)</a> Alexander et al. demonstrated that type II inhibitor molecules compete with cyclin binding, suggesting that CDK2 can be prevented from activation by cyclins through type II inhibitors. Though the compounds were promiscuous and require further optimization, the disclosed crystal structure of a slow off-rate cyclin-competitive CDK2 inhibitor (K03861, <i>K</i><sub>d</sub> = 52.7 nM) targeting the inactive DFG-out state of CDK2 can be used as basis for further design of more selective type II CDK2 inhibitors. In general, type II kinase inhibitors have four core structural components: a heterocyclic hinge binding core, a linker, a hydrogen bonding structure (an amide or urea), and a hydrophobic moiety (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173,174)</a> While the heterocyclic hinge binding moiety occupies the region normally filled by the adenine of ATP, a linker crosses the region adjacent to the Phe80 gatekeeper residue. Following the linker is a hydrogen bonding structure that is required to fix the compound to the DFG-out pocket through hydrogen bonds with the Glu51 and Asp144 of the αC-helix and the Asp144 of the DFG motif, respectively. Finally, the allosteric site created by the DFG-out flip that would otherwise be occupied by Phe of the DFG motif is packed by a hydrophobic moiety. CDK2 selectivity can be tuned by modifying all four structural components described above.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> For example, the hinge binding moiety can be optimized with various substitutions (e.g., bicyclic heterocycles) that can take advantage of forming additional hydrogen bonding with Glu81 and the topological features of the hinge. It is possible to extend the substitution on the hinge binding moiety to the solvent exposed region in order to get access to less conserved residues of CDK2 (e.g Lys89).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The linker segment can be changed to a flexible aliphatic chain instead of the rigid aromatic ring system. The amide or urea of the hydrogen bonding motif can be interrogated by using a single hydrogen bond forming an ether or amine linkage. The hydrophobic moiety can contain a structural feature that can improve physicochemical properties (e.g., a basic nitrogen to improve water solubility) and can contribute additional H-bonding interactions with the kinase. Since the amino acids adjoining the pocket where this hydrophobic moiety binds are less preserved when compared with those in the ATP binding pocket,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> the site offers an advantage to fine-tune selectivity toward CDK2. In sum, the pharmacophore model described above in conjunction with molecular modeling and the fact that inactive conformations are more diverse across the kinase family are highly useful tools for the design of selective type II inhibitors of CDK2. It is therefore essential to diversify the scaffolds being explored where only a very limited number of chemotypes have been reported as type II inhibitors of CDK2.</div><div class="NLM_p">Another design strategy for selective CDK2 inhibitors is to convert type I inhibitors into type II inhibitors by attaching a type II tail onto a type I scaffold.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> This hybrid strategy can start by selecting a type I scaffold that will occupy the hinge region based on its potency and selectivity and the feasibility of attaching a linker. Subsequently, the type II tail, which consists of a hydrogen bond donor–acceptor pair and a hydrophobic motif, is attached. The designed prospective type II molecule can then be docked to the DFG-out CDK2 structure to verify the expected interactions.</div><div class="NLM_p last">A third category of kinase inhibitors is allosteric (type III).<a onclick="showRef(event, 'ref165 ref179'); return false;" href="javascript:void(0);" class="ref ref165 ref179">(165,179)</a> Type III inhibitors are usually the most selective, as they exploit binding pockets and regulatory mechanisms that are unique to a particular kinase and may help overcome drug resistance to ATP-competitive inhibitors. To date, there are only few well-characterized allosteric inhibitors of CDK2. High throughput virtual screening of compound libraries using the allosteric pockets identified on the CDK2 structure coupled with suitable biochemical assays such as the ANS-displacement assay have the potential to deliver the next generation of CDK2 allosteric inhibitors.<a onclick="showRef(event, 'ref165 ref179'); return false;" href="javascript:void(0);" class="ref ref165 ref179">(165,179)</a> In fact, this approach has been used to identify a hexahydrocyclopenta[<i>c</i>]quinoline scaffold as the first type III CDK2 inhibitor that inhibited the CDK2-mediated phosphorylation of the Rb protein. As the optimized compounds from this scaffold were not potent, further rational design of derivatives with improved kinase inhibition and anticancer activity is warranted. New understanding into the chemistry and biology of the allosteric targeting of CDK2 will certainly contribute to the rational design of new generations of more selective and potent CDK2 inhibitors.</div></div><div id="sec6_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Summary and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Over the past decades, a number of CDK inhibitors have entered clinical trials for the treatment of cancer, and the clinical development of CDK4/6-selective inhibitors has led to practice-changing outcomes in breast cancer treatment. This has energized the field and brought hope to developing new therapy by targeting other members of the CDK family. Deregulation of CDK2 and its cyclin partners is observed in a range of tumor types, and CDK2 has emerged as a promising therapeutic target in cancer. Also, the addition of CDK2 inhibitors to a variety of established treatments has the potential to improve responses and may help overcome treatment resistance. However, one of the major challenges in CDK2-directed drug discovery is selectivity. Development of highly selective CDK2 inhibitors is important to minimize drug toxicity due to off-target effects, to establish a clear mechanism of action, and to facilitate biomarker discovery. A selective CDK2 inhibitor will also be instrumental to studying cellular signaling cascades involving CDK2. Thus, the success of CDK2-targeted therapies will depend on the development of selective and potent compounds with favorable pharmacokinetic properties and on the identification of determinants of tumor sensitivity (predictive biomarkers) to CDK2 inhibition so as to identify that best responding patient subsets.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01469" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shudong Wang</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Discovery and Development, University
of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link">http://orcid.org/0000-0001-6225-5525</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#297a415c4d46474e077e48474e695c47405a48074c4d5c07485c"><span class="__cf_email__" data-cfemail="47142f322328292069102629200732292e342669222332692632">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Solomon Tadesse</span> - <span class="hlFld-Affiliation affiliation">Centre
for Drug Discovery and Development, University
of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9966-2236" title="Orcid link">http://orcid.org/0000-0002-9966-2236</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth C. Caldon</span> - <span class="hlFld-Affiliation affiliation">The
Kinghorn Cancer Centre, Garvan Institute
of Medical Research, Darlinghurst, NSW 2010, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">St Vincent’s
Clinical School, UNSW Medicine, UNSW Sydney, Darlinghurst, NSW 2010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wayne Tilley</span> - <span class="hlFld-Affiliation affiliation">Adelaide
Medical School, University of Adelaide, Adelaide, SA 5000, Australia</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Solomon Tadesse</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=BIO-d7e1334-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Solomon Tadesse</b> received his B.Pharm. and M.Sc. from the Addis Ababa University, Ethiopia. He then pursued doctoral studies under the supervision of Professor Shudong Wang at the University of South Australia (2014 to 2017), where he is now a postdoctoral research associate. Solomon’s medicinal chemistry research program investigates the discovery and development of small-molecule inhibitors targeting cyclin-dependent kinases (CDKs). He has participated in identification of novel CDK4- and CDK4/6-selective inhibitors for the potential treatment of cancer. He is particularly interested in understanding of protein structural features that might lead to the design and synthesis of selective inhibitors, and his current efforts are focused on the discovery of novel CDK-selective inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Elizabeth C. Caldon</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=BIO-d7e1339-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>C. Elizabeth Caldon</b> is a group leader at the Garvan Institute of Medical Research and conjoint senior lecturer at UNSW Sydney. She completed an MSc at the University of Toronto in 2003 and was awarded a PhD from UNSW Sydney in 2007. Her research interests are breast cancer, resistance to hormone therapy, and genomic instability, with a focus on CDK biology in these areas. She has published ∼20 research papers and reviews that specifically discuss CDK and cyclin dysregulation in cancer, including the identification of unique functions for cyclin E2.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Wayne Tilley</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=BIO-d7e1344-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wayne Tilley</b> is the Director of the Dame Roma Mitchell Cancer Research Laboratories, the University of Adelaide, Australia. His research is unique in leveraging similarities in prostate and breast cancer to forge new insights into disease mechanisms. He is recognized internationally for discoveries on steroid hormone receptor action. He cloned the human androgen receptor (AR) gene and described how perturbations in AR signaling are critical to prostate cancer progression. He identified a protective effect of AR signaling in estrogen receptor (ER)-driven breast cancer, leading to a clinical trial with a novel AR agonist. Most recently, his research revealed that activated progesterone receptor (PR) can alter ER function by a novel reprogramming mechanism, leading to three clinical trials assessing PR activation in ER-driven breast cancer.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Shudong Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=BIO-d7e1349-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shudong Wang</b> is Chair of Medicinal Chemistry at the University of South Australia. She began her research and academic career in a British biotech company (CYCC) and then the School of Pharmacy at University of Nottingham, UK. She is currently the Head of the Centre for Drug Discovery and Development where she leads a multidisciplinary team with research spanning computational & medicinal chemistry, biochemistry, cell biology, pharmacology, and preclinical drug evaluation. Her research interests focus on the discovery and development of novel classes of kinase targeted anticancer therapeutics.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">APC/C</td><td class="NLM_def"><p class="first last">anaphase-promoting complex/cyclosome</p></td></tr><tr><td class="NLM_term">B-MYB</td><td class="NLM_def"><p class="first last">Myb-related protein B</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 4</p></td></tr><tr><td class="NLM_term">CAK</td><td class="NLM_def"><p class="first last">CDK-activating kinase</p></td></tr><tr><td class="NLM_term">Cdc25</td><td class="NLM_def"><p class="first last">cell division cycle 25</p></td></tr><tr><td class="NLM_term">E2F</td><td class="NLM_def"><p class="first last">E2 promoter binding factors</p></td></tr><tr><td class="NLM_term">FOXM1</td><td class="NLM_def"><p class="first last">forkhead box protein M1</p></td></tr><tr><td class="NLM_term">FOXO1</td><td class="NLM_def"><p class="first last">forkhead box protein O1</p></td></tr><tr><td class="NLM_term">ID2</td><td class="NLM_def"><p class="first last">helix–loop–helix protein inhibitor of DNA binding 2</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">mRNA</p></td></tr><tr><td class="NLM_term">MYC</td><td class="NLM_def"><p class="first last">Myc proto-oncogene protein</p></td></tr><tr><td class="NLM_term">NFY</td><td class="NLM_def"><p class="first last">nuclear factor Y</p></td></tr><tr><td class="NLM_term">SAC</td><td class="NLM_def"><p class="first last">spindle assembly checkpoint</p></td></tr><tr><td class="NLM_term">SCF</td><td class="NLM_def"><p class="first last">Skp/Cullin/F-box-containing complex</p></td></tr><tr><td class="NLM_term">SMAD3</td><td class="NLM_def"><p class="first last">decapentaplegic homologue 3</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">UBF</td><td class="NLM_def"><p class="first last">upstream binding factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17132" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17132" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 179 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norbury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurse, P.</span></span> <span> </span><span class="NLM_article-title">Animal Cell Cycles and Their Control</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.61.070192.002301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1146%2Fannurev.bi.61.070192.002301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1497317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK38XlsVOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1992&pages=441-468&author=C.+Norburyauthor=P.+Nurse&title=Animal+Cell+Cycles+and+Their+Control&doi=10.1146%2Fannurev.bi.61.070192.002301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Animal cell cycles and their control</span></div><div class="casAuthors">Norbury, Chris; Nurse, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">441-70</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review, with 261 refs., of the following aspects of the regulation of the animal cell cycle: the onset of M phase and control of the cycle in G1 phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcub5v_XAKwLVg90H21EOLACvtfcHk0lilGREj6pwAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVOlsLg%253D&md5=f385da1a83b4593191b2a68b893ee48e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.61.070192.002301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.61.070192.002301%26sid%3Dliteratum%253Aachs%26aulast%3DNorbury%26aufirst%3DC.%26aulast%3DNurse%26aufirst%3DP.%26atitle%3DAnimal%2520Cell%2520Cycles%2520and%2520Their%2520Control%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1992%26volume%3D61%26spage%3D441%26epage%3D468%26doi%3D10.1146%2Fannurev.bi.61.070192.002301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartwell, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, T. A.</span></span> <span> </span><span class="NLM_article-title">Checkpoints: Controls that Ensure the Order of Cell Cycle Events</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1126/science.2683079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.2683079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=2683079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK3cXis12k" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=629-634&author=L.+H.+Hartwellauthor=T.+A.+Weinert&title=Checkpoints%3A+Controls+that+Ensure+the+Order+of+Cell+Cycle+Events&doi=10.1126%2Fscience.2683079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Checkpoints:  controls that ensure the order of cell cycle events</span></div><div class="casAuthors">Hartwell, Leland H.; Weinert, Ted A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">4930</span>),
    <span class="NLM_cas:pages">629-34</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 69 refs., on the cell cycle ordering into dependent pathways in which the initiation of late events is dependent on the completion of early events.  Eliminating control mechanisms enforcing dependency in the cell cycle may result in cell death, infidelity in the distribution of chromosomes or other organelles, or increased susceptibility to environmental perturbations such as DNA damaging agents.  Checkpoints elimination during the early embryonic development is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EHhxKuk-g7Vg90H21EOLACvtfcHk0lilGREj6pwAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXis12k&md5=e542c8dec21bd8df3b814da86236b2f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.2683079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2683079%26sid%3Dliteratum%253Aachs%26aulast%3DHartwell%26aufirst%3DL.%2BH.%26aulast%3DWeinert%26aufirst%3DT.%2BA.%26atitle%3DCheckpoints%253A%2520Controls%2520that%2520Ensure%2520the%2520Order%2520of%2520Cell%2520Cycle%2520Events%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D629%26epage%3D634%26doi%3D10.1126%2Fscience.2683079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cell Cycle: A New Approach to Cancer Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9408</span>– <span class="NLM_lpage">9421</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.01.5594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1200%2FJCO.2005.01.5594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16361640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=9408-9421&author=G.+K.+Schwartzauthor=M.+A.+Shah&title=Targeting+the+Cell+Cycle%3A+A+New+Approach+to+Cancer+Therapy&doi=10.1200%2FJCO.2005.01.5594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell cycle: a new approach to cancer therapy</span></div><div class="casAuthors">Schwartz, Gary K.; Shah, Manish A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9408-9421</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate.  Crit. parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next.  The CDKs are regulated pos. by cyclins and regulated neg. by naturally occurring CDK inhibitors (CDKIs).  Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth.  The cell cycle also serves to protect the cell from DNA damage.  Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA.  Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death.  Now in clin. trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest.  Recent attention has also focused on these drugs as inhibitors of transcription.  In addn., there are now agents that abrogate the cell cycle checkpoints at crit. time points that make the tumor cell susceptible to apoptosis.  An understanding of the cell cycle is crit. to understanding how best to clin. develop these agents, both as single agents and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAmpAkG9yEhLVg90H21EOLACvtfcHk0lilGREj6pwAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D&md5=e3085a43360bfd59b1be9cbd30d581fa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.5594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.5594%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DShah%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520Cell%2520Cycle%253A%2520A%2520New%2520Approach%2520to%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D9408%26epage%3D9421%26doi%3D10.1200%2FJCO.2005.01.5594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Milestones in Cell Division: To Cycle or Not To Cycle: A Critical Decision in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+Cell+Division%3A+To+Cycle+or+Not+To+Cycle%3A+A+Critical+Decision+in+Cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0liOzy7KSk4SqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520Cell%2520Division%253A%2520To%2520Cycle%2520or%2520Not%2520To%2520Cycle%253A%2520A%2520Critical%2520Decision%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Physiological Relevance of Cell Cycle Kinases</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1152/physrev.00025.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1152%2Fphysrev.00025.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=973-1007&author=M.+Malumbres&title=Physiological+Relevance+of+Cell+Cycle+Kinases&doi=10.1152%2Fphysrev.00025.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00025.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00025.2010%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DPhysiological%2520Relevance%2520of%2520Cell%2520Cycle%2520Kinases%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26spage%3D973%26epage%3D1007%26doi%3D10.1152%2Fphysrev.00025.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Kinases as Therapeutic Targets for Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+Cycle+Kinases+as+Therapeutic+Targets+for+Cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0liOzy7KSk4SqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520Cycle%2520Kinases%2520as%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, B. J.</span></span> <span> </span><span class="NLM_article-title">Cyclin C/cdk3 Promotes Rb-dependent G0 Exit</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00300-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0092-8674%2804%2900300-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15084261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=239-251&author=S.+Renauthor=B.+J.+Rollins&title=Cyclin+C%2Fcdk3+Promotes+Rb-dependent+G0+Exit&doi=10.1016%2FS0092-8674%2804%2900300-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin C/Cdk3 promotes Rb-dependent G0 exit</span></div><div class="casAuthors">Ren, Shengjun; Rollins, Barrett J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-251</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">G0 is a physiol. state occupied by resting or terminally differentiated cells that have exited the cell cycle.  In contrast to the well-characterized cyclin/cdk-mediated inactivation of pRb that controls the G1/S transition, little is known about regulation of the G0/G1 transition.  However, pRb is likely to participate in this process because its acute somatic inactivation is sufficient for G0-arrested cells to reenter the cell cycle.  One physiol. regulator of this event may be cyclin C because its highest mRNA levels occur during G0 exit.  Here we show that a non-cdk8-assocd. cellular pool of cyclin C combines with cdk3 to stimulate pRb phosphorylation at S807/811 during the G0/G1 transition, and that this phosphorylation is required for cells to exit G0 efficiently.  Thus, G1 entry is regulated in an analogous fashion to S phase entry, but involves a distinct cyclin/cdk combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrTpjovsiErVg90H21EOLACvtfcHk0liOzy7KSk4SqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFyru78%253D&md5=9bac0bd41fb681e82789589f342b8330</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900300-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900300-9%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26atitle%3DCyclin%2520C%252Fcdk3%2520Promotes%2520Rb-dependent%2520G0%2520Exit%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D239%26epage%3D251%26doi%3D10.1016%2FS0092-8674%2804%2900300-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolupaeva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, V.</span></span> <span> </span><span class="NLM_article-title">PP1 and PP2A Phosphatases-cooperating Partners in Modulating Retinoblastoma Protein Activation</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08511.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1111%2Fj.1742-4658.2012.08511.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=627-643&author=V.+Kolupaevaauthor=V.+Janssens&title=PP1+and+PP2A+Phosphatases-cooperating+Partners+in+Modulating+Retinoblastoma+Protein+Activation&doi=10.1111%2Fj.1742-4658.2012.08511.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08511.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08511.x%26sid%3Dliteratum%253Aachs%26aulast%3DKolupaeva%26aufirst%3DV.%26aulast%3DJanssens%26aufirst%3DV.%26atitle%3DPP1%2520and%2520PP2A%2520Phosphatases-cooperating%2520Partners%2520in%2520Modulating%2520Retinoblastoma%2520Protein%2520Activation%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D627%26epage%3D643%26doi%3D10.1111%2Fj.1742-4658.2012.08511.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrière, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cdk1 is Sufficient to Drive the Mammalian Cell Cycle</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nature06046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnature06046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17700700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=811-815&author=D.+Santamar%C3%ADaauthor=C.+Barri%C3%A8reauthor=A.+Cerqueiraauthor=S.+Huntauthor=C.+Tardyauthor=K.+Newtonauthor=J.+F.+C%C3%A1ceresauthor=P.+Dubusauthor=M.+Malumbresauthor=M.+Barbacid&title=Cdk1+is+Sufficient+to+Drive+the+Mammalian+Cell+Cycle&doi=10.1038%2Fnature06046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk1 is sufficient to drive the mammalian cell cycle</span></div><div class="casAuthors">Santamaria, David; Barriere, Cedric; Cerqueira, Antonio; Hunt, Sarah; Tardy, Claudine; Newton, Kathryn; Caceres, Javier F.; Dubus, Pierre; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7155</span>),
    <span class="NLM_cas:pages">811-815</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Unicellular organisms such as yeasts require a single cyclin-dependent kinase, Cdk1, to drive cell division.  In contrast, mammalian cells are thought to require the sequential activation of at least four different cyclin-dependent kinases, Cdk2, Cdk3, Cdk4 and Cdk6, to drive cells through interphase, as well as Cdk1 to proceed through mitosis.  This model has been challenged by recent genetic evidence that mice survive in the absence of individual interphase Cdks.  Moreover, most mouse cell types proliferate in the absence of two or even three interphase Cdks.  Similar results have been obtained on ablation of some of the activating subunits of Cdks, such as the D-type and E-type cyclins.  Here we show that mouse embryos lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6) undergo organogenesis and develop to midgestation.  In these embryos, Cdk1 binds to all cyclins, resulting in the phosphorylation of the retinoblastoma protein pRb and the expression of genes that are regulated by E2F transcription factors.  Mouse embryonic fibroblasts derived from these embryos proliferate in vitro, albeit with an extended cell cycle due to inefficient inactivation of Rb proteins.  However, they become immortal on continuous passage.  We also report that embryos fail to develop to the morula and blastocyst stages in the absence of Cdk1.  These results indicate that Cdk1 is the only essential cell cycle Cdk.  Moreover, they show that in the absence of interphase Cdks, Cdk1 can execute all the events that are required to drive cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEdshMg-kRLVg90H21EOLACvtfcHk0lhX5FouJD_edQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D&md5=d427cb68fc6c8758df24423761a89264</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature06046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06046%26sid%3Dliteratum%253Aachs%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarri%25C3%25A8re%26aufirst%3DC.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DS.%26aulast%3DTardy%26aufirst%3DC.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DJ.%2BF.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCdk1%2520is%2520Sufficient%2520to%2520Drive%2520the%2520Mammalian%2520Cell%2520Cycle%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D811%26epage%3D815%26doi%3D10.1038%2Fnature06046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle, Cdks and Cancer: A Changing Paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+Cycle%2C+Cdks+and+Cancer%3A+A+Changing+Paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lhX5FouJD_edQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520Cycle%252C%2520Cdks%2520and%2520Cancer%253A%2520A%2520Changing%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Proteins as Promising Targets in Cancer Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrc.2016.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28127048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=93-115&author=T.+Ottoauthor=P.+Sicinski&title=Cell+Cycle+Proteins+as+Promising+Targets+in+Cancer+Therapy&doi=10.1038%2Fnrc.2016.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle proteins as promising targets in cancer therapy</span></div><div class="casAuthors">Otto, Tobias; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-115</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer is characterized by uncontrolled tumor cell proliferation resulting from aberrant activity of various cell cycle proteins.  Therefore, cell cycle regulators are considered attractive targets in cancer therapy.  Intriguingly, animal models demonstrate that some of these proteins are not essential for proliferation of non-transformed cells and development of most tissues.  By contrast, many cancers are uniquely dependent on these proteins and hence are selectively sensitive to their inhibition.  After decades of research on the physiol. functions of cell cycle proteins and their relevance for cancer, this knowledge recently translated into the first approved cancer therapeutic targeting of a direct regulator of the cell cycle.  In this review, we focus on proteins that directly regulate cell cycle progression (such as cyclin-dependent kinases (CDKs)), as well as checkpoint kinases, Aurora kinases and Polo-like kinases (PLKs).  We discuss the role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment and results of clin. trials, as well as the future therapeutic potential of various cell cycle inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDKWC7de8OLVg90H21EOLACvtfcHk0lhX5FouJD_edQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GqsrY%253D&md5=42d0185e537bebbe203be6bae0595376</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.138%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DT.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DCell%2520Cycle%2520Proteins%2520as%2520Promising%2520Targets%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D93%26epage%3D115%26doi%3D10.1038%2Fnrc.2016.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laderian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1053%2Fj.seminoncol.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29935901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=395-403&author=B.+Laderianauthor=T.+Fojo&title=CDK4%2F6+Inhibition+as+a+Therapeutic+Strategy+in+Breast+Cancer%3A+Palbociclib%2C+Ribociclib%2C+and+Abemaciclib&doi=10.1053%2Fj.seminoncol.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span></div><div class="casAuthors">Laderian, Bahar; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">395-403</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With 40,920 American women expected to die from breast cancer in 2018 and global health ests. that more than 508,000 women died in 2011 from this disease, the identification of novel therapeutic strategies for the treatment of breast cancer cannot be ignored.  A breakthrough class of cancer drugs that has emerged in recent years and has had an impact in the treatment of breast cancer are the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, with palbociclib the first in class to have received regulatory approval for breast cancer.  In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer.  Ribociclib and abemaciclib developed after the success of palbociclib represent examples of "me-too" therapies increasingly being deployed in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThrkaFQi4NbVg90H21EOLACvtfcHk0lixHKUlLakcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK&md5=9e8dd8a2354559a98c90178c12fdffd8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLaderian%26aufirst%3DB.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCDK4%252F6%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Breast%2520Cancer%253A%2520Palbociclib%252C%2520Ribociclib%252C%2520and%2520Abemaciclib%26jtitle%3DSemin.%2520Oncol.%26date%3D2017%26volume%3D44%26spage%3D395%26epage%3D403%26doi%3D10.1053%2Fj.seminoncol.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lixHKUlLakcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vylicil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase Inhibitors for Cancer Therapy: a Patent Review (2009 - 2014)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1517/13543776.2015.1045414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1517%2F13543776.2015.1045414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26161698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=953-970&author=V.+Malinkovaauthor=J.+Vylicilauthor=V.+Krystof&title=Cyclin-dependent+Kinase+Inhibitors+for+Cancer+Therapy%3A+a+Patent+Review+%282009+-+2014%29&doi=10.1517%2F13543776.2015.1045414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014)</span></div><div class="casAuthors">Malinkova, Veronika; Vylicil, Jakub; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">953-970</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell cycle deregulation is a common characteristic of cancer cells.  Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of mol. mechanisms.  Based on these observations, small mol. CDK inhibitors are being developed as potential cancer therapeutics.  Some of these compds. have entered Phase III clin. trials and one of them, palbociclib, recently received accelerated approval from the FDA.  However, the complexity of CDK biol. and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues.  This article reviews patent applications related to small mol. CDK inhibitors published between 2009 and 2014.  Clin. trials with pan-specific inhibitors have generally yielded unambiguously pos. outcomes.  However, better results have been achieved with highly specific inhibitors of CDK4/CDK6.  This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors.  The development of such compds. is challenging because all CDKs have very similar active sites.  Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPDLi65wpHSrVg90H21EOLACvtfcHk0lixHKUlLakcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrjK&md5=b0fbe03411a8f0aea9775a16683f2b2c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1045414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1045414%26sid%3Dliteratum%253Aachs%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DVylicil%26aufirst%3DJ.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DCyclin-dependent%2520Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%253A%2520a%2520Patent%2520Review%2520%25282009%2520-%25202014%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D953%26epage%3D970%26doi%3D10.1517%2F13543776.2015.1045414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+Sanchez-Martinezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadler, S.</span></span> <span> </span><span class="NLM_article-title">Perspectives for Cancer Therapies with Cdk2 Inhibitors</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1054/drup.2001.0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1054%2Fdrup.2001.0224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12030783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlsl2hsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=347-367&author=S.+Wadler&title=Perspectives+for+Cancer+Therapies+with+Cdk2+Inhibitors&doi=10.1054%2Fdrup.2001.0224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives for cancer therapies with cdk2 inhibitors</span></div><div class="casAuthors">Wadler, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">347-367</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern anticancer strategies are designed against specific mol. targets with the goal of sparing normal, non-neoplastic tissues.  Choosing specific mol. targets, however, is problematic.  Cdk2 (cyclin dependent kinase 2, cell division kinase 2, p33) is an important candidate target for therapeutic intervention.  Phosphorylation of retinoblastoma protein (pRb) by Cdk2 is the penultimate step in the transition from G1 to S phase.  Inhibition of this step could potentially result in inhibition of proliferation, cytostasis, and possibly apoptosis in human tumors.  Cdk2 also plays a crit. role in the transition through S phase and the S to G2 transition as well.  Inhibitors of the cyclin dependent kinases, such as Flavopiridol and UCN-01, are currently in clin. trials.  While demonstrating clin. activity, neither acts specifically against Cdk2.  Other more specific Cdk2 inhibitors are currently in preclin. development.  Further studies to explore the therapeutic worth of such agents are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopsjFO8cg8-LVg90H21EOLACvtfcHk0liwIVhaBYYn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlsl2hsbk%253D&md5=429a5960a1117919f2700b68238de3a1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1054%2Fdrup.2001.0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.2001.0224%26sid%3Dliteratum%253Aachs%26aulast%3DWadler%26aufirst%3DS.%26atitle%3DPerspectives%2520for%2520Cancer%2520Therapies%2520with%2520Cdk2%2520Inhibitors%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2001%26volume%3D4%26spage%3D347%26epage%3D367%26doi%3D10.1054%2Fdrup.2001.0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shchemelinin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sefc, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necas, E.</span></span> <span> </span><span class="NLM_article-title">Protein Kinases, Their Function and Implication in Cancer and Other Diseases</span>. <i>Folia Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17089919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BD28nls1GgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=81-100&author=I.+Shchemelininauthor=L.+Sefcauthor=E.+Necas&title=Protein+Kinases%2C+Their+Function+and+Implication+in+Cancer+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases, their function and implication in cancer and other diseases</span></div><div class="casAuthors">Shchemelinin I; Sefc L; Necas E</div><div class="citationInfo"><span class="NLM_cas:title">Folia biologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">81-100</span>
        ISSN:<span class="NLM_cas:issn">0015-5500</span>.
    </div><div class="casAbstract">Protein phosphorylation is known to play an important role in various cellular processes such as cell division, metabolism, survival and apoptosis.  It is driven by specific enzymes, tyrosine and serine-threonine protein kinases.  Human protein kinases constitute a complicated system with intricate internal and external interactions.  The complexity and sophistication of the system implies its vulnerability.  Alterations in functions of these enzymes may launch series of pathological changes within the cell and as a result cause diseases.  Protein kinases have been shown to be involved in various pathological processes, first of all malignancies.  Deregulation of different protein kinases has been found in chronic myelogenous leukaemia, gastrointestinal stromal tumours, various other sarcomas and cancers as well as non-malignant disorders.  Therefore, they are regarded as important effectors in human pathology and represent prospective therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzDhllLp8mfv3jf77P2BG3fW6udTcc2eZr8CPwNa0X8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nls1GgtA%253D%253D&md5=e5262093a6dc1d589c614afdeccd9c2b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShchemelinin%26aufirst%3DI.%26aulast%3DSefc%26aufirst%3DL.%26aulast%3DNecas%26aufirst%3DE.%26atitle%3DProtein%2520Kinases%252C%2520Their%2520Function%2520and%2520Implication%2520in%2520Cancer%2520and%2520Other%2520Diseases%26jtitle%3DFolia%2520Biol.%26date%3D2006%26volume%3D52%26spage%3D81%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Cyclin-Dependent Kinase Regulation: Structures of Cdks, Their Cyclin Activators, and Cip and INK4 Inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.2640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1006%2Fjmbi.1999.2640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1999&pages=821-828&author=N.+P.+Pavletich&title=Mechanisms+of+Cyclin-Dependent+Kinase+Regulation%3A+Structures+of+Cdks%2C+Their+Cyclin+Activators%2C+and+Cip+and+INK4+Inhibitors&doi=10.1006%2Fjmbi.1999.2640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.2640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.2640%26sid%3Dliteratum%253Aachs%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DMechanisms%2520of%2520Cyclin-Dependent%2520Kinase%2520Regulation%253A%2520Structures%2520of%2520Cdks%252C%2520Their%2520Cyclin%2520Activators%252C%2520and%2520Cip%2520and%2520INK4%2520Inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D287%26spage%3D821%26epage%3D828%26doi%3D10.1006%2Fjmbi.1999.2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-Dependent+Kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2eZr8CPwNa0X8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewald, J. C.</span></span> <span> </span><span class="NLM_article-title">Fueling the Cycle: CDKs in Carbon and Energy Metabolism</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.3389/fcell.2018.00093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3389%2Ffcell.2018.00093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=30175098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BB3c3kvVWgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=93&author=M.+Solakiauthor=J.+C.+Ewald&title=Fueling+the+Cycle%3A+CDKs+in+Carbon+and+Energy+Metabolism&doi=10.3389%2Ffcell.2018.00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fueling the Cycle: CDKs in Carbon and Energy Metabolism</span></div><div class="casAuthors">Solaki Maria; Ewald Jennifer C</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are the central regulators of the eukaryotic cell cycle, and are conserved across eukaryotes.  Their main and well-studied function lies in the regulation and the time-keeping of cell cycle entry and progression.  Additionally, more and more non canonical functions of CDKs are being uncovered.  One fairly recently discovered role of CDKs is the coordination of carbon and energy metabolism with proliferation.  Evidence from different model organisms is accumulating that CDKs can directly and indirectly control fluxes through metabolism, for example by phosphorylating metabolic enzymes.  In this mini-review, we summarize the emerging role of CDKs in regulating carbon and energy metabolism and discuss examples in different models from yeast to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlxeUlx0N0y6e0F5ixvZgXfW6udTcc2eZr8CPwNa0X8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3kvVWgsw%253D%253D&md5=570222933abd3202fe868ce94ed9e63b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2018.00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2018.00093%26sid%3Dliteratum%253Aachs%26aulast%3DSolaki%26aufirst%3DM.%26aulast%3DEwald%26aufirst%3DJ.%2BC.%26atitle%3DFueling%2520the%2520Cycle%253A%2520CDKs%2520in%2520Carbon%2520and%2520Energy%2520Metabolism%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2018%26volume%3D6%26spage%3D93%26doi%3D10.3389%2Ffcell.2018.00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hydbring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Non-canonical Functions of Cell Cycle Cyclins and Cyclin-dependent Kinases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1038/nrm.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrm.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27033256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlOksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=280-292&author=P.+Hydbringauthor=M.+Malumbresauthor=P.+Sicinski&title=Non-canonical+Functions+of+Cell+Cycle+Cyclins+and+Cyclin-dependent+Kinases&doi=10.1038%2Fnrm.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases</span></div><div class="casAuthors">Hydbring, Per; Malumbres, Marcos; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">280-292</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The roles of cyclins and their catalytic partners, the cyclin-dependent kinases (CDKs), as core components of the machinery that drives cell cycle progression are well established.  Increasing evidence indicates that mammalian cyclins and CDKs also carry out important functions in other cellular processes, such as transcription, DNA damage repair, control of cell death, differentiation, the immune response and metab.  Some of these non-canonical functions are performed by cyclins or CDKs, independently of their resp. cell cycle partners, suggesting that there was a substantial divergence in the functions of these proteins during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqltFQjJuMXrbVg90H21EOLACvtfcHk0lgrhhWLUFaeWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlOksLw%253D&md5=4d8aaf10c0542828112c561f5311f7da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DHydbring%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DNon-canonical%2520Functions%2520of%2520Cell%2520Cycle%2520Cyclins%2520and%2520Cyclin-dependent%2520Kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D280%26epage%3D292%26doi%3D10.1038%2Fnrm.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhavan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">A Decade of CDK5</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/35096019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2F35096019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=11584302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=749-759&author=R.+Dhavanauthor=L.+H.+Tsai&title=A+Decade+of+CDK5&doi=10.1038%2F35096019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of CDK5</span></div><div class="casAuthors">Dhavan, Rani; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-759</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since it was identified a decade ago, cyclin-dependent kinase 5 (CDK5) has emerged as a crucial regulator of neuronal migration in the developing central nervous system, CDK5 phosphorylates a diverse list of substrates, implicating it in the regulation of a range of cellular processes - from adhesion and motility, to synaptic plasticity and drug addiction.  Recent evidence indicates that deregulation of this kinase is involved in the pathol. of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJjFohRrOz2LVg90H21EOLACvtfcHk0lgrhhWLUFaeWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVajsLg%253D&md5=e1f256de5c9fb733c3b28ccb060fe2ad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F35096019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35096019%26sid%3Dliteratum%253Aachs%26aulast%3DDhavan%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DA%2520Decade%2520of%2520CDK5%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D749%26epage%3D759%26doi%3D10.1038%2F35096019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. F.</span></span> <span> </span><span class="NLM_article-title">In a Nongenomic Action, Steroid Hormone 20-Hydroxyecdysone Induces Phosphorylation of Cyclin-dependent Kinase 10 to Promote Gene Transcription</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1750</span>, <span class="refDoi"> DOI: 10.1210/en.2013-2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1210%2Fen.2013-2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24517229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFensL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2014&pages=1738-1750&author=W.+Liuauthor=M.+J.+Caiauthor=J.+X.+Wangauthor=X.+F.+Zhao&title=In+a+Nongenomic+Action%2C+Steroid+Hormone+20-Hydroxyecdysone+Induces+Phosphorylation+of+Cyclin-dependent+Kinase+10+to+Promote+Gene+Transcription&doi=10.1210%2Fen.2013-2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">In a nongenomic action, steroid hormone 20-hydroxyecdysone induces phosphorylation of cyclin-dependent kinase 10 to promote gene transcription</span></div><div class="casAuthors">Liu, Wen; Cai, Mei-Juan; Wang, Jin-Xing; Zhao, Xiao-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1738-1750, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The insect steroid hormone 20-hydroxyecdysone (20E) regulates gene transcription via a genomic pathway by forming a transcription complex that binds to DNA with the help of the chaperone proteins, heat shock proteins (Hsps) Hsc70 and Hsp90.  However, the nongenomic mechanisms by which 20E regulates gene expression remain unclear.  In this study, we found that 20E regulated the phosphorylation of serine/threonine protein kinase cyclin-dependent kinase 10 (CDK10) through a nongenomic pathway to mediate gene transcription in the lepidopteran Helicoverpa armigera.  The down-regulation of CDK10 by RNA interference in larvae and the epidermal cell line delayed development and suppressed 20E-induced gene transcription.  CDK10 was localized to the nucleus via its KKRR motif, and this nuclear localization and the ATPase motif were necessary for the efficient expression of the 20E-inducible gene.  The rapid phosphorylation of CDK10 was induced by 20E, whereas it was repressed by the inhibitors of G-protein-coupled receptors, phospholipase C, and Ca2+ channels.  Phosphorylated CDK10 exhibited increased interactions with Hsps Hsc70 and Hsp90 and then promoted the interactions between Hsps and ecdysone receptor EcRB1 and the binding of the Hsps-EcRB1 complex to the 20E response element for the regulation of gene transcription.  CDK10 depletion suppressed the formation of the Hsps-EcRB1 complex at the hormone receptor 3 promoter.  These results suggest that 20E induces CDK10 phosphorylation via a nongenomic pathway to regulate gene transcription in the nucleus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-VhfqbCrtS7Vg90H21EOLACvtfcHk0lgrhhWLUFaeWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFensL%252FP&md5=33cdc1721c715a3357d80ae8bf2707a9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1210%2Fen.2013-2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2013-2020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BX.%26aulast%3DZhao%26aufirst%3DX.%2BF.%26atitle%3DIn%2520a%2520Nongenomic%2520Action%252C%2520Steroid%2520Hormone%252020-Hydroxyecdysone%2520Induces%2520Phosphorylation%2520of%2520Cyclin-dependent%2520Kinase%252010%2520to%2520Promote%2520Gene%2520Transcription%26jtitle%3DEndocrinology%26date%3D2014%26volume%3D155%26spage%3D1738%26epage%3D1750%26doi%3D10.1210%2Fen.2013-2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, V. J.</span></span> <span> </span><span class="NLM_article-title">CDK11 Complexes Promote pre-mRNA Splicing</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">8623</span>– <span class="NLM_lpage">8629</span>, <span class="refDoi"> DOI: 10.1074/jbc.M210057200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M210057200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=8623-8629&author=D.+Huauthor=A.+Mayedaauthor=J.+H.+Trembleyauthor=J.+M.+Lahtiauthor=V.+J.+Kidd&title=CDK11+Complexes+Promote+pre-mRNA+Splicing&doi=10.1074%2Fjbc.M210057200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210057200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210057200%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DD.%26aulast%3DMayeda%26aufirst%3DA.%26aulast%3DTrembley%26aufirst%3DJ.%2BH.%26aulast%3DLahti%26aufirst%3DJ.%2BM.%26aulast%3DKidd%26aufirst%3DV.%2BJ.%26atitle%3DCDK11%2520Complexes%2520Promote%2520pre-mRNA%2520Splicing%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D8623%26epage%3D8629%26doi%3D10.1074%2Fjbc.M210057200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span> <span> </span><span class="NLM_article-title">Structural Dissection of Cyclin Dependent Kinases Regulation and Protein Recognition Properties</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.4161/cc.9.8.11195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.9.8.11195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20372077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1551-1561&author=G.+Lolli&title=Structural+Dissection+of+Cyclin+Dependent+Kinases+Regulation+and+Protein+Recognition+Properties&doi=10.4161%2Fcc.9.8.11195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dissection of cyclin dependent kinases regulation and protein recognition properties</span></div><div class="casAuthors">Lolli, Graziano</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1561</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  They are regulated by their cyclin partners and by a variety of addnl. protein effectors (inhibitors, kinases, phosphatases).  Each CDK serves its function by means of specific protein recognition properties.  These are also responsible for the differential regulation of CDKs/Cyclin couples involved in processes as different as cell cycle and transcription.  The structural features detg. general and specific properties for CDKs/Cyclin complexes are analyzed.  They reside in an overall conserved architecture with divergent spots used by the complexes to present themselves to specific substrates or other protein effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28MAQ6SOxDLVg90H21EOLACvtfcHk0li5CWcS44BSGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP&md5=34d193f3e930ba5043f152a252063f36</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.8.11195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.8.11195%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26atitle%3DStructural%2520Dissection%2520of%2520Cyclin%2520Dependent%2520Kinases%2520Regulation%2520and%2520Protein%2520Recognition%2520Properties%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D1551%26epage%3D1561%26doi%3D10.4161%2Fcc.9.8.11195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor’s-eye View of the ATP-binding Site of CDKs in Different Regulatory States</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1021/cb500135f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500135f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1251-1256&author=A.+Echalierauthor=A.+J.+Holeauthor=G.+Lolliauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=An+Inhibitor%E2%80%99s-eye+View+of+the+ATP-binding+Site+of+CDKs+in+Different+Regulatory+States&doi=10.1021%2Fcb500135f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States</span></div><div class="casAuthors">Echalier, Aude; Hole, Alison J.; Lolli, Graziano; Endicott, Jane A.; Noble, Martin E. M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1256</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have used a chem. diverse panel of kinase inhibitors to assess the chem. similarity of the ATP-binding sites of cyclin-dependent kinase (CDK) subfamily members in a range of activation states.  Using this approach, we find that different activation states of a particular CDK may differ from each other as much as different CDKs in the same activation state.  We also find that inhibitors discriminate more effectively among CDK family members in their monomeric state than in their cyclin-bound state, providing direct evidence for the belief that selective binding to inactive kinase states might be more readily achieved than selective binding to active states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokueQs6w8YR7Vg90H21EOLACvtfcHk0li5CWcS44BSGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrtr0%253D&md5=4419c60fe22d593aa23c8136030535f6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb500135f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500135f%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DAn%2520Inhibitor%25E2%2580%2599s-eye%2520View%2520of%2520the%2520ATP-binding%2520Site%2520of%2520CDKs%2520in%2520Different%2520Regulatory%2520States%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1251%26epage%3D1256%26doi%3D10.1021%2Fcb500135f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Discovery of Cyclin-Dependent Protein Kinase Inhibitors</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1042/EBC20170040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1042%2FEBC20170040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29118092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=439-452&author=M.+P.+Martinauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=Structure-based+Discovery+of+Cyclin-Dependent+Protein+Kinase+Inhibitors&doi=10.1042%2FEBC20170040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span></div><div class="casAuthors">Martin Mathew P; Endicott Jane A; Noble Martin E M</div><div class="citationInfo"><span class="NLM_cas:title">Essays in biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond.  After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer.  Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings.  Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members.  We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor-target interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqZGQ3bfUY0XELvajU9pjPfW6udTcc2ebVIojN2kS-srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D&md5=7795a97e063f43e77499e9a03020d6cb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1042%2FEBC20170040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20170040%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DStructure-based%2520Discovery%2520of%2520Cyclin-Dependent%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DEssays%2520Biochem.%26date%3D2017%26volume%3D61%26spage%3D439%26epage%3D452%26doi%3D10.1042%2FEBC20170040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skamnaki, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The Structure of Cyclin E1/CDK2: Implications for CDK2 Activation and CDK2-Independent Roles</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsj.emboj.7600554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=452-463&author=R.+Hondaauthor=E.+D.+Loweauthor=E.+Dubininaauthor=V.+Skamnakiauthor=A.+Cookauthor=N.+R.+Brownauthor=L.+N.+Johnson&title=The+Structure+of+Cyclin+E1%2FCDK2%3A+Implications+for+CDK2+Activation+and+CDK2-Independent+Roles&doi=10.1038%2Fsj.emboj.7600554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600554%26sid%3Dliteratum%253Aachs%26aulast%3DHonda%26aufirst%3DR.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DDubinina%26aufirst%3DE.%26aulast%3DSkamnaki%26aufirst%3DV.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520Structure%2520of%2520Cyclin%2520E1%252FCDK2%253A%2520Implications%2520for%2520CDK2%2520Activation%2520and%2520CDK2-Independent%2520Roles%26jtitle%3DEMBO%2520J.%26date%3D2005%26volume%3D24%26spage%3D452%26epage%3D463%26doi%3D10.1038%2Fsj.emboj.7600554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Cyclin-Dependent Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(02)00182-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0163-7258%2802%2900182-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12191605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=125-133&author=T.+G.+Daviesauthor=D.+J.+Prattauthor=J.+A.+Endicottauthor=L.+N.+Johnsonauthor=M.+E.+Noble&title=Structure-Based+Design+of+Cyclin-Dependent+Kinase+Inhibitors&doi=10.1016%2FS0163-7258%2802%2900182-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Davies, Thomas G.; Pratt, David J.; Endicott, Jane A.; Johnson, Louise N.; Noble, Martin E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 44 refs.  The eukaryotic cell cycle is tightly regulated by the sequential activation and deactivation of the cyclin-dependent kinases (CDKs).  Aberrant CDK activity is a common defect in human tumors, and clin., it often confers a poor prognosis.  The strong genetic link between CDKs and the mol. pathol. of cancer has provided the rationale for developing small-mol. inhibitors of these kinases.  X-ray crystallog. recently has revealed the mol. details of CDK regulation by cyclin binding and phosphorylation, and by complex formation with endogenous inhibitors.  Knowledge of the structure of CDK2 has been key in driving the design and development of a large no. of ATP competitive inhibitors.  Crystallog. has revealed that the ATP-binding site of CDK2 can accommodate a no. of diverse mol. frameworks, exploiting various sites of interaction.  In addn., residues outside the main ATP-binding cleft have been identified that could be targeted to increase specificity and potency.  These results suggest that it may be possible to design pharmacol. relevant ligands that act as specific and potent inhibitors of CDK activity.  The authors provide a review of the current state of the field, along with an overview of their current inhibitor design studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3hEq4qfNuH7Vg90H21EOLACvtfcHk0ligJERisKOPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShtbs%253D&md5=30c6073dccb49ef417ca0130b00756a9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900182-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900182-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DStructure-Based%2520Design%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D125%26epage%3D133%26doi%3D10.1016%2FS0163-7258%2802%2900182-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Dephosphorylation of Cdk2 Thr160 by the Cyclin-dependent Kinase-interacting Phosphatase KAP in the Absence of Cyclin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1126/science.270.5233.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.270.5233.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=7569954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2MXosFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=90-93&author=R.+Y.+Poonauthor=T.+Hunter&title=Dephosphorylation+of+Cdk2+Thr160+by+the+Cyclin-dependent+Kinase-interacting+Phosphatase+KAP+in+the+Absence+of+Cyclin&doi=10.1126%2Fscience.270.5233.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin</span></div><div class="casAuthors">Poon, Randy Y. C.; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5233</span>),
    <span class="NLM_cas:pages">90-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The activation of cyclin-dependent kinases (CDKs) requires the phosphorylation of a conserved Thr residue (Thr-160 in Cdk2) by CDK-activating kinase (CAK).  Human KAP (also called Cdi1), a CDK-assocd. phosphoprotein phosphatase, was shown to dephosphorylate Thr-160 in human Cdk2.  KAP was unable to dephosphorylate Tyr-15 and only dephosphorylated Thr-160 in native monomeric Cdk2.  The binding of cyclin A to Cdk2 inhibited the dephosphorylation of Thr-160 by KAP but did not preclude the binding of KAP to the cyclin A-Cdk2 complex.  Moreover, the dephosphorylation of Thr-160 by KAP prevented Cdk2 kinase activity upon subsequent assocn. with cyclin A.  These results suggest that KAP binds to Cdk2 and dephosphorylates Thr-160 when the assocd. cyclin subunit is degraded or dissocs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZeoyQxRXcOLVg90H21EOLACvtfcHk0ligJERisKOPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosFOmsLY%253D&md5=a74ab260ad484d166c9ed02ad420f8a3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5233.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5233.90%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DR.%2BY.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DDephosphorylation%2520of%2520Cdk2%2520Thr160%2520by%2520the%2520Cyclin-dependent%2520Kinase-interacting%2520Phosphatase%2520KAP%2520in%2520the%2520Absence%2520of%2520Cyclin%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D90%26epage%3D93%26doi%3D10.1126%2Fscience.270.5233.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Putting One Step Before the Other: Distinct Activation Pathways for Cdk1 and Cdk2 Bring Order to the Mammalian Cell Cycle</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.4161/cc.9.4.10732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.9.4.10732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20139727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=706-714&author=K.+A.+Merrickauthor=R.+P.+Fisher&title=Putting+One+Step+Before+the+Other%3A+Distinct+Activation+Pathways+for+Cdk1+and+Cdk2+Bring+Order+to+the+Mammalian+Cell+Cycle&doi=10.4161%2Fcc.9.4.10732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle</span></div><div class="casAuthors">Merrick, Karl A.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">706-714</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Eukaryotic cell division is controlled by the activity of cyclin-dependent kinases (CDKs).  Cdk1 and Cdk2, which function at different stages of the mammalian cell cycle, both require cyclin-binding and phosphorylation of the activation (T-) loop for full activity, but differ with respect to the order in which the two steps occur in vivo.  To form stable complexes with either of its partners-cyclins A and B-Cdk1 must be phosphorylated on its T-loop, but that phosphorylation in turn depends on the presence of cyclin.  Cdk2 can follow a kinetically distinct path to activation in which T-loop phosphorylation precedes cyclin-binding, and thereby out-compete the more abundant Cdk1 for limiting amts. of cyclin A.  Math. modeling suggests this could be a principal basis for the temporal ordering of CDK activation during S phase, which may dictate the sequence in which replication origins fire.  Still to be detd. are how: (1) the activation machinery discriminates between closely related CDKs, and (2) coordination of the cell cycle is affected when this mechanism of pathway insulation breaks down.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuode7wYph7Vg90H21EOLACvtfcHk0ligJERisKOPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cju7k%253D&md5=ddd15a097eb40d1b728f688c44dd2347</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.4.10732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.4.10732%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DPutting%2520One%2520Step%2520Before%2520the%2520Other%253A%2520Distinct%2520Activation%2520Pathways%2520for%2520Cdk1%2520and%2520Cdk2%2520Bring%2520Order%2520to%2520the%2520Mammalian%2520Cell%2520Cycle%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D706%26epage%3D714%26doi%3D10.4161%2Fcc.9.4.10732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Distinct Activation Pathways Confer Cyclin-binding Specificity on Cdk1 and Cdk2 in Human Cells</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molcel.2008.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=662-672&author=K.+A.+Merrickauthor=S.+Larochelleauthor=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=R.+P.+Fisher&title=Distinct+Activation+Pathways+Confer+Cyclin-binding+Specificity+on+Cdk1+and+Cdk2+in+Human+Cells&doi=10.1016%2Fj.molcel.2008.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DDistinct%2520Activation%2520Pathways%2520Confer%2520Cyclin-binding%2520Specificity%2520on%2520Cdk1%2520and%2520Cdk2%2520in%2520Human%2520Cells%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D32%26spage%3D662%26epage%3D672%26doi%3D10.1016%2Fj.molcel.2008.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremner, R.</span></span> <span> </span><span class="NLM_article-title">A CDK2 Activity Signature Predicts Outcome in CDK2-low Cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2491</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2016.409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27819669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2gtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=2491-2502&author=S.+R.+McCurdyauthor=M.+Pacalauthor=M.+Ahmadauthor=R.+Bremner&title=A+CDK2+Activity+Signature+Predicts+Outcome+in+CDK2-low+Cancers&doi=10.1038%2Fonc.2016.409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A CDK2 activity signature predicts outcome in CDK2-low cancers</span></div><div class="casAuthors">McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2491-2502</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The role of cyclin-dependent kinase 2 (CDK2) in cancer is controversial.  A major hurdle is the availability of tools to easily assess its activity across many samples.  Here, we introduce a transcriptional signature to specifically track CDK2 activity.  It responds to genetic and chem. perturbations in the CDK-RB-E2F axis, correlates with mitotic rate in vitro and in vivo and reacts rapidly to changes in CDK2 activity during cell cycle progression.  We find that CDK2 activity is specifically elevated in human testes, mirroring its crit. function in mice, and report very distinct profiles across human cancers.  Increased CDK2 activity decreases risk in colon cancer, but elevates poor outcome two- to fivefold in specific tumors, including low grade glioma, kidney, thyroid, adrenocortical and prostate cancer.  These are typically 'CDK2-low' cancers, suggesting that above a certain threshold CDK2 promotes progression, but further increases do not influence outcome.  Multivariate anal. revealed that the CDK2 signature is the most important predictive feature in these cancers vs. dozens of other clin. parameters, such as tumor grade or mitotic index.  Thus, transcriptome data provides a novel, straightforward method to monitor CDK2 activity, implicates key roles for the kinase in a subset of human tissues and tumors and enhances cancer risk prediction.  The strategy used here for CDK2 could be applied to other kinases that influence transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkkYovR0LeFrVg90H21EOLACvtfcHk0lhzamQC9gshVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2gtbzF&md5=0836de84a5e04824d9e2c1c48da3469a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.409%26sid%3Dliteratum%253Aachs%26aulast%3DMcCurdy%26aufirst%3DS.%2BR.%26aulast%3DPacal%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DBremner%26aufirst%3DR.%26atitle%3DA%2520CDK2%2520Activity%2520Signature%2520Predicts%2520Outcome%2520in%2520CDK2-low%2520Cancers%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26spage%3D2491%26epage%3D2502%26doi%3D10.1038%2Fonc.2016.409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diril, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisteau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnacaram, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janela, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noffke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldis, P.</span></span> <span> </span><span class="NLM_article-title">Cdk2 Catalytic Activity is Essential for Meiotic Cell Division <i>In vivo</i></span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>473</i></span>,  <span class="NLM_fpage">2783</span>– <span class="NLM_lpage">2798</span>, <span class="refDoi"> DOI: 10.1042/BCJ20160607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1042%2FBCJ20160607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2016&pages=2783-2798&author=S.+Chauhanauthor=M.+K.+Dirilauthor=J.+H.+Leeauthor=X.+Bisteauauthor=V.+Manoharanauthor=D.+Adhikariauthor=C.+K.+Ratnacaramauthor=B.+Janelaauthor=J.+Noffkeauthor=F.+Ginhouxauthor=V.+Coppolaauthor=K.+Liuauthor=L.+Tessarolloauthor=P.+Kaldis&title=Cdk2+Catalytic+Activity+is+Essential+for+Meiotic+Cell+Division+In+vivo&doi=10.1042%2FBCJ20160607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1042%2FBCJ20160607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20160607%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DS.%26aulast%3DDiril%26aufirst%3DM.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DBisteau%26aufirst%3DX.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DAdhikari%26aufirst%3DD.%26aulast%3DRatnacaram%26aufirst%3DC.%2BK.%26aulast%3DJanela%26aufirst%3DB.%26aulast%3DNoffke%26aufirst%3DJ.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DCoppola%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DKaldis%26aufirst%3DP.%26atitle%3DCdk2%2520Catalytic%2520Activity%2520is%2520Essential%2520for%2520Meiotic%2520Cell%2520Division%2520In%2520vivo%26jtitle%3DBiochem.%2520J.%26date%3D2016%26volume%3D473%26spage%3D2783%26epage%3D2798%26doi%3D10.1042%2FBCJ20160607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narasimha, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaulich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, S. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin D Activates the Rb Tumor Suppressor by Mono-phosphorylation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02872</span>, <span class="refDoi"> DOI: 10.7554/eLife.02872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.7554%2FeLife.02872" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02872&author=A.+M.+Narasimhaauthor=M.+Kaulichauthor=G.+S.+Shapiroauthor=Y.+J.+Choiauthor=P.+Sicinskiauthor=S.+F.+Dowdy&title=Cyclin+D+Activates+the+Rb+Tumor+Suppressor+by+Mono-phosphorylation&doi=10.7554%2FeLife.02872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.7554%2FeLife.02872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02872%26sid%3Dliteratum%253Aachs%26aulast%3DNarasimha%26aufirst%3DA.%2BM.%26aulast%3DKaulich%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DG.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DDowdy%26aufirst%3DS.%2BF.%26atitle%3DCyclin%2520D%2520Activates%2520the%2520Rb%2520Tumor%2520Suppressor%2520by%2520Mono-phosphorylation%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02872%26doi%3D10.7554%2FeLife.02872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denissova, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinases Regulate the Antiproliferative Function of Smads</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nature02650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnature02650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15241418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2004&pages=226-231&author=I.+Matsuuraauthor=N.+G.+Denissovaauthor=G.+Wangauthor=D.+Heauthor=J.+Longauthor=F.+Liu&title=Cyclin-Dependent+Kinases+Regulate+the+Antiproliferative+Function+of+Smads&doi=10.1038%2Fnature02650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases regulate the antiproliferative function of Smads</span></div><div class="casAuthors">Matsuura, Isao; Denissova, Natalia G.; Wang, Guannan; He, Dongming; Long, Jianyin; Liu, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">6996</span>),
    <span class="NLM_cas:pages">226-231</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transforming growth factor-β (TGF-β) potently inhibits cell cycle progression at the G1 phase.  Smad3 has a key function in mediating the TGF-β growth-inhibitory response.  Here we show that Smad3 is a major physiol. substrate of the G1 cyclin-dependent kinases CDK4 and CDK2.  Except for the retinoblastoma protein family, Smad3 is the only CDK4 substrate demonstrated so far.  We have mapped CDK4 and CDK2 phosphorylation sites to Thr 8, Thr 178 and Ser 212 in Smad3.  Mutation of the CDK phosphorylation sites increases Smad3 transcriptional activity, leading to higher expression of the CDK inhibitor p15.  Mutation of the CDK phosphorylation sites of Smad3 also increases its ability to downregulate the expression of c-myc.  Using Smad3-/- mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability.  Taken together, these findings indicate that CDK phosphorylation of Smad3 inhibits its transcriptional activity and antiproliferative function.  Because cancer cells often contain high levels of CDK activity, diminishing Smad3 activity by CDK phosphorylation may contribute to tumorigenesis and TGF-β resistance in cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCSqptmYD0rVg90H21EOLACvtfcHk0lhzamQC9gshVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVGjsr0%253D&md5=f129c1f8e2748a9aac36adebd937e704</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature02650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02650%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuura%26aufirst%3DI.%26aulast%3DDenissova%26aufirst%3DN.%2BG.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DCyclin-Dependent%2520Kinases%2520Regulate%2520the%2520Antiproliferative%2520Function%2520of%2520Smads%26jtitle%3DNature%26date%3D2004%26volume%3D430%26spage%3D226%26epage%3D231%26doi%3D10.1038%2Fnature02650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Major, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, R. H.</span></span> <span> </span><span class="NLM_article-title">Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-cyclin Complexes for Phosphorylation-Dependent Recruitment of P300/CBP Coactivators</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2661</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.7.2649-2661.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1128%2FMCB.24.7.2649-2661.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15024056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1emsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2649-2661&author=M.+L.+Majorauthor=R.+Lepeauthor=R.+H.+Costa&title=Forkhead+Box+M1B+Transcriptional+Activity+Requires+Binding+of+Cdk-cyclin+Complexes+for+Phosphorylation-Dependent+Recruitment+of+P300%2FCBP+Coactivators&doi=10.1128%2FMCB.24.7.2649-2661.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators</span></div><div class="casAuthors">Major, Michael L.; Lepe, Rita; Costa, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2649-2661</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Previous liver regeneration studies demonstrated that the mouse forkhead box M1B (FoxM1B) transcription factor regulates hepatocyte proliferation through expression of cell cycle genes that stimulate cyclin-dependent kinase 2 (Cdk2) and Cdk1 activity.  In this study, the authors demonstrated that disruption of the FoxM1B Cdk1/2 phosphorylation site at Thr residue 596 significantly reduced both FoxM1B transcriptional activity and Cdk phosphorylation of the FoxM1B T596A mutant protein in vivo.  Retention of this FoxM1B 596 Cdk phosphorylation site was found to be essential for recruiting the histone acetyltransferase CREB binding protein (CBP) to the FoxM1B transcriptional activation domain.  Consistent with these findings, dominant neg. Cdk1 protein significantly reduced FoxM1B transcriptional activity and inhibited FoxM1B recruitment of the CBP coactivator protein.  Likewise, Cdc25B-mediated stimulation of Cdk activity together with elevated levels of the CBP coactivator protein provided a 6.2-fold synergistic increase in FoxM1B transcriptional activity.  Furthermore, mutation of the FoxM1B Leu-641 residue within an LXL motif (residues 639 to 641) inhibited recruitment of Cdk-cyclin complexes and caused significant redn. in both FoxM1B transcriptional activity and in vivo Cdk phosphorylation of the FoxM1B Thr-596 residue.  The authors demonstrated that FoxM1B transcriptional activity requires binding of either S-phase or M-phase Cdk-cyclin complexes to mediate efficient Cdk phosphorylation of the FoxM1B Thr-596 residue, which is essential for recruitment of p300/CBP coactivator proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtw_ZOkr-5orVg90H21EOLACvtfcHk0ljDfmO9Wl1lGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1emsL4%253D&md5=357b671b9d86d5cdeaa0ce2d7c70082f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.7.2649-2661.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.7.2649-2661.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMajor%26aufirst%3DM.%2BL.%26aulast%3DLepe%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DR.%2BH.%26atitle%3DForkhead%2520Box%2520M1B%2520Transcriptional%2520Activity%2520Requires%2520Binding%2520of%2520Cdk-cyclin%2520Complexes%2520for%2520Phosphorylation-Dependent%2520Recruitment%2520of%2520P300%252FCBP%2520Coactivators%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D2649%26epage%3D2661%26doi%3D10.1128%2FMCB.24.7.2649-2661.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tindall, D. J.</span></span> <span> </span><span class="NLM_article-title">CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1126/science.1130512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.1130512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17038621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOgtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2006&pages=294-297&author=H.+Huangauthor=K.+M.+Reganauthor=Z.+Louauthor=J.+Chenauthor=D.+J.+Tindall&title=CDK2-Dependent+Phosphorylation+of+FOXO1+as+an+Apoptotic+Response+to+DNA+Damage&doi=10.1126%2Fscience.1130512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage</span></div><div class="casAuthors">Huang, Haojie; Regan, Kevin M.; Lou, Zhenkun; Chen, Junjie; Tindall, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">5797</span>),
    <span class="NLM_cas:pages">294-297</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The function of cyclin-dependent kinase 2 (CDK2) is often abolished after DNA damage.  The inhibition of CDK2 plays a central role in DNA damage-induced cell cycle arrest and DNA repair.  However, whether CDK2 also influences the survival of cells under genotoxic stress is unknown.  Forkhead box O (FOXO) transcription factors are emerging as key regulators of cell survival.  CDK2 specifically phosphorylated FOXO1 at serine-249 (Ser249) in vitro and in vivo.  Phosphorylation of Ser249 resulted in cytoplasmic localization and inhibition of FOXO1.  This phosphorylation was abrogated upon DNA damage through the cell cycle checkpoint pathway that is dependent on the protein kinases Chk1 and Chk2.  Moreover, silencing of FOXO1 by small interfering RNA diminished DNA damage-induced death in both p53-deficient and p53-proficient cells.  This effect was reversed by restored expression of FOXO1 in a manner depending on phosphorylation of Ser249.  Functional interaction between CDK2 and FOXO1 provides a mechanism that regulates apoptotic cell death after DNA strand breakage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD9appoowtV7Vg90H21EOLACvtfcHk0ljDfmO9Wl1lGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOgtrvI&md5=e3011ebb7cbc313b277e7c1be2f3f5a2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1130512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1130512%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DRegan%26aufirst%3DK.%2BM.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTindall%26aufirst%3DD.%2BJ.%26atitle%3DCDK2-Dependent%2520Phosphorylation%2520of%2520FOXO1%2520as%2520an%2520Apoptotic%2520Response%2520to%2520DNA%2520Damage%26jtitle%3DScience%26date%3D2006%26volume%3D314%26spage%3D294%26epage%3D297%26doi%3D10.1126%2Fscience.1130512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span> <span> </span><span class="NLM_article-title">Cdk2-Dependent Phosphorylation of Id2 Modulates Activity of E2A-Related Transcription Factors</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.2.332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Femboj%2F16.2.332" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=332-342&author=E.+Haraauthor=M.+Hallauthor=G.+Peters&title=Cdk2-Dependent+Phosphorylation+of+Id2+Modulates+Activity+of+E2A-Related+Transcription+Factors&doi=10.1093%2Femboj%2F16.2.332"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.2.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.2.332%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DE.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DCdk2-Dependent%2520Phosphorylation%2520of%2520Id2%2520Modulates%2520Activity%2520of%2520E2A-Related%2520Transcription%2520Factors%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D332%26epage%3D342%26doi%3D10.1093%2Femboj%2F16.2.332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grummt, I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of UBF at Serine 388 is Required for Interaction with RNA Polymerase I and Activation of Rdna Transcription</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">13631</span>– <span class="NLM_lpage">13636</span>, <span class="refDoi"> DOI: 10.1073/pnas.231071698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.231071698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=13631-13636&author=R.+Voitauthor=I.+Grummt&title=Phosphorylation+of+UBF+at+Serine+388+is+Required+for+Interaction+with+RNA+Polymerase+I+and+Activation+of+Rdna+Transcription&doi=10.1073%2Fpnas.231071698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.231071698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.231071698%26sid%3Dliteratum%253Aachs%26aulast%3DVoit%26aufirst%3DR.%26aulast%3DGrummt%26aufirst%3DI.%26atitle%3DPhosphorylation%2520of%2520UBF%2520at%2520Serine%2520388%2520is%2520Required%2520for%2520Interaction%2520with%2520RNA%2520Polymerase%2520I%2520and%2520Activation%2520of%2520Rdna%2520Transcription%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D13631%26epage%3D13636%26doi%3D10.1073%2Fpnas.231071698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. Y.</span></span> <span> </span><span class="NLM_article-title">Cdk2-Dependent Phosphorylation of the NF-Y Transcription Factor and Its Involvement in the P<sup>53</sup>-P<sup>21</sup> Signaling Pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">36966</span>– <span class="NLM_lpage">36972</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305178200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M305178200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=36966-36972&author=J.+Yunauthor=H.+D.+Chaeauthor=T.+S.+Choiauthor=E.+H.+Kimauthor=Y.+J.+Bangauthor=J.+Chungauthor=K.+S.+Choiauthor=R.+Mantovaniauthor=D.+Y.+Shin&title=Cdk2-Dependent+Phosphorylation+of+the+NF-Y+Transcription+Factor+and+Its+Involvement+in+the+P53-P21+Signaling+Pathway&doi=10.1074%2Fjbc.M305178200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305178200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305178200%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DH.%2BD.%26aulast%3DChoi%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DK.%2BS.%26aulast%3DMantovani%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DD.%2BY.%26atitle%3DCdk2-Dependent%2520Phosphorylation%2520of%2520the%2520NF-Y%2520Transcription%2520Factor%2520and%2520Its%2520Involvement%2520in%2520the%2520P53-P21%2520Signaling%2520Pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D36966%26epage%3D36972%26doi%3D10.1074%2Fjbc.M305178200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebold, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempnauer, K. H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Activation of B-Myb by Cyclin A-Cdk2</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00121-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-9822%2806%2900121-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9094315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=253-260&author=U.+Zieboldauthor=O.+Bartschauthor=R.+Maraisauthor=S.+Ferrariauthor=K.+H.+Klempnauer&title=Phosphorylation+and+Activation+of+B-Myb+by+Cyclin+A-Cdk2&doi=10.1016%2FS0960-9822%2806%2900121-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and activation of B-Myb by cyclin A-Cdk2</span></div><div class="casAuthors">Ziebold, Ulrike; Bartsch, Olaf; Marais, Richard; Ferrari, Stefano; Klempnauer, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-260</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Background: Cyclins and their catalytic partners, the cyclin-dependent kinases (Cdks), function as key regulators of the eukaryotic cell cycle.  Specific cyclin-Cdk complexes are active at successive stages during the cell cycle and control cell-cycle progression by phosphorylating specific target proteins, most of which have not yet been identified.  B-Myb, a conserved member of the Myb oncoprotein family, is a sequence-specific DNA-binding protein expressed in virtually all proliferating mammalian cells.  Increasing evidence suggests that B-Myb lays an important role during the late G1 and early S phases of the cell cycle.  In this study, we have examd. the regulation of B-Myb activity by cyclin-Cdks.  Results: We found that the transcriptional transactivation potential of B-Myb was repressed by a regulatory domain located at the carboxyl terminus of the protein.  Coexpression of B-Myb and cyclin A relieved this repression by phosphorylation of B-Myb in its carboxy-terminal region.  Tryptic phosphopeptide mapping revealed that endogenous B-Myb was phosphorylated in cells undergoing S phase.  Conclusions: This work provides evidence for a link between the Myb oncoprotein family and the cell-cycle machinery.  We have shown that the carboxyl terminus of B-Myb acts as a cell-cycle sensor that regulates the transactivation function of B-Myb.  Moreover, our studies have identified B-Myb as a target of cyclin A-Cdk2 and have indicated that B-Myb activity is regulated by phosphorylation mediated by cyclin A-Cdk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpspxO-Ly3L1bVg90H21EOLACvtfcHk0ljZ0MR1PuWcPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtLc%253D&md5=b5a3d1ab5812c76a0a21454c5aa79b22</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900121-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900121-7%26sid%3Dliteratum%253Aachs%26aulast%3DZiebold%26aufirst%3DU.%26aulast%3DBartsch%26aufirst%3DO.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DKlempnauer%26aufirst%3DK.%2BH.%26atitle%3DPhosphorylation%2520and%2520Activation%2520of%2520B-Myb%2520by%2520Cyclin%2520A-Cdk2%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D253%26epage%3D260%26doi%3D10.1016%2FS0960-9822%2806%2900121-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hydbring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahram, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronnersjo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogstrand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Lehr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilischkis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vervoorts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, L. G.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation by Cdk2 is Required for Myc to Repress Ras-induced Senescence in Cotransformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1073/pnas.0900121106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0900121106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=58-63&author=P.+Hydbringauthor=F.+Bahramauthor=Y.+Suauthor=S.+Tronnersjoauthor=K.+Hogstrandauthor=N.+von+der+Lehrauthor=H.+R.+Sharifiauthor=R.+Lilischkisauthor=N.+Heinauthor=S.+Wuauthor=J.+Vervoortsauthor=M.+Henrikssonauthor=A.+Grandienauthor=B.+Luscherauthor=L.+G.+Larsson&title=Phosphorylation+by+Cdk2+is+Required+for+Myc+to+Repress+Ras-induced+Senescence+in+Cotransformation&doi=10.1073%2Fpnas.0900121106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900121106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900121106%26sid%3Dliteratum%253Aachs%26aulast%3DHydbring%26aufirst%3DP.%26aulast%3DBahram%26aufirst%3DF.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DTronnersjo%26aufirst%3DS.%26aulast%3DHogstrand%26aufirst%3DK.%26aulast%3Dvon%2Bder%2BLehr%26aufirst%3DN.%26aulast%3DSharifi%26aufirst%3DH.%2BR.%26aulast%3DLilischkis%26aufirst%3DR.%26aulast%3DHein%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DVervoorts%26aufirst%3DJ.%26aulast%3DHenriksson%26aufirst%3DM.%26aulast%3DGrandien%26aufirst%3DA.%26aulast%3DLuscher%26aufirst%3DB.%26aulast%3DLarsson%26aufirst%3DL.%2BG.%26atitle%3DPhosphorylation%2520by%2520Cdk2%2520is%2520Required%2520for%2520Myc%2520to%2520Repress%2520Ras-induced%2520Senescence%2520in%2520Cotransformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D58%26epage%3D63%26doi%3D10.1073%2Fpnas.0900121106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattes, B.</span></span> <span> </span><span class="NLM_article-title">A Novel Cdk2 Interactor is Phosphorylated by Cdc7 and Associates with Components of the Replication Complexes</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">4120</span>– <span class="NLM_lpage">4126</span>, <span class="refDoi"> DOI: 10.4161/cc.4.8.1918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.4.8.1918" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=4120-4126&author=I.+Grishinaauthor=B.+Lattes&title=A+Novel+Cdk2+Interactor+is+Phosphorylated+by+Cdc7+and+Associates+with+Components+of+the+Replication+Complexes&doi=10.4161%2Fcc.4.8.1918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.4161%2Fcc.4.8.1918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.4.8.1918%26sid%3Dliteratum%253Aachs%26aulast%3DGrishina%26aufirst%3DI.%26aulast%3DLattes%26aufirst%3DB.%26atitle%3DA%2520Novel%2520Cdk2%2520Interactor%2520is%2520Phosphorylated%2520by%2520Cdc7%2520and%2520Associates%2520with%2520Components%2520of%2520the%2520Replication%2520Complexes%26jtitle%3DCell%2520Cycle%26date%3D2005%26volume%3D4%26spage%3D4120%26epage%3D4126%26doi%3D10.4161%2Fcc.4.8.1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chunder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A. D.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Controls Peripheral Immune Tolerance</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">5659</span>– <span class="NLM_lpage">5666</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4049%2Fjimmunol.1202313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=5659-5666&author=N.+Chunderauthor=L.+Wangauthor=C.+Chenauthor=W.+W.+Hancockauthor=A.+D.+Wells&title=Cyclin-dependent+Kinase+2+Controls+Peripheral+Immune+Tolerance&doi=10.4049%2Fjimmunol.1202313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202313%26sid%3Dliteratum%253Aachs%26aulast%3DChunder%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BD.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Controls%2520Peripheral%2520Immune%2520Tolerance%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D5659%26epage%3D5666%26doi%3D10.4049%2Fjimmunol.1202313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2698</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-813139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1182%2Fblood-2017-10-813139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29720484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2698-2711&author=M.+Yingauthor=X.+Shaoauthor=H.+Jingauthor=Y.+Liuauthor=X.+Qiauthor=J.+Caoauthor=Y.+Chenauthor=S.+Xiangauthor=H.+Songauthor=R.+Huauthor=G.+Weiauthor=B.+Yangauthor=Q.+He&title=Ubiquitin-dependent+Degradation+of+CDK2+Drives+the+Therapeutic+Differentiation+of+AML+by+Targeting+PRDX2&doi=10.1182%2Fblood-2017-10-813139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span></div><div class="casAuthors">Ying, Meidan; Shao, Xuejing; Jing, Hui; Liu, Yujia; Qi, Xiaotian; Cao, Ji; Chen, Yingqian; Xiang, Senfeng; Song, Hua; Hu, Ronggui; Wei, Guoqing; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2698-2711</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A distinct hallmark of acute myeloid leukemia (AML) is the arrest of leukemic myeloblasts at an immature stage of development.  Therapies that overcome differentiation arrest have emerged as a powerful strategy for treating AML, but targeting leukemia differentiation remains challenging, mainly because of an incomplete mechanistic understanding of the process.  Here, we unveil a new role for cyclin-dependent kinase 2 (CDK2) in blocking myeloid differentiation in AML.  We show that among several interphase CDK, only CDK2 undergoes ubiquitin-dependent proteasome degrdn., which is accompanied by AML cell differentiation.  By using the yeast 2-hybrid system and functional analyses, KLHL6 was identified as a specific E3 ubiquitin ligase regulating the degrdn. of CDK2.  Importantly, inhibiting CDK2, but not other cyclin-dependent kinases CDK1/4/6, effectively induced granulocytic differentiation in AML cell lines and 5 major subtypes of primary patientderived AML samples.  Mechanistically, CDK2 depletion led to the reactivation of differentiation pathway translation, and the differentiation blockade function of CDK2 may be achieved directly by maintaining the activity of PRDX2.  Finally, CDK2 depletion arrested tumor growth of AML cells in nude mice and extended survival in both AML cell line and PDX-AML cells derived xenograft mouse models.  Thus, our work not only provides exptl. evidence for validating CDK2 as a potential therapeutic target for differentiation, but also uncovers the biol. function of the CDK2-PRDX2 axis in blocking AML differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-1GnzdaOHrVg90H21EOLACvtfcHk0ljlhNXnJ_u8GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M&md5=0f3345fd7dba32cf4809bfb302a037dd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-813139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-813139%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DUbiquitin-dependent%2520Degradation%2520of%2520CDK2%2520Drives%2520the%2520Therapeutic%2520Differentiation%2520of%2520AML%2520by%2520Targeting%2520PRDX2%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2698%26epage%3D2711%26doi%3D10.1182%2Fblood-2017-10-813139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saurus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtonen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogarty, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassenius, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groop, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtonen, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Protects Podocytes from Apoptosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21664</span>, <span class="refDoi"> DOI: 10.1038/srep21664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsrep21664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26876672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21664&author=P.+Saurusauthor=S.+Kuuselaauthor=V.+Dumontauthor=E.+Lehtonenauthor=C.+L.+Fogartyauthor=M.+I.+Lasseniusauthor=C.+Forsblomauthor=M.+Lehtoauthor=M.+A.+Saleemauthor=P.+H.+Groopauthor=S.+Lehtonen&title=Cyclin-dependent+Kinase+2+Protects+Podocytes+from+Apoptosis&doi=10.1038%2Fsrep21664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 2 protects podocytes from apoptosis</span></div><div class="casAuthors">Saurus, Pauliina; Kuusela, Sara; Dumont, Vincent; Lehtonen, Eero; Fogarty, Christopher L.; Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Saleem, Moin A.; Groop, Per-Henrik; Lehtonen, Sanna</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21664</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Loss of podocytes is an early feature of diabetic nephropathy (DN) and predicts its progression.  We found that treatment of podocytes with sera from normoalbuminuric type 1 diabetes patients with high lipopolysaccharide (LPS) activity, known to predict progression of DN, downregulated CDK2 (cyclin-dependent kinase 2).  LPS-treatment of mice also reduced CDK2 expression.  LPS-induced downregulation of CDK2 was prevented in vitro and in vivo by inhibiting the Toll-like receptor (TLR) pathway using immunomodulatory agent GIT27.  We also obsd. that CDK2 is downregulated in the glomeruli of obese Zucker rats before the onset of proteinuria.  Knockdown of CDK2, or inhibiting its activity with roscovitine in podocytes increased apoptosis.  CDK2 knockdown also reduced expression of PDK1, an activator of the cell survival kinase Akt, and reduced Akt phosphorylation.  This suggests that CDK2 regulates the activity of the cell survival pathway via PDK1.  Furthermore, PDK1 knockdown reduced the expression of CDK2 suggesting a regulatory loop between CDK2 and PDK1.  Collectively, our data show that CDK2 protects podocytes from apoptosis and that reduced expression of CDK2 assocs. with the development of DN.  Preventing downregulation of CDK2 by blocking the TLR pathway with GIT27 may provide a means to prevent podocyte apoptosis and progression of DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpggm0ysr1PyrVg90H21EOLACvtfcHk0ljlhNXnJ_u8GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFKht70%253D&md5=7fd91e429810792d76430fe90e62367c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep21664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21664%26sid%3Dliteratum%253Aachs%26aulast%3DSaurus%26aufirst%3DP.%26aulast%3DKuusela%26aufirst%3DS.%26aulast%3DDumont%26aufirst%3DV.%26aulast%3DLehtonen%26aufirst%3DE.%26aulast%3DFogarty%26aufirst%3DC.%2BL.%26aulast%3DLassenius%26aufirst%3DM.%2BI.%26aulast%3DForsblom%26aufirst%3DC.%26aulast%3DLehto%26aufirst%3DM.%26aulast%3DSaleem%26aufirst%3DM.%2BA.%26aulast%3DGroop%26aufirst%3DP.%2BH.%26aulast%3DLehtonen%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Protects%2520Podocytes%2520from%2520Apoptosis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21664%26doi%3D10.1038%2Fsrep21664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roig, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Gomez, G.</span></span> <span> </span><span class="NLM_article-title">Cdk2 Activation Acts Upstream of the Mitochondrion During Glucocorticoid Induced Thymocyte Apoptosis</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2790</span>, <span class="refDoi"> DOI: 10.1002/eji.200425154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Feji.200425154" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=2781-2790&author=F.+Granesauthor=M.+B.+Roigauthor=H.+J.+Bradyauthor=G.+Gil-Gomez&title=Cdk2+Activation+Acts+Upstream+of+the+Mitochondrion+During+Glucocorticoid+Induced+Thymocyte+Apoptosis&doi=10.1002%2Feji.200425154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Feji.200425154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.200425154%26sid%3Dliteratum%253Aachs%26aulast%3DGranes%26aufirst%3DF.%26aulast%3DRoig%26aufirst%3DM.%2BB.%26aulast%3DBrady%26aufirst%3DH.%2BJ.%26aulast%3DGil-Gomez%26aufirst%3DG.%26atitle%3DCdk2%2520Activation%2520Acts%2520Upstream%2520of%2520the%2520Mitochondrion%2520During%2520Glucocorticoid%2520Induced%2520Thymocyte%2520Apoptosis%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2004%26volume%3D34%26spage%3D2781%26epage%3D2790%26doi%3D10.1002%2Feji.200425154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusdra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlbold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goga, A.</span></span> <span> </span><span class="NLM_article-title">Chemical-genetic Analysis of Cyclin Dependent Kinase 2 Function Reveals an Important Role in Cellular Transformation by Multiple Oncogenic Pathways</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E1019</span>– <span class="NLM_lpage">E1027</span>, <span class="refDoi"> DOI: 10.1073/pnas.1111317109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.1111317109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22474407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslGmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E1019-E1027&author=D.+Horiuchiauthor=N.+E.+Huskeyauthor=L.+Kusdraauthor=L.+Wohlboldauthor=K.+A.+Merrickauthor=C.+Zhangauthor=K.+J.+Creasmanauthor=K.+M.+Shokatauthor=R.+P.+Fisherauthor=A.+Goga&title=Chemical-genetic+Analysis+of+Cyclin+Dependent+Kinase+2+Function+Reveals+an+Important+Role+in+Cellular+Transformation+by+Multiple+Oncogenic+Pathways&doi=10.1073%2Fpnas.1111317109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways</span></div><div class="casAuthors">Horiuchi, Dai; Huskey, Noelle E.; Kusdra, Leonard; Wohlbold, Lara; Merrick, Karl A.; Zhang, Chao; Creasman, Katelyn J.; Shokat, Kevan M.; Fisher, Robert P.; Goga, Andrei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">E1019-E1027, SE1019/1-SE1019/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A family of conserved serine/threonine kinases known as cyclin-dependent kinases (CDKs) drives orderly cell cycle progression in mammalian cells.  Prior studies have suggested that CDK2 regulates S-phase entry and progression, and frequently shows increased activity in a wide spectrum of human tumors.  Genetic KO/knockdown approaches, however, have suggested that lack of CDK2 protein does not prevent cellular proliferation, both during somatic development in mice as well as in human cancer cell lines.  Here, we use an alternative, chem.-genetic approach to achieve specific inhibition of CDK2 kinase activity in cells.  We directly compare small-mol. inhibition of CDK2 kinase activity with siRNA knockdown and show that small-mol. inhibition results in marked defects in proliferation of nontransformed cells, whereas siRNA knockdown does not, highlighting the differences between these two approaches.  In addn., CDK2 inhibition drastically diminishes anchorage-independent growth of human cancer cells and cells transformed with various oncogenes.  Our results establish that CDK2 activity is necessary for normal mammalian cell cycle progression and suggest that it might be a useful therapeutic target for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr38-RTvuFoa7Vg90H21EOLACvtfcHk0ljlhNXnJ_u8GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslGmtLk%253D&md5=dcb463a6fc2696712617034313e8960a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1111317109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1111317109%26sid%3Dliteratum%253Aachs%26aulast%3DHoriuchi%26aufirst%3DD.%26aulast%3DHuskey%26aufirst%3DN.%2BE.%26aulast%3DKusdra%26aufirst%3DL.%26aulast%3DWohlbold%26aufirst%3DL.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCreasman%26aufirst%3DK.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26aulast%3DGoga%26aufirst%3DA.%26atitle%3DChemical-genetic%2520Analysis%2520of%2520Cyclin%2520Dependent%2520Kinase%25202%2520Function%2520Reveals%2520an%2520Important%2520Role%2520in%2520Cellular%2520Transformation%2520by%2520Multiple%2520Oncogenic%2520Pathways%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE1019%26epage%3DE1027%26doi%3D10.1073%2Fpnas.1111317109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Pelt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Cdk2 is Required for Breast Cancer Mediated by the Low-molecular-weight Isoform of Cyclin E</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3377</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-10-4086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3377-3386&author=S.+Akliauthor=C.+S.+Van+Peltauthor=T.+Buiauthor=L.+Meijerauthor=K.+Keyomarsi&title=Cdk2+is+Required+for+Breast+Cancer+Mediated+by+the+Low-molecular-weight+Isoform+of+Cyclin+E&doi=10.1158%2F0008-5472.CAN-10-4086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4086%26sid%3Dliteratum%253Aachs%26aulast%3DAkli%26aufirst%3DS.%26aulast%3DVan%2BPelt%26aufirst%3DC.%2BS.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DCdk2%2520is%2520Required%2520for%2520Breast%2520Cancer%2520Mediated%2520by%2520the%2520Low-molecular-weight%2520Isoform%2520of%2520Cyclin%2520E%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3377%26epage%3D3386%26doi%3D10.1158%2F0008-5472.CAN-10-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 is an Ideal Target for Ovary Tumors with Elevated Cyclin E1 Expression</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20801</span>– <span class="NLM_lpage">20812</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.18632%2Foncotarget.4600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=20801-20812&author=L.+Yangauthor=D.+Fangauthor=H.+Chenauthor=Y.+Luauthor=Z.+Dongauthor=H.+F.+Dingauthor=Q.+Jingauthor=S.+B.+Suauthor=S.+Huang&title=Cyclin-dependent+Kinase+2+is+an+Ideal+Target+for+Ovary+Tumors+with+Elevated+Cyclin+E1+Expression&doi=10.18632%2Foncotarget.4600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4600%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DH.%2BF.%26aulast%3DJing%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DS.%2BB.%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520is%2520an%2520Ideal%2520Target%2520for%2520Ovary%2520Tumors%2520with%2520Elevated%2520Cyclin%2520E1%2520Expression%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D20801%26epage%3D20812%26doi%3D10.18632%2Foncotarget.4600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Cyclin E Ablation in the Mouse</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00645-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0092-8674%2803%2900645-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12941272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2003&pages=431-443&author=Y.+Gengauthor=Q.+Yuauthor=E.+Sicinskaauthor=M.+Dasauthor=J.+E.+Schneiderauthor=S.+Bhattacharyaauthor=W.+M.+Rideoutauthor=R.+T.+Bronsonauthor=H.+Gardnerauthor=P.+Sicinski&title=Cyclin+E+Ablation+in+the+Mouse&doi=10.1016%2FS0092-8674%2803%2900645-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E ablation in the mouse</span></div><div class="casAuthors">Geng, Yan; Yu, Qunyan; Sicinska, Ewa; Das, Manjusri; Schneider, Juergen E.; Bhattacharya, Shoumo; Rideout, William M., III; Bronson, Roderick T.; Gardner, Humphrey; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">E type cyclins-(E1 and E2) are believed to drive cell entry into the S phase.  It is widely assumed that the two E type cyclins are critically required for proliferation of all cell types.  Here, we demonstrate that E type cyclins are largely dispensable for mouse development.  However, endoreplication of trophoblast giant cells and megakaryocytes is severely impaired in the absence of cyclin E.  Cyclin E-deficient cells proliferate actively under conditions of continuous cell cycling but are unable to reenter the cell cycle from the quiescent G0 state.  Mol. analyses revealed that cells lacking cyclin E fail to normally incorporate MCM proteins into DNA replication origins during G0→S progression.  We also found that cyclin E-deficient cells are relatively resistant to oncogenic transformation.  These findings define a mol. function for E type cyclins in cell cycle reentry and reveal a differential requirement for cyclin E in normal vs. oncogenic proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5aUZi6Q1drVg90H21EOLACvtfcHk0ljF3R-c2WFFKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFahtbo%253D&md5=00c88c0b39e844628c8fc78bfb894755</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900645-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900645-7%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DSicinska%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%2BE.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DRideout%26aufirst%3DW.%2BM.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DCyclin%2520E%2520Ablation%2520in%2520the%2520Mouse%26jtitle%3DCell%26date%3D2003%26volume%3D114%26spage%3D431%26epage%3D443%26doi%3D10.1016%2FS0092-8674%2803%2900645-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callister, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedrosian, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knickerbocker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyofuku, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herliczek, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacus, S. S.</span></span> <span> </span><span class="NLM_article-title">Cyclin E and Survival in Patients with Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa021153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1056%2FNEJMoa021153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12432043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1KhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=1566-1575&author=K.+Keyomarsiauthor=S.+L.+Tuckerauthor=T.+A.+Buchholzauthor=M.+Callisterauthor=Y.+Dingauthor=G.+N.+Hortobagyiauthor=I.+Bedrosianauthor=C.+Knickerbockerauthor=W.+Toyofukuauthor=M.+Loweauthor=T.+W.+Herliczekauthor=S.+S.+Bacus&title=Cyclin+E+and+Survival+in+Patients+with+Breast+Cancer&doi=10.1056%2FNEJMoa021153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E and survival in patients with breast cancer</span></div><div class="casAuthors">Keyomarsi, Khandan; Tucker, Susan L.; Buchholz, Thomas A.; Callister, Matthew; Ding, Ye; Hortobagyi, Gabriel N.; Bedrosian, Isabelle; Knickerbocker, Christopher; Toyofuku, Wendy; Lowe, Michael; Herliczek, Thaddues W.; Bacus, Sarah S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1566-1575</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cyclin E, a regulator of the cell cycle, affects the behavior of breast-cancer cells.  We investigated whether levels of cyclin E in the tumor correlated with survival among patients with breast cancer.  Tumor tissue from 395 patients with breast cancer was assayed for cyclin E, cyclin D1, cyclin D3, and the HER-2/neu oncogene with the use of Western blot anal.  Full-length, low-mol.-wt., and total cyclin E were measured.  Immunohistochem. assessments of cyclin E were also made of 256 tumors.  We sought correlations between levels of these mol. markers and disease-specific and overall survival.  The median follow-up was 6.4 yr.  A high level of the low-mol.-wt. isoforms of cyclin E, as detected by Western blotting, correlated strongly with disease-specific survival whether axillary lymph nodes were neg. or pos. for metastases (P< 0.001).  Among 114 patients with stage 1 breast cancer, none of the 102 patients with low levels of cyclin E in the tumor had died of breast cancer by five years after diagnosis, whereas all 12 patients with a high level of low-mol.-wt. cyclin E had died of breast cancer within that period.  In multivariate anal., a high total cyclin E level or high levels of the low-mol.-wt. forms of cyclin E were significantly correlated with poor outcome.  The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 - about eight times as high as the hazard ratios assocd. with other independent clin. and pathol. risk factors.  Levels of total cyclin E and low-mol.-wt. cyclin E in tumor tissue, as measured by Western blot assay, correlate strongly with survival in patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTvbHMGyGsi7Vg90H21EOLACvtfcHk0ljF3R-c2WFFKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1KhsLo%253D&md5=472d2c057c9d73ab386ada5c910662b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa021153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa021153%26sid%3Dliteratum%253Aachs%26aulast%3DKeyomarsi%26aufirst%3DK.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DBuchholz%26aufirst%3DT.%2BA.%26aulast%3DCallister%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DBedrosian%26aufirst%3DI.%26aulast%3DKnickerbocker%26aufirst%3DC.%26aulast%3DToyofuku%26aufirst%3DW.%26aulast%3DLowe%26aufirst%3DM.%26aulast%3DHerliczek%26aufirst%3DT.%2BW.%26aulast%3DBacus%26aufirst%3DS.%2BS.%26atitle%3DCyclin%2520E%2520and%2520Survival%2520in%2520Patients%2520with%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D1566%26epage%3D1575%26doi%3D10.1056%2FNEJMoa021153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiering, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memoli, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsongalis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Transgenic Cyclin E Triggers Dysplasia and Multiple Pulmonary Adenocarcinomas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1073/pnas.0606537104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0606537104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4089-4094&author=Y.+Maauthor=S.+Fieringauthor=C.+Blackauthor=X.+Liuauthor=Z.+Yuanauthor=V.+A.+Memoliauthor=D.+J.+Robbinsauthor=H.+A.+Bentleyauthor=G.+J.+Tsongalisauthor=E.+Demidenkoauthor=S.+J.+Freemantleauthor=E.+Dmitrovsky&title=Transgenic+Cyclin+E+Triggers+Dysplasia+and+Multiple+Pulmonary+Adenocarcinomas&doi=10.1073%2Fpnas.0606537104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0606537104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0606537104%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DFiering%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DMemoli%26aufirst%3DV.%2BA.%26aulast%3DRobbins%26aufirst%3DD.%2BJ.%26aulast%3DBentley%26aufirst%3DH.%2BA.%26aulast%3DTsongalis%26aufirst%3DG.%2BJ.%26aulast%3DDemidenko%26aufirst%3DE.%26aulast%3DFreemantle%26aufirst%3DS.%2BJ.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DTransgenic%2520Cyclin%2520E%2520Triggers%2520Dysplasia%2520and%2520Multiple%2520Pulmonary%2520Adenocarcinomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D4089%26epage%3D4094%26doi%3D10.1073%2Fpnas.0606537104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tetsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Proliferation of Cancer Cells Despite CDK2 Inhibition</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(03)00053-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS1535-6108%2803%2900053-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12676582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=233-245&author=O.+Tetsuauthor=F.+McCormick&title=Proliferation+of+Cancer+Cells+Despite+CDK2+Inhibition&doi=10.1016%2FS1535-6108%2803%2900053-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Proliferation of cancer cells despite CDK2 inhibition</span></div><div class="casAuthors">Tetsu, Osamu; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors have investigated the contribution of CDK4 and CDK2 inhibition to G1 arrest in colon cancers following inhibition of the MEK/MAP kinase pathway.  CDK4 inhibition is sufficient to cause arrest, but inhibition of CDK2 by p27 Kip1 redistribution or ectopic expression has no effect on proliferation.  Likewise, inhibition of CDK2 through expression of dominant-neg. (DN) CDK2 or antisense oligonucleotides did not prevent cell proliferation in these cells.  The authors therefore tested whether CDK2 activity is dispensable in other cells.  Surprisingly, osteosarcomas and Rb-neg. cervical cancers continued to proliferate after depletion of CDK2 through antisense oligonucleotides or small interfering (si) RNA.  Here the authors report sustained cell proliferation in the absence of CDK2, and the authors suggest that CDK2 is not a suitable target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlrtla8E307Vg90H21EOLACvtfcHk0lgjpvd6lG3RdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislOrtb0%253D&md5=a4c67cbe660ff486912ab5113cfe53bb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2803%2900053-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252803%252900053-9%26sid%3Dliteratum%253Aachs%26aulast%3DTetsu%26aufirst%3DO.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DProliferation%2520of%2520Cancer%2520Cells%2520Despite%2520CDK2%2520Inhibition%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D233%26epage%3D245%26doi%3D10.1016%2FS1535-6108%2803%2900053-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhout, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span> <span> </span><span class="NLM_article-title">Inactivation of CDK2 is Synthetically Lethal to MYCN Over-expressing Cancer Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12968</span>– <span class="NLM_lpage">12973</span>, <span class="refDoi"> DOI: 10.1073/pnas.0901418106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0901418106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19525400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12968-12973&author=J.+J.+Molenaarauthor=M.+E.+Ebusauthor=D.+Geertsauthor=J.+Kosterauthor=F.+Lamersauthor=L.+J.+Valentijnauthor=E.+M.+Westerhoutauthor=R.+Versteegauthor=H.+N.+Caron&title=Inactivation+of+CDK2+is+Synthetically+Lethal+to+MYCN+Over-expressing+Cancer+Cells&doi=10.1073%2Fpnas.0901418106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span></div><div class="casAuthors">Molenaar, Jan J.; Ebus, Marli E.; Geerts, Dirk; Koster, Jan; Lamers, Fieke; Valentijn, Linda J.; Westerhout, Ellen M.; Versteeg, Rogier; Caron, Huib N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">12968-12973</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two genes have a synthetically lethal relationship when the silencing or inhibiting of 1 gene is only lethal in the context of a mutation or activation of the second gene.  This situation offers an attractive therapeutic strategy, as inhibition of such a gene will only trigger cell death in tumor cells with an activated second oncogene but spare normal cells without activation of the second oncogene.  Here we present evidence that CDK2 is synthetically lethal to neuroblastoma cells with MYCN amplification and over-expression.  Neuroblastomas are childhood tumors with an often lethal outcome.  Twenty percent of the tumors have MYCN amplification, and these tumors are ultimately refractory to any therapy.  Targeted silencing of CDK2 by 3 RNA interference techniques induced apoptosis in MYCN-amplified neuroblastoma cell lines, but not in MYCN single copy cells.  Silencing of MYCN abrogated this apoptotic response in MYCN-amplified cells.  Inversely, silencing of CDK2 in MYCN single copy cells did not trigger apoptosis, unless a MYCN transgene was activated.  The MYCN induced apoptosis after CDK2 silencing was accompanied by nuclear stabilization of P53, and mRNA profiling showed up-regulation of P53 target genes.  Silencing of P53 rescued the cells from MYCN-driven apoptosis.  The synthetic lethality of CDK2 silencing in MYCN activated neuroblastoma cells can also be triggered by inhibition of CDK2 with a small mol. drug.  Treatment of neuroblastoma cells with roscovitine, a CDK inhibitor, at clin. achievable concns. induced MYCN-dependent apoptosis.  The synthetically lethal relationship between CDK2 and MYCN indicates CDK2 inhibitors as potential MYCN-selective cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr48u4K0MeszLVg90H21EOLACvtfcHk0lgjpvd6lG3RdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P&md5=016ebf4ccc1f5c6e3b965e999cca58c7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0901418106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0901418106%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DGeerts%26aufirst%3DD.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DLamers%26aufirst%3DF.%26aulast%3DValentijn%26aufirst%3DL.%2BJ.%26aulast%3DWesterhout%26aufirst%3DE.%2BM.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26atitle%3DInactivation%2520of%2520CDK2%2520is%2520Synthetically%2520Lethal%2520to%2520MYCN%2520Over-expressing%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D12968%26epage%3D12973%26doi%3D10.1073%2Fpnas.0901418106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26304236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2576-2585&author=S.+Huauthor=Y.+Luauthor=B.+Orrauthor=K.+Godekauthor=L.+M.+Mustachioauthor=M.+Kawakamiauthor=D.+Sekulaauthor=D.+A.+Comptonauthor=S.+Freemantleauthor=E.+Dmitrovsky&title=Specific+CP110+Phosphorylation+Sites+Mediate+Anaphase+Catastrophe+after+CDK2+Inhibition%3A+Evidence+for+Cooperation+with+USP33+Knockdown&doi=10.1158%2F1535-7163.MCT-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span></div><div class="casAuthors">Hu, Shanhu; Lu, Yun; Orr, Bernardo; Godek, Kristina; Mustachio, Lisa Maria; Kawakami, Masanori; Sekula, David; Compton, Duane A.; Freemantle, Sarah; Dmitrovsky, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal instability (CIN) is a hallmark of solid tumor biol. and is implicated in carcinogenesis.  Preferentially eliminating malignant cells by targeting CIN and aneuploidy is an attractive antineoplastic strategy.  We previously reported that CDK2 antagonism causes lung cancer cells to undergo anaphase catastrophe and apoptosis through inhibition of phosphorylation of the centrosomal protein CP110.  Cells with activating KRAS mutations were particularly sensitive to CDK2 inhibition due to downregulation of CP110 protein levels.  This study investigated mechanisms of CDK2 antagonism that mediate anaphase catastrophe via changes in CP110 protein expression and how activated KRAS affects CP110 levels in lung cancers.  Site-directed mutagenesis revealed candidate CDK phosphorylation sites of CP110 (residues Ser 170 and Thr 194) crit. for conferring anaphase catastrophe by altering centrosome clustering in mitosis.  Intriguingly, KRAS mutation can promote CP110 protein degrdn. by upregulating the ubiquitin ligase SCFcyclinF, which targets CP110 protein for destabilization.  Finally, CDK2 inhibitor response was enhanced when combined with knockdown of the deubiquitinase USP33 that in turn accelerates CP110 protein degrdn.  Thus, this study provides mol. pharmacol. insights into how CP110 expression regulates response to CDK2 inhibition.  An improved understanding of in vitro antineoplastic mechanisms of combining CDK2 antagonism with induced CP110 repression provides a rationale for exploring clin. consequences of this strategy.  Taken together, preclin. findings obtained from combining CDK2 inhibition with USP33 repression have implications for treating patients with non-small cell lung cancers.  Mol Cancer Ther; 14(11); 2576-85. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWB2T3vMoX87Vg90H21EOLACvtfcHk0lj-w5XJAEcQBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ&md5=3426ae1dcbdd54def483fb95afda5eaa</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DOrr%26aufirst%3DB.%26aulast%3DGodek%26aufirst%3DK.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DSekula%26aufirst%3DD.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26aulast%3DFreemantle%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DSpecific%2520CP110%2520Phosphorylation%2520Sites%2520Mediate%2520Anaphase%2520Catastrophe%2520after%2520CDK2%2520Inhibition%253A%2520Evidence%2520for%2520Cooperation%2520with%2520USP33%2520Knockdown%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2576%26epage%3D2585%26doi%3D10.1158%2F1535-7163.MCT-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuzuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, G. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis <i>via</i> Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4881</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-17-1240" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4881-4893&author=M.+Takadaauthor=W.+Zhangauthor=A.+Suzukiauthor=T.+S.+Kurodaauthor=Z.+Yuauthor=H.+Inuzukaauthor=D.+Gaoauthor=L.+Wanauthor=M.+Zhuangauthor=L.+Huauthor=B.+Zhaiauthor=C.+J.+Fryauthor=K.+Bloomauthor=G.+Liauthor=G.+H.+Karpen&title=FBW7+Loss+Promotes+Chromosomal+Instability+and+Tumorigenesis+via+Cyclin+E1%2FCDK2-Mediated+Phosphorylation+of+CENP-A&doi=10.1158%2F0008-5472.CAN-17-1240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1240%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DInuzuka%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhuang%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DFry%26aufirst%3DC.%2BJ.%26aulast%3DBloom%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKarpen%26aufirst%3DG.%2BH.%26atitle%3DFBW7%2520Loss%2520Promotes%2520Chromosomal%2520Instability%2520and%2520Tumorigenesis%2520via%2520Cyclin%2520E1%252FCDK2-Mediated%2520Phosphorylation%2520of%2520CENP-A%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4881%26epage%3D4893%26doi%3D10.1158%2F0008-5472.CAN-17-1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2016.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.tranon.2016.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27863310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=548-556&author=J.+Wangauthor=T.+Yangauthor=G.+Xuauthor=H.+Liuauthor=C.+Renauthor=W.+Xieauthor=M.+Wang&title=Cyclin-Dependent+Kinase+2+Promotes+Tumor+Proliferation+and+Induces+Radio+Resistance+in+Glioblastoma&doi=10.1016%2Fj.tranon.2016.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span></div><div class="casAuthors">Wang Jia; Yang Tong; Xu Gaofeng; Liu Hao; Ren Chunying; Xie Wanfu; Wang Maode</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Accumulating evidence indicates that CDK2 promotes hyperproliferation and is associated to poor prognosis in multiple cancer cells.  However, the physiological role of CDK2 in GBM and the biological mechanism still remains unclear.  In this study, we identified that CDK2 expression was significantly enriched in GBM tumors compared with normal brain.  Additionally, CDK2 was functionally required for tumor proliferation and its expression was associated to poor prognosis in GBM patients.  Mechanically, CDK2 induced radio resistance in GBM cells and CDK2 knock down increased cell apoptosis when combined with radiotherapy.  Therapeutically, we found that CDK2 inhibitor attenuated tumor growth both in vitro and in vivo.  Collectively, CDK2 promotes proliferation, induces radio resistance in GBM, and could become a therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9a1Ej-CIqi7mQt-ICR3qNfW6udTcc2eZf0aD3qXXvs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D&md5=e994dad0c2785ed5a8d7ca0fe87f98d7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2016.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%25202%2520Promotes%2520Tumor%2520Proliferation%2520and%2520Induces%2520Radio%2520Resistance%2520in%2520Glioblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D548%26epage%3D556%26doi%3D10.1016%2Fj.tranon.2016.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiles, T. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2982</span>– <span class="NLM_lpage">2989</span>, <span class="refDoi"> DOI: 10.4161/cc.6.23.4994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.6.23.4994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18156799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2982-2989&author=A.+C.+Faberauthor=T.+C.+Chiles&title=Inhibition+of+Cyclin-dependent+Kinase-2+Induces+Apoptosis+in+Human+Diffuse+Large+B-cell+Lymphomas&doi=10.4161%2Fcc.6.23.4994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas</span></div><div class="casAuthors">Faber, Anthony C.; Chiles, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2982-2989</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (cdk) inhibitors have the potential to induce growth arrest and apoptosis in cancer cells.  The genes encoding cdks involved in G1-S progression are often amplified in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).  Here, we evaluated the in vitro cytotoxic activity of the cdk2 inhibitor CVT-313 against several human DLBCL cells.  Treatment of DLBCL cells with CVT-313 resulted in apoptosis.  CVT-313 treatment reduced cdk2-mediated phosphorylation of the retinoblastoma gene product (Rb) on T821, but did not affect cyclin D-cdk4/6-mediated Rb phosphorylation on S807/811.  Depletion of endogenous cdk2 by short interfering (si)RNA also resulted in apoptosis in human LY3, LY8 and LY18 DLBCL cells.  Importantly, inhibition of cdk2 with CVT-313 or knockdown of endogenous cdk2 with siRNA resulted in downregulation of the anti-apoptotic factor Myeloid cell leukemia-1 (Mcl-1), suggesting that decreased levels of cellular Mcl-1 contribute to apoptosis.  In support of this, siRNA-mediated knockdown of Mcl-1 was sufficient to induce apoptosis in all 3 DLBCL.  Further, cdk2 inhibition led to decreased Mcl-1 mRNA levels, which was proceeded by reduced phosphorylation of serine 2 on the carboxyl terminal domain (CTD) of RNA polymerase II.  Taken together, these data suggest that cdk2 activity is necessary for the survival of human DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB15Y3Mu-wf7Vg90H21EOLACvtfcHk0lj-w5XJAEcQBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOlur4%253D&md5=7240ad70e193d385ae41269e469c54fd</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.23.4994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.23.4994%26sid%3Dliteratum%253Aachs%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DChiles%26aufirst%3DT.%2BC.%26atitle%3DInhibition%2520of%2520Cyclin-dependent%2520Kinase-2%2520Induces%2520Apoptosis%2520in%2520Human%2520Diffuse%2520Large%2520B-cell%2520Lymphomas%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D2982%26epage%3D2989%26doi%3D10.4161%2Fcc.6.23.4994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Identification of CDK2 as a Novel Target in Treatment of Prostate Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.2217/fon-2017-0561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.2217%2Ffon-2017-0561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29323532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=709-718&author=X.+Yinauthor=J.+Yuauthor=Y.+Zhouauthor=C.+Wangauthor=Z.+Jiaoauthor=Z.+Qianauthor=H.+Sunauthor=B.+Chen&title=Identification+of+CDK2+as+a+Novel+Target+in+Treatment+of+Prostate+Cancer&doi=10.2217%2Ffon-2017-0561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CDK2 as a novel target in treatment of prostate cancer</span></div><div class="casAuthors">Yin, Xifeng; Yu, Jun; Zhou, Yang; Wang, Chengyue; Jiao, Zhimin; Qian, Zhounan; Sun, Hao; Chen, Binghai</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study aims the potential gene involved in the metastasis of prostate cancer (Pca).  PubMed GEO datasets (GSE6605 and GSE6606) were downloaded.  It used multiple bioinformatics methods to screen differentially expressed genes in Pca.  Gene network was built by STRING and visualized by Cytoscape.  All of the hub genes were analyzed by cBioPortal.  Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay.  Downstream genes of CDK2 were analyzed by western blot.  Sequencing data were analyzed to screen the genes with expression alterations.  The top genes were validated in our samples.  11 Hub genes were screened out.  Among these genes, STAT3 and CDK2 were significantly assocd. with recurrence.  Further study suggested that inhibition of CDK2 reduced invasion of Pca cell lines.  The invasion ability was rescued after reintroduction of CDK2.  These data indicated that CDK2 was a crucial factor in metastasis of Pca and might be a novel therapy target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42ZzW6tNPUbVg90H21EOLACvtfcHk0liqkk8sNgjGnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D&md5=c91131983f10d0ef4458d1bcec32b2d4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2217%2Ffon-2017-0561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2017-0561%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DZ.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520CDK2%2520as%2520a%2520Novel%2520Target%2520in%2520Treatment%2520of%2520Prostate%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2018%26volume%3D14%26spage%3D709%26epage%3D718%26doi%3D10.2217%2Ffon-2017-0561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Potentiation of Human Estrogen Receptor Alpha Transcriptional Activation through Phosphorylation of Serines 104 and 106 by the Cyclin A-CDK2 Complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">22296</span>– <span class="NLM_lpage">22302</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.32.22296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.274.32.22296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=22296-22302&author=I.+Rogatskyauthor=J.+M.+Trowbridgeauthor=M.+J.+Garabedian&title=Potentiation+of+Human+Estrogen+Receptor+Alpha+Transcriptional+Activation+through+Phosphorylation+of+Serines+104+and+106+by+the+Cyclin+A-CDK2+Complex&doi=10.1074%2Fjbc.274.32.22296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.32.22296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.32.22296%26sid%3Dliteratum%253Aachs%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DPotentiation%2520of%2520Human%2520Estrogen%2520Receptor%2520Alpha%2520Transcriptional%2520Activation%2520through%2520Phosphorylation%2520of%2520Serines%2520104%2520and%2520106%2520by%2520the%2520Cyclin%2520A-CDK2%2520Complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D22296%26epage%3D22302%26doi%3D10.1074%2Fjbc.274.32.22296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of Estrogen Receptor Transcriptional Enhancement by the Cyclin A/Cdk2 Complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10137</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.94.19.10132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9294175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10132-10137&author=J.+M.+Trowbridgeauthor=I.+Rogatskyauthor=M.+J.+Garabedian&title=Regulation+of+Estrogen+Receptor+Transcriptional+Enhancement+by+the+Cyclin+A%2FCdk2+Complex&doi=10.1073%2Fpnas.94.19.10132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span></div><div class="casAuthors">Trowbridge, Janet M.; Rogatsky, Inez; Garabedian, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10132-10137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have found that ectopic expression of cyclin A increases hormone-dependent and hormone-independent transcriptional activation by the estrogen receptor in vivo in a no. of cell lines, including HeLa cells, U-2 OS osteosarcoma cells and Hs 578Bst breast epithelial cells.  This effect can be further enhanced in HeLa cells by the concurrent expression of the cyclin-dependent kinase activator, cyclin H, and cdk7, and abolished by expression of the cdk inhibitor, p27KIPI, or by the expression of a dominant neg. catalytically inactive cdk2 mutant.  ER is phosphorylated between amino acids 82 and 121 in vitro by the cyclin A/cdk2 complex and incorporation of phosphate into ER is stimulated by ectopic expression of cyclin A in vivo.  Together, these results strongly suggest a direct role for the cyclin A/cdk2 complex in phosphorylating ER and regulating its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpi2Mjjhy1LVg90H21EOLACvtfcHk0liqkk8sNgjGnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D&md5=b8a8e2916b409988346b8decb8973d77</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10132%26sid%3Dliteratum%253Aachs%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DRegulation%2520of%2520Estrogen%2520Receptor%2520Transcriptional%2520Enhancement%2520by%2520the%2520Cyclin%2520A%252FCdk2%2520Complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D10132%26epage%3D10137%26doi%3D10.1073%2Fpnas.94.19.10132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierson-Mullany, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">10542</span>– <span class="NLM_lpage">10557</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.24.10542-10557.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1128%2FMCB.24.24.10542-10557.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15572662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=10542-10557&author=L.+K.+Pierson-Mullanyauthor=C.+A.+Lange&title=Phosphorylation+of+Progesterone+Receptor+Serine+400+Mediates+Ligand-independent+Transcriptional+Activity+in+Response+to+Activation+of+Cyclin-Dependent+Protein+Kinase+2&doi=10.1128%2FMCB.24.24.10542-10557.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span></div><div class="casAuthors">Pierson-Mullany, Lisa K.; Lange, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10542-10557</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human progesterone receptors (PR) are phosphorylated by cyclin-dependent protein kinase 2 (CDK2) at multiple sites, including Ser400.  Herein, we have addressed the significance of phosphorylation of this residue.  PR phospho-Ser400-specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity.  Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand.  Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin.  Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence, of progestin.  PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNA interference knock-down of p27 partially restored CDK2-induced ligand-independent PR activation.  Similarly, in p27-/- mouse embryonic fibroblasts, elevated CDK2 activity increased wild-type (wt) but not S400A PR transcriptional activity in the absence of progestin.  CDK2 induced nuclear localization of unliganded wt but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation.  These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFBJTUucg5LVg90H21EOLACvtfcHk0liqkk8sNgjGnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI&md5=9389bfbb80fcf468cc99194a9a6afb25</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.24.10542-10557.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.24.10542-10557.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPierson-Mullany%26aufirst%3DL.%2BK.%26aulast%3DLange%26aufirst%3DC.%2BA.%26atitle%3DPhosphorylation%2520of%2520Progesterone%2520Receptor%2520Serine%2520400%2520Mediates%2520Ligand-independent%2520Transcriptional%2520Activity%2520in%2520Response%2520to%2520Activation%2520of%2520Cyclin-Dependent%2520Protein%2520Kinase%25202%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D10542%26epage%3D10557%26doi%3D10.1128%2FMCB.24.24.10542-10557.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">HOXA7 stimulates Human Hepatocellular Carcinoma Proliferation through Cyclin E1/CDK2</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3892/or.2014.3668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3892%2For.2014.3668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25501982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=990-996&author=Y.+Liauthor=X.+H.+Yangauthor=S.+J.+Fangauthor=C.+F.+Qinauthor=R.+L.+Sunauthor=Z.+Y.+Liuauthor=B.+Y.+Jiangauthor=X.+Wuauthor=G.+Li&title=HOXA7+stimulates+Human+Hepatocellular+Carcinoma+Proliferation+through+Cyclin+E1%2FCDK2&doi=10.3892%2For.2014.3668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span></div><div class="casAuthors">Li, Yuehui; Yang, Xiao Hui; Fang, Shu Juang; Qin, Chang Fei; Sun, Rui Li; Liu, Zhao Yang; Jiang, Bin Yuan; Wu, Xiang; Li, Guancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">990-996</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">HOX genes are transcription factors that control morphogenesis, organogenesis and differentiation.  Increasing evidence suggests that HOX genes play a role in hepatocellular carcinoma (HCC) progression; however few studies have defined the functional roles and mechanisms of action.  In the present study, we used siRNA and forced-expression in multiple cell lines to define the role of HOXA7 in the regulation of proliferation of HCC in vitro and in vivo.  Knockdown of endogenous HOXA7 decreased the proliferation of HepG2 and QGY-7703 cells.  These changes were not assocd. with significant changes in cyclin D1 and CDK4.  However, down-regulation of HOXA7 significantly reduced cyclin E1 and CDK2 protein levels.  Conversely, overexpression of HOXA7 in QSG-7701 cells stimulated proliferation and increased cyclin E1 and CDK2 protein levels.  Our results confirmed that HOXA7 promoted cell proliferation, and these changes were mediated by cyclin E1/CDK2.  These observations contribute to our understanding of the important roles of HOXA7 in HCC development and progression and HOXA7 could be a promising mol. target for the development of new diagnostic and therapeutic strategies for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0l6a-l8_-GrVg90H21EOLACvtfcHk0lhbiwdfqmNEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D&md5=d5d441e42812540323143f763b5e2520</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3892%2For.2014.3668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3668%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DFang%26aufirst%3DS.%2BJ.%26aulast%3DQin%26aufirst%3DC.%2BF.%26aulast%3DSun%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DJiang%26aufirst%3DB.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DHOXA7%2520stimulates%2520Human%2520Hepatocellular%2520Carcinoma%2520Proliferation%2520through%2520Cyclin%2520E1%252FCDK2%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D990%26epage%3D996%26doi%3D10.3892%2For.2014.3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horstmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Critical Role of CDK2 for Melanoma Growth Linked to its Melanocyte-specific Transcriptional Regulation by MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.ccr.2004.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=565-576&author=J.+Duauthor=H.+R.+Widlundauthor=M.+A.+Horstmannauthor=S.+Ramaswamyauthor=K.+Rossauthor=W.+E.+Huberauthor=E.+K.+Nishimuraauthor=T.+R.+Golubauthor=D.+E.+Fisher&title=Critical+Role+of+CDK2+for+Melanoma+Growth+Linked+to+its+Melanocyte-specific+Transcriptional+Regulation+by+MITF&doi=10.1016%2Fj.ccr.2004.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span></div><div class="casAuthors">Du, Jinyan; Widlund, Hans R.; Horstmann, Martin A.; Ramaswamy, Sridhar; Ross, Ken; Huber, Wade E.; Nishimura, Emi K.; Golub, Todd R.; Fisher, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-576</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The genomic organization of the CDK2 gene, which overlaps the melanocyte-specific gene SILV/PMEL17, poses an interesting regulatory challenge.  The authors show that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the essential melanocyte lineage transcription factor MITF.  In addn., functional studies revealed this regulation to be crit. for maintaining CDK2 kinase activity and growth of melanoma cells.  Expression levels of MITF and CDK2 are tightly correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibitor roscovitine.  CDK2 depletion suppressed growth and cell cycle progression in melanoma, but not other cancers, corroborating previous results.  Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzGPfKfEQmWLVg90H21EOLACvtfcHk0lhbiwdfqmNEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D&md5=0fdd6a6f788af5fb429c464358782881</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DHorstmann%26aufirst%3DM.%2BA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DW.%2BE.%26aulast%3DNishimura%26aufirst%3DE.%2BK.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DCritical%2520Role%2520of%2520CDK2%2520for%2520Melanoma%2520Growth%2520Linked%2520to%2520its%2520Melanocyte-specific%2520Transcriptional%2520Regulation%2520by%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.ccr.2004.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barriere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Mice Thrive Without Cdk4 and Cdk2</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molonc.2007.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19383288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=72-83&author=C.+Barriereauthor=D.+Santamariaauthor=A.+Cerqueiraauthor=J.+Galanauthor=A.+Martinauthor=S.+Ortegaauthor=M.+Malumbresauthor=P.+Dubusauthor=M.+Barbacid&title=Mice+Thrive+Without+Cdk4+and+Cdk2&doi=10.1016%2Fj.molonc.2007.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Mice thrive without Cdk4 and Cdk2</span></div><div class="casAuthors">Barriere, Cedric; Santamaria, David; Cerqueira, Antonio; Galan, Javier; Martin, Alberto; Ortega, Sagrario; Malumbres, Marcos; Dubus, Pierre; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mammalian cell division is thought to be driven by sequential activation of several Cyclin-dependent kinases (Cdk), mainly Cdk4, Cdk6, Cdk2 and Cdk1.  Since mice lacking Cdk4, Cdk6 or Cdk2 are viable, it has been proposed that they play compensatory roles.  We report here that mice lacking Cdk4 and Cdk2 complete embryonic development to die shortly thereafter presumably due to heart failure.  However, conditional ablation of Cdk2 in adult mice lacking Cdk4 does not result in obvious abnormalities.  Moreover, these double mutant mice recover normally after partial hepatectomy.  In culture, Cdk4-/-; Cdk2-/- embryonic fibroblasts become immortal, display robust pRb phosphorylation and have normal S phase kinetics.  These observations indicate that Cdk4 and Cdk2 are dispensable for the mammalian cell cycle and for adult homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpa46WnMjB7Vg90H21EOLACvtfcHk0lhbiwdfqmNEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbbM&md5=360c62de1a9209a076add5d1e6d896fb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarriere%26aufirst%3DC.%26aulast%3DSantamaria%26aufirst%3DD.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DGalan%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMice%2520Thrive%2520Without%2520Cdk4%2520and%2520Cdk2%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D72%26epage%3D83%26doi%3D10.1016%2Fj.molonc.2007.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haagensen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span> <span> </span><span class="NLM_article-title">Combined PI3K and CDK2 Inhibition Induces Cell Death and Enhances <i>In vivo</i> Antitumour Activity in Colorectal Cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fbjc.2016.238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27529512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGmtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=682-690&author=G.+Bealeauthor=E.+J.+Haagensenauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=C.+H.+Revillauthor=S.+L.+Payneauthor=B.+T.+Goldingauthor=I.+R.+Hardcastleauthor=D.+R.+Newellauthor=R.+J.+Griffinauthor=C.+Cano&title=Combined+PI3K+and+CDK2+Inhibition+Induces+Cell+Death+and+Enhances+In+vivo+Antitumour+Activity+in+Colorectal+Cancer&doi=10.1038%2Fbjc.2016.238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer</span></div><div class="casAuthors">Beale, Gary; Haagensen, Emma J.; Thomas, Huw D.; Wang, Lan-Zhen; Revill, Charlotte H.; Payne, Sara L.; Golding, Bernard T.; Hardcastle, Ian R.; Newell, David R.; Griffin, Roger J.; Cano, Celine</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clin. trials.  Similarly, CDKs have been investigated as cancer drug targets.  We have synthesized and characterized a series of 6-aminopyrimidines identified from a kinase screen that inhibit PI3K and/or mTOR and/or CDK2.  Kinase inhibition, tumor cell growth, cell cycle distribution, cytotoxicity and signalling expts. were undertaken in HCT116 and HT29 colorectal cancer cell lines, and in vivo HT29 efficacy studies.  2,6-Diaminopyrimidines with an O4-cyclohexylmethyl substituent and a C-5-nitroso or cyano group (1,2,5) induced cell cycle phase alterations and were growth inhibitory (GI50<20 μM).  Compd. 1, but not 2 or 5, potently inhibits CDK2 (IC50=0.1 nM) as well as PI3K, and was cytotoxic at growth inhibitory concns.  Consistent with kinase inhibition data, compd. 1 reduced phospho-Rb and phospho-rS6 at GI50 concns.  Combination of NU6102 (CDK2 inhibitor) and pictilisib (GDC-0941; pan-PI3K inhibitor) resulted in synergistic growth inhibition, and enhanced cytotoxicity in HT29 cells in vitro and HT29 tumor growth inhibition in vivo.  These studies identified a novel series of mixed CDK2/PI3K inhibitors and demonstrate that dual targeting of CDK2 and PI3K can result in enhanced antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpketwbgW-9zLVg90H21EOLACvtfcHk0ljbuVB4oLJm2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGmtrfM&md5=dfd21e42c0a173c476cc9619c677682e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.238%26sid%3Dliteratum%253Aachs%26aulast%3DBeale%26aufirst%3DG.%26aulast%3DHaagensen%26aufirst%3DE.%2BJ.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DRevill%26aufirst%3DC.%2BH.%26aulast%3DPayne%26aufirst%3DS.%2BL.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26atitle%3DCombined%2520PI3K%2520and%2520CDK2%2520Inhibition%2520Induces%2520Cell%2520Death%2520and%2520Enhances%2520In%2520vivo%2520Antitumour%2520Activity%2520in%2520Colorectal%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fbjc.2016.238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgenvik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weishaupt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartling, F. J.</span></span> <span> </span><span class="NLM_article-title">Combined BET Bromodomain and CDK2 Inhibition in MYC-driven Medulloblastoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2850</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0135-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fs41388-018-0135-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29511348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslGgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=2850-2862&author=S.+Bolinauthor=A.+Borgenvikauthor=C.+U.+Perssonauthor=A.+Sundstromauthor=J.+Qiauthor=J.+E.+Bradnerauthor=W.+A.+Weissauthor=Y.+J.+Choauthor=H.+Weishauptauthor=F.+J.+Swartling&title=Combined+BET+Bromodomain+and+CDK2+Inhibition+in+MYC-driven+Medulloblastoma&doi=10.1038%2Fs41388-018-0135-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma</span></div><div class="casAuthors">Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstroem, Anders; Qi, Jun; Bradner, James E.; Weiss, William A.; Cho, Yoon-Jae; Weishaupt, Holger; Swartling, Fredrik J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2850-2862</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Medulloblastoma (MB) is the most common malignant brain tumor in children.  MYC genes are frequently amplified and correlate with poor prognosis in MB.  BET bromodomains recognize acetylated lysine residues and often promote and maintain MYC transcription.  Certain cyclin-dependent kinases (CDKs) are further known to support MYC stabilization in tumor cells.  In this report, MB cells were suppressed by combined targeting of MYC expression and MYC stabilization using BET bromodomain inhibition and CDK2 inhibition, resp.  Such combination treatment worked synergistically and caused cell cycle arrest as well as massive apoptosis.  Immediate transcriptional changes from this combined MYC blockade were found using RNA-Seq profiling and showed remarkable similarities to changes in MYC target gene expression when MYCN was turned off with doxycycline in our MYCN-inducible animal model for Group 3 MB.  In addn., the combination treatment significantly prolonged survival as compared to single-agent therapy in orthotopically transplanted human Group 3 MB with MYC amplifications.  Our data suggest that dual inhibition of CDK2 and BET bromodomains can be a novel treatment approach for suppressing MYC-driven cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ooD_WtfsW7Vg90H21EOLACvtfcHk0ljbuVB4oLJm2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslGgsbo%253D&md5=a5e5ba828ddb5796d90e08deb4c2f936</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0135-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0135-1%26sid%3Dliteratum%253Aachs%26aulast%3DBolin%26aufirst%3DS.%26aulast%3DBorgenvik%26aufirst%3DA.%26aulast%3DPersson%26aufirst%3DC.%2BU.%26aulast%3DSundstrom%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DWeishaupt%26aufirst%3DH.%26aulast%3DSwartling%26aufirst%3DF.%2BJ.%26atitle%3DCombined%2520BET%2520Bromodomain%2520and%2520CDK2%2520Inhibition%2520in%2520MYC-driven%2520Medulloblastoma%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D2850%26epage%3D2862%26doi%3D10.1038%2Fs41388-018-0135-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefanikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klacanova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilchova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racay, P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Inhibitor SU9516 Increases Sensitivity of Colorectal Carcinoma Cells Caco-2 but not HT29 to BH3Mimetic ABT-737</span>. <i>Gen. Physiol. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.4149/gpb_2017030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4149%2Fgpb_2017030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29372687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=539-547&author=A.+Stefanikovaauthor=K.+Klacanovaauthor=I.+Pilchovaauthor=J.+Hatokauthor=P.+Racay&title=Cyclin-dependent+Kinase+2+Inhibitor+SU9516+Increases+Sensitivity+of+Colorectal+Carcinoma+Cells+Caco-2+but+not+HT29+to+BH3Mimetic+ABT-737&doi=10.4149%2Fgpb_2017030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737</span></div><div class="casAuthors">Stefanikova, Andrea; Klacanova, Katarina; Pilchova, Ivana; Hatok, Jozef; Racay, Peter</div><div class="citationInfo"><span class="NLM_cas:title">General Physiology and Biophysics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">GPBIE2</span>;
        ISSN:<span class="NLM_cas:issn">0231-5882</span>.
    
            (<span class="NLM_cas:orgname">Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) that represents one of the major causes for cancer related death in humans is often assocd. with over-expression of anti-apoptotic proteins of Bcl-2 family.  The aim of presented study was to det. the effect of ABT-737 inhibitor of anti-apoptotic pro- teins Bcl-2, Bcl-XL and Bcl-w as well as cyclin-dependent kinase 2 (CDK2) inhibitor SU9516 alone and in combination with ABT-737 on survival of colorectal cell lines HT29 and Caco-2.  We have shown that both Caco-2 and HT29 cells that are relatively resistant to ABT-737 are also partially sensitive to SU9516, which increased sensitivity of Caco-2 but not HT29 cells to ABT-737.  Increased sensitivity of Caco-2 cells to ABT-737 after addn. of SU9516 correlated well with SU9516-induced decrease of Mcl-l expression while we have not obsd. downregiilation of Mcl-1 after the treat- ment of HT29 cells with SU9516.  Instead of this, we have shown that treatment of HT29 cells with SU9516 is assocd. with decreased expression of tumor suppressor protein p53.  Our findings provide a rationale for clin. use of Bcl-2 family inhibitors in combination with CDK2 inhibitors for treatment of Mcl-1-dependent colorectal tumors assocd. with expression of Bcl-2, Bcl-XL and Bcl-w proteins.  In addn., we have shown potential of CDK2 inhibitors for treatment of tumors expressing R273H mutant p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopRluv-W8m7Vg90H21EOLACvtfcHk0ljbuVB4oLJm2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGntL4%253D&md5=a90466a8e776a5647afaeb938c52b058</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.4149%2Fgpb_2017030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4149%252Fgpb_2017030%26sid%3Dliteratum%253Aachs%26aulast%3DStefanikova%26aufirst%3DA.%26aulast%3DKlacanova%26aufirst%3DK.%26aulast%3DPilchova%26aufirst%3DI.%26aulast%3DHatok%26aufirst%3DJ.%26aulast%3DRacay%26aufirst%3DP.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Inhibitor%2520SU9516%2520Increases%2520Sensitivity%2520of%2520Colorectal%2520Carcinoma%2520Cells%2520Caco-2%2520but%2520not%2520HT29%2520to%2520BH3Mimetic%2520ABT-737%26jtitle%3DGen.%2520Physiol.%2520Biophys.%26date%3D2017%26volume%3D36%26spage%3D539%26epage%3D547%26doi%3D10.4149%2Fgpb_2017030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancusi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Self, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Poele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Molecular Profiling and Combinatorial Activity of CCT068127: A Potent CDK2 and CDK9 Inhibitor</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2F1878-0261.12148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29063678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=287-304&author=S.+R.+Whittakerauthor=C.+Barlowauthor=M.+P.+Martinauthor=C.+Mancusiauthor=S.+Wagnerauthor=A.+Selfauthor=E.+Barrieauthor=R.+Te+Poeleauthor=S.+Sharpauthor=N.+Brownauthor=S.+Wilsonauthor=W.+Jacksonauthor=P.+M.+Fischerauthor=P.+A.+Clarkeauthor=M.+I.+Waltonauthor=E.+McDonaldauthor=J.+Blaggauthor=M.+Nobleauthor=M.+D.+Garrettauthor=P.+Workman&title=Molecular+Profiling+and+Combinatorial+Activity+of+CCT068127%3A+A+Potent+CDK2+and+CDK9+Inhibitor&doi=10.1002%2F1878-0261.12148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor</span></div><div class="casAuthors">Whittaker, Steven R.; Barlow, Clare; Martin, Mathew P.; Mancusi, Caterina; Wagner, Steve; Self, Annette; Barrie, Elaine; Te Poele, Robert; Sharp, Swee; Brown, Nathan; Wilson, Stuart; Jackson, Wayne; Fischer, Peter M.; Clarke, Paul A.; Walton, Michael I.; McDonald, Edward; Blagg, Julian; Noble, Martin; Garrett, Michelle D.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-304</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types.  Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer.  We describe herein the mol. and cellular effects of CCT068127, a novel inhibitor of CDK2 and CDK9.  Optimized from the purine template of seliciclib, CCT068127 exhibits greater potency and selectivity against purified CDK2 and CDK9 and superior antiproliferative activity against human colon cancer and melanoma cell lines.  X-ray crystallog. studies reveal that hydrogen bonding with the DFG motif of CDK2 is the likely mechanism of greater enzymic potency.  Commensurate with inhibition of CDK activity, CCT068127 treatment results in decreased retinoblastoma protein (RB) phosphorylation, reduced phosphorylation of RNA polymerase II, and induction of cell cycle arrest and apoptosis.  The transcriptional signature of CCT068127 shows greatest similarity to other small-mol. CDK and also HDAC inhibitors.  CCT068127 caused a dramatic loss in expression of DUSP6 phosphatase, alongside elevated ERK phosphorylation and activation of MAPK pathway target genes.  MCL1 protein levels are rapidly decreased by CCT068127 treatment and this assocs. with synergistic antiproliferative activity after combined treatment with CCT068127 and ABT263, a BCL2 family inhibitor.  These findings support the rational combination of this series of CDK2/9 inhibitors and BCL2 family inhibitors for the treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAsEQ-SIktWbVg90H21EOLACvtfcHk0ljYtkRHrGXnXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslylur4%253D&md5=8af4ee8d1ac372e854891dc73025364f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12148%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DMancusi%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DSelf%26aufirst%3DA.%26aulast%3DBarrie%26aufirst%3DE.%26aulast%3DTe%2BPoele%26aufirst%3DR.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DMolecular%2520Profiling%2520and%2520Combinatorial%2520Activity%2520of%2520CCT068127%253A%2520A%2520Potent%2520CDK2%2520and%2520CDK9%2520Inhibitor%26jtitle%3DMol.%2520Oncol.%26date%3D2018%26volume%3D12%26spage%3D287%26epage%3D304%26doi%3D10.1002%2F1878-0261.12148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramuta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seashore-Ludlow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edfors, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuominen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krijgsman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeper, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyhazi
Brage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddalo, G.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK2 Overcomes Melanoma Resistance Against BRAF and Hsp90 Inhibitors</span>. <i>Mol. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e7858</span>, <span class="refDoi"> DOI: 10.15252/msb.20177858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.15252%2Fmsb.20177858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29507054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e7858&author=A.+Azimiauthor=S.+Caramutaauthor=B.+Seashore-Ludlowauthor=J.+Bostromauthor=J.+L.+Robinsonauthor=F.+Edforsauthor=R.+Tuominenauthor=K.+Kemperauthor=O.+Krijgsmanauthor=D.+S.+Peeperauthor=J.+Nielsenauthor=J.+Hanssonauthor=S.+Egyhazi%0ABrageauthor=M.+Altunauthor=M.+Uhlenauthor=G.+Maddalo&title=Targeting+CDK2+Overcomes+Melanoma+Resistance+Against+BRAF+and+Hsp90+Inhibitors&doi=10.15252%2Fmsb.20177858"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.15252%2Fmsb.20177858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fmsb.20177858%26sid%3Dliteratum%253Aachs%26aulast%3DAzimi%26aufirst%3DA.%26aulast%3DCaramuta%26aufirst%3DS.%26aulast%3DSeashore-Ludlow%26aufirst%3DB.%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26aulast%3DEdfors%26aufirst%3DF.%26aulast%3DTuominen%26aufirst%3DR.%26aulast%3DKemper%26aufirst%3DK.%26aulast%3DKrijgsman%26aufirst%3DO.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DEgyhazi%2BBrage%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DMaddalo%26aufirst%3DG.%26atitle%3DTargeting%2520CDK2%2520Overcomes%2520Melanoma%2520Resistance%2520Against%2520BRAF%2520and%2520Hsp90%2520Inhibitors%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3De7858%26doi%3D10.15252%2Fmsb.20177858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palafox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Murillas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cortesauthor=R.+Elliottauthor=S.+Pancholiauthor=C.+J.+Lord&title=Early+Adaptation+and+Acquired+Resistance+to+CDK4%2F6+Inhibition+in+Estrogen+Receptor-Positive+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26atitle%3DEarly%2520Adaptation%2520and%2520Acquired%2520Resistance%2520to%2520CDK4%252F6%2520Inhibition%2520in%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 Inhibition in Breast Cancer: Current Practice and Future Directions</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1177/1758835918786451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1177%2F1758835918786451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1-15&author=S.+Pernasauthor=S.+M.+Tolaneyauthor=E.+P.+Winerauthor=S.+Goel&title=CDK4%2F6+Inhibition+in+Breast+Cancer%3A+Current+Practice+and+Future+Directions&doi=10.1177%2F1758835918786451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1177%2F1758835918786451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835918786451%26sid%3Dliteratum%253Aachs%26aulast%3DPernas%26aufirst%3DS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DCDK4%252F6%2520Inhibition%2520in%2520Breast%2520Cancer%253A%2520Current%2520Practice%2520and%2520Future%2520Directions%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2018%26volume%3D10%26spage%3D1%26epage%3D15%26doi%3D10.1177%2F1758835918786451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeruss, J. S.</span></span> <span> </span><span class="NLM_article-title">Synergistic Effect of Eribulin and CDK Inhibition for the Treatment of Triple Negative Breast Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">83925</span>– <span class="NLM_lpage">83939</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.18632%2Foncotarget.20202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=83925-83939&author=S.+S.+Raoauthor=J.+Stoehrauthor=D.+Dokicauthor=L.+Wanauthor=J.+T.+Deckerauthor=K.+Konopkaauthor=A.+L.+Thomasauthor=J.+Wuauthor=V.+G.+Kaklamaniauthor=L.+D.+Sheaauthor=J.+S.+Jeruss&title=Synergistic+Effect+of+Eribulin+and+CDK+Inhibition+for+the+Treatment+of+Triple+Negative+Breast+Cancer&doi=10.18632%2Foncotarget.20202"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20202%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%2BS.%26aulast%3DStoehr%26aufirst%3DJ.%26aulast%3DDokic%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DDecker%26aufirst%3DJ.%2BT.%26aulast%3DKonopka%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKaklamani%26aufirst%3DV.%2BG.%26aulast%3DShea%26aufirst%3DL.%2BD.%26aulast%3DJeruss%26aufirst%3DJ.%2BS.%26atitle%3DSynergistic%2520Effect%2520of%2520Eribulin%2520and%2520CDK%2520Inhibition%2520for%2520the%2520Treatment%2520of%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D83925%26epage%3D83939%26doi%3D10.18632%2Foncotarget.20202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deans, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNees, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heierhorst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Functions in Normal DNA Repair and is a Therapeutic Target in BRCA1-deficient Cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8219</span>– <span class="NLM_lpage">8226</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-3945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-05-3945" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8219-8226&author=A.+J.+Deansauthor=K.+K.+Khannaauthor=C.+J.+McNeesauthor=C.+Mercurioauthor=J.+Heierhorstauthor=G.+A.+McArthur&title=Cyclin-dependent+Kinase+2+Functions+in+Normal+DNA+Repair+and+is+a+Therapeutic+Target+in+BRCA1-deficient+Cancers&doi=10.1158%2F0008-5472.CAN-05-3945"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-3945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-3945%26sid%3Dliteratum%253Aachs%26aulast%3DDeans%26aufirst%3DA.%2BJ.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26aulast%3DMcNees%26aufirst%3DC.%2BJ.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DHeierhorst%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Functions%2520in%2520Normal%2520DNA%2520Repair%2520and%2520is%2520a%2520Therapeutic%2520Target%2520in%2520BRCA1-deficient%2520Cancers%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8219%26epage%3D8226%26doi%3D10.1158%2F0008-5472.CAN-05-3945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Cyclin E Amplification/overexpression is a Mechanism of Trastuzumab Resistance in HER2<sup>+</sup> Breast Cancer Patients</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3761</span>– <span class="NLM_lpage">3766</span>, <span class="refDoi"> DOI: 10.1073/pnas.1014835108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.1014835108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21321214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFOltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=3761-3766&author=M.+Scaltritiauthor=P.+J.+Eichhornauthor=J.+Cortesauthor=L.+Prudkinauthor=C.+Auraauthor=J.+Jimenezauthor=S.+Chandarlapatyauthor=V.+Serraauthor=A.+Pratauthor=Y.+H.+Ibrahimauthor=M.+Guzmanauthor=M.+Giliauthor=O.+Rodriguezauthor=S.+Rodriguezauthor=J.+Perezauthor=S.+R.+Greenauthor=S.+Maiauthor=N.+Rosenauthor=C.+Hudisauthor=J.+Baselga&title=Cyclin+E+Amplification%2Foverexpression+is+a+Mechanism+of+Trastuzumab+Resistance+in+HER2%2B+Breast+Cancer+Patients&doi=10.1073%2Fpnas.1014835108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in her2+ breast cancer patients</span></div><div class="casAuthors">Scaltriti, Maurizio; Eichhorn, Pieter J.; Cortes, Javier; Prudkin, Ludmila; Aura, Claudia; Jimenez, Jose; Chandarlapaty, Sarat; Serra, Violeta; Prat, Aleix; Ibrahim, Yasir H.; Guzman, Marta; Gili, Magui; Rodriguez, Olga; Rodriguez, Sonia; Perez, Jose; Green, Simon R.; Mai, Sabine; Rosen, Neal; Hudis, Clifford; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3761-3766, S3761/1-S3761/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Clin. benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified-breast cancer remain limited by primary or acquired resistance.  To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment.  Genome-wide copy-no. variation analyses of.the resistant cells compared with parental cells revealed a focal amplification of genomic DNA contg. the cyclin E gene.  In a cohort of 34 HER2+ patients treated with trastuzumab-based therapy, we found that cyclin E amplification/overexpression was assocd. with a worse clin. benefit (33.3% compared with 87.5%, P < 0.02) and a lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared with nonoverexpressing cyclin E tumors.  To dissect the potential role of cyclin E in trastuzumab resistance, we studied the effects of cyclin E overexpression and cyclin E suppression.  Cyclin E overexpression resulted in resistance to trastuzumab both in vitro and in vivo.  Inhibition of cyclin E activity in cyclin E-amplified trastuzumab resistant clones, either by knockdown of cyclin E expression or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic decrease in proliferation and enhanced apoptosis.  In vivo, CDK2 inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts.  Our findings point to a causative role for cyclin E overexpression and the consequent increase in CDK2 activity in trastuzumab resistance and suggest that treatment with CDK2 inhibitors may be a valid strategy in patients with breast tumors with HER2 and cyclin E coamplification/overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcdApAmM38rVg90H21EOLACvtfcHk0ljEYrLst3AVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFOltLY%253D&md5=548c62757110e5caa86ae588af0a27f4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1014835108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1014835108%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DP.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DGili%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26aulast%3DMai%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DCyclin%2520E%2520Amplification%252Foverexpression%2520is%2520a%2520Mechanism%2520of%2520Trastuzumab%2520Resistance%2520in%2520HER2%252B%2520Breast%2520Cancer%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D3761%26epage%3D3766%26doi%3D10.1073%2Fpnas.1014835108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span> <span> </span><span class="NLM_article-title">Pre-clinical Evaluation of Cyclin-dependent Kinase 2 and 1 Inhibition in Anti-estrogen-Sensitive and Resistant Breast Cancer Cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsj.bjc.6605479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20010939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=342-350&author=N.+Johnsonauthor=J.+Bentleyauthor=L.+Z.+Wangauthor=D.+R.+Newellauthor=C.+N.+Robsonauthor=G.+I.+Shapiroauthor=N.+J.+Curtin&title=Pre-clinical+Evaluation+of+Cyclin-dependent+Kinase+2+and+1+Inhibition+in+Anti-estrogen-Sensitive+and+Resistant+Breast+Cancer+Cells&doi=10.1038%2Fsj.bjc.6605479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells</span></div><div class="casAuthors">Johnson, N.; Bentley, J.; Wang, L.-Z.; Newell, D. R.; Robson, C. N.; Shapiro, G. I.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) and their cyclin partners, is deregulated in cancer.  Anti-estrogens, such as tamoxifen, antagonize estrogen-induced ERα transactivation of cyclin D1, resulting in reduced CDK4/6 activity, p27Kip1-mediated inhibition of CDK2 and growth arrest.  We hypothesised that direct inhibition of CDK2 and CDK1 may overcome the major clin. problem of anti-estrogen resistance.  Methods: The cellular effects of CDK2/1 siRNA knockdown and purine-based CDK2/1 inhibitors, NU2058 and NU6102, were measured in anti-estrogen-sensitive and resistant breast cancer cell lines.  Results: CDK2 knockdown caused G1 accumulation, whereas CDK1 depletion caused G2/M slowing, and dual CDK1/2 depletion resulted in further G2/M accumulation and cell death in both anti-estrogen-sensitive and resistant cells, confirming CDK2 and CDK1 as targets for breast cancer therapy.  In contrast to tamoxifen, which only affected hormone-sensitive cells, NU2058 and NU6102 reduced CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and proliferation, ultimately resulting in cell death, in both anti-estrogen-sensitive and resistant cells.  Both drugs caused G2/M arrest, reflective of combined CDK2/1 knockdown, with a variable degree of G1 accumulation.  Conclusion: These studies confirm the therapeutic potential of CDK2 and CDK1 inhibitors for cancer therapy, and support their use as an alternative treatment for endocrine-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOsy7PhpambVg90H21EOLACvtfcHk0ljEYrLst3AVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKiuw%253D%253D&md5=832cf69fc4b80a85e01f6d0bdf6233c7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605479%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPre-clinical%2520Evaluation%2520of%2520Cyclin-dependent%2520Kinase%25202%2520and%25201%2520Inhibition%2520in%2520Anti-estrogen-Sensitive%2520and%2520Resistant%2520Breast%2520Cancer%2520Cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D342%26epage%3D350%26doi%3D10.1038%2Fsj.bjc.6605479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goktug, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonga, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlitt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iconaru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morfouace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umans, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">CDK2 Inhibitors as Candidate Therapeutics for Cisplatin- and Noise-induced Hearing Loss</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1084/jem.20172246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1084%2Fjem.20172246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2018&pages=1187-1203&author=T.+Teitzauthor=J.+Fangauthor=A.+N.+Goktugauthor=J.+D.+Bongaauthor=S.+Diaoauthor=R.+A.+Hazlittauthor=L.+Iconaruauthor=M.+Morfouaceauthor=D.+Currierauthor=Y.+Zhouauthor=R.+A.+Umansauthor=M.+R.+Taylorauthor=C.+Chengauthor=J.+Minauthor=B.+Freemanauthor=J.+Pengauthor=M.+F.+Rousselauthor=R.+Kriwackiauthor=R.+K.+Guyauthor=T.+Chenauthor=J.+Zuo&title=CDK2+Inhibitors+as+Candidate+Therapeutics+for+Cisplatin-+and+Noise-induced+Hearing+Loss&doi=10.1084%2Fjem.20172246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1084%2Fjem.20172246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20172246%26sid%3Dliteratum%253Aachs%26aulast%3DTeitz%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DGoktug%26aufirst%3DA.%2BN.%26aulast%3DBonga%26aufirst%3DJ.%2BD.%26aulast%3DDiao%26aufirst%3DS.%26aulast%3DHazlitt%26aufirst%3DR.%2BA.%26aulast%3DIconaru%26aufirst%3DL.%26aulast%3DMorfouace%26aufirst%3DM.%26aulast%3DCurrier%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DUmans%26aufirst%3DR.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DCDK2%2520Inhibitors%2520as%2520Candidate%2520Therapeutics%2520for%2520Cisplatin-%2520and%2520Noise-induced%2520Hearing%2520Loss%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2018%26volume%3D215%26spage%3D1187%26epage%3D1203%26doi%3D10.1084%2Fjem.20172246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabr, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta1–42 (Abeta1–42) Induces the CDK2-Mediated Phosphorylation of Tau through the Activation of the mTORC1 Signaling Pathway While Promoting Neuronal Cell Death</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">229</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3389%2Ffnmol.2017.00229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28790888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOksLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=229&author=K.+H.+Leeauthor=S.+J.+Leeauthor=H.+J.+Leeauthor=G.+E.+Choiauthor=Y.+H.+Jungauthor=D.+I.+Kimauthor=A.+A.+Gabrauthor=J.+M.+Ryuauthor=H.+J.+Han&title=Amyloid+beta1%E2%80%9342+%28Abeta1%E2%80%9342%29+Induces+the+CDK2-Mediated+Phosphorylation+of+Tau+through+the+Activation+of+the+mTORC1+Signaling+Pathway+While+Promoting+Neuronal+Cell+Death&doi=10.3389%2Ffnmol.2017.00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid β1-42 (Aβ1-42) induces the CDK2-mediated phosphorylation of tau through the activation of the mTORC1 Signaling pathway while promoting neuronal cell death</span></div><div class="casAuthors">Lee, Ki Hoon; Lee, Sei-Jung; Lee, Hyun Jik; Choi, Gee Euhn; Jung, Young Hyun; Kim, Dah Ihm; Gabr, Amr Ahmed; Ryu, Jung Min; Han, Ho Jae</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">229/1-229/15</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by cognitive impairment and memory loss.  Amyloid β1-42 (Aβ) and hyper-phosphorylation of microtubule-assocd. protein tau have been considered as major histol. features in AD.  However, the mechanism of how Aβ induces the hyper-phosphorylation of tau remains to be clarified.  In the present study, we investigated the underlying cellular mechanisms of Aβ with regard to the cell cycle regulatory protein-mediated phosphorylation of tau in promoting neuronal cell death.  The oligomer Aβ (5 μM) significantly increased the level of caspase 3 cleavage and has the ability to induce cytotoxicity in human neuroblastoma SK-N-MC cells.  Aβ induced the degree of extracellular calcium influx via the L-type channel to facilitate the prodn. of reactive oxygen species (ROS).  Aβ signaling through ROS prodn. is uniquely mediated by the activation of PI3K/Akt, which is in turn required for mammalian target of rapamycin complex 1 (mTORC1) phosphorylation. mTORC1 activated by Aβ further increased the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), a binding protein (4E-BP1) and p70S6K1 to stimulate the HIF1α synthesis responsible for the induction of cyclinD1/cyclin-dependent kinase 4 (CDK4) and cyclinE/CDK2, whereas it significantly attenuated the activation of autophagy.  Aβ distinctively induced the CDK2-mediated phosphorylation of tau, which is responsible for microtubule destabilization in promoting neuronal apoptosis.  In mouse hippocampal primary neurons, the apoptotic cell death induced by Aβ is highly susceptible to the mTORC1 signaling pathway.  These results demonstrate that Aβ efficiently stimulates the mTORC1 signaling pathway to facilitate HIF1α synthesis and autophagy inhibition to promote the expression of cell cycle regulatory proteins, during which CDK2 uniquely stimulates tau phosphorylation for microtubule destabilization-mediated neuronal apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrH1nGss8wRbVg90H21EOLACvtfcHk0liDGnCkrOrPqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOksLjF&md5=0740a4e0ab23a83cc090895886180a20</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00229%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DG.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BI.%26aulast%3DGabr%26aufirst%3DA.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BM.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26atitle%3DAmyloid%2520beta1%25E2%2580%259342%2520%2528Abeta1%25E2%2580%259342%2529%2520Induces%2520the%2520CDK2-Mediated%2520Phosphorylation%2520of%2520Tau%2520through%2520the%2520Activation%2520of%2520the%2520mTORC1%2520Signaling%2520Pathway%2520While%2520Promoting%2520Neuronal%2520Cell%2520Death%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D229%26doi%3D10.3389%2Ffnmol.2017.00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+Cyclin-dependent+Kinases+%28CDKs%29+as+Novel+Targets+for+Antiviral+Drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0liDGnCkrOrPqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520Cyclin-dependent%2520Kinases%2520%2528CDKs%2529%2520as%2520Novel%2520Targets%2520for%2520Antiviral%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prigge, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. C.</span></span> <span> </span><span class="NLM_article-title">Targeting Malaria with Specific CDK Inhibitors</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bbapap.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16185941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=160-170&author=J.+A.+Geyerauthor=S.+T.+Priggeauthor=N.+C.+Waters&title=Targeting+Malaria+with+Specific+CDK+Inhibitors&doi=10.1016%2Fj.bbapap.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting malaria with specific CDK inhibitors</span></div><div class="casAuthors">Geyer, Jeanne A.; Prigge, Sean T.; Waters, Norman C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">160-170</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent protein kinases (CDKs) are attractive targets for drug discovery and efforts have led to the identification of novel CDK selective inhibitors in the development of treatments for cancers, neurol. disorders, and infectious diseases.  More recently, they have become the focus of rational drug design programs for the development of new antimalarial agents.  CDKs are valid targets as they function as essential regulators of cell growth and differentiation.  To date, several CDKs have been characterized from the genome of the malaria-causing protozoan Plasmodium falciparum.  Our approach employs exptl. and virtual screening methodologies to identify and refine chem. inhibitors of the parasite CDK Pfmrk, a sequence homolog of human CDK7.  Chemotypes of Pfmrk inhibitors include the purines, quinolinones, oxindoles, and chalcones, which have sub-micromolar IC50 values against the parasite enzyme, but not the human CDKs.  Addnl., we have developed and validated a pharmacophore, based on Pfmrk inhibitors, which contains two hydrogen bond acceptor functions and two hydrophobic sites, including one arom. ring hydrophobic site.  This pharmacophore has been exploited to identify addnl. compds. that demonstrate significant inhibitory activity against Pfmrk.  A mol. model of Pfmrk designed using the crystal structure of human CDK7 highlights key amino acid substitutions in the ATP binding pocket.  Mol. modeling and docking of the active site pocket with selective inhibitors has identified possible receptor-ligand interactions that may be responsible for inhibitor specificity.  Overall, the unique biochem. characteristics assocd. with this protein, to include distinctive active site amino acid residues and variable inhibitor profiles, distinguishes the Pfmrk drug screen as a paradigm for CDK inhibitor anal. in the parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqme2F3kHlrt7Vg90H21EOLACvtfcHk0lhgbXpBiYrkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nK&md5=fcc6769d81111c242cff806abc75e0ac</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DJ.%2BA.%26aulast%3DPrigge%26aufirst%3DS.%2BT.%26aulast%3DWaters%26aufirst%3DN.%2BC.%26atitle%3DTargeting%2520Malaria%2520with%2520Specific%2520CDK%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D160%26epage%3D170%26doi%3D10.1016%2Fj.bbapap.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholkar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, J. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical Dissection of the Cell Cycle: Probes for Cell Biology and Anti-cancer Drug Development</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1462</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fcddis.2014.420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25321469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2htbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e1462&author=S.+Seneseauthor=Y.+C.+Loauthor=D.+Huangauthor=T.+A.+Zangleauthor=A.+A.+Gholkarauthor=L.+Robertauthor=B.+Hometauthor=A.+Ribasauthor=M.+K.+Summersauthor=M.+A.+Teitellauthor=R.+Damoiseauxauthor=J.+Z.+Torres&title=Chemical+Dissection+of+the+Cell+Cycle%3A+Probes+for+Cell+Biology+and+Anti-cancer+Drug+Development&doi=10.1038%2Fcddis.2014.420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development</span></div><div class="casAuthors">Senese, S.; Lo, Y. C.; Huang, D.; Zangle, T. A.; Gholkar, A. A.; Robert, L.; Homet, B.; Ribas, A.; Summers, M. K.; Teitell, M. A.; Damoiseaux, R.; Torres, J. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1462</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cell proliferation relies on the ability of cancer cells to grow, transition through the cell cycle, and divide.  To identify novel chem. probes for dissecting the mechanisms governing cell cycle progression and cell division, and for developing new anti-cancer therapeutics, we developed and performed a novel cancer cell-based high-throughput chem. screen for cell cycle modulators.  This approach identified novel G1, S, G2, and M-phase specific inhibitors with drug-like properties and diverse chemotypes likely targeting a broad array of processes.  We further characterized the M-phase inhibitors and highlight the most potent M-phase inhibitor MI-181, which targets tubulin, inhibits tubulin polymn., activates the spindle assembly checkpoint, arrests cells in mitosis, and triggers a fast apoptotic cell death.  Importantly, MI-181 has broad anti-cancer activity, esp. against BRAFV600E melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUCZpnsdcB_7Vg90H21EOLACvtfcHk0lhgbXpBiYrkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2htbbK&md5=951a258769bdb3dbaa008ec59bb30a47</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.420%26sid%3Dliteratum%253Aachs%26aulast%3DSenese%26aufirst%3DS.%26aulast%3DLo%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZangle%26aufirst%3DT.%2BA.%26aulast%3DGholkar%26aufirst%3DA.%2BA.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DHomet%26aufirst%3DB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DSummers%26aufirst%3DM.%2BK.%26aulast%3DTeitell%26aufirst%3DM.%2BA.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DJ.%2BZ.%26atitle%3DChemical%2520Dissection%2520of%2520the%2520Cell%2520Cycle%253A%2520Probes%2520for%2520Cell%2520Biology%2520and%2520Anti-cancer%2520Drug%2520Development%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2014%26volume%3D5%26spage%3De1462%26doi%3D10.1038%2Fcddis.2014.420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemethova, V.</span></span> <span> </span><span class="NLM_article-title">Selective Therapeutic Intervention: A Challenge Against Off-Target Effects</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2017.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molmed.2017.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=671-674&author=F.+Razgaauthor=V.+Nemethova&title=Selective+Therapeutic+Intervention%3A+A+Challenge+Against+Off-Target+Effects&doi=10.1016%2Fj.molmed.2017.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2017.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2017.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DRazga%26aufirst%3DF.%26aulast%3DNemethova%26aufirst%3DV.%26atitle%3DSelective%2520Therapeutic%2520Intervention%253A%2520A%2520Challenge%2520Against%2520Off-Target%2520Effects%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D671%26epage%3D674%26doi%3D10.1016%2Fj.molmed.2017.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lhgbXpBiYrkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Preclinical and Clinical Development of the Cyclin-dependent Kinase Inhibitor Flavopiridol</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4270S</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-040020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1078-0432.CCR-040020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15217973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFWls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4270S&author=G.+I.+Shapiro&title=Preclinical+and+Clinical+Development+of+the+Cyclin-dependent+Kinase+Inhibitor+Flavopiridol&doi=10.1158%2F1078-0432.CCR-040020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12, Pt. 2</span>),
    <span class="NLM_cas:pages">4270s-4275s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (cdks) to reach clin. trial.  In the majority of solid tumor cell lines and xenografts, flavopiridol induces cell cycle arrest and tumor growth inhibition.  This is reflected in clin. outcomes: across multiple Phase II trials there are subsets of patients with prolonged stable disease, although few responses have been obsd.  Flavopiridol displays sequence-dependent cytotoxic synergy with chemotherapy agents.  These effects are most marked when chemotherapy precedes flavopiridol.  In the case of DNA-damaging agents that impose S-phase delay, flavopiridol-mediated cdk inhibition disrupts the phosphorylation of E2F-1, leading to inappropriate persistence of its activity, inducing apoptotic pathways.  This mechanism has been exploited in a Phase I trial of sequential gemcitabine and flavopiridol that has produced promising results.  Flavopiridol is also synergistic with taxanes.  Inhibition of cyclin B-cdk1 by flavopiridol accelerates exit from an abnormal mitosis assocd. with taxane-induced cell death and reduces the phosphorylation of survivin, preventing its stabilization and the cellular protection it affords after taxane exposure.  The sequential combination of docetaxel and flavopiridol has been investigated in a Phase I trial in patients with advanced non-small cell lung cancer, and a randomized Phase II study is under way.  Initial schedules of flavopiridol used prolonged continuous infusions that produced nanomolar levels of drug thought to be capable of achieving cdk inhibition based on results in tumor cell lines.  Recently, it has been discovered that micromolar concns. are likely to be more effective, and shorter infusions that achieve a higher Cmax have now been adopted.  Loading followed by maintenance infusions are also under development, designed to achieve sustained micromolar drug levels.  Clin. trials remain complicated by the absence of pharmacodynamic end points to confirm target inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2TCVhblpcLVg90H21EOLACvtfcHk0lg4GdvpbPe-sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFWls7o%253D&md5=4b1d241a5fa7b8183d36e87e54f99e62</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-040020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-040020%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPreclinical%2520and%2520Clinical%2520Development%2520of%2520the%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520Flavopiridol%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4270S%26doi%3D10.1158%2F1078-0432.CCR-040020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClue, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span> <span> </span><span class="NLM_article-title">Seliciclib, A Cell-Cycle Modulator that Acts through the Inhibition of Cyclin-Dependent Kinases</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.1.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1517%2F17460441.3.1.131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=131-143&author=R.+C.+Jacksonauthor=A.+L.+Barnettauthor=S.+J.+McClueauthor=S.+R.+Green&title=Seliciclib%2C+A+Cell-Cycle+Modulator+that+Acts+through+the+Inhibition+of+Cyclin-Dependent+Kinases&doi=10.1517%2F17460441.3.1.131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.1.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.1.131%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26atitle%3DSeliciclib%252C%2520A%2520Cell-Cycle%2520Modulator%2520that%2520Acts%2520through%2520the%2520Inhibition%2520of%2520Cyclin-Dependent%2520Kinases%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D131%26epage%3D143%26doi%3D10.1517%2F17460441.3.1.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulstridge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Early, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seavers, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), A Novel Cyclin Dependent Kinase Inhibitor Using Fragment-based X-ray Crystallography and Structure Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4986</span>– <span class="NLM_lpage">4999</span>, <span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-Piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+A+Novel+Cyclin+Dependent+Kinase+Inhibitor+Using+Fragment-based+X-ray+Crystallography+and+Structure+Based+Drug+Design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-Piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520A%2520Novel%2520Cyclin%2520Dependent%2520Kinase%2520Inhibitor%2520Using%2520Fragment-based%2520X-ray%2520Crystallography%2520and%2520Structure%2520Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccadoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">AT7519, A Novel Small Molecule Multi-cyclin-dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma <i>via</i> GSK-3beta Activation and RNA Polymerase II Inhibition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2325</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2009.510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20101221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2325-2336&author=L.+Santoauthor=S.+Valletauthor=T.+Hideshimaauthor=D.+Cirsteaauthor=H.+Ikedaauthor=S.+Pozziauthor=K.+Patelauthor=Y.+Okawaauthor=G.+Gorgunauthor=G.+Perroneauthor=E.+Calabreseauthor=M.+Yuleauthor=M.+Squiresauthor=M.+Ladettoauthor=M.+Boccadoroauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=K.+C.+Andersonauthor=N.+Raje&title=AT7519%2C+A+Novel+Small+Molecule+Multi-cyclin-dependent+Kinase+Inhibitor%2C+Induces+Apoptosis+in+Multiple+Myeloma+via+GSK-3beta+Activation+and+RNA+Polymerase+II+Inhibition&doi=10.1038%2Fonc.2009.510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition</span></div><div class="casAuthors">Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Yule, M.; Squires, M.; Ladetto, M.; Boccadoro, M.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2325-2336</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent kinases (CDKs) and their cyclin partners.  Overexpression of individual complexes are reported in multiple myeloma (MM), making them attractive therapeutic targets.  In this study, we investigate the preclin. activity of a novel small-mol. multi-CDK inhibitor, AT7519, in MM.  We show the anti-MM activity of AT7519 displaying potent cytotoxicity and apoptosis; assocd. with in vivo tumor growth inhibition and prolonged survival.  At the mol. level, AT7519 inhibited RNA polymerase II (RNA pol II) phosphorylation, a CDK9, 7 substrate, assocd. with decreased RNA synthesis confirmed by [3H] Uridine incorporation.  In addn., AT7519 inhibited glycogen synthase kinase 3β (GSK-3β) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3β knockdown restored MM survival, suggesting the involvement of GSK-3β in AT7519-induced apoptosis.  GSK-3β activation was independent of RNA pol II dephosphorylation confirmed by α-amanitin, a specific RNA pol II inhibitor, showing potent inhibition of RNA pol II phosphorylation without corresponding effects on GSK-3β phosphorylation.  These results offer new insights into the crucial, yet controversial role of GSK-3β in MM and show significant anti-MM activity of AT7519, providing the rationale for its clin. evaluation in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ02d-731b97Vg90H21EOLACvtfcHk0lg4GdvpbPe-sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbY%253D&md5=0b2e88ad2fb5bd776607465c308423f5</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.510%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DPerrone%26aufirst%3DG.%26aulast%3DCalabrese%26aufirst%3DE.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DLadetto%26aufirst%3DM.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DAT7519%252C%2520A%2520Novel%2520Small%2520Molecule%2520Multi-cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520via%2520GSK-3beta%2520Activation%2520and%2520RNA%2520Polymerase%2520II%2520Inhibition%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D2325%26epage%3D2336%26doi%3D10.1038%2Fonc.2009.510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span> <span> </span><span class="NLM_article-title">Biological Characterization of AT7519, A Small-Molecule Inhibitor of Cyclin-Dependent Kinases, in Human Tumor Cell Lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-08-0890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19174555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFamsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=324-332&author=M.+S.+Squiresauthor=R.+E.+Feltellauthor=N.+G.+Wallisauthor=E.+J.+Lewisauthor=D.+M.+Smithauthor=D.+M.+Crossauthor=J.+F.+Lyonsauthor=N.+T.+Thompson&title=Biological+Characterization+of+AT7519%2C+A+Small-Molecule+Inhibitor+of+Cyclin-Dependent+Kinases%2C+in+Human+Tumor+Cell+Lines&doi=10.1158%2F1535-7163.MCT-08-0890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines</span></div><div class="casAuthors">Squires, Matthew S.; Feltell, Ruth E.; Wallis, Nicola G.; Lewis, E. Jonathan; Smith, Donna-Michelle; Cross, David M.; Lyons, John F.; Thompson, Neil T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-332</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK), and their regulatory cyclin partners, play a central role in eukaryotic cell growth, division, and death.  This key role in cell cycle progression, as well as their de-regulation in several human cancers, makes them attractive therapeutic targets in oncol.  A series of CDK inhibitors was developed using Astex's fragment-based medicinal chem. approach, linked to high-throughput X-ray crystallog.  A compd. from this series, designated AT7519, is currently in early-phase clin. development.  We describe here the biol. characterization of AT7519, a potent inhibitor of several CDK family members.  AT7519 showed potent anti-proliferative activity (40-940 nmol/L) in a panel of human tumor cell lines, and the mechanism of action was shown here to be consistent with the inhibition of CDK1 and CDK2 in solid tumor cell lines.  AT7519 caused cell cycle arrest followed by apoptosis in human tumor cells and inhibited tumor growth in human tumor xenograft models.  Tumor regression was obsd. following twice daily dosing of AT7519 in the HCT116 and HT29 colon cancer xenograft models.  We show that these biol. effects are linked to inhibition of CDKs in vivo and that AT7519 induces tumor cell apoptosis in these xenograft models.  AT7519 has an attractive biol. profile for development as a clin. candidate, and the tolerability and efficacy in animal models compare favorably with other CDK inhibitors in clin. development.  Studies described here formed the biol. rationale for investigating the potential therapeutic benefit of AT7519 in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7VBX-MzHDbVg90H21EOLACvtfcHk0licqSIiQI-8EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFamsL0%253D&md5=55ab6736e850d3acfb3c6095554eb006</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0890%26sid%3Dliteratum%253Aachs%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26atitle%3DBiological%2520Characterization%2520of%2520AT7519%252C%2520A%2520Small-Molecule%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Kinases%252C%2520in%2520Human%2520Tumor%2520Cell%2520Lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D324%26epage%3D332%26doi%3D10.1158%2F1535-7163.MCT-08-0890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seftel, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouroukis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalchal, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sederias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, A. E.</span></span> <span> </span><span class="NLM_article-title">The CDK Inhibitor AT7519M in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma. A Phase II study of the Canadian Cancer Trials Group</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1239259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1080%2F10428194.2016.1239259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27750483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1358-1365&author=M.+D.+Seftelauthor=J.+Kuruvillaauthor=T.+Kouroukisauthor=V.+Banerjiauthor=G.+Fraserauthor=M.+Crumpauthor=R.+Kumarauthor=H.+I.+Chalchalauthor=M.+Salimauthor=R.+C.+Laisterauthor=S.+Crockerauthor=S.+B.+Gibsonauthor=M.+Toguchiauthor=J.+F.+Lyonsauthor=H.+Xuauthor=J.+Powersauthor=J.+Sederiasauthor=L.+Seymourauthor=A.+E.+Hay&title=The+CDK+Inhibitor+AT7519M+in+Patients+with+Relapsed+or+Refractory+Chronic+Lymphocytic+Leukemia+%28CLL%29+and+Mantle+Cell+Lymphoma.+A+Phase+II+study+of+the+Canadian+Cancer+Trials+Group&doi=10.1080%2F10428194.2016.1239259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group</span></div><div class="casAuthors">Seftel, Matthew D.; Kuruvilla, John; Kouroukis, Tom; Banerji, Versha; Fraser, Graeme; Crump, Michael; Kumar, Rajat; Chalchal, Haji I.; Salim, Muhammad; Laister, Rob C.; Crocker, Susan; Gibson, Spencer B.; Toguchi, Marcia; Lyons, John F.; Xu, Hao; Powers, Jean; Sederias, Joana; Seymour, Lesley; Hay, Annette E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1358-1365</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">AT7519M is a small mol. inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies.  In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m2 twice weekly for 2 of every 3 wk.  Primary objective was objective response rate (ORR).  Nineteen patients were accrued (7 CLL, 12 MCL).  Four CLL patients achieved stable disease (SD).  Two MCL patients achieved partial response (PR), and 6 had SD.  One addnl. MCL patient with SD subsequently achieved PR 9 mo after completion of AT7519M.  Tumor lysis syndrome was not reported.  In conclusion, AT7519M was safely administered to patients with relapsed/refractory CLL and MCL.  In CLL, some patients had tumor redns., but the ORR was low.  In MCL, activity was noted with ORR of 27%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZUMQXDw67bVg90H21EOLACvtfcHk0lhl_n-YddhxUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsLvM&md5=4a63e3a5cb34a9e8eb22826f76ffe113</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1239259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1239259%26sid%3Dliteratum%253Aachs%26aulast%3DSeftel%26aufirst%3DM.%2BD.%26aulast%3DKuruvilla%26aufirst%3DJ.%26aulast%3DKouroukis%26aufirst%3DT.%26aulast%3DBanerji%26aufirst%3DV.%26aulast%3DFraser%26aufirst%3DG.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DChalchal%26aufirst%3DH.%2BI.%26aulast%3DSalim%26aufirst%3DM.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DCrocker%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DS.%2BB.%26aulast%3DToguchi%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSederias%26aufirst%3DJ.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DHay%26aufirst%3DA.%2BE.%26atitle%3DThe%2520CDK%2520Inhibitor%2520AT7519M%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%2520and%2520Mantle%2520Cell%2520Lymphoma.%2520A%2520Phase%2520II%2520study%2520of%2520the%2520Canadian%2520Cancer%2520Trials%2520Group%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1358%26epage%3D1365%26doi%3D10.1080%2F10428194.2016.1239259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Cyclin-dependent Kinase Inhibitor, AT7519, in Patients with Advanced Cancer: NCIC Clinical Trials Group IND 177</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2262</span>– <span class="NLM_lpage">2267</span>, <span class="refDoi"> DOI: 10.1038/bjc.2014.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fbjc.2014.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25393368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKksr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=2262-2267&author=E.+X.+Chenauthor=S.+Hotteauthor=H.+Hirteauthor=L.+L.+Siuauthor=J.+Lyonsauthor=M.+Squiresauthor=S.+Lovellauthor=S.+Turnerauthor=L.+McIntoshauthor=L.+Seymour&title=A+Phase+I+Study+of+Cyclin-dependent+Kinase+Inhibitor%2C+AT7519%2C+in+Patients+with+Advanced+Cancer%3A+NCIC+Clinical+Trials+Group+IND+177&doi=10.1038%2Fbjc.2014.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177</span></div><div class="casAuthors">Chen, E. X.; Hotte, S.; Hirte, H.; Siu, L. L.; Lyons, J.; Squires, M.; Lovell, S.; Turner, S.; McIntosh, L.; Seymour, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2262-2267</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: AT7519 is a small-mol. inhibitor of multiple cyclin-dependent kinases (CDKs).  It shows encouraging anti-cancer activity against multiple cell lines and in tumor xenografts.  This phase I study was conducted to evaluate the safety and tolerability of AT7519 given as 1-h i.v. infusion on days 1, 4, 8 and 11 every 3 wk.  Methods: Patients with advanced refractory solid tumors or non-Hodgkin's lymphoma were enrolled.  Dose escalation occurred in a 3+3 manner based on toxicity assessment.  Pharmacokinetic samples were collected after first AT7519 infusion, whereas pharmacodynamics (PD) samples were obtained in selected patients.  Results: Thirty-four patients were enrolled, and 32 received study treatments over 4 dose levels.  Dose-limiting toxicities included mucositis, febrile neutropenia, rash, fatigue and hypokalemia.  The recommended phase II dose (RP2D) was 27.0 mg m-2.  Ten of 19 patients evaluable for efficacy had stable disease as the best response (median duration: 3.3 mo; range: 2.5 to 11.1 mo).  There was no clin. significant QTc prolongation.  There was an apparent dose proportional increase in AT7519 exposure.  The PD studies showed redn. in markers of CDK activity in selected patients' skin biopsies post treatment.  Conclusions: AT7519, when administered as an i.v. infusion on days 1, 4, 8 and 11, was well tolerated.  The RP2D is 27.0 mg m-2.  At this dose level, plasma AT7519 concns. were above the biol. active concns., and preliminary anti-cancer activity was obsd. in patients.  This dosing schedule is being further evaluated in multiple phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdHgaphfp-7Vg90H21EOLACvtfcHk0lhl_n-YddhxUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKksr3I&md5=666089cc20121c9903e22e297125882c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.565%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DHotte%26aufirst%3DS.%26aulast%3DHirte%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DS.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520AT7519%252C%2520in%2520Patients%2520with%2520Advanced%2520Cancer%253A%2520NCIC%2520Clinical%2520Trials%2520Group%2520IND%2520177%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D111%26spage%3D2262%26epage%3D2267%26doi%3D10.1038%2Fbjc.2014.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rensvold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretzinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span> <span> </span><span class="NLM_article-title">A Phase I Pharmacokinetic and Pharmacodynamic Study of AT7519, A Cyclin-dependent Kinase Inhibitor in Patients with Refractory Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdq734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fannonc%2Fmdq734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21325451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2137-2143&author=D.+Mahadevanauthor=R.+Plummerauthor=M.+S.+Squiresauthor=D.+Rensvoldauthor=S.+Kurtinauthor=C.+Pretzingerauthor=T.+Dragovichauthor=J.+Adamsauthor=V.+Lockauthor=D.+M.+Smithauthor=D.+Von+Hoffauthor=H.+Calvert&title=A+Phase+I+Pharmacokinetic+and+Pharmacodynamic+Study+of+AT7519%2C+A+Cyclin-dependent+Kinase+Inhibitor+in+Patients+with+Refractory+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdq734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors</span></div><div class="casAuthors">Mahadevan D; Plummer R; Squires M S; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith D M; Von Hoff D; Calvert H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2137-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs).  Based on potent antitumor activity in preclinical models, a first-in-human clinical trial in refractory solid tumors investigated its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD).  PATIENTS AND METHODS:  AT7519 was administered in a '3 + 3' dose- escalation scheme on 5 consecutive days every 3 weeks to patients with advanced, refractory solid tumors.  Samples to monitor AT7519 PK and PD were obtained.  RESULTS:  Twenty-eight patients were treated at seven dose levels (1.8-40 mg/m(2)/day).  At 40 mg/m(2)/day, one patient developed hypotension and ST segment elevation.  At 34 mg/m(2)/day, dose-limiting toxic effects (DLTs) were QTc prolongation with one death (grade 5), fatigue (grade 4) and mucositis (grade 3).  Electrocardiogram review suggested a dose-dependent increase in QTc and recruitment was discontinued without establishing a maximum tolerated dose.  Four patients exhibited stable disease for >6 months and one had a prolonged partial response.  PK profile revealed modest interpatient variation with linear exposure at increasing doses.  Inhibition of markers of CDK activity was observed across the dose range and manifested in antiproliferative activity at a dose of 28 mg/m(2).  CONCLUSION:  AT7519 elicited clinical and PD activity resulting from CDK inhibition at doses below the appearance of DLT of QTc prolongation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7SqqcneEtCi92fW6udTcc2eYbivsBcavuBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVWjug%253D%253D&md5=1ea32b63b87ca82732bf0fbf1f182f0c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq734%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DRensvold%26aufirst%3DD.%26aulast%3DKurtin%26aufirst%3DS.%26aulast%3DPretzinger%26aufirst%3DC.%26aulast%3DDragovich%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DA%2520Phase%2520I%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520AT7519%252C%2520A%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520in%2520Patients%2520with%2520Refractory%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2137%26epage%3D2143%26doi%3D10.1093%2Fannonc%2Fmdq734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. J.</span></span> <span> </span><span class="NLM_article-title">Peripheral White Blood Cell Toxicity Induced by Broad Spectrum Cyclin-dependent Kinase Inhibitors</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/jat.1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fjat.1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17211896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=133-142&author=B.+A.+Jessenauthor=L.+Leeauthor=T.+Koudriakovaauthor=M.+Hainesauthor=K.+Lundgrenauthor=S.+Priceauthor=J.+Nonomiyaauthor=C.+Lewisauthor=G.+J.+Stevens&title=Peripheral+White+Blood+Cell+Toxicity+Induced+by+Broad+Spectrum+Cyclin-dependent+Kinase+Inhibitors&doi=10.1002%2Fjat.1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Jessen, Bart A.; Lee, Leo; Koudriakova, Tatiana; Haines, Morgan; Lundgren, Karen; Price, Sharon; Nonomiya, Jim; Lewis, Cristina; Stevens, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) were pursued for more than a decade for the treatment of cancer.  CDK inhibitors are expected to slow the rate of cell division and potentially increase the apoptotic fraction of rapidly dividing cells.  Although CDK activity is often increased in tumors, normal dividing tissues are also susceptible to the cytostatic and cytotoxic effects of CDK inhibitor action.  Therefore the typical toxicity profile assocd. with cytotoxic anti-cancer therapy, bone marrow suppression and gastrointestinal toxicity, is expected with CDK inhibitors.  Bone marrow toxicity and the ensuing delayed peripheral leukocyte suppression often limit the therapeutic application of cytotoxic anticancer drugs.  Here we characterize an unusual bone marrow-independent acute toxicity toward leukocytes from broad spectrum CDK inhibitors in monkeys and rodents.  The potential combination of both acute and delayed immunosuppression would likely further restrict the application of these particular compds.  Since the cells targeted were non-proliferating, it was assumed that the toxicity was not driven by the intended pharmacol. mechanism thereby facilitating the development of a testing strategy to identify compds. with a reduced potential for acute leukocyte toxicity.  This testing strategy resulted in a CDK inhibitor void of bone marrow-independent leukocyte toxicity that is currently undergoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiTrhjO_2vsbVg90H21EOLACvtfcHk0lj0D4vvu2-Acw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D&md5=d8d707eaa40d555e176c15336c8e885b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fjat.1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1177%26sid%3Dliteratum%253Aachs%26aulast%3DJessen%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DHaines%26aufirst%3DM.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%2BJ.%26atitle%3DPeripheral%2520White%2520Blood%2520Cell%2520Toxicity%2520Induced%2520by%2520Broad%2520Spectrum%2520Cyclin-dependent%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2007%26volume%3D27%26spage%3D133%26epage%3D142%26doi%3D10.1002%2Fjat.1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkhivker, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AG-024322 is a Multi-Targeted CDK Inhibitor with Potent Antitumor Activity <i>In vivo</i></span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1044-1045&author=C.+C.+Zhangauthor=G.+Trocheauthor=Z.+Yanauthor=M.+E.+Arangoauthor=J.+Higginsauthor=D.+Romeroauthor=S.+Kephartauthor=I.+McAlpineauthor=T.+Koudriakovaauthor=J.+Skaptasonauthor=J.+Nonomiyaauthor=D.+Knightonauthor=R.+A.+Ferreauthor=J.+Tikheauthor=G.+Verkhivker&title=AG-024322+is+a+Multi-Targeted+CDK+Inhibitor+with+Potent+Antitumor+Activity+In+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BC.%26aulast%3DTroche%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DTikhe%26aufirst%3DJ.%26aulast%3DVerkhivker%26aufirst%3DG.%26atitle%3DAG-024322%2520is%2520a%2520Multi-Targeted%2520CDK%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activity%2520In%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1044%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), A Novel and Potent Cyclin-dependent Kinase Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oft&title=Dinaciclib+%28SCH+727965%29%2C+A+Novel+and+Potent+Cyclin-dependent+Kinase+Inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lj0D4vvu2-Acw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520A%2520Novel%2520and%2520Potent%2520Cyclin-dependent%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karikari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Laguna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasheed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenhof, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeshkumar, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B. D.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase Inhibitor Dinaciclib (SCH727965) Inhibits Pancreatic Cancer Growth and Progression in Murine Xenograft Models</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.4161/cbt.12.7.16475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcbt.12.7.16475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21768779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1yitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=598-609&author=G.+Feldmannauthor=A.+Mishraauthor=S.+Bishtauthor=C.+Karikariauthor=I.+Garrido-Lagunaauthor=Z.+Rasheedauthor=N.+A.+Ottenhofauthor=T.+Dadonauthor=H.+Alvarezauthor=V.+Fendrichauthor=N.+V.+Rajeshkumarauthor=W.+Matsuiauthor=P.+Brossartauthor=M.+Hidalgoauthor=R.+Bannerjiauthor=A.+Maitraauthor=B.+D.+Nelkin&title=Cyclin-dependent+Kinase+Inhibitor+Dinaciclib+%28SCH727965%29+Inhibits+Pancreatic+Cancer+Growth+and+Progression+in+Murine+Xenograft+Models&doi=10.4161%2Fcbt.12.7.16475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models</span></div><div class="casAuthors">Feldmann, Georg; Mishra, Anjali; Bisht, Savita; Karikari, Collins; Garrido-Laguna, Ignacio; Rasheed, Zeshaan; Ottenhof, Niki A.; Dadon, Tikva; Alvarez, Hector; Fendrich, Volker; Rajeshkumar, N. V.; Matsui, William; Brossart, Peter; Hidalgo, Manuel; Bannedi, Rajat; Maitra, Anirban; Nelkin, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">598-609</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the most lethal of human malignancies, and potent therapeutic options are lacking.  Inhibition of cell cycle progression through pharmacol. blockade of cyclin-dependent kinases (CDK) has been suggested as a potential treatment option for human cancers with deregulated cell cycle control.  Dinaciclib (SCH727965) is a novel small mol. multi-CDK inhibitor with low nanomolar potency against CDK1, CDK2, CDK5 and CDK9 that has shown favorable toxicity and efficacy in preliminary mouse expts., and has been well tolerated in phase I clin. trials.  In the current study, the therapeutic efficacy of SCH727965 on human pancreatic cancer cells was tested using in vitro and in vivo model systems.  Treatment with SCH727965 significantly reduced in vitro cell growth, motility and colony formation in soft agar of MIAPaCa-2 and Pa20C cells.  These phenotypic changes were accompanied by marked redn. of phosphorylation of Retinoblastoma (Rb) and reduced activation of RalA.  Single agent therapy with SCH727965 (40 mg/kg i.p. twice weekly) for 4 wk significantly reduced s.c. tumor growth in 10/10 (100%) of tested low-passage human pancreatic cancer xenografts.  Treatment of low passage pancreatic cancer xenografts with a combination of SCH727965 and gemcitabine was significantly more effective than either agent alone.  Gene Set Enrichment Anal. identified overrepresentation of the Notch and Transforming Growth Factor-β (TGFβ) signaling pathways in the xenografts least responsive to SCH727965 treatment.  Treatment with the cyclin-dependent kinase inhibitor SCH727965 alone or in combination is a highly promising novel exptl. therapeutic strategy against pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKxXezCaUs9bVg90H21EOLACvtfcHk0lh0yAfzQpvHxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1yitro%253D&md5=1edbe3fd0d2e95a362cf30cc41230293</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.7.16475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.7.16475%26sid%3Dliteratum%253Aachs%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DKarikari%26aufirst%3DC.%26aulast%3DGarrido-Laguna%26aufirst%3DI.%26aulast%3DRasheed%26aufirst%3DZ.%26aulast%3DOttenhof%26aufirst%3DN.%2BA.%26aulast%3DDadon%26aufirst%3DT.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DFendrich%26aufirst%3DV.%26aulast%3DRajeshkumar%26aufirst%3DN.%2BV.%26aulast%3DMatsui%26aufirst%3DW.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DNelkin%26aufirst%3DB.%2BD.%26atitle%3DCyclin-dependent%2520Kinase%2520Inhibitor%2520Dinaciclib%2520%2528SCH727965%2529%2520Inhibits%2520Pancreatic%2520Cancer%2520Growth%2520and%2520Progression%2520in%2520Murine%2520Xenograft%2520Models%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D598%26epage%3D609%26doi%3D10.4161%2Fcbt.12.7.16475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-dependent Kinases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1021/ml100051d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100051d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFWis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=204-208&author=K.+Paruchauthor=M.+P.+Dwyerauthor=C.+Alvarezauthor=C.+Brownauthor=T.-Y.+Chanauthor=R.+J.+Dollauthor=K.+Keertikarauthor=C.+Knutsonauthor=B.+McKittrickauthor=J.+Riveraauthor=R.+Rossmanauthor=G.+Tuckerauthor=T.+Fischmannauthor=A.+Hruzaauthor=V.+Madison&title=Discovery+of+Dinaciclib+%28SCH+727965%29%3A+A+Potent+and+Selective+Inhibitor+of+Cyclin-dependent+Kinases&doi=10.1021%2Fml100051d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Paruch, Kamil; Dwyer, Michael P.; Alvarez, Carmen; Brown, Courtney; Chan, Tin-Yau; Doll, Ronald J.; Keertikar, Kerry; Knutson, Chad; McKittrick, Brian; Rivera, Jocelyn; Rossman, Randall; Tucker, Greg; Fischmann, Thierry; Hruza, Alan; Madison, Vincent; Nomeir, Amin A.; Wang, Yaolin; Kirschmeier, Paul; Lees, Emma; Parry, David; Sgambellone, Nicole; Seghezzi, Wolfgang; Schultz, Lesley; Shanahan, Frances; Wiswell, Derek; Xu, Xiaoying; Zhou, Quiao; James, Ray A.; Paradkar, Vidyadhar M.; Park, Haengsoon; Rokosz, Laura R.; Stauffer, Tara M.; Guzi, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncol. therapeutics.  Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability.  This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrwrMq6CW6rVg90H21EOLACvtfcHk0lh0yAfzQpvHxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFWis78%253D&md5=3b982547e064f658748fe4887a208659</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fml100051d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100051d%26sid%3Dliteratum%253Aachs%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DT.-Y.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DKnutson%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520Dinaciclib%2520%2528SCH%2520727965%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D204%26epage%3D208%26doi%3D10.1021%2Fml100051d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">A cyclin-dependent Kinase Inhibitor, Dinaciclib in Preclinical Treatment Models of Thyroid Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0172315</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0172315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1371%2Fjournal.pone.0172315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28207834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvV2js70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0172315&author=S.+F.+Linauthor=J.+D.+Linauthor=C.+Hsuehauthor=T.+C.+Chouauthor=R.+J.+Wong&title=A+cyclin-dependent+Kinase+Inhibitor%2C+Dinaciclib+in+Preclinical+Treatment+Models+of+Thyroid+Cancer&doi=10.1371%2Fjournal.pone.0172315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer</span></div><div class="casAuthors">Lin, Shu-Fu; Lin, Jen-Der; Hsueh, Chuen; Chou, Ting-Chao; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0172315/1-e0172315/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer.  Materials and methods: Seven cell lines originating from three pathol. types of thyroid cancer (papillary, follicular and anaplastic) were studied.  The cytotoxicity of dinaciclib was measured using a lactate dehydrogenase assay.  The expression of proteins assocd. with cell cycle and apoptosis was assessed using Western blot anal. and immunofluorescence microscopy.  Cell cycle distribution was measured by flow cytometry and immunofluorescence microscopy.  Apoptosis and caspase-3 activity were measured by flow cytometry and fluorometric assay.  Mice bearing flank anaplastic thyroid cancer (ATC) were treated with i.p. injections of dinaciclib.  Results: Dinaciclib inhibited thyroid cancer cell proliferation in a dose-dependent manner.  Dinaciclib had a low median-effect dose (≤ 16.0 nM) to inhibit cell proliferation in seven thyroid cancer cell lines.  Dinaciclib decreased CDK1, cyclin B1, and Aurora A expression, induced cell cycle arrest in the G2/M phase, and induced accumulation of prophase mitotic cells.  Dinaciclib decreased Mcl-1, Bcl-xL and survivin expression, activated caspase-3 and induced apoptosis.  In vivo, the growth of ATC xenograft tumors was retarded in a dose-dependent fashion with daily dinaciclib treatment.  Higher-dose dinaciclib (50 mg/kg) caused slight, but significant wt. loss, which was absent with lower-dose dinaciclib (40 mg/kg) treatment.  Conclusions: Dinaciclib inhibited thyroid cancer proliferation both in vitro and in vivo.  These findings support dinaciclib as a potential drug for further studies in clin. trials for the treatment of patients with refractory thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEykCdurzeXrVg90H21EOLACvtfcHk0lh0yAfzQpvHxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvV2js70%253D&md5=a849ddd6669c23b1c966a469ce810fb9</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0172315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0172315%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DJ.%2BD.%26aulast%3DHsueh%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DT.%2BC.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DA%2520cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520Dinaciclib%2520in%2520Preclinical%2520Treatment%2520Models%2520of%2520Thyroid%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0172315%26doi%3D10.1371%2Fjournal.pone.0172315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieerkehazhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiple CDK Inhibitor Dinaciclib Suppresses Neuroblastoma Growth <i>via</i> Inhibiting CDK2 and CDK9 Activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29090</span>, <span class="refDoi"> DOI: 10.1038/srep29090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsrep29090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27378523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29090&author=Z.+Chenauthor=Z.+Wangauthor=J.+C.+Pangauthor=Y.+Yuauthor=S.+Bieerkehazhiauthor=J.+Luauthor=T.+Huauthor=Y.+Zhaoauthor=X.+Xuauthor=H.+Zhangauthor=J.+S.+Yiauthor=S.+Liuauthor=J.+Yang&title=Multiple+CDK+Inhibitor+Dinaciclib+Suppresses+Neuroblastoma+Growth+via+Inhibiting+CDK2+and+CDK9+Activity&doi=10.1038%2Fsrep29090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span></div><div class="casAuthors">Chen, Zhenghu; Wang, Zhenyu; Pang, Jonathan C.; Yu, Yang; Bieerkehazhi, Shayahati; Lu, Jiaxiong; Hu, Ting; Zhao, Yanling; Xu, Xin; Zhang, Hong; Yi, Joanna S.; Liu, Shangfeng; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29090</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approx. 15% of cancer-related mortality in children.  Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contribute to tumor cell progression in many cancers including NB.  Therefore, small mol. inhibitors of CDKs comprise a strategic option in cancer therapy.  Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.  Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16).  Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse model of two NB cell lines and blocked tumor development in the TH-MYCN transgenic NB mouse model.  Taken together, this study suggests that CDK2 and CDK9 are potential therapeutic targets in NB and that abrogating CDK2 and CDK9 activity by small mols. like dinaciclib is a promising strategy and a treatment option for NB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpobqy7FGRmgLVg90H21EOLACvtfcHk0lj5tCxuxstt1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M&md5=056d13b71230bd6cbe127371ea5ca3f3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fsrep29090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29090%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBieerkehazhi%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiple%2520CDK%2520Inhibitor%2520Dinaciclib%2520Suppresses%2520Neuroblastoma%2520Growth%2520via%2520Inhibiting%2520CDK2%2520and%2520CDK9%2520Activity%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D29090%26doi%3D10.1038%2Fsrep29090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moharram, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the CDK Inhibitor Dinaciclib <i>in vitro</i> and <i>in vivo</i> in T-cell Acute Lymphoblastic Leukemia</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.canlet.2017.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28756008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1CkurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2017&pages=73-78&author=S.+A.+Moharramauthor=K.+Shahauthor=F.+Khanumauthor=A.+Marhallauthor=M.+Gaziauthor=J.+U.+Kazi&title=Efficacy+of+the+CDK+Inhibitor+Dinaciclib+in+vitro+and+in+vivo+in+T-cell+Acute+Lymphoblastic+Leukemia&doi=10.1016%2Fj.canlet.2017.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Moharram, Sausan A.; Shah, Kinjal; Khanum, Fatima; Marhaell, Alissa; Gazi, Mohiuddin; Kazi, Julhash U.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease of the blood affecting children, adolescents and adults.  Although current treatment protocols for T-ALL have improved overall survival, a portion of T-ALL patients still experiences treatment failure.  Thus, the development of novel therapies is needed.  In this study, we used several patient-derived T-ALL cell lines to screen for an effective drug for T-ALL.  Using a panel of 378 inhibitors against different kinases, we identified the CDK inhibitor dinaciclib as a potential drug for T-ALL.  Dinaciclib treatment significantly reduced cell viability and completely blocked colony formation.  Furthermore, cells treated with dinaciclib showed decreased expression of several pro-survival proteins including survivin, cyclin T1 and c-MYC.  Dinaciclib treatment also increased accumulation of cells in G2/M phase and significantly induced apoptosis.  Finally, dinaciclib extended survival of mice in a T-ALL cell xenograft model.  Collectively, these data suggest that the CDK inhibitor dinaciclib is an active drug for T-ALL in the preclin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptsRZLPpSpE7Vg90H21EOLACvtfcHk0lj5tCxuxstt1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1CkurbF&md5=873f899cd70d91a1afe2bec1b7c8b1d5</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DMoharram%26aufirst%3DS.%2BA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DKhanum%26aufirst%3DF.%26aulast%3DMarhall%26aufirst%3DA.%26aulast%3DGazi%26aufirst%3DM.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DEfficacy%2520of%2520the%2520CDK%2520Inhibitor%2520Dinaciclib%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520T-cell%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D405%26spage%3D73%26epage%3D78%26doi%3D10.1016%2Fj.canlet.2017.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarfo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathiraja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derosier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrary
Sisk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Dinaciclib <i>vs</i> Ofatumumab in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1876</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-748210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1182%2Fblood-2016-10-748210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28126927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1876-1878&author=P.+Ghiaauthor=L.+Scarfoauthor=S.+Perezauthor=K.+Pathirajaauthor=M.+Derosierauthor=K.+Smallauthor=C.+McCrary%0ASiskauthor=N.+Patton&title=Efficacy+and+Safety+of+Dinaciclib+vs+Ofatumumab+in+Patients+with+Relapsed%2Frefractory+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fblood-2016-10-748210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Ghia, Paolo; Scarfo, Lydia; Perez, Susan; Pathiraja, Kumudu; Derosier, Martha; Small, Karen; Sisk, Christine McCrary; Patton, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1876-1878</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article relates to results of a randomized, open-label, phase 3 trial designed to compare the efficacy and tolerability of dinaciclib with ofatumumab in patients with relapsed/refractory CLL.  This article relates to potential antileukemic activity and signals an acceptable safety and tolerability profile of dinaciclib compared with ofatumumab in patients with relapsed/refractory CLL, even among high-risk subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBDG-gJoqKebVg90H21EOLACvtfcHk0lj5tCxuxstt1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7vL&md5=aa30f64f5458fb0def0ad959ab58d666</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-748210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-748210%26sid%3Dliteratum%253Aachs%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DScarfo%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPathiraja%26aufirst%3DK.%26aulast%3DDerosier%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DMcCrary%2BSisk%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DN.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Dinaciclib%2520vs%2520Ofatumumab%2520in%2520Patients%2520with%2520Relapsed%252Frefractory%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1876%26epage%3D1878%26doi%3D10.1182%2Fblood-2016-10-748210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saladino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D.</span></span> <span> </span><span class="NLM_article-title">CYC065, Potential Therapeutic Agent for AML and MLL Leukaemia</span>. <i>Clin. Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">S183</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2015.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.clml.2015.04.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=S183&author=S.+Frameauthor=C.+Saladinoauthor=S.+Davisauthor=D.+Blakeauthor=D.+Zheleva&title=CYC065%2C+Potential+Therapeutic+Agent+for+AML+and+MLL+Leukaemia&doi=10.1016%2Fj.clml.2015.04.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DS.%26aulast%3DSaladino%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DD.%26aulast%3DZheleva%26aufirst%3DD.%26atitle%3DCYC065%252C%2520Potential%2520Therapeutic%2520Agent%2520for%2520AML%2520and%2520MLL%2520Leukaemia%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26spage%3DS183%26doi%3D10.1016%2Fj.clml.2015.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, P. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">djw297</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fjnci%2Fdjw297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=djw297&author=M.+Kawakamiauthor=L.+M.+Mustachioauthor=J.+Rodriguez-Canalesauthor=B.+Minoauthor=J.+Roszikauthor=P.+Tongauthor=J.+Wangauthor=J.+J.+Leeauthor=J.+H.+Myungauthor=J.+V.+Heymachauthor=F.+M.+Johnsonauthor=S.+Hongauthor=L.+Zhengauthor=S.+Huauthor=P.+A.+Villalobos&title=Next-Generation+CDK2%2F9+Inhibitors+and+Anaphase+Catastrophe+in+Lung+Cancer&doi=10.1093%2Fjnci%2Fdjw297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw297%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DMino%26aufirst%3DB.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DMyung%26aufirst%3DJ.%2BH.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DJohnson%26aufirst%3DF.%2BM.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DVillalobos%26aufirst%3DP.%2BA.%26atitle%3DNext-Generation%2520CDK2%252F9%2520Inhibitors%2520and%2520Anaphase%2520Catastrophe%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2017%26volume%3D109%26spage%3Ddjw297%26doi%3D10.1093%2Fjnci%2Fdjw297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1000394, A Novel Cyclin-dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono-and in Combination Treatment upon Oral Application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&author=G.+Siemeisterauthor=U.+L%C3%BCckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+1000394%2C+A+Novel+Cyclin-dependent+Kinase+Inhibitor%2C+with+Potent+Antitumor+Activity+in+Mono-and+in+Combination+Treatment+upon+Oral+Application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0liThPYoMSiqTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%25201000394%252C%2520A%2520Novel%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Mono-and%2520in%2520Combination%2520Treatment%2520upon%2520Oral%2520Application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, A Novel Oral Multi-kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+A+Novel+Oral+Multi-kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0liThPYoMSiqTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520A%2520Novel%2520Oral%2520Multi-kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covaciu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonmassar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Atri, S.</span></span> <span> </span><span class="NLM_article-title">The Cyclin-dependent Kinase Inhibitor PHA-848125 Suppresses the <i>In vitro</i> Growth of Human Melanomas Sensitive or Resistant to Temozolomide, and Shows Synergistic Effects in Combination with this Triazene Compound</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2009.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.phrs.2009.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20026273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=437-448&author=S.+Caporaliauthor=E.+Alvinoauthor=G.+Staraceauthor=M.+Ciomeiauthor=M.+G.+Brascaauthor=L.+Levatiauthor=A.+Garbinauthor=D.+Castigliaauthor=C.+Covaciuauthor=E.+Bonmassarauthor=S.+D%E2%80%99Atri&title=The+Cyclin-dependent+Kinase+Inhibitor+PHA-848125+Suppresses+the+In+vitro+Growth+of+Human+Melanomas+Sensitive+or+Resistant+to+Temozolomide%2C+and+Shows+Synergistic+Effects+in+Combination+with+this+Triazene+Compound&doi=10.1016%2Fj.phrs.2009.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound</span></div><div class="casAuthors">Caporali, Simona; Alvino, Ester; Starace, Giuseppe; Ciomei, Marina; Brasca, Maria Gabriella; Levati, Lauretta; Garbin, Alberto; Castiglia, Daniele; Covaciu, Claudia; Bonmassar, Enzo; D'Atri, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">437-448</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PHA-848125 is a novel cyclin-dependent kinase inhibitor under Phase I/II clin. investigation.  In this study, we describe, for the first time, the effect of PHA-848125 on human melanoma cells in vitro.  Seven melanoma cell lines with different sensitivity to temozolomide (TMZ) were exposed to PHA-848125 for 5 days and then assayed for cell growth.  In all cases, including TMZ-resistant cells, PHA-848125 IC50 values were significantly below the max. plasma concns. achievable in the clinic.  In the most PHA-848125-sensitive cell line, the drug caused a concn.-dependent G1 arrest.  PHA-848125 also impaired phosphorylation of the retinoblastoma protein at CDK2 and CDK4 specific sites, decreased retinoblastoma protein and cyclin A levels, and increased p21Cip1, p27Kip1 and p53 expression.  Combined treatment with fixed ratios of TMZ plus PHA-848125 was studied in three melanoma cell lines.  PHA-848125 was added to the cells 48 h after TMZ and cell growth was evaluated after 3 addnl. days of culture.  Parallel expts. were performed in the presence of O6-benzylguanine (BG), to prevent repair of Me adducts at O6-guanine induced by TMZ.  Drug combination of TMZ plus BG and PHA-848125 produced additive or synergistic effects on cell growth, depending on the cell line.  In the absence of BG, the combination was still more active than the single agents in the cell line moderately sensitive to TMZ, but comparable to PHA-848125 alone in the two TMZ-resistant cell lines.  When TMZ plus BG were used in combination with PHA-848125 against cultured normal melanocytes, neither synergistic nor additive antiproliferative effects were obsd.  Our results indicate that PHA-848125 can have a therapeutic potential in melanoma patients, alone or combined with TMZ.  Moreover this agent appears to be particularly attractive on the bases of its effectiveness against TMZ-resistant melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvf6wmJ-DGabVg90H21EOLACvtfcHk0lh1xfwjyh9D5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCitL8%253D&md5=ecae4f53c2ee5100cfbc79a9742ed7fc</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DCaporali%26aufirst%3DS.%26aulast%3DAlvino%26aufirst%3DE.%26aulast%3DStarace%26aufirst%3DG.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DLevati%26aufirst%3DL.%26aulast%3DGarbin%26aufirst%3DA.%26aulast%3DCastiglia%26aufirst%3DD.%26aulast%3DCovaciu%26aufirst%3DC.%26aulast%3DBonmassar%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Atri%26aufirst%3DS.%26atitle%3DThe%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520PHA-848125%2520Suppresses%2520the%2520In%2520vitro%2520Growth%2520of%2520Human%2520Melanomas%2520Sensitive%2520or%2520Resistant%2520to%2520Temozolomide%252C%2520and%2520Shows%2520Synergistic%2520Effects%2520in%2520Combination%2520with%2520this%2520Triazene%2520Compound%26jtitle%3DPharmacol.%2520Res.%26date%3D2010%26volume%3D61%26spage%3D437%26epage%3D448%26doi%3D10.1016%2Fj.phrs.2009.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), A Potent, Orally Available Cyclin Dependent Kinase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1021/jm9006559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-Tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+A+Potent%2C+Orally+Available+Cyclin+Dependent+Kinase+Inhibitor&doi=10.1021%2Fjm9006559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-Tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520A%2520Potent%252C%2520Orally%2520Available%2520Cyclin%2520Dependent%2520Kinase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163%26doi%3D10.1021%2Fjm9006559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giusti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of PHA-848125, A Cyclin-dependent Kinase Inhibitor, on the K-Ras(G12D)LA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-09-0726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20197397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=673-681&author=A.+Degrassiauthor=M.+Russoauthor=C.+Nanniauthor=V.+Pattonauthor=R.+Alzaniauthor=A.+M.+Giustiauthor=S.+Fantiauthor=M.+Ciomeiauthor=E.+Pesentiauthor=G.+Texido&title=Efficacy+of+PHA-848125%2C+A+Cyclin-dependent+Kinase+Inhibitor%2C+on+the+K-Ras%28G12D%29LA2+Lung+Adenocarcinoma+Transgenic+Mouse+Model%3A+Evaluation+by+Multimodality+Imaging&doi=10.1158%2F1535-7163.MCT-09-0726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging</span></div><div class="casAuthors">Degrassi, Anna; Russo, Micaela; Nanni, Cristina; Patton, Veronica; Alzani, Rachele; Giusti, Anna M.; Fanti, Stefano; Ciomei, Marina; Pesenti, Enrico; Texido, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-681</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">K-ras is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), the most common form of lung cancer.  Recent studies indicate that NSCLC patients with mutant K-ras do not respond to epidermal growth factor receptor inhibitors.  In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clin. trial, on a transgenic mouse model, K-RasG12DLA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.  We used magnetic resonance imaging and positron emission tomog. to follow longitudinally disease progression and evaluate therapeutic efficacy in this model.  Treatment of K-RasG12DLA2 mice with 40 mg/kg twice daily for 10 days with PHA-848125 induced a significant tumor growth inhibition at the end of treatment (P < 0.005) and this was accompanied by a redn. in the cell membrane turnover, as seen by 11C-Choline-positron emission tomog. (P < 0.05).  Magnetic resonance imaging data were validated vs. histol. and the mechanism of action of the compd. was verified by immunohistochem., using cyclin-dependent kinase-related biomarkers phospho-Retinoblastoma and cyclin A.  In this study, multimodality imaging was successfully used for the preclin. assessment of PHA-848125 therapeutic efficacy on a lung adenocarcinoma mouse model.  This compd. induced a volumetric and metabolic anticancer effect and could represent a valid therapeutic approach for NSCLC patients with mutant K-ras.  Mol Cancer Ther; 9(3); 673-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUdhs7i0u7T7Vg90H21EOLACvtfcHk0lh1xfwjyh9D5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensL8%253D&md5=d3f302a36706c2e6a1f6c28b1cba9962</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0726%26sid%3Dliteratum%253Aachs%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DGiusti%26aufirst%3DA.%2BM.%26aulast%3DFanti%26aufirst%3DS.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DTexido%26aufirst%3DG.%26atitle%3DEfficacy%2520of%2520PHA-848125%252C%2520A%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520on%2520the%2520K-Ras%2528G12D%2529LA2%2520Lung%2520Adenocarcinoma%2520Transgenic%2520Mouse%2520Model%253A%2520Evaluation%2520by%2520Multimodality%2520Imaging%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D673%26epage%3D681%26doi%3D10.1158%2F1535-7163.MCT-09-0726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancera, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skylaris, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciacchi, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, M. C.</span></span> <span> </span><span class="NLM_article-title">Novel Structural Features of CDK Inhibition Revealed by <i>an ab Initio</i> Computational Method Combined with Dynamic Simulations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5141</span>– <span class="NLM_lpage">5153</span>, <span class="refDoi"> DOI: 10.1021/jm060190+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060190%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5141-5153&author=L.+Headyauthor=M.+Fernandez-Serraauthor=R.+L.+Manceraauthor=S.+Joyceauthor=A.+R.+Venkitaramanauthor=E.+Artachoauthor=C.+K.+Skylarisauthor=L.+C.+Ciacchiauthor=M.+C.+Payne&title=Novel+Structural+Features+of+CDK+Inhibition+Revealed+by+an+ab+Initio+Computational+Method+Combined+with+Dynamic+Simulations&doi=10.1021%2Fjm060190%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm060190%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060190%252B%26sid%3Dliteratum%253Aachs%26aulast%3DHeady%26aufirst%3DL.%26aulast%3DFernandez-Serra%26aufirst%3DM.%26aulast%3DMancera%26aufirst%3DR.%2BL.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26aulast%3DArtacho%26aufirst%3DE.%26aulast%3DSkylaris%26aufirst%3DC.%2BK.%26aulast%3DCiacchi%26aufirst%3DL.%2BC.%26aulast%3DPayne%26aufirst%3DM.%2BC.%26atitle%3DNovel%2520Structural%2520Features%2520of%2520CDK%2520Inhibition%2520Revealed%2520by%2520an%2520ab%2520Initio%2520Computational%2520Method%2520Combined%2520with%2520Dynamic%2520Simulations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5141%26epage%3D5153%26doi%3D10.1021%2Fjm060190%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Purine and Pyrimidine Cyclin-dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2797</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.1021/jm990628o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990628o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2797-2804&author=C.+E.+Arrisauthor=F.+T.+Boyleauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=E.+F.+Garmanauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=S.+Grantauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=A.+M.+Lawrieauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=E.+A.+Sausvilleauthor=R.+Schultzauthor=W.+Yu&title=Identification+of+Novel+Purine+and+Pyrimidine+Cyclin-dependent+Kinase+Inhibitors+with+Distinct+Molecular+Interactions+and+Tumor+Cell+Growth+Inhibition+Profiles&doi=10.1021%2Fjm990628o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm990628o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990628o%26sid%3Dliteratum%253Aachs%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGarman%26aufirst%3DE.%2BF.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520Novel%2520Purine%2520and%2520Pyrimidine%2520Cyclin-dependent%2520Kinase%2520Inhibitors%2520with%2520Distinct%2520Molecular%2520Interactions%2520and%2520Tumor%2520Cell%2520Growth%2520Inhibition%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2797%26epage%3D2804%26doi%3D10.1021%2Fjm990628o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, H. J.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of a Potent Purine-based Cyclin-dependent Kinase Inhibitor</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1038/nsb842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnsb842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=745-749&author=T.+G.+Daviesauthor=J.+Bentleyauthor=C.+E.+Arrisauthor=F.+T.+Boyleauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=I.+R.+Hardcastleauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=J.+A.+Tuckerauthor=L.+Wangauthor=H.+J.+Whitfield&title=Structure-based+Design+of+a+Potent+Purine-based+Cyclin-dependent+Kinase+Inhibitor&doi=10.1038%2Fnsb842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnsb842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb842%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhitfield%26aufirst%3DH.%2BJ.%26atitle%3DStructure-based%2520Design%2520of%2520a%2520Potent%2520Purine-based%2520Cyclin-dependent%2520Kinase%2520Inhibitor%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D745%26epage%3D749%26doi%3D10.1038%2Fnsb842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span> <span> </span><span class="NLM_article-title">4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00884-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-894X%2802%2900884-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=217-222&author=V.+Mesguicheauthor=R.+J.+Parsonsauthor=C.+E.+Arrisauthor=J.+Bentleyauthor=F.+T.+Boyleauthor=N.+J.+Curtinauthor=T.+G.+Daviesauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=L.+Z.+Wangauthor=I.+R.+Hardcastle&title=4-Alkoxy-2%2C6-diaminopyrimidine+Derivatives%3A+Inhibitors+of+Cyclin+Dependent+Kinases+1+and+2&doi=10.1016%2FS0960-894X%2802%2900884-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900884-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900884-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DParsons%26aufirst%3DR.%2BJ.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26atitle%3D4-Alkoxy-2%252C6-diaminopyrimidine%2520Derivatives%253A%2520Inhibitors%2520of%2520Cyclin%2520Dependent%2520Kinases%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D217%26epage%3D222%26doi%3D10.1016%2FS0960-894X%2802%2900884-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyerol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, H. J.</span></span> <span> </span><span class="NLM_article-title">N2-Substituted O6-cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-dependent Kinases 1 and 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3710</span>– <span class="NLM_lpage">3722</span>, <span class="refDoi"> DOI: 10.1021/jm0311442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0311442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3710-3722&author=I.+R.+Hardcastleauthor=C.+E.+Arrisauthor=J.+Bentleyauthor=F.+T.+Boyleauthor=Y.+Chenauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=J.+Menyerolauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=D.+J.+Prattauthor=L.+Z.+Wangauthor=H.+J.+Whitfield&title=N2-Substituted+O6-cyclohexylmethylguanine+Derivatives%3A+Potent+Inhibitors+of+Cyclin-dependent+Kinases+1+and+2&doi=10.1021%2Fjm0311442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2</span></div><div class="casAuthors">Hardcastle, Ian R.; Arris, Christine E.; Bentley, Johanne; Boyle, F. Thomas; Chen, Yuzhu; Curtin, Nicola J.; Endicott, Jane A.; Gibson, Ashleigh E.; Golding, Bernard T.; Griffin, Roger J.; Jewsbury, Philip; Menyerol, Jerome; Mesguiche, Veronique; Newell, David R.; Noble, Martin E. M.; Pratt, David J.; Wang, Lan-Zhen; Whitfield, Hayley J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3710-3722</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ATP competitive cyclin-dependent kinase inhibitor O6-cyclohexylmethylguanine (NU2058, 1) has been employed as the lead in a structure-based drug discovery program resulting in the discovery of the potent CDK1 and -2 inhibitor NU6102 (3, IC50 = 9.5 nM and 5.4 nM vs CDK1/cyclin B and CDK2/cyclin A3, resp.).  The SAR for this series have been explored further by the synthesis and evaluation of 45 N2-substituted analogs of NU2058.  These studies have confirmed the requirement for the hydrogen bonding N2-NH group and the requirement for an arom. N2-substituent to confer potency in the series.  Addnl. potency is conferred by the presence of a group capable of donating a hydrogen bond at the 4'-position, for example, the 4'-hydroxy deriv. (25, IC50 = 94 nM and 69 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.), 4'-monomethylsulfonamide deriv. (28, IC50 = 9 nM and 7.0 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.), and 4'-carboxamide deriv. (34, IC50 = 67 nM and 64 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.).  X-ray crystal structures have been obtained for key compds. and have been used to explain the obsd. trends in activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdDB9D6YHzKLVg90H21EOLACvtfcHk0licZd8RP3HQWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gisbg%253D&md5=305eef50961c3f1ffad033cf9ab18c3f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm0311442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0311442%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DMenyerol%26aufirst%3DJ.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWhitfield%26aufirst%3DH.%2BJ.%26atitle%3DN2-Substituted%2520O6-cyclohexylmethylguanine%2520Derivatives%253A%2520Potent%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%25201%2520and%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3710%26epage%3D3722%26doi%3D10.1021%2Fjm0311442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayle, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggerty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of 2-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1577</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1039/b703241b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1039%2Fb703241b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=1577-1585&author=F.+Marchettiauthor=K.+L.+Sayleauthor=J.+Bentleyauthor=W.+Cleggauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=K.+Haggertyauthor=R.+W.+Harringtonauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=R.+J.+Parsonsauthor=D.+J.+Prattauthor=L.+Z.+Wangauthor=I.+R.+Hardcastle&title=Structure-based+Design+of+2-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.1039%2Fb703241b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1039%2Fb703241b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703241b%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DF.%26aulast%3DSayle%26aufirst%3DK.%2BL.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DClegg%26aufirst%3DW.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHarrington%26aufirst%3DR.%2BW.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DParsons%26aufirst%3DR.%2BJ.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26atitle%3DStructure-based%2520Design%2520of%25202-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2007%26volume%3D5%26spage%3D1577%26epage%3D1585%26doi%3D10.1039%2Fb703241b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaurasia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A New Scaffold Endowed with Potent CDK2 Inhibitory Activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.ejmech.2013.07.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=333-338&author=D.+Boschiauthor=P.+Toscoauthor=N.+Chandraauthor=S.+Chaurasiaauthor=R.+Frutteroauthor=R.+Griffinauthor=L.+Z.+Wangauthor=A.+Gasco&title=6-Cyclohexylmethoxy-5-%28cyano-NNO-azoxy%29pyrimidine-4-amine%3A+A+New+Scaffold+Endowed+with+Potent+CDK2+Inhibitory+Activity&doi=10.1016%2Fj.ejmech.2013.07.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DBoschi%26aufirst%3DD.%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DChandra%26aufirst%3DN.%26aulast%3DChaurasia%26aufirst%3DS.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3D6-Cyclohexylmethoxy-5-%2528cyano-NNO-azoxy%2529pyrimidine-4-amine%253A%2520A%2520New%2520Scaffold%2520Endowed%2520with%2520Potent%2520CDK2%2520Inhibitory%2520Activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D333%26epage%3D338%26doi%3D10.1016%2Fj.ejmech.2013.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carbain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggerty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">8-Substituted O(6)-cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-based Inhibitor Design to Optimize an Alternative Binding Mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1021/jm401555v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401555v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=56-70&author=B.+Carbainauthor=D.+J.+Patersonauthor=E.+Anscombeauthor=A.+J.+Campbellauthor=C.+Canoauthor=A.+Echalierauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=K.+Haggertyauthor=I.+R.+Hardcastleauthor=P.+J.+Jewsburyauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=C.+Rocheauthor=L.+Z.+Wangauthor=R.+J.+Griffin&title=8-Substituted+O%286%29-cyclohexylmethylguanine+CDK2+Inhibitors%3A+Using+Structure-based+Inhibitor+Design+to+Optimize+an+Alternative+Binding+Mode&doi=10.1021%2Fjm401555v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm401555v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401555v%26sid%3Dliteratum%253Aachs%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DD.%2BJ.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3D8-Substituted%2520O%25286%2529-cyclohexylmethylguanine%2520CDK2%2520Inhibitors%253A%2520Using%2520Structure-based%2520Inhibitor%2520Design%2520to%2520Optimize%2520an%2520Alternative%2520Binding%2520Mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D56%26epage%3D70%26doi%3D10.1021%2Fjm401555v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meschini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Vidal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuillon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of an Irreversible Inhibitor of CDK2</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1159</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2015.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26320860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1159-1164&author=E.+Anscombeauthor=E.+Meschiniauthor=R.+Mora-Vidalauthor=M.+P.+Martinauthor=D.+Stauntonauthor=M.+Geitmannauthor=U.+H.+Danielsonauthor=W.+A.+Stanleyauthor=L.+Z.+Wangauthor=T.+Reuillonauthor=B.+T.+Goldingauthor=C.+Canoauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=S.+R.+Wedgeauthor=J.+A.+Endicottauthor=R.+J.+Griffin&title=Identification+and+Characterization+of+an+Irreversible+Inhibitor+of+CDK2&doi=10.1016%2Fj.chembiol.2015.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of an Irreversible Inhibitor of CDK2</span></div><div class="casAuthors">Anscombe, Elizabeth; Meschini, Elisa; Mora-Vidal, Regina; Martin, Mathew P.; Staunton, David; Geitmann, Matthis; Danielson, U. Helena; Stanley, Will A.; Wang, Lan Z.; Reuillon, Tristan; Golding, Bernard T.; Cano, Celine; Newell, David R.; Noble, Martin E. M.; Wedge, Stephen R.; Endicott, Jane A.; Griffin, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1159-1164</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible inhibitors that modify cysteine or lysine residues within a protein kinase ATP binding site offer, through their distinctive mode of action, an alternative to ATP-competitive agents.  4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)benzenesulfonamide (NU6102) is a potent and selective ATP-competitive inhibitor of CDK2 in which the sulfonamide moiety is positioned close to a pair of lysine residues.  Guided by the CDK2/NU6102 structure, we designed 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300), which binds covalently to CDK2 as shown by a co-complex crystal structure.  Acute incubation with NU6300 produced a durable inhibition of Rb phosphorylation in SKUT-1B cells, consistent with it acting as an irreversible CDK2 inhibitor.  NU6300 is the first covalent CDK2 inhibitor to be described, and illustrates the potential of vinyl sulfones for the design of more potent and selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEjfhxiEvjbVg90H21EOLACvtfcHk0lhtspW9qvWCVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL7M&md5=e6a29b14eb31abd659a48511bb11ed98</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DMeschini%26aufirst%3DE.%26aulast%3DMora-Vidal%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DStaunton%26aufirst%3DD.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DStanley%26aufirst%3DW.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DReuillon%26aufirst%3DT.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520an%2520Irreversible%2520Inhibitor%2520of%2520CDK2%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1159%26epage%3D1164%26doi%3D10.1016%2Fj.chembiol.2015.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of N(2)-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcmdc.201600108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27355194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1705-1708&author=D.+Corteseauthor=K.+Chegaevauthor=S.+Guglielmoauthor=L.+Z.+Wangauthor=B.+T.+Goldingauthor=C.+Canoauthor=R.+Fruttero&title=Synthesis+and+Biological+Evaluation+of+N%282%29-Substituted+2%2C4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines+and+Related+5-Cyano-NNO-azoxy+Derivatives+as+Cyclin-Dependent+Kinase+2+%28CDK2%29+Inhibitors&doi=10.1002%2Fcmdc.201600108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors</span></div><div class="casAuthors">Cortese, Daniela; Chegaev, Konstantin; Guglielmo, Stefano; Wang, Lan Z.; Golding, Bernard T.; Cano, Celine; Fruttero, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1705-1708</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor NU6027 (6-cyclohexylmethoxy-5-nitroso-2,4-diaminopyrimidine) was used as the lead for the synthesis of a series of analogs in order to provide further insight into the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.  Aliph. amino substituents were introduced at position 2.  The use of linear or less sterically hindered amines gave rise to compds. endowed with slightly better activity than the lead; on the other hand, the compds. were less active if a bulkier amino substituent was used.  Substitution of the 5-nitroso group with a 5-cyano-NNO-azoxy moiety afforded a new class of inhibitors, the activity of which against CDK2 was found to be similar to that of the nitroso series.  The most active nitroso compd. was (2S)-2-[(4-amino-6-cyclohexylmethoxy-5-nitrosopyrimidin-2-yl)amino]propan-1-ol (IC50=0.16 μm), while in the 5-cyano-NNO-azoxy series the most active compd. was 4-amino-5-[(Z)-cyano-NNO-azoxy]-2-{[(2S)-1-hydroxypropan-2-yl]amino}-6-cyclohexylmethoxypyrimidine (IC50=0.30 μm).  Taken together, these new analogs of NU6027 enhance our understanding of the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc8zFq1q29fLVg90H21EOLACvtfcHk0lhtspW9qvWCVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7fK&md5=d04c8a4f75b087b79d5eca20afba87cf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600108%26sid%3Dliteratum%253Aachs%26aulast%3DCortese%26aufirst%3DD.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DFruttero%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520N%25282%2529-Substituted%25202%252C4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines%2520and%2520Related%25205-Cyano-NNO-azoxy%2520Derivatives%2520as%2520Cyclin-Dependent%2520Kinase%25202%2520%2528CDK2%2529%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1705%26epage%3D1708%26doi%3D10.1002%2Fcmdc.201600108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harnor, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudhope, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1746</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1746-1767&author=C.+R.+Coxonauthor=E.+Anscombeauthor=S.+J.+Harnorauthor=M.+P.+Martinauthor=B.+Carbainauthor=B.+T.+Goldingauthor=I.+R.+Hardcastleauthor=L.+K.+Harlowauthor=S.+Korolchukauthor=C.+J.+Mathesonauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=M.+Sivaprakasamauthor=S.+J.+Tudhopeauthor=D.+M.+Turnerauthor=L.+Z.+Wangauthor=S.+R.+Wedgeauthor=C.+Wongauthor=R.+J.+Griffinauthor=J.+A.+Endicottauthor=C.+Cano&title=Cyclin-Dependent+Kinase+%28CDK%29+Inhibitors%3A+Structure-Activity+Relationships+and+Insights+into+the+CDK-2+Selectivity+of+6-Substituted+2-Arylaminopurines&doi=10.1021%2Facs.jmedchem.6b01254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines</span></div><div class="casAuthors">Coxon, Christopher R.; Anscombe, Elizabeth; Harnor, Suzannah J.; Martin, Mathew P.; Carbain, Benoit; Golding, Bernard T.; Hardcastle, Ian R.; Harlow, Lisa K.; Korolchuk, Svitlana; Matheson, Christopher J.; Newell, David R.; Noble, Martin E. M.; Sivaprakasam, Mangaleswaran; Tudhope, Susan J.; Turner, David M.; Wang, Lan Z.; Wedge, Stephen R.; Wong, Christopher; Griffin, Roger J.; Endicott, Jane A.; Cano, Celine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1746-1767</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Purines and related heterocycles substituted at C-2 with 4'-sulfamoylanilino and at C-6 with a variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1.  6-Substituents that favor competitive inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1.  Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) that exhibited high potency towards CDK2 (IC50 0.044 μM), but was ∼ 2000-fold less active towards CDK1 (IC50 86 μM).  This compd. is therefore a useful tool for studies of cell cycle regulation.  Crystal structures of inhibitor-kinase complexes showed that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket, and that is preferred in CDK2, but has not been obsd. in CDK1.  This aspect of the active site may be exploited for the design of inhibitors that distinguish between CDK1 and CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYzXYCKo7CrVg90H21EOLACvtfcHk0lgNk7WBGhYIkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7fK&md5=520549b69fec2b2af9758bfcf8708c55</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01254%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DC.%2BR.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DHarnor%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DHarlow%26aufirst%3DL.%2BK.%26aulast%3DKorolchuk%26aufirst%3DS.%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSivaprakasam%26aufirst%3DM.%26aulast%3DTudhope%26aufirst%3DS.%2BJ.%26aulast%3DTurner%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DCano%26aufirst%3DC.%26atitle%3DCyclin-Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%253A%2520Structure-Activity%2520Relationships%2520and%2520Insights%2520into%2520the%2520CDK-2%2520Selectivity%2520of%25206-Substituted%25202-Arylaminopurines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1746%26epage%3D1767%26doi%3D10.1021%2Facs.jmedchem.6b01254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Gahmen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1002/prot.340220408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fprot.340220408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1995&pages=378-391&author=U.+Schulze-Gahmenauthor=J.+Brandsenauthor=H.+D.+Jonesauthor=D.+O.+Morganauthor=L.+Meijerauthor=J.+Veselyauthor=S.+H.+Kim&title=Multiple+Modes+of+Ligand+Recognition%3A+Crystal+Structures+of+Cyclin-dependent+Protein+Kinase+2+in+Complex+with+ATP+and+Two+Inhibitors%2C+Olomoucine+and+Isopentenyladenine&doi=10.1002%2Fprot.340220408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fprot.340220408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340220408%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26aulast%3DBrandsen%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DVesely%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DMultiple%2520Modes%2520of%2520Ligand%2520Recognition%253A%2520Crystal%2520Structures%2520of%2520Cyclin-dependent%2520Protein%2520Kinase%25202%2520in%2520Complex%2520with%2520ATP%2520and%2520Two%2520Inhibitors%252C%2520Olomoucine%2520and%2520Isopentenyladenine%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1995%26volume%3D22%26spage%3D378%26epage%3D391%26doi%3D10.1002%2Fprot.340220408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oumata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">CR8, A Potent and Selective, Roscovitine-derived Inhibitor of Cyclin-dependent Kinases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5797</span>– <span class="NLM_lpage">5807</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2008.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18574471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFyqtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5797-5807&author=K.+Bettayebauthor=N.+Oumataauthor=A.+Echalierauthor=Y.+Ferandinauthor=J.+A.+Endicottauthor=H.+Galonsauthor=L.+Meijer&title=CR8%2C+A+Potent+and+Selective%2C+Roscovitine-derived+Inhibitor+of+Cyclin-dependent+Kinases&doi=10.1038%2Fonc.2008.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases</span></div><div class="casAuthors">Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J. A.; Galons, H.; Meijer, L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">5797-5807</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Among the ten pharmacol. inhibitors of cyclin-dependent kinases (CDKs) currently in clin. trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers.  An extensive medicinal chem. study, designed to generate more potent analogs of roscovitine, led to the identification of an optimal substitution at the N6 position (compd. CR8).  An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9.  CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases.  Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions.  The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells.  CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine.  CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium redn. (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold).  This improved cell death-inducing activity of CR8 over (R)-roscovitine was obsd. in 25 different cell lines.  Altogether these results show that second-generation analogs of (R)-roscovitine can be designed with improved antitumor potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvXAJQBwEMJbVg90H21EOLACvtfcHk0lgNk7WBGhYIkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFyqtrfI&md5=31e226f8a2f23caf88e6c9422138d2d7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.191%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DOumata%26aufirst%3DN.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGalons%26aufirst%3DH.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DCR8%252C%2520A%2520Potent%2520and%2520Selective%252C%2520Roscovitine-derived%2520Inhibitor%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5797%26epage%3D5807%26doi%3D10.1038%2Fonc.2008.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thunnissen, A.-M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeClerc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1126/science.281.5376.533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.281.5376.533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9677190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=533-538&author=N.+S.+Grayauthor=L.+Wodickaauthor=A.-M.+W.+H.+Thunnissenauthor=T.+C.+Normanauthor=S.+Kwonauthor=F.+H.+Espinozaauthor=D.+O.+Morganauthor=G.+Barnesauthor=S.+LeClercauthor=L.+Meijerauthor=S.-H.+Kimauthor=D.+J.+Lockhartauthor=P.+G.+Schultz&title=Exploiting+Chemical+Libraries%2C+Structure%2C+and+Genomics+in+the+Search+for+Kinase+Inhibitors&doi=10.1126%2Fscience.281.5376.533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span></div><div class="casAuthors">Gray, Nathanael S.; Wodicka, Lisa; Thunnissen, Andy-Mark W. H.; Norman, Thea C.; Kwon, Soojin; Espinoza, F. Hernan; Morgan, David O.; Barnes, Georjana; LeClerc, Sophie; Meijer, Laurent; Kim, Sung-Hou; Lockhart, David J.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5376</span>),
    <span class="NLM_cas:pages">533-538</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP-binding site of the human cyclin-dependent kinase 2 (CDK2).  By iterating chem. library synthesis and biol. screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified.  The structural basis for the binding affinity and selectivity was detd. by anal. of a three-dimensional crystal structure of a CDK2-inhibitor complex.  The cellular effects of these compds. were characterized in mammalian cells and yeast.  In the latter case the effects were characterized on a genome-wide scale by monitoring changes in mRNA levels in treated cells with high-d. oligonucleotide probe arrays.  Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may led to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTOOPjk16tbVg90H21EOLACvtfcHk0lg8zA7K55K2uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D&md5=08b8debe4d05c1169c152ccd6676def8</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5376.533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5376.533%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWodicka%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.-M.%2BW.%2BH.%26aulast%3DNorman%26aufirst%3DT.%2BC.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DEspinoza%26aufirst%3DF.%2BH.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DLeClerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DExploiting%2520Chemical%2520Libraries%252C%2520Structure%252C%2520and%2520Genomics%2520in%2520the%2520Search%2520for%2520Kinase%2520Inhibitors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D533%26epage%3D538%26doi%3D10.1126%2Fscience.281.5376.533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camasses, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodimont, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheinerman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasinska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D.</span></span> <span> </span><span class="NLM_article-title">An Integrated Chemical Biology Approach Provides Insight Into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2012.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22921070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1028-1040&author=A.+Echalierauthor=E.+Cotauthor=A.+Camassesauthor=E.+Hodimontauthor=F.+Hohauthor=P.+Jayauthor=F.+Sheinermanauthor=L.+Krasinskaauthor=D.+Fisher&title=An+Integrated+Chemical+Biology+Approach+Provides+Insight+Into+Cdk2+Functional+Redundancy+and+Inhibitor+Sensitivity&doi=10.1016%2Fj.chembiol.2012.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span></div><div class="casAuthors">Echalier, Aude; Cot, Emilie; Camasses, Alain; Hodimont, Elsie; Hoh, Francois; Jay, Philippe; Sheinerman, Felix; Krasinska, Liliana; Fisher, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cdk2 promotes DNA replication and is a promising cancer therapeutic target, but its functions appear redundant with Cdk1, an essential Cdk affected by most Cdk2 inhibitors.  Here, we present an integrated multidisciplinary approach to address Cdk redundancy.  Math. modeling of enzymol. data predicted conditions allowing selective chem. Cdk2 inhibition.  Together with expts. in Xenopus egg exts., this supports a rate-limiting role for Cdk2 in DNA replication.  To confirm this we designed inhibitor-resistant (ir)-Cdk2 mutants using a novel bioinformatics approach.  Bypassing inhibition with ir-Cdk2 or with Cdk1 shows that Cdk2 is rate-limiting for replication in this system because Cdk1 is insufficiently active.  Addnl., crystal structures and kinetics reveal alternative binding modes of Cdk1-selective and Cdk2-selective inhibitors and mechanisms of Cdk2 inhibitor resistance.  Our approach thus provides insight into structure, functions, and biochem. of a cyclin-dependent kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa9UiVuPpOLVg90H21EOLACvtfcHk0lg8zA7K55K2uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN&md5=d134c52fd1ad5442e07bec46a3edd9be</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DCot%26aufirst%3DE.%26aulast%3DCamasses%26aufirst%3DA.%26aulast%3DHodimont%26aufirst%3DE.%26aulast%3DHoh%26aufirst%3DF.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DSheinerman%26aufirst%3DF.%26aulast%3DKrasinska%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DD.%26atitle%3DAn%2520Integrated%2520Chemical%2520Biology%2520Approach%2520Provides%2520Insight%2520Into%2520Cdk2%2520Functional%2520Redundancy%2520and%2520Inhibitor%2520Sensitivity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1028%26epage%3D1040%26doi%3D10.1016%2Fj.chembiol.2012.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filgueira De Azevedo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlicek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-dependent Kinases by Purine Analogues: Crystal Structure of Human Cdk2 Complexed with Roscovitine</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.0518a.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1111%2Fj.1432-1033.1997.0518a.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9030780" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=518-526&author=W.+Filgueira+De+Azevedoauthor=S.+Leclercauthor=L.+Meijerauthor=L.+Havlicekauthor=M.+Strnadauthor=S.+H.+Kim&title=Inhibition+of+Cyclin-dependent+Kinases+by+Purine+Analogues%3A+Crystal+Structure+of+Human+Cdk2+Complexed+with+Roscovitine&doi=10.1111%2Fj.1432-1033.1997.0518a.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.0518a.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.0518a.x%26sid%3Dliteratum%253Aachs%26aulast%3DFilgueira%2BDe%2BAzevedo%26aufirst%3DW.%26aulast%3DLeclerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DInhibition%2520of%2520Cyclin-dependent%2520Kinases%2520by%2520Purine%2520Analogues%253A%2520Crystal%2520Structure%2520of%2520Human%2520Cdk2%2520Complexed%2520with%2520Roscovitine%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D518%26epage%3D526%26doi%3D10.1111%2Fj.1432-1033.1997.0518a.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J.</span></span> <span> </span><span class="NLM_article-title">Probing the Links Between <i>In vitro</i> Potency, ADMET and Physicochemical Parameters</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1038/nrd3367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+Links+Between+In+vitro+Potency%2C+ADMET+and+Physicochemical+Parameters&doi=10.1038%2Fnrd3367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0lgu7EzVe4pr8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520Links%2520Between%2520In%2520vitro%2520Potency%252C%2520ADMET%2520and%2520Physicochemical%2520Parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208%26doi%3D10.1038%2Fnrd3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisinga, W.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based Inhibition: Deriving K<sub>I</sub> and K<sub>inact</sub> Directly from Time-Dependent IC<sub>50</sub> Values</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">923</span>, <span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.-F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-based+Inhibition%3A+Deriving+KI+and+Kinact+Directly+from+Time-Dependent+IC50+Values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0lgu7EzVe4pr8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.-F.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-based%2520Inhibition%253A%2520Deriving%2520KI%2520and%2520Kinact%2520Directly%2520from%2520Time-Dependent%2520IC50%2520Values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span> <span> </span><span class="NLM_article-title">Covalent Modification of CDK2 by 4-Hydroxynonenal as a Mechanism of Inhibition of Cell Cycle Progression</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=323-332&author=J.+M.+Camarilloauthor=K.+L.+Roseauthor=J.+J.+Galliganauthor=S.+Xuauthor=L.+J.+Marnett&title=Covalent+Modification+of+CDK2+by+4-Hydroxynonenal+as+a+Mechanism+of+Inhibition+of+Cell+Cycle+Progression&doi=10.1021%2Facs.chemrestox.5b00485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DCamarillo%26aufirst%3DJ.%2BM.%26aulast%3DRose%26aufirst%3DK.%2BL.%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DCovalent%2520Modification%2520of%2520CDK2%2520by%25204-Hydroxynonenal%2520as%2520a%2520Mechanism%2520of%2520Inhibition%2520of%2520Cell%2520Cycle%2520Progression%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D323%26epage%3D332%26doi%3D10.1021%2Facs.chemrestox.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluations of Pyrazolo[3,4-<i>d</i>]pyrimidines as Cyclin-dependent Kinase 2 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(03)00065-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0223-5234%2803%2900065-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=525-532&author=D.+C.+Kimauthor=Y.+R.+Leeauthor=B.+S.+Yangauthor=K.+J.+Shinauthor=D.+J.+Kimauthor=B.+Y.+Chungauthor=K.+H.+Yoo&title=Synthesis+and+Biological+Evaluations+of+Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Cyclin-dependent+Kinase+2+Inhibitors&doi=10.1016%2FS0223-5234%2803%2900065-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900065-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900065-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DYang%26aufirst%3DB.%2BS.%26aulast%3DShin%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DChung%26aufirst%3DB.%2BY.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluations%2520of%2520Pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Cyclin-dependent%2520Kinase%25202%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D525%26epage%3D532%26doi%3D10.1016%2FS0223-5234%2803%2900065-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merugu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushwaha, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpoormath, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Some Novel 4,6-disubstituted Pyrazolo[3,4-<i>d</i>]pyrimidines as Cyclin-dependent Kinase 2 (CDK2) Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bioorg.2018.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29753773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptl2ju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2018&pages=46-59&author=S.+Cherukupalliauthor=B.+Chandrasekaranauthor=V.+Krystofauthor=R.+R.+Aletiauthor=N.+Sayyadauthor=S.+R.+Meruguauthor=N.+D.+Kushwahaauthor=R.+Karpoormath&title=Synthesis%2C+Anticancer+Evaluation%2C+and+Molecular+Docking+Studies+of+Some+Novel+4%2C6-disubstituted+Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Cyclin-dependent+Kinase+2+%28CDK2%29+Inhibitors&doi=10.1016%2Fj.bioorg.2018.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors</span></div><div class="casAuthors">Cherukupalli, Srinivasulu; Chandrasekaran, Balakumar; Krystof, Vladimir; Aleti, Rajeshwar Reddy; Sayyad, Nisar; Merugu, Srinivas Reddy; Kushwaha, Narva Deshwar; Karpoormath, Rajshekhar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of 4,6-disubstituted pyrazolo[3,4-d]pyrimidines (7-43) bearing various anilines at C-4 position and thiophenethyl or thiopentane moieties at C-6 position have been designed and synthesized by mol. hybridization approach.  All the synthesized compds. were evaluated for in vitro CDK2/cyclin E and Abl kinase inhibitory activity as well as anti-proliferative activity against K-562 (chronic myelogeneous leukemia), and MCF-7 (breast adenocarcinoma) cell lines.  The structure-activity relationship (SAR) studies revealed that compds. with thiophenethyl group at C-6 with mono-substituted anilines at C-4 exhibited better CDK2 inhibitory activity compared to alkyl group (thiopentane) at C-6 and di-substituted anilines at C-4 of the scaffold.  In particular, compds. having 2-chloro, 3-nitro and 4-methylthio aniline groups at C-4 displayed significant enzymic inhibitory activity against CDK2 with single digit micromolar IC50 values.  The in silico mol. docking studies suggested possible binding orientation and the binding energies were in agreement with the obsd. SAR as well as exptl. results.  In addn., some of the synthesized compds. showed anti-proliferative effects against K-562 and MCF-7 cancer cell lines with IC50 values in a micromolar range.  Thus, the synthesized compds. could be considered as new anticancer hits for further lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2PV0fqijqG7Vg90H21EOLACvtfcHk0lj21NtpC5EFqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptl2ju78%253D&md5=730e49d92ab8d7f20eab898ef9c29a47</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DChandrasekaran%26aufirst%3DB.%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DMerugu%26aufirst%3DS.%2BR.%26aulast%3DKushwaha%26aufirst%3DN.%2BD.%26aulast%3DKarpoormath%26aufirst%3DR.%26atitle%3DSynthesis%252C%2520Anticancer%2520Evaluation%252C%2520and%2520Molecular%2520Docking%2520Studies%2520of%2520Some%2520Novel%25204%252C6-disubstituted%2520Pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Cyclin-dependent%2520Kinase%25202%2520%2528CDK2%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D79%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.bioorg.2018.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alikian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine is a Potent Inhibitor of Cyclin-dependent Protein Kinases 1, 2, and 9, which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8508</span>– <span class="NLM_lpage">8522</span>, <span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+Potent+Inhibitor+of+Cyclin-dependent+Protein+Kinases+1%2C+2%2C+and+9%2C+which+Demonstrates+Antitumor+Effects+in+Human+Tumor+Xenografts+Following+Oral+Administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0lj21NtpC5EFqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin-dependent%2520Protein%2520Kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520Demonstrates%2520Antitumor%2520Effects%2520in%2520Human%2520Tumor%2520Xenografts%2520Following%2520Oral%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambellone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T. J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]pyrimidines as Orally Available Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6220</span>– <span class="NLM_lpage">6223</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2007.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6220-6223&author=K.+Paruchauthor=M.+P.+Dwyerauthor=C.+Alvarezauthor=C.+Brownauthor=T.+Y.+Chanauthor=R.+J.+Dollauthor=K.+Keertikarauthor=C.+Knutsonauthor=B.+McKittrickauthor=J.+Riveraauthor=R.+Rossmanauthor=G.+Tuckerauthor=T.+O.+Fischmannauthor=A.+Hruzaauthor=V.+Madisonauthor=A.+A.+Nomeirauthor=Y.+Wangauthor=E.+Leesauthor=D.+Parryauthor=N.+Sgambelloneauthor=W.+Seghezziauthor=L.+Schultzauthor=F.+Shanahanauthor=D.+Wiswellauthor=X.+Xuauthor=Q.+Zhouauthor=R.+A.+Jamesauthor=V.+M.+Paradkarauthor=H.+Parkauthor=L.+R.+Rokoszauthor=T.+M.+Staufferauthor=T.+J.+Guzi&title=Pyrazolo%5B1%2C5-a%5Dpyrimidines+as+Orally+Available+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.1016%2Fj.bmcl.2007.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DT.%2BY.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DKnutson%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DSgambellone%26aufirst%3DN.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DSchultz%26aufirst%3DL.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJames%26aufirst%3DR.%2BA.%26aulast%3DParadkar%26aufirst%3DV.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DRokosz%26aufirst%3DL.%2BR.%26aulast%3DStauffer%26aufirst%3DT.%2BM.%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520Orally%2520Available%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6220%26epage%3D6223%26doi%3D10.1016%2Fj.bmcl.2007.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popowycz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamigeon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo-Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-dependent Kinase Inhibitor (<i>R</i>)-RoscovitineAnalogue</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1021/jm801340z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801340z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=655-663&author=F.+Popowyczauthor=G.+Fournetauthor=C.+Schneiderauthor=K.+Bettayebauthor=Y.+Ferandinauthor=C.+Lamigeonauthor=O.+M.+Tiradoauthor=S.+Mateo-Lozanoauthor=V.+Notarioauthor=P.+Colasauthor=P.+Bernardauthor=L.+Meijerauthor=B.+Joseph&title=Pyrazolo%5B1%2C5-a%5D-1%2C3%2C5-triazine+as+a+Purine+Bioisostere%3A+Access+to+Potent+Cyclin-dependent+Kinase+Inhibitor+%28R%29-RoscovitineAnalogue&doi=10.1021%2Fjm801340z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm801340z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801340z%26sid%3Dliteratum%253Aachs%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLamigeon%26aufirst%3DC.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DPyrazolo%255B1%252C5-a%255D-1%252C3%252C5-triazine%2520as%2520a%2520Purine%2520Bioisostere%253A%2520Access%2520to%2520Potent%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520%2528R%2529-RoscovitineAnalogue%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D655%26epage%3D663%26doi%3D10.1021%2Fjm801340z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popowycz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">N- & -N, A New Class of Cell Death-inducing Kinase Inhibitors Derived from the Purine Roscovitine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2724</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-08-0080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18790752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2713-2724&author=K.+Bettayebauthor=H.+Sallamauthor=Y.+Ferandinauthor=F.+Popowyczauthor=G.+Fournetauthor=M.+Hassanauthor=A.+Echalierauthor=P.+Bernardauthor=J.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=N-+%26+-N%2C+A+New+Class+of+Cell+Death-inducing+Kinase+Inhibitors+Derived+from+the+Purine+Roscovitine&doi=10.1158%2F1535-7163.MCT-08-0080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine</span></div><div class="casAuthors">Bettayeb, Karima; Sallam, Hatem; Ferandin, Yoan; Popowycz, Florence; Fournet, Guy; Hassan, Moustapha; Echalier, Aude; Bernard, Philippe; Endicott, Jane; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2713-2724</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) and their regulators show frequent abnormalities in tumors.  Ten low mol. wt. pharmacol. inhibitors of CDKs are currently in clin. trials against various cancers, including the 2,6,9-trisubstituted purine (R)-roscovitine (CYC202/Seliciclib).  We here report the characterization of N-&-N1, a bioisoster of roscovitine displaying improved antitumoral properties.  N-&-N1 shows exquisite selectivity for CDKs, with 2- to 3-fold enhanced potency compared with (R)-roscovitine.  Inhibition of retinoblastoma protein phosphorylation and RNA polymerase II Ser2 phosphorylation in neuroblastoma SH-SY5Y cells exposed to N-&-N1 indicates that N-&-N1 is able to inhibit CDKs in a cellular context.  N-&-N1 also down-regulates the expression of RNA polymerase.  Cocrystal structures of N-&-N1 and (R)-roscovitine in complex with CDK2/cyclin A reveal that both inhibitors adopt similar binding modes.  A competitive assay shows that, compared with (R)-roscovitine, N-&-N1 has reduced affinity for Erk2 and pyridoxal kinase.  N-&-N1 triggers cell death in a panel of diverse cell lines.  Cell death is accompanied by events characteristic of apoptosis: cytochrome c release, activation of effector caspases, and poly(ADP-ribose) polymerase cleavage.  Induction of p53 and p21CIP1 and down-regulation of the Mcl-1 antiapoptotic factor were also obsd.  Studies in mice show that N-&-N1 has pharmacokinetics properties similar to those of (R)-roscovitine.  Altogether, these results show that analogs of (R)-roscovitine can be designed with improved antitumor potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAdPDD672MabVg90H21EOLACvtfcHk0liRBzyA1GbPFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7nL&md5=a2d1cc3e59c608be45064a2ace6f0426</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0080%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DSallam%26aufirst%3DH.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DEndicott%26aufirst%3DJ.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DN-%2520%2526%2520-N%252C%2520A%2520New%2520Class%2520of%2520Cell%2520Death-inducing%2520Kinase%2520Inhibitors%2520Derived%2520from%2520the%2520Purine%2520Roscovitine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2713%26epage%3D2724%26doi%3D10.1158%2F1535-7163.MCT-08-0080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridine Inhibitors of Cyclin-dependent Kinases: Highly Potent 2,6-Difluorophenacyl Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-894X%2803%2900381-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2405-2408&author=R.+N.+Misraauthor=H.+Xiaoauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=S.+D.+Kimballauthor=K.+R.+Webster&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridine+Inhibitors+of+Cyclin-dependent+Kinases%3A+Highly+Potent+2%2C6-Difluorophenacyl+Analogues&doi=10.1016%2FS0960-894X%2803%2900381-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900381-0%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridine%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%253A%2520Highly%2520Potent%25202%252C6-Difluorophenacyl%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2405%26epage%3D2408%26doi%3D10.1016%2FS0960-894X%2803%2900381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambellone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T. J.</span></span> <span> </span><span class="NLM_article-title">Versatile Templates for the Development of Novel Kinase Inhibitors: Discovery of Novel CDK Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6216</span>– <span class="NLM_lpage">6219</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2007.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17904366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6216-6219&author=M.+P.+Dwyerauthor=K.+Paruchauthor=C.+Alvarezauthor=R.+J.+Dollauthor=K.+Keertikarauthor=J.+Ducaauthor=T.+O.+Fischmannauthor=A.+Hruzaauthor=V.+Madisonauthor=E.+Leesauthor=D.+Parryauthor=W.+Seghezziauthor=N.+Sgambelloneauthor=F.+Shanahanauthor=D.+Wiswellauthor=T.+J.+Guzi&title=Versatile+Templates+for+the+Development+of+Novel+Kinase+Inhibitors%3A+Discovery+of+Novel+CDK+Inhibitors&doi=10.1016%2Fj.bmcl.2007.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors</span></div><div class="casAuthors">Dwyer, Michael P.; Paruch, Kamil; Alvarez, Carmen; Doll, Ronald J.; Keertikar, Kerry; Duca, Jose; Fischmann, Thierry O.; Hruza, Alan; Madison, Vincent; Lees, Emma; Parry, David; Seghezzi, Wolfgang; Sgambellone, Nicole; Shanahan, Frances; Wiswell, Derek; Guzi, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6216-6219</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of four bicyclic cores were prepd. and evaluated as cyclin-dependent kinase-2 (CDK2) inhibitors.  From the in-vitro and cell-based anal., the pyrazolo[1,5-a]pyrimidine core I emerged as the superior core for further elaboration in the identification of novel CDK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXTjUqi5x5LVg90H21EOLACvtfcHk0liRBzyA1GbPFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zL&md5=7f9cf88bfa50cc06f6b6235da7835ae9</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DDuca%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DSgambellone%26aufirst%3DN.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26atitle%3DVersatile%2520Templates%2520for%2520the%2520Development%2520of%2520Novel%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520Novel%2520CDK%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6216%26epage%3D6219%26doi%3D10.1016%2Fj.bmcl.2007.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Azabenzimidazole Derivatives as Potent, Selective Inhibitors of TBK1/IKKepsilon Kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2063</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2012.01.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2063-2069&author=T.+Wangauthor=M.+A.+Blockauthor=S.+Cowenauthor=A.+M.+Daviesauthor=E.+Devereauxauthor=L.+Gingipalliauthor=J.+Johannesauthor=N.+A.+Larsenauthor=Q.+Suauthor=J.+A.+Tuckerauthor=D.+Whitstonauthor=J.+Wuauthor=H.+J.+Zhangauthor=M.+Zindaauthor=C.+Chuaqui&title=Discovery+of+Azabenzimidazole+Derivatives+as+Potent%2C+Selective+Inhibitors+of+TBK1%2FIKKepsilon+Kinases&doi=10.1016%2Fj.bmcl.2012.01.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBlock%26aufirst%3DM.%2BA.%26aulast%3DCowen%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DDevereaux%26aufirst%3DE.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DJohannes%26aufirst%3DJ.%26aulast%3DLarsen%26aufirst%3DN.%2BA.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWhitston%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Azabenzimidazole%2520Derivatives%2520as%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520TBK1%252FIKKepsilon%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2063%26epage%3D2069%26doi%3D10.1016%2Fj.bmcl.2012.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, H. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of a New Class of Highly Selective Aminoimidazo[1,2-<i>a</i>]pyridine-based Inhibitors of Cyclin Dependent Kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2005.01.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1943-1947&author=C.+Hamdouchiauthor=B.+Zhongauthor=J.+Mendozaauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+De+Diegoauthor=D.+Robertsonauthor=C.+D.+Spencerauthor=B.+D.+Andersonauthor=S.+A.+Watkinsauthor=F.+Zhangauthor=H.+B.+Brooks&title=Structure-based+Design+of+a+New+Class+of+Highly+Selective+Aminoimidazo%5B1%2C2-a%5Dpyridine-based+Inhibitors+of+Cyclin+Dependent+Kinases&doi=10.1016%2Fj.bmcl.2005.01.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DMendoza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DDe%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DStructure-based%2520Design%2520of%2520a%2520New%2520Class%2520of%2520Highly%2520Selective%2520Aminoimidazo%255B1%252C2-a%255Dpyridine-based%2520Inhibitors%2520of%2520Cyclin%2520Dependent%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1943%26epage%3D1947%26doi%3D10.1016%2Fj.bmcl.2005.01.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Prado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span> <span> </span><span class="NLM_article-title">Aminoimidazo[1,2-<i>a</i>]pyridines as a New Structural Class of Cyclin-Dependent Kinase Inhibitors. Part 1: Design, Synthesis, and Biological Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6095</span>– <span class="NLM_lpage">6099</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2004.09.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=6095-6099&author=C.+Jaramilloauthor=J.+E.+de+Diegoauthor=C.+Hamdouchiauthor=E.+Collinsauthor=H.+Keyserauthor=C.+Sanchez-Martinezauthor=M.+del+Pradoauthor=B.+Normanauthor=H.+B.+Brooksauthor=S.+A.+Watkinsauthor=C.+D.+Spencerauthor=J.+A.+Dempseyauthor=B.+D.+Andersonauthor=R.+M.+Campbellauthor=T.+Leggettauthor=B.+Patelauthor=R.+M.+Schultzauthor=J.+Espinosaauthor=M.+Viethauthor=F.+Zhangauthor=D.+E.+Timm&title=Aminoimidazo%5B1%2C2-a%5Dpyridines+as+a+New+Structural+Class+of+Cyclin-Dependent+Kinase+Inhibitors.+Part+1%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1016%2Fj.bmcl.2004.09.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DKeyser%26aufirst%3DH.%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3Ddel%2BPrado%26aufirst%3DM.%26aulast%3DNorman%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DLeggett%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DEspinosa%26aufirst%3DJ.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26atitle%3DAminoimidazo%255B1%252C2-a%255Dpyridines%2520as%2520a%2520New%2520Structural%2520Class%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors.%2520Part%25201%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D6095%26epage%3D6099%26doi%3D10.1016%2Fj.bmcl.2004.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The Discovery of a New Structural Class of Cyclin-dependent Kinase Inhibitors, Aminoimidazo[1,2-<i>a</i>]pyridines</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=14749470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1-9&author=C.+Hamdouchiauthor=H.+Keyserauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+De+Diegoauthor=C.+D.+Spencerauthor=J.+A.+Dempseyauthor=B.+D.+Andersonauthor=T.+Leggettauthor=N.+B.+Stammauthor=R.+M.+Schultzauthor=S.+A.+Watkinsauthor=K.+Cockeauthor=S.+Lemkeauthor=T.+F.+Burke&title=The+Discovery+of+a+New+Structural+Class+of+Cyclin-dependent+Kinase+Inhibitors%2C+Aminoimidazo%5B1%2C2-a%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines</span></div><div class="casAuthors">Hamdouchi, Chafiq; Keyser, Heather; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Spencer, Charles D.; Dempsey, Jack Alan; Anderson, Bryan D.; Leggett, Tillie; Stamm, Nancy B.; Schultz, Richard M.; Watkins, Scott A.; Cocke, Kim; Lemke, Stephanie; Burke, Teresa F.; Beckmann, Richard P.; Dixon, Jeffrey T.; Gurganus, Thomas M.; Rankl, Nancy B.; Houck, Keith A.; Zhang, Faming; Vieth, Michal; Espinosa, Juan; Timm, David E.; Campbell, Robert M.; Patel, Bharvin K. R.; Brooks, Harold B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The protein kinase family represents an enormous opportunity for drug development.  However, the current limitation in structural diversity of kinase inhibitors has complicated efforts to identify effective treatments of diseases that involve protein kinase signaling pathways.  We have identified a new structural class of protein serine/threonine kinase inhibitors comprising an aminoimidazo[1,2-a]pyridine nucleus.  In this report, we describe the first successful use of this class of aza-heterocycles to generate potent inhibitors of cyclin-dependent kinases that compete with ATP for binding to a catalytic subunit of the protein.  Co-crystal structures of CDK2 in complex with lead compds. reveal a unique mode of binding.  Using this knowledge, a structure-based design approach directed this chem. scaffold toward generating potent and selective CDK2 inhibitors, which selectively inhibited the CDK2-dependent phosphorylation of Rb and induced caspase-3-dependent apoptosis in HCT 116 tumor cells.  The discovery of this new class of ATP-site-directed protein kinase inhibitors, aminoimidazo[1,2-a]pyridines, provides the basis for a new medicinal chem. tool to be used in the search for effective treatments of cancer and other diseases that involve protein kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMw2VkQ5EuPLVg90H21EOLACvtfcHk0liVCX42UKoFQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFajtg%253D%253D&md5=0d78d757d0deb6089b996765cd189df1</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DKeyser%26aufirst%3DH.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DDe%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DLeggett%26aufirst%3DT.%26aulast%3DStamm%26aufirst%3DN.%2BB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DK.%26aulast%3DLemke%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26atitle%3DThe%2520Discovery%2520of%2520a%2520New%2520Structural%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%252C%2520Aminoimidazo%255B1%252C2-a%255Dpyridines%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minshull, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauptit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowsell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanway, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span> <span> </span><span class="NLM_article-title">Imidazo[1,2-<i>b</i>]pyridazines: A Potent and Selective Class of Cyclin-dependent Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2249</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2004.02.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2249-2252&author=K.+F.+Bythauthor=N.+Cooperauthor=J.+D.+Culshawauthor=D.+W.+Heatonauthor=S.+E.+Oakesauthor=C.+A.+Minshullauthor=R.+A.+Normanauthor=R.+A.+Pauptitauthor=J.+A.+Tuckerauthor=J.+Breedauthor=A.+Panniferauthor=S.+Rowsellauthor=J.+J.+Stanwayauthor=A.+L.+Valentineauthor=A.+P.+Thomas&title=Imidazo%5B1%2C2-b%5Dpyridazines%3A+A+Potent+and+Selective+Class+of+Cyclin-dependent+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2004.02.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DByth%26aufirst%3DK.%2BF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DOakes%26aufirst%3DS.%2BE.%26aulast%3DMinshull%26aufirst%3DC.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DPannifer%26aufirst%3DA.%26aulast%3DRowsell%26aufirst%3DS.%26aulast%3DStanway%26aufirst%3DJ.%2BJ.%26aulast%3DValentine%26aufirst%3DA.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26atitle%3DImidazo%255B1%252C2-b%255Dpyridazines%253A%2520A%2520Potent%2520and%2520Selective%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2249%26epage%3D2252%26doi%3D10.1016%2Fj.bmcl.2004.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokurno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, C. J.</span></span> <span> </span><span class="NLM_article-title">Triazolo[1,5-<i>a</i>]pyrimidines as Novel CDK2 Inhibitors: Protein Structure-guided Design and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1357</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2005.11.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1353-1357&author=C.+M.+Richardsonauthor=D.+S.+Williamsonauthor=M.+J.+Parrattauthor=J.+Borgognoniauthor=A.+D.+Cansfieldauthor=P.+Dokurnoauthor=G.+L.+Francisauthor=R.+Howesauthor=J.+D.+Mooreauthor=J.+B.+Murrayauthor=A.+Robertsonauthor=A.+E.+Surgenorauthor=C.+J.+Torrance&title=Triazolo%5B1%2C5-a%5Dpyrimidines+as+Novel+CDK2+Inhibitors%3A+Protein+Structure-guided+Design+and+SAR&doi=10.1016%2Fj.bmcl.2005.11.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DC.%2BM.%26aulast%3DWilliamson%26aufirst%3DD.%2BS.%26aulast%3DParratt%26aufirst%3DM.%2BJ.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DCansfield%26aufirst%3DA.%2BD.%26aulast%3DDokurno%26aufirst%3DP.%26aulast%3DFrancis%26aufirst%3DG.%2BL.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BB.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DSurgenor%26aufirst%3DA.%2BE.%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26atitle%3DTriazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520Novel%2520CDK2%2520Inhibitors%253A%2520Protein%2520Structure-guided%2520Design%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1353%26epage%3D1357%26doi%3D10.1016%2Fj.bmcl.2005.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indirubin-3′-monoxime Derivatives as Potent Inhibitors Against CDK2 and CDK9</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2447</span>– <span class="NLM_lpage">2451</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25908517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVeksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2447-2451&author=L.+Yanauthor=F.+Laiauthor=X.+Chenauthor=Z.+Xiao&title=Discovery+of+Novel+Indirubin-3%E2%80%B2-monoxime+Derivatives+as+Potent+Inhibitors+Against+CDK2+and+CDK9&doi=10.1016%2Fj.bmcl.2015.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9</span></div><div class="casAuthors">Yan, Lei; Lai, Fangfang; Chen, Xiaoguang; Xiao, Zhiyan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2447-2451</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indirubin 3'-monoxime (IM) is a potent cyclin-dependent kinase (CDK) inhibitor.  Twenty novel IM derivs. were prepd. to investigate the structure-activity relationships (SAR) of this compd. class.  Six compds. showed significant inhibition against both CDK2/cyclin E1 and CDK9/cyclin T1.  The most potent compd. exhibited IC50 values at submicromolar level.  Preliminary SAR trends were suggested and cytotoxicity of these compds. was investigated.  Mol. docking studies on two compds. provided conducive clues for further structural optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodx4x7bHuIJLVg90H21EOLACvtfcHk0liVCX42UKoFQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVeksL4%253D&md5=110a858faa3d296ca3352ffdfc439840</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Novel%2520Indirubin-3%25E2%2580%25B2-monoxime%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520Against%2520CDK2%2520and%2520CDK9%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2447%26epage%3D2451%26doi%3D10.1016%2Fj.bmcl.2015.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-activity Relationships of Novel Indirubin Derivatives as Potent Anti-proliferative Agents with CDK2 Inhibitory Activities</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmc.2005.08.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=237-246&author=M.+J.+Moonauthor=S.+K.+Leeauthor=J.+W.+Leeauthor=W.+K.+Songauthor=S.+W.+Kimauthor=J.+I.+Kimauthor=C.+Choauthor=S.+J.+Choiauthor=Y.+C.+Kim&title=Synthesis+and+Structure-activity+Relationships+of+Novel+Indirubin+Derivatives+as+Potent+Anti-proliferative+Agents+with+CDK2+Inhibitory+Activities&doi=10.1016%2Fj.bmc.2005.08.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DSong%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DCho%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BC.%26atitle%3DSynthesis%2520and%2520Structure-activity%2520Relationships%2520of%2520Novel%2520Indirubin%2520Derivatives%2520as%2520Potent%2520Anti-proliferative%2520Agents%2520with%2520CDK2%2520Inhibitory%2520Activities%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D237%26epage%3D246%26doi%3D10.1016%2Fj.bmc.2005.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prien, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span> <span> </span><span class="NLM_article-title">From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2-inhibitors</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1002/cbic.200400108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.200400108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=531-540&author=R.+Jautelatauthor=T.+Brumbyauthor=M.+Schaferauthor=H.+Briemauthor=G.+Eisenbrandauthor=S.+Schwahnauthor=M.+Krugerauthor=U.+Luckingauthor=O.+Prienauthor=G.+Siemeister&title=From+the+Insoluble+Dye+Indirubin+towards+Highly+Active%2C+Soluble+CDK2-inhibitors&doi=10.1002%2Fcbic.200400108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400108%26sid%3Dliteratum%253Aachs%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DBrumby%26aufirst%3DT.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DEisenbrand%26aufirst%3DG.%26aulast%3DSchwahn%26aufirst%3DS.%26aulast%3DKruger%26aufirst%3DM.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DPrien%26aufirst%3DO.%26aulast%3DSiemeister%26aufirst%3DG.%26atitle%3DFrom%2520the%2520Insoluble%2520Dye%2520Indirubin%2520towards%2520Highly%2520Active%252C%2520Soluble%2520CDK2-inhibitors%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D531%26epage%3D540%26doi%3D10.1002%2Fcbic.200400108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlbeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">Novel Indirubin Derivatives, Promising Anti-Tumor Agents Inhibiting Cyclin-Dependent Kinases</span>. <i>Int. J. Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.5414/CPP42656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.5414%2FCPP42656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15598038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BD2cnit1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2004&pages=656-658&author=K.+H.+Merzauthor=S.+Schwahnauthor=F.+Hippeauthor=S.+Muhlbeyerauthor=S.+Jakobsauthor=G.+Eisenbrand&title=Novel+Indirubin+Derivatives%2C+Promising+Anti-Tumor+Agents+Inhibiting+Cyclin-Dependent+Kinases&doi=10.5414%2FCPP42656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases</span></div><div class="casAuthors">Merz K H; Schwahn S; Hippe F; Muhlbeyer S; Jakobs S; Eisenbrand G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">656-8</span>
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAEHro78iunsuCWE5mhx1RfW6udTcc2eandLVKcgO177ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnit1yqtw%253D%253D&md5=a0adc10cdb67538599d3f1bd3c26cadb</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.5414%2FCPP42656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCPP42656%26sid%3Dliteratum%253Aachs%26aulast%3DMerz%26aufirst%3DK.%2BH.%26aulast%3DSchwahn%26aufirst%3DS.%26aulast%3DHippe%26aufirst%3DF.%26aulast%3DMuhlbeyer%26aufirst%3DS.%26aulast%3DJakobs%26aufirst%3DS.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DNovel%2520Indirubin%2520Derivatives%252C%2520Promising%2520Anti-Tumor%2520Agents%2520Inhibiting%2520Cyclin-Dependent%2520Kinases%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D42%26spage%3D656%26epage%3D658%26doi%3D10.5414%2FCPP42656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polychronopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaltsounis, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrianthopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarricone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-dependent Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1021/jm031016d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031016d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=935-946&author=P.+Polychronopoulosauthor=P.+Magiatisauthor=A.+L.+Skaltsounisauthor=V.+Myrianthopoulosauthor=E.+Mikrosauthor=A.+Tarriconeauthor=A.+Musacchioauthor=S.+M.+Roeauthor=L.+Pearlauthor=M.+Leostauthor=P.+Greengardauthor=L.+Meijer&title=Structural+Basis+for+the+Synthesis+of+Indirubins+as+Potent+and+Selective+Inhibitors+of+Glycogen+Synthase+Kinase-3+and+Cyclin-dependent+Kinases&doi=10.1021%2Fjm031016d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases</span></div><div class="casAuthors">Polychronopoulos, Panagiotis; Magiatis, Prokopios; Skaltsounis, Alexios-Leandros; Myrianthopoulos, Vassilios; Mikros, Emmanuel; Tarricone, Aldo; Musacchio, Andrea; Roe, S. Mark; Pearl, Laurence; Leost, Maryse; Greengard, Paul; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">935-946</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease.  Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3.  Using the co-crystal structures of various indirubins with GSK-3β, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases.  This modeling approach provided some insight into the mol. basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors.  Predicted mols., including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors.  Control, kinase-inactive indirubins were obtained by introduction of a Me substitution on N1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBEh_1jE0e7Vg90H21EOLACvtfcHk0lisWO8F6_Ft-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCjtA%253D%253D&md5=3bfe8cccc4cbe23bffae66bb3569b889</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm031016d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031016d%26sid%3Dliteratum%253Aachs%26aulast%3DPolychronopoulos%26aufirst%3DP.%26aulast%3DMagiatis%26aufirst%3DP.%26aulast%3DSkaltsounis%26aufirst%3DA.%2BL.%26aulast%3DMyrianthopoulos%26aufirst%3DV.%26aulast%3DMikros%26aufirst%3DE.%26aulast%3DTarricone%26aufirst%3DA.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DPearl%26aufirst%3DL.%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Synthesis%2520of%2520Indirubins%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase-3%2520and%2520Cyclin-dependent%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D935%26epage%3D946%26doi%3D10.1021%2Fjm031016d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muehlbeyer, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Indirubin and its Derivatives: Novel Anticancer Molecules with Their Origin in Traditional Chinese Phytomedicine</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1007/s00432-004-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs00432-004-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2004&pages=627-635&author=G.+Eisenbrandauthor=F.+Hippeauthor=S.+Jakobsauthor=S.+Muehlbeyer&title=Molecular+Mechanisms+of+Indirubin+and+its+Derivatives%3A+Novel+Anticancer+Molecules+with+Their+Origin+in+Traditional+Chinese+Phytomedicine&doi=10.1007%2Fs00432-004-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs00432-004-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-004-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DEisenbrand%26aufirst%3DG.%26aulast%3DHippe%26aufirst%3DF.%26aulast%3DJakobs%26aufirst%3DS.%26aulast%3DMuehlbeyer%26aufirst%3DS.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Indirubin%2520and%2520its%2520Derivatives%253A%2520Novel%2520Anticancer%2520Molecules%2520with%2520Their%2520Origin%2520in%2520Traditional%2520Chinese%2520Phytomedicine%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D130%26spage%3D627%26epage%3D635%26doi%3D10.1007%2Fs00432-004-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, R. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montana, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuyper, L. F.</span></span> <span> </span><span class="NLM_article-title">Oxindole-based Inhibitors of Cyclin-dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4339</span>– <span class="NLM_lpage">4358</span>, <span class="refDoi"> DOI: 10.1021/jm010117d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010117d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4339-4358&author=H.+N.+Bramsonauthor=J.+Coronaauthor=S.+T.+Davisauthor=S.+H.+Dickersonauthor=M.+Edelsteinauthor=S.+V.+Fryeauthor=R.+T.+Gampeauthor=P.+A.+Harrisauthor=A.+Hassellauthor=W.+D.+Holmesauthor=R.+N.+Hunterauthor=K.+E.+Lackeyauthor=B.+Lovejoyauthor=M.+J.+Luzzioauthor=V.+Montanaauthor=W.+J.+Rocqueauthor=D.+Rusnakauthor=L.+Shewchukauthor=J.+M.+Vealauthor=D.+H.+Walkerauthor=L.+F.+Kuyper&title=Oxindole-based+Inhibitors+of+Cyclin-dependent+Kinase+2+%28CDK2%29%3A+Design%2C+Synthesis%2C+Enzymatic+Activities%2C+and+X-ray+Crystallographic+Analysis&doi=10.1021%2Fjm010117d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span></div><div class="casAuthors">Bramson, H. Neal; Corona, John; Davis, Stephen T.; Dickerson, Scott H.; Edelstein, Mark; Frye, Stephen V.; Gampe, Robert T., Jr.; Harris, Phil A.; Hassell, Anne; Holmes, William D.; Hunter, Robert N.; Lackey, Karen E.; Lovejoy, Brett; Luzzio, Michael J.; Montana, Val; Rocque, Warren J.; Rusnak, David; Shewchuk, Lisa; Veal, James M.; Walker, Duncan H.; Kuyper, Lee F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4339-4358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related classes of oxindole-based compds., 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).  The initial lead compd. was prepd. as a homolog of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor.  Crystallog. anal. of the lead compd. bound to CDK2 provided the basis for analog design.  A semiautomated method of ligand docking was used to select compds. for synthesis, and a no. of compds. with low nanomolar inhibitory activity vs. CDK2 were identified.  Enzyme binding determinants for several analogs were evaluated by X-ray crystallog.  Compds. in this series inhibited CDK2 with a potency ∼10-fold greater than that for CDK1.  Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOmtXxUWKlrVg90H21EOLACvtfcHk0lisWO8F6_Ft-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D&md5=d628549913ca46f9edf6b4692c82419d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm010117d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010117d%26sid%3Dliteratum%253Aachs%26aulast%3DBramson%26aufirst%3DH.%2BN.%26aulast%3DCorona%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DS.%2BT.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DLovejoy%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMontana%26aufirst%3DV.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DKuyper%26aufirst%3DL.%2BF.%26atitle%3DOxindole-based%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%2520%2528CDK2%2529%253A%2520Design%252C%2520Synthesis%252C%2520Enzymatic%2520Activities%252C%2520and%2520X-ray%2520Crystallographic%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4339%26epage%3D4358%26doi%3D10.1021%2Fjm010117d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecointre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleval, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouft, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejoncour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyvinec, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loaec, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honnorat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, H.</span></span> <span> </span><span class="NLM_article-title">Impact of Meriolins, A New Class of Cyclin-dependent Kinase Inhibitors, on Malignant Glioma Proliferation and Neo-angiogenesis</span>. <i>Neuro. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nou102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fneuonc%2Fnou102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24891448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1484-1498&author=M.+Jarryauthor=C.+Lecointreauthor=C.+Mallevalauthor=L.+Desruesauthor=M.+T.+Schouftauthor=V.+Lejoncourauthor=F.+Ligerauthor=G.+Lyvinecauthor=B.+Josephauthor=N.+Loaecauthor=L.+Meijerauthor=J.+Honnoratauthor=P.+Gandolfoauthor=H.+Castel&title=Impact+of+Meriolins%2C+A+New+Class+of+Cyclin-dependent+Kinase+Inhibitors%2C+on+Malignant+Glioma+Proliferation+and+Neo-angiogenesis&doi=10.1093%2Fneuonc%2Fnou102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis</span></div><div class="casAuthors">Jarry, Marie; Lecointre, Celine; Malleval, Celine; Desrues, Laurence; Schouft, Marie-Therese; Lejoncour, Vadim; Liger, Francois; Lyvinec, Gildas; Joseph, Benoit; Loaec, Nadege; Meijer, Laurent; Honnorat, Jerome; Gandolfo, Pierrick; Castel, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1484-1498</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Glioblastomas are the most frequent and most aggressive primary brain tumors in adults.  The median overall survival is limited to a few months despite surgery, radiotherapy, and chemotherapy.  It is now clearly established that hyperactivity of cyclin-dependent kinases (CDKs) is one of the processes underlying hyperproliferation and tumoral growth.  The marine natural products meridianins and variolins, characterized as CDK inhibitors, display a kinase-inhibitory activity assocd. with cytotoxic effects.  In order to improve selectivity and efficiency of these CDK inhibitors, a series of hybrid compds. called meriolins have been synthesized.  Methods.  The potential antitumoral activity of meriolins was investigated in vitro on glioma cell lines (SW1088 and U87), native neural cells, and a human endothelial cell line (HUV-EC-C).  The impact of i.p. or intratumoral administrations of meriolin 15 was evaluated in vivo on 2 different nude mice-xenografted glioma models.  Results.  Meriolins 3, 5, and 15 exhibited antiproliferative properties with nanomolar IC50 and induced cell-cycle arrest and CDK inhibition assocd. with apoptotic events in human glioma cell lines.  These meriolins blocked the proliferation rate of HUV-EC-C through cell cycle arrest and apoptosis.  In vivo, meriolin 15 provoked a robust redn. in tumor vol. in spite of toxicity for highest doses, assocd. with inhibition of cell division, activation of caspase 3, redn. of CD133 cells, and modifications of the vascular architecture.  Conclusion.  Meriolins, and meriolin 15 in particular, exhibit antiproliferative and proapoptotic activities on both glioma and intratumoral endothelial cells, constituting key promising therapeutic lead compds. for the treatment of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3AVyoDsGa7Vg90H21EOLACvtfcHk0ljj5y4D9r_z9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7vJ&md5=d915cd825fc5f9d1e23b0cc3a46cbe7b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnou102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnou102%26sid%3Dliteratum%253Aachs%26aulast%3DJarry%26aufirst%3DM.%26aulast%3DLecointre%26aufirst%3DC.%26aulast%3DMalleval%26aufirst%3DC.%26aulast%3DDesrues%26aufirst%3DL.%26aulast%3DSchouft%26aufirst%3DM.%2BT.%26aulast%3DLejoncour%26aufirst%3DV.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DLyvinec%26aufirst%3DG.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DLoaec%26aufirst%3DN.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DHonnorat%26aufirst%3DJ.%26aulast%3DGandolfo%26aufirst%3DP.%26aulast%3DCastel%26aufirst%3DH.%26atitle%3DImpact%2520of%2520Meriolins%252C%2520A%2520New%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%252C%2520on%2520Malignant%2520Glioma%2520Proliferation%2520and%2520Neo-angiogenesis%26jtitle%3DNeuro.%2520Oncol.%26date%3D2014%26volume%3D16%26spage%3D1484%26epage%3D1498%26doi%3D10.1093%2Fneuonc%2Fnou102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/cyclin A/meriolin Complex</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/jm700940h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700940h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=737-751&author=A.+Echalierauthor=K.+Bettayebauthor=Y.+Ferandinauthor=O.+Lozachauthor=M.+Clementauthor=A.+Valetteauthor=F.+Ligerauthor=B.+Marquetauthor=J.+C.+Morrisauthor=J.+A.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=Meriolins+%283-%28pyrimidin-4-yl%29-7-azaindoles%29%3A+Synthesis%2C+Kinase+Inhibitory+Activity%2C+Cellular+Effects%2C+and+Structure+of+a+CDK2%2Fcyclin+A%2Fmeriolin+Complex&doi=10.1021%2Fjm700940h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex</span></div><div class="casAuthors">Echalier, Aude; Bettayeb, Karima; Ferandin, Yoan; Lozach, Olivier; Clelment, Monique; Valette, Annie; Liger, Francois; Marquet, Bernard; Morris, Jonathan C.; Endicott, Jane A.; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-751</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. characterization of 3-(pyrimidin-4-yl)-7-azaindoles (meriolins), a chem. hybrid between the natural products meridianins and variolins, derived from marine organisms.  Meriolins display potent inhibitory activities toward cyclin-dependent kinases (CDKs) and, to a lesser extent, other kinases (GSK-3, DYRK1A).  The crystal structures of I (meriolin 5) and variolin B in complex with CDK2/cyclin A reveal that the two inhibitors are oriented in very different ways inside the ATP-binding pocket of the kinase.  A structure-activity relationship provides further insight into the mol. mechanism of action of this family of kinase inhibitors.  Meriolins are also potent antiproliferative and proapoptotic agents in cells cultured either as monolayers or in spheroids.  Proapoptotic efficacy of meriolins correlates best with their CDK2 and CDK9 inhibitory activity.  Meriolins thus constitute a promising class of pharmacol. agents to be further evaluated against the numerous human diseases that imply abnormal regulation of CDKs including cancers, neurodegenerative disorders, and polycystic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJgno3A1_7LVg90H21EOLACvtfcHk0ljj5y4D9r_z9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D&md5=1bfb3d02c6894c04237eee27bbccaa5b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm700940h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700940h%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DClement%26aufirst%3DM.%26aulast%3DValette%26aufirst%3DA.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%2520%25283-%2528pyrimidin-4-yl%2529-7-azaindoles%2529%253A%2520Synthesis%252C%2520Kinase%2520Inhibitory%2520Activity%252C%2520Cellular%2520Effects%252C%2520and%2520Structure%2520of%2520a%2520CDK2%252Fcyclin%2520A%252Fmeriolin%2520Complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D737%26epage%3D751%26doi%3D10.1021%2Fjm700940h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chashoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aruri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatikonda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madishetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Design of Novel 3-Pyrimidinylazaindole based CDK2/9 Inhibitors with Potent <i>In-vitro</i> and <i>In-vivo</i> Antitumor Efficacy in a Triple-Negative Breast Cancer Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9470</span>– <span class="NLM_lpage">9489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9470-9489&author=U.+Singhauthor=G.+Chashooauthor=S.+U.+Khanauthor=P.+Mahajanauthor=A.+Nargotraauthor=G.+Mahajanauthor=A.+Singhauthor=A.+Sharmaauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=H.+Aruriauthor=T.+Thatikondaauthor=P.+Sahuauthor=P.+Chibberauthor=V.+Kumarauthor=S.+A.+Mirauthor=S.+S.+Bharateauthor=S.+Madishettiauthor=U.+Nandiauthor=G.+Singhauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=F.+Malikauthor=S.+Mignaniauthor=R.+A.+Vishwakarmaauthor=P.+P.+Singh&title=Design+of+Novel+3-Pyrimidinylazaindole+based+CDK2%2F9+Inhibitors+with+Potent+In-vitro+and+In-vivo+Antitumor+Efficacy+in+a+Triple-Negative+Breast+Cancer+Model&doi=10.1021%2Facs.jmedchem.7b00663"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00663%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%26aulast%3DChashoo%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DS.%2BU.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DAruri%26aufirst%3DH.%26aulast%3DThatikonda%26aufirst%3DT.%26aulast%3DSahu%26aufirst%3DP.%26aulast%3DChibber%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMir%26aufirst%3DS.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DMadishetti%26aufirst%3DS.%26aulast%3DNandi%26aufirst%3DU.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DF.%26aulast%3DMignani%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26atitle%3DDesign%2520of%2520Novel%25203-Pyrimidinylazaindole%2520based%2520CDK2%252F9%2520Inhibitors%2520with%2520Potent%2520In-vitro%2520and%2520In-vivo%2520Antitumor%2520Efficacy%2520in%2520a%2520Triple-Negative%2520Breast%2520Cancer%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9470%26epage%3D9489%26doi%3D10.1021%2Facs.jmedchem.7b00663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roongta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadive, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span> <span> </span><span class="NLM_article-title">N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-dependent Kinase 2. <i>N</i>-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), A Highly Efficacious and Selective Antitumor Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1728</span>, <span class="refDoi"> DOI: 10.1021/jm0305568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Y.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+Inhibitors+of+Cyclin-dependent+Kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-+piperidinecarboxamide+%28BMS-387032%29%2C+A+Highly+Efficacious+and+Selective+Antitumor+Agent&doi=10.1021%2Fjm0305568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-%2520piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520A%2520Highly%2520Efficacious%2520and%2520Selective%2520Antitumor%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728%26doi%3D10.1021%2Fjm0305568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursuker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roongta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Aminothiazole Inhibitors of Cyclin-dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3905</span>– <span class="NLM_lpage">3927</span>, <span class="refDoi"> DOI: 10.1021/jm0201520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0201520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3905-3927&author=K.+S.+Kimauthor=S.+D.+Kimballauthor=R.+N.+Misraauthor=D.+B.+Rawlinsauthor=J.+T.+Huntauthor=H.+Y.+Xiaoauthor=S.+Luauthor=L.+Qianauthor=W.+C.+Hanauthor=W.+Shanauthor=T.+Mittauthor=Z.+W.+Caiauthor=M.+A.+Possauthor=H.+Zhuauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Y.+Changauthor=N.+Pavletichauthor=A.+Kamathauthor=W.+G.+Humphreysauthor=P.+Maratheauthor=I.+Bursukerauthor=K.+A.+Kellarauthor=U.+Roongtaauthor=R.+Batorskyauthor=J.+G.+Mulheronauthor=D.+Bolauthor=C.+R.+Fairchildauthor=F.+Y.+Leeauthor=K.+R.+Webster&title=Discovery+of+Aminothiazole+Inhibitors+of+Cyclin-dependent+Kinase+2%3A+Synthesis%2C+X-ray+Crystallographic+Analysis%2C+and+Biological+Activities&doi=10.1021%2Fjm0201520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm0201520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0201520%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPavletich%26aufirst%3DN.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DBursuker%26aufirst%3DI.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBol%26aufirst%3DD.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DDiscovery%2520of%2520Aminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%253A%2520Synthesis%252C%2520X-ray%2520Crystallographic%2520Analysis%252C%2520and%2520Biological%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3905%26epage%3D3927%26doi%3D10.1021%2Fjm0201520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockett, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span> <span> </span><span class="NLM_article-title">SNS-032 is a Potent and Selective CDK 2, 7 and 9 Inhibitor that Drives Target Modulation in Patient Samples</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1007/s00280-008-0921-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs00280-008-0921-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19169685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=723-732&author=A.+Conroyauthor=D.+E.+Stockettauthor=D.+Walkerauthor=M.+R.+Arkinauthor=U.+Hochauthor=J.+A.+Foxauthor=R.+E.+Hawtin&title=SNS-032+is+a+Potent+and+Selective+CDK+2%2C+7+and+9+Inhibitor+that+Drives+Target+Modulation+in+Patient+Samples&doi=10.1007%2Fs00280-008-0921-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span></div><div class="casAuthors">Conroy, Andrew; Stockett, David E.; Walker, Duncan; Arkin, Michelle R.; Hoch, Ute; Fox, Judith A.; Hawtin, Rachael Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-732</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clin. trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).  We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis.  We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.  Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS anal. to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.  SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9.  Treatment of RPMI-8226 MM cells at 300 nM (IC90) for 6 h was sufficient for commitment to apoptosis.  This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling mols.  SNS-032 activity was unaffected by human serum.  Target modulation was obsd. in PBMC from treated patients.  These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis.  Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clin. study of SNS-032 in MM and CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlNcab7zzo7Vg90H21EOLACvtfcHk0lg5aM5V8BAw6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D&md5=231b8ddb93821ba00d912ed28dbc1ccb</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0921-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0921-5%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DA.%26aulast%3DStockett%26aufirst%3DD.%2BE.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26atitle%3DSNS-032%2520is%2520a%2520Potent%2520and%2520Selective%2520CDK%25202%252C%25207%2520and%25209%2520Inhibitor%2520that%2520Drives%2520Target%2520Modulation%2520in%2520Patient%2520Samples%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26spage%3D723%26epage%3D732%26doi%3D10.1007%2Fs00280-008-0921-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrasali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakkaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubitt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlehurst, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tash, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span> <span> </span><span class="NLM_article-title">Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-dependent Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3768</span>– <span class="NLM_lpage">3782</span>, <span class="refDoi"> DOI: 10.1021/jm301234k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301234k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtF2jtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3768-3782&author=E.+Schonbrunnauthor=S.+Betziauthor=R.+Alamauthor=M.+P.+Martinauthor=A.+Beckerauthor=H.+Hanauthor=R.+Francisauthor=R.+Chakrasaliauthor=S.+Jakkarajauthor=A.+Kaziauthor=S.+M.+Sebtiauthor=C.+L.+Cubittauthor=A.+W.+Gebhardauthor=L.+A.+Hazlehurstauthor=J.+S.+Tashauthor=G.+I.+Georg&title=Development+of+Highly+Potent+and+Selective+Diaminothiazole+Inhibitors+of+Cyclin-dependent+Kinases&doi=10.1021%2Fjm301234k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Schonbrunn, Ernst; Betzi, Stephane; Alam, Riazul; Martin, Mathew P.; Becker, Andreas; Han, Huijong; Francis, Rawle; Chakrasali, Ramappa; Jakkaraj, Sudhakar; Kazi, Aslamuzzaman; Sebti, Said M.; Cubitt, Christopher L.; Gebhard, Anthony W.; Hazlehurst, Lori A.; Tash, Joseph S.; Georg, Gunda I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3768-3782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diaminothiazoles such as I were prepd. as inhibitors of cyclin-dependent kinase 2 (CDK2) for potential use as antitumor agents and as male contraceptive agents based on the optimization of a hit compd. with weak inhibitory activity (IC50 = 15 μM) discovered by high-throughput screening.  Using cocrystal structures of 35 diaminothiazoles with CDK2, the structure-activity relations of diaminothiazoles for CDK2 inhibition were detd. and used to find I.  I was tested for inhibition against a panel of 339 kinases; cyclin-dependent kinases were inhibited selectively, particularly CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6.  I inhibited the proliferation of 13 out of 15 cancer cell lines with IC50 values of 0.27-6.9 μM; the antiproliferative activity correlated to complete suppression of retinoblastoma phosphorylation and the onset of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeM-VFFhEenrVg90H21EOLACvtfcHk0lg5aM5V8BAw6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtF2jtb8%253D&md5=067bdf2349f9cd853b83d19131e0770f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm301234k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301234k%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DChakrasali%26aufirst%3DR.%26aulast%3DJakkaraj%26aufirst%3DS.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DCubitt%26aufirst%3DC.%2BL.%26aulast%3DGebhard%26aufirst%3DA.%2BW.%26aulast%3DHazlehurst%26aufirst%3DL.%2BA.%26aulast%3DTash%26aufirst%3DJ.%2BS.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26atitle%3DDevelopment%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Diaminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3768%26epage%3D3782%26doi%3D10.1021%2Fjm301234k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osnowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkinshaw, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-ray Crystallography, and Biological Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.1021/jm0309957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1662-1675&author=S.+Wangauthor=C.+Meadesauthor=G.+Woodauthor=A.+Osnowskiauthor=S.+Andersonauthor=R.+Yuillauthor=M.+Thomasauthor=M.+Meznaauthor=W.+Jacksonauthor=C.+Midgleyauthor=G.+Griffithsauthor=I.+Flemingauthor=S.+Greenauthor=I.+McNaeauthor=S.+Y.+Wuauthor=C.+McInnesauthor=D.+Zhelevaauthor=M.+D.+Walkinshawauthor=P.+M.+Fischer&title=2-Anilino-4-%28thiazol-5-yl%29pyrimidine+CDK+Inhibitors%3A+Synthesis%2C+SAR+analysis%2C+X-ray+Crystallography%2C+and+Biological+Activity&doi=10.1021%2Fjm0309957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm0309957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DOsnowski%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DYuill%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DMidgley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3D2-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520CDK%2520Inhibitors%253A%2520Synthesis%252C%2520SAR%2520analysis%252C%2520X-ray%2520Crystallography%252C%2520and%2520Biological%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1662%26epage%3D1675%26doi%3D10.1021%2Fjm0309957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of 2-Methyl- and 2-Amino-<i>N</i>-aryl-4,5-dihydrothiazolo[4,5-<i>h</i>]quinazolin-8-amines as Ring-constrained 2-Anilino-4-(thiazol-5-yl)pyrimidine Cyclin-Dependent Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1021/jm901660c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901660c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2136-2145&author=N.+A.+McIntyreauthor=C.+McInnesauthor=G.+Griffithsauthor=A.+L.+Barnettauthor=G.+Kontopidisauthor=A.+M.+Slawinauthor=W.+Jacksonauthor=M.+Thomasauthor=D.+I.+Zhelevaauthor=S.+Wangauthor=D.+G.+Blakeauthor=N.+J.+Westwoodauthor=P.+M.+Fischer&title=Design%2C+Synthesis%2C+and+Evaluation+of+2-Methyl-+and+2-Amino-N-aryl-4%2C5-dihydrothiazolo%5B4%2C5-h%5Dquinazolin-8-amines+as+Ring-constrained+2-Anilino-4-%28thiazol-5-yl%29pyrimidine+Cyclin-Dependent+Kinase+Inhibitors&doi=10.1021%2Fjm901660c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm901660c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901660c%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntyre%26aufirst%3DN.%2BA.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DSlawin%26aufirst%3DA.%2BM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DWestwood%26aufirst%3DN.%2BJ.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%25202-Methyl-%2520and%25202-Amino-N-aryl-4%252C5-dihydrothiazolo%255B4%252C5-h%255Dquinazolin-8-amines%2520as%2520Ring-constrained%25202-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2136%26epage%3D2145%26doi%3D10.1021%2Fjm901660c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakowec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4308</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-05-2507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16618755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4299-4308&author=M.+Paytonauthor=G.+Chungauthor=P.+Yakowecauthor=A.+Wongauthor=D.+Powersauthor=L.+Xiongauthor=N.+Zhangauthor=J.+Lealauthor=T.+L.+Bushauthor=V.+Santoraauthor=B.+Askewauthor=A.+Taskerauthor=R.+Radinskyauthor=R.+Kendallauthor=S.+Coats&title=Discovery+and+Evaluation+of+Dual+CDK1+and+CDK2+Inhibitors&doi=10.1158%2F0008-5472.CAN-05-2507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors</span></div><div class="casAuthors">Payton, Marc; Chung, Grace; Yakowec, Peter; Wong, Andrew; Powers, Dave; Xiong, Ling; Zhang, Nancy; Leal, Juan; Bush, Tammy L.; Santora, Vincent; Askew, Ben; Tasker, Andrew; Radinsky, Robert; Kendall, Richard; Coats, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4299-4308</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In eukaryotic cells, cyclin-dependent kinase (CDK) complexes regulate the temporal progression of cells through the cell cycle.  Deregulation in the cell cycle is an essential component in the evolution of cancer.  Here, we validate CDK1 and CDK2 as potential therapeutic targets using novel selective small-mol. inhibitors of cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes (CDKi).  Flow cytometry-based methods were developed to assess intracellular retinoblastoma (Rb) phosphorylation to show inhibition of the CDK pathway.  Tumor cells treated with CDK inhibitors showed an overall decrease in cell proliferation, accumulation of cells in G1 and G2, and apoptosis in a cell line-specific manner.  Although CDK inhibitors activate p53, the inhibitors were equipotent in arresting the cell cycle in isogenic breast and colon tumor cells lacking p53, suggesting the response is independent of p53.  In vivo, the CDK inhibitors prevented the growth of colon and prostate tumors, blocked proliferation of tumor cells, and inhibited Rb phosphorylation.  The discovery and evaluation of novel potent and selective CDK1 and CDK2 inhibitors will help delineate the role that CDK complexes play in regulating tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD-1KHUKXUl7Vg90H21EOLACvtfcHk0lhQ1xc82mIQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSltb8%253D&md5=2f2585ff3af06a4523cc144344d8d08f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2507%26sid%3Dliteratum%253Aachs%26aulast%3DPayton%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DG.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLeal%26aufirst%3DJ.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DSantora%26aufirst%3DV.%26aulast%3DAskew%26aufirst%3DB.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DCoats%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520Evaluation%2520of%2520Dual%2520CDK1%2520and%2520CDK2%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4299%26epage%3D4308%26doi%3D10.1158%2F0008-5472.CAN-05-2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and the Human Kinome: Recent Trends</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2011.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21256157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=144-156&author=R.+Eglenauthor=T.+Reisine&title=Drug+Discovery+and+the+Human+Kinome%3A+Recent+Trends&doi=10.1016%2Fj.pharmthera.2011.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and the human kinome: Recent trends</span></div><div class="casAuthors">Eglen, Richard; Reisine, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-156</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major new trend in drugs targeted at protein kinases is the discovery of allosteric modulators.  These compds. differ from ATP-centric drugs in that they do not compete with ATP for binding to the catalytic domain, generally acting by inducing conformational changes to modulate activity.  They could provide a no. of advantages over more classical protein kinase drugs.  For example, they are likely to be more selective, since they bind to unique regions of the kinase and may be useful in overcoming resistance that has developed to drugs that compete with ATP.  They offer the ability of activating the kinases either by removing factors that inhibit kinase activity or by simply producing changes to the enzyme to foster catalytic activity.  Furthermore, they provide more subtle modulation of kinase activity than simply blocking ATP access to inhibit activity.  One hurdle to overcome in discovering these compds. is that allosteric modulators may need to inhibit protein-protein interactions; generally difficult to accomplish with small mols.  Despite the tech. problems of identifying allosteric modulators, major gains have been made in identifying allosteric inhibitors and activators of the growth factor receptors as well as sol. tyrosine and serine/threonine kinases and some of these drugs are now in various stages of clin. trials.  This review will focus on the discovery of novel allosteric modulators of protein kinases and drug discovery approaches that have been employed to identify such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3aFpUgbPaHrVg90H21EOLACvtfcHk0lhQ1xc82mIQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFyiu78%253D&md5=08edb08d2845b8a51924b46a8546c2bb</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%26aulast%3DReisine%26aufirst%3DT.%26atitle%3DDrug%2520Discovery%2520and%2520the%2520Human%2520Kinome%253A%2520Recent%2520Trends%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D144%26epage%3D156%26doi%3D10.1016%2Fj.pharmthera.2011.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duyne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span> <span> </span><span class="NLM_article-title">A Novel Binding Pocket of Cyclin-dependent Kinase 2</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/prot.22136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fprot.22136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=122-132&author=H.+Chenauthor=R.+Van+Duyneauthor=N.+Zhangauthor=F.+Kashanchiauthor=C.+Zeng&title=A+Novel+Binding+Pocket+of+Cyclin-dependent+Kinase+2&doi=10.1002%2Fprot.22136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fprot.22136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22136%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DVan%2BDuyne%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DKashanchi%26aufirst%3DF.%26aulast%3DZeng%26aufirst%3DC.%26atitle%3DA%2520Novel%2520Binding%2520Pocket%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2009%26volume%3D74%26spage%3D122%26epage%3D132%26doi%3D10.1002%2Fprot.22136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadgar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIV-1 Virus Replication Using Small Soluble Tat Peptides</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2005.09.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.virol.2005.09.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16289656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2006&pages=373-389&author=E.+Agbottahauthor=N.+Zhangauthor=S.+Dadgarauthor=A.+Pumferyauthor=J.+D.+Wadeauthor=C.+Zengauthor=F.+Kashanchi&title=Inhibition+of+HIV-1+Virus+Replication+Using+Small+Soluble+Tat+Peptides&doi=10.1016%2Fj.virol.2005.09.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HIV-1 virus replication using small soluble Tat peptides</span></div><div class="casAuthors">Agbottah, Emmanuel; Zhang, Naigong; Dadgar, Shabnam; Pumfery, Anne; Wade, John D.; Zeng, Chen; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">373-389</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although the introduction of highly active antiretroviral therapy (HAART) has led to a significant redn. in AIDS-related morbidity and mortality, unfortunately, many patients discontinue their initial HAART regimen, resulting in development of viral resistance.  During HIV infection, the viral activator Tat is needed for viral progeny formation, and the basic and core domains of Tat are the most conserved parts of the protein.  Here, the authors show that a Tat 41/44 peptide from the core domain can inhibit HIV-1 gene expression and replication.  The peptides are not toxic to cells and target the Cdk2/Cyclin E complex, inhibiting the phosphorylation of serine 5 of RNAPII.  Using the Cdk2 x-ray crystallog. structure, the authors found that the low-energy wild-type peptides could bind to the ATP binding pocket, whereas the mutant peptide bound to the Cdk2 interface.  Finally, the authors show that these peptides do not allow loading of the catalytic domain of the cdk/cyclin complex onto the HIV-1 promoter in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUzniCAMWU7Vg90H21EOLACvtfcHk0lhQ1xc82mIQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCrsbo%253D&md5=2bebdc565e9cb905dce573ef91877589</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2005.09.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2005.09.062%26sid%3Dliteratum%253Aachs%26aulast%3DAgbottah%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDadgar%26aufirst%3DS.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520HIV-1%2520Virus%2520Replication%2520Using%2520Small%2520Soluble%2520Tat%2520Peptides%26jtitle%3DVirology%26date%3D2006%26volume%3D345%26spage%3D373%26epage%3D389%26doi%3D10.1016%2Fj.virol.2005.09.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakkaraj, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potential Allosteric Ligand Binding Site in CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/cb100410m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100410m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=492-501&author=S.+Betziauthor=R.+Alamauthor=M.+Martinauthor=D.+J.+Lubbersauthor=H.+Hanauthor=S.+R.+Jakkarajauthor=G.+I.+Georgauthor=E.+Schonbrunn&title=Discovery+of+a+Potential+Allosteric+Ligand+Binding+Site+in+CDK2&doi=10.1021%2Fcb100410m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potential Allosteric Ligand Binding Site in CDK2</span></div><div class="casAuthors">Betzi, Stephane; Alam, Riazul; Martin, Mathew; Lubbers, Donna J.; Han, Huijong; Jakkaraj, Sudhakar R.; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">492-501</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key regulatory enzymes in cell cycle progression and transcription.  Aberrant activity of CDKs has been implicated in a no. of medical conditions, and numerous small mol. CDK inhibitors have been reported as potential drug leads.  However, these inhibitors exclusively bind to the ATP site, which is largely conserved among protein kinases, and clin. trials have not resulted in viable drug candidates, attributed in part to the lack of target selectivity.  CDKs are unique among protein kinases, as their functionality strictly depends on assocn. with their partner proteins, the cyclins.  In an effort to identify potential target sites for disruption of the CDK-cyclin interaction, we probed the extrinsic fluorophore 8-anilino-1-naphthalene sulfonate (ANS) with human CDK2 and cyclin A using fluorescence spectroscopy and protein crystallog.  ANS interacts with free CDK2 in a satn.-dependent manner with an apparent Kd of 37 μM, and cyclin A displaced ANS from CDK2 with an EC50 value of 0.6 μM.  Co-crystal structures with ANS alone and in ternary complex with ATP site-directed inhibitors revealed two ANS mols. bound adjacent to one another, away from the ATP site, in a large pocket that extends from the DFG region above the C-helix.  Binding of ANS is accompanied by substantial structural changes in CDK2, resulting in a C-helix conformation that is incompatible for cyclin A assocn.  These findings indicate the potential of the ANS binding pocket as a new target site for allosteric inhibitors disrupting the interaction of CDKs and cyclins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlhg8YO4Yl7Vg90H21EOLACvtfcHk0li1broOQ3iMlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Gisb4%253D&md5=893aed13b1638f7626fbb4851014fe6e</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fcb100410m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100410m%26sid%3Dliteratum%253Aachs%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DJakkaraj%26aufirst%3DS.%2BR.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520a%2520Potential%2520Allosteric%2520Ligand%2520Binding%2520Site%2520in%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D492%26epage%3D501%26doi%3D10.1021%2Fcb100410m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingles, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">A Novel Approach to the Discovery of Small-molecule Ligands of CDK2</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2136</span>, <span class="refDoi"> DOI: 10.1002/cbic.201200316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.201200316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22893598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOqt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=2128-2136&author=M.+P.+Martinauthor=R.+Alamauthor=S.+Betziauthor=D.+J.+Inglesauthor=J.+Y.+Zhuauthor=E.+Schonbrunn&title=A+Novel+Approach+to+the+Discovery+of+Small-molecule+Ligands+of+CDK2&doi=10.1002%2Fcbic.201200316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2</span></div><div class="casAuthors">Martin, Mathew P.; Alam, Riazul; Betzi, Stephane; Ingles, Donna J.; Zhu, Jin-Yi; Schoenbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2128-2136, S2128/1-S2128/6</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In an attempt to identify novel small-mol. ligands of cyclin-dependent kinase 2 (CDK2) with potential as allosteric inhibitors, we have devised a robust and cost-effective fluorescence-based high-throughput screening assay.  The assay is based on the specific interaction of CDK2 with the extrinsic fluorophore 8-anilino-1-naphthalene sulfonate (ANS), which binds to a large allosteric pocket adjacent to the ATP site.  Hit compds. that displace ANS directly or indirectly from CDK2 are readily classified as ATP site binders or allosteric ligands through the use of staurosporine, which blocks the ATP site without displacing ANS.  Pilot screening of 1453 compds. led to the discovery of 12 compds. with displacement activities (EC50 values) ranging from 6 to 44 μ, all of which were classified as ATP-site-directed ligands.  Four new type I inhibitor scaffolds were confirmed by x-ray crystallog.  Although this small compd. library contained only ATP-site-directed ligands, the application of this assay to large compd. libraries has the potential to reveal previously unrecognized chem. scaffolds suitable for structure-based design of CDK2 inhibitors with new mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5zgMh94f7rVg90H21EOLACvtfcHk0li1broOQ3iMlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOqt7bK&md5=829eb8234fb945d206cd9324c3a1f845</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200316%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DIngles%26aufirst%3DD.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DA%2520Novel%2520Approach%2520to%2520the%2520Discovery%2520of%2520Small-molecule%2520Ligands%2520of%2520CDK2%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D2128%26epage%3D2136%26doi%3D10.1002%2Fcbic.201200316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chripkova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Discovery of the First Allosteric Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2305</span>, <span class="refDoi"> DOI: 10.4161/cc.29295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.29295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24911186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2296-2305&author=G.+Rastelliauthor=A.+Anighoroauthor=M.+Chripkovaauthor=L.+Carrassaauthor=M.+Broggini&title=Structure-based+Discovery+of+the+First+Allosteric+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.4161%2Fcc.29295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2</span></div><div class="casAuthors">Rastelli, Giulio; Anighoro, Andrew; Chripkova, Martina; Carrassa, Laura; Broggini, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2296-2305</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is currently gaining a foothold in drug discovery.  Recently, the first crystal structure of CDK2 with an open allosteric pocket adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the structure has not yet been exploited for the structure-based design of type III allosteric inhibitors.  In this work we report the results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2.  Using a combination of docking and post-docking analyses made with our tool BEAR, 7 allosteric ligands (hit rate of 20%) with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the micromolar range.  Competition expts. performed in the presence of the ATP-competitive inhibitor staurosporine confirmed that the 7 ligands are truly allosteric, in agreement with their design.  Of these, compd. 2 bound CDK2 with an EC50 value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75-1 breast cancer cells with IC50 values of approx. 20 μM, while compd. 4 had an EC50 value of 71 μM and IC50 values around 4 μM.  Remarkably, the most potent compd. 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells.  Finally, hit expansion through analog search of the most potent inhibitor 4 revealed an addnl. ligand 4g with similar in vitro potency on breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGYE_h0shsbVg90H21EOLACvtfcHk0lhnmKr3QNIqjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF&md5=e790fc2920b61e6b85b5097a49cbc7bb</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4161%2Fcc.29295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29295%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DChripkova%26aufirst%3DM.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DBroggini%26aufirst%3DM.%26atitle%3DStructure-based%2520Discovery%2520of%2520the%2520First%2520Allosteric%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2296%26epage%3D2305%26doi%3D10.4161%2Fcc.29295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Nonpeptide Allosteric Inhibitors Interrupting the Interaction of CDK2/cyclin A3 by Virtual Screening and Bioassays</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4069</span>– <span class="NLM_lpage">4073</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.08.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4069-4073&author=Y.+Huauthor=S.+Liauthor=F.+Liuauthor=L.+Gengauthor=X.+Shuauthor=J.+Zhang&title=Discovery+of+Novel+Nonpeptide+Allosteric+Inhibitors+Interrupting+the+Interaction+of+CDK2%2Fcyclin+A3+by+Virtual+Screening+and+Bioassays&doi=10.1016%2Fj.bmcl.2015.08.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Novel%2520Nonpeptide%2520Allosteric%2520Inhibitors%2520Interrupting%2520the%2520Interaction%2520of%2520CDK2%252Fcyclin%2520A3%2520by%2520Virtual%2520Screening%2520and%2520Bioassays%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4069%26epage%3D4073%26doi%3D10.1016%2Fj.bmcl.2015.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryanarayanan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cyclin-binding Groove Site to Inhibit the Catalytic Activity of CDK2/cyclin A Complex Using p27(KIP1)-derived Peptidomimetic Inhibitors</span>. <i>J. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1007/s12154-014-0124-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs12154-014-0124-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25584078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2MvlvFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=11-24&author=A.+Karthigaauthor=S.+K.+Tripathiauthor=R.+Shanmugamauthor=V.+Suryanarayananauthor=S.+K.+Singh&title=Targeting+the+Cyclin-binding+Groove+Site+to+Inhibit+the+Catalytic+Activity+of+CDK2%2Fcyclin+A+Complex+Using+p27%28KIP1%29-derived+Peptidomimetic+Inhibitors&doi=10.1007%2Fs12154-014-0124-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors</span></div><div class="casAuthors">Karthiga Arumugasamy; Tripathi Sunil Kumar; Suryanarayanan Venkatesan; Singh Sanjeev Kumar; Shanmugam Ramasamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Functionally activated cyclin-dependent kinase 2 (CDK2)/cyclin A complex has been validated as an interesting therapeutic target to develop the efficient antineoplastic drug based on the cell cycle arrest.  Cyclin A binds to CDK2 and activates the kinases as well as recruits the substrate and inhibitors using a hydrophobic cyclin-binding groove (CBG).  Blocking the cyclin substrate recruitment on CBG is an alternative approach to override the specificity hurdle of the currently available ATP site targeting CDK2 inhibitors.  Greater understanding of the interaction of CDK2/cyclin A complex with p27 (negative regulator) reveals that the Leu-Phe-Gly (LFG) motif region of p27 binds with the CBG site of cyclin A to arrest the malignant cell proliferation that induces apoptosis.  In the present study, Replacement with Partial Ligand Alternatives through Computational Enrichment (REPLACE) drug design strategies have been applied to acquire LFG peptide-derived peptidomimetics library.  The peptidomimetics function is equivalent with respect to substrate p27 protein fashion but does not act as an ATP antagonist.  The combined approach of molecular docking, molecular dynamics (MD), and molecular electrostatic potential and ADME/T prediction were carried out to evaluate the peptidomimetics.  Resultant interaction and electrostatic potential maps suggested that smaller substituent is desirable at the position of phenyl ring to interact with Trp217, Arg250, and Gln254 residues in the active site.  The best docked poses were refined by the MD simulations which resulted in conformational changes.  After equilibration, the structure of the peptidomimetic and receptor complex was stable.  The results revealed that the various substrate protein-derived peptidomimetics could serve as perfect leads against CDK2 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLKGDiEiQ4VrHHuJhbyicZfW6udTcc2eZlYKHq-214Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvlvFSlsg%253D%253D&md5=3682b29af420bc71e46b6ab952fd9821</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2Fs12154-014-0124-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-014-0124-y%26sid%3Dliteratum%253Aachs%26aulast%3DKarthiga%26aufirst%3DA.%26aulast%3DTripathi%26aufirst%3DS.%2BK.%26aulast%3DShanmugam%26aufirst%3DR.%26aulast%3DSuryanarayanan%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26atitle%3DTargeting%2520the%2520Cyclin-binding%2520Groove%2520Site%2520to%2520Inhibit%2520the%2520Catalytic%2520Activity%2520of%2520CDK2%252Fcyclin%2520A%2520Complex%2520Using%2520p27%2528KIP1%2529-derived%2520Peptidomimetic%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D8%26spage%3D11%26epage%3D24%26doi%3D10.1007%2Fs12154-014-0124-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premnath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1582</span>, <span class="refDoi"> DOI: 10.1021/jm3013882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3013882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1573-1582&author=S.+Liuauthor=P.+N.+Premnathauthor=J.+K.+Bolgerauthor=T.+L.+Perkinsauthor=L.+O.+Kirklandauthor=G.+Kontopidisauthor=C.+McInnes&title=Optimization+of+Non-ATP+Competitive+CDK%2FCyclin+Groove+Inhibitors+through+REPLACE-Mediated+Fragment+Assembly&doi=10.1021%2Fjm3013882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm3013882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3013882%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DPremnath%26aufirst%3DP.%2BN.%26aulast%3DBolger%26aufirst%3DJ.%2BK.%26aulast%3DPerkins%26aufirst%3DT.%2BL.%26aulast%3DKirkland%26aufirst%3DL.%2BO.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520Non-ATP%2520Competitive%2520CDK%252FCyclin%2520Groove%2520Inhibitors%2520through%2520REPLACE-Mediated%2520Fragment%2520Assembly%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1573%26epage%3D1582%26doi%3D10.1021%2Fjm3013882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plater, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1002/cbic.200600189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.200600189" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=1909-1915&author=M.+J.+Andrewsauthor=G.+Kontopidisauthor=C.+McInnesauthor=A.+Platerauthor=L.+Innesauthor=A.+Cowanauthor=P.+Jewsburyauthor=P.+M.+Fischer&title=REPLACE%3A+A+Strategy+for+Iterative+Design+of+Cyclin-Binding+Groove+Inhibitors&doi=10.1002%2Fcbic.200600189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600189%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BJ.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DPlater%26aufirst%3DA.%26aulast%3DInnes%26aufirst%3DL.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DREPLACE%253A%2520A%2520Strategy%2520for%2520Iterative%2520Design%2520of%2520Cyclin-Binding%2520Groove%2520Inhibitors%26jtitle%3DChemBioChem%26date%3D2006%26volume%3D7%26spage%3D1909%26epage%3D1915%26doi%3D10.1002%2Fcbic.200600189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Premnath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Benzamide Capped Peptidomimetics as Non-ATP Competitive Inhibitors of CDK2 Using the REPLACE Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3754</span>– <span class="NLM_lpage">3760</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2016.05.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3754-3760&author=P.+N.+Premnathauthor=S.+N.+Craigauthor=S.+Liuauthor=C.+McInnes&title=Benzamide+Capped+Peptidomimetics+as+Non-ATP+Competitive+Inhibitors+of+CDK2+Using+the+REPLACE+Strategy&doi=10.1016%2Fj.bmcl.2016.05.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.067%26sid%3Dliteratum%253Aachs%26aulast%3DPremnath%26aufirst%3DP.%2BN.%26aulast%3DCraig%26aufirst%3DS.%2BN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DBenzamide%2520Capped%2520Peptidomimetics%2520as%2520Non-ATP%2520Competitive%2520Inhibitors%2520of%2520CDK2%2520Using%2520the%2520REPLACE%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3754%26epage%3D3760%26doi%3D10.1016%2Fj.bmcl.2016.05.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gondeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrian-Herrada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divita, G.</span></span> <span> </span><span class="NLM_article-title">Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/cyclin Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">13793</span>– <span class="NLM_lpage">13800</span>, <span class="refDoi"> DOI: 10.1074/jbc.M413690200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M413690200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=13793-13800&author=C.+Gondeauauthor=S.+Gerbal-Chaloinauthor=P.+Belloauthor=G.+Aldrian-Herradaauthor=M.+C.+Morrisauthor=G.+Divita&title=Design+of+a+Novel+Class+of+Peptide+Inhibitors+of+Cyclin-dependent+Kinase%2Fcyclin+Activation&doi=10.1074%2Fjbc.M413690200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413690200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413690200%26sid%3Dliteratum%253Aachs%26aulast%3DGondeau%26aufirst%3DC.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DP.%26aulast%3DAldrian-Herrada%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DM.%2BC.%26aulast%3DDivita%26aufirst%3DG.%26atitle%3DDesign%2520of%2520a%2520Novel%2520Class%2520of%2520Peptide%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%252Fcyclin%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D13793%26epage%3D13800%26doi%3D10.1074%2Fjbc.M413690200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Type II Inhibitors Targeting CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+Mobitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+Inhibitors+Targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0ljcgaoWgXxueg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520Inhibitors%2520Targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+Approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljcgaoWgXxueg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520Approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Inhibitors that Bind to Inactive Kinase Conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+Design+of+Inhibitors+that+Bind+to+Inactive+Kinase+Conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0li4_A9giEnKnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520Design%2520of%2520Inhibitors%2520that%2520Bind%2520to%2520Inactive%2520Kinase%2520Conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2004.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15123247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=525-534&author=C.+McInnesauthor=S.+Wangauthor=S.+Andersonauthor=J.+O%E2%80%99Boyleauthor=W.+Jacksonauthor=G.+Kontopidisauthor=C.+Meadesauthor=M.+Meznaauthor=M.+Thomasauthor=G.+Woodauthor=D.+P.+Laneauthor=P.+M.+Fischer&title=Structural+Determinants+of+CDK4+Inhibition+and+Design+of+Selective+ATP+Competitive+Inhibitors&doi=10.1016%2Fj.chembiol.2004.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span></div><div class="casAuthors">McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice; Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-534</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of selective inhibitors of the CDK4/cyclin D1 complex have been reported recently.  Due to the absence of an exptl. CDK4 structure, the ligand and protein determinants contributing to CDK4 selectivity are poorly understood at present.  Here, we report the use of computational methods to elucidate the characteristics of selectivity and to derive the structural basis for specific, high-affinity binding of inhibitors to the CDK4 active site.  From these data, the hypothesis emerged that appropriate incorporation of an ionizable function into a CDK2 inhibitor results in more favorable binding to CDK4.  This knowledge was applied to the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore that are potent and highly selective ATP antagonists of CDK4/cyclin D1.  The findings of this study also have significant implications in the design of CDK4 mimic structures based on CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU07M2Ugw65bVg90H21EOLACvtfcHk0li4_A9giEnKnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D&md5=94d613c28266a51507bf63d34965d792</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DStructural%2520Determinants%2520of%2520CDK4%2520Inhibition%2520and%2520Design%2520of%2520Selective%2520ATP%2520Competitive%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D525%26epage%3D534%26doi%3D10.1016%2Fj.chembiol.2004.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+Structural+and+Functional+Studies+of+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+Inhibitors+Suggest+the+Basis+for+Isotype+Selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0li4_A9giEnKnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520Structural%2520and%2520Functional%2520Studies%2520of%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520Inhibitors%2520Suggest%2520the%2520Basis%2520for%2520Isotype%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A General Strategy for Creating ″Inactive-conformation″ abl Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=X.+Wangauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+General+Strategy+for+Creating+%E2%80%B3Inactive-conformation%E2%80%B3+abl+Inhibitors&doi=10.1016%2Fj.chembiol.2006.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0lgjW--kR-bYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520General%2520Strategy%2520for%2520Creating%2520%25E2%2580%25B3Inactive-conformation%25E2%2580%25B3%2520abl%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D779%26epage%3D786%26doi%3D10.1016%2Fj.chembiol.2006.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Small-molecule Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0lgjW--kR-bYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christodoulou, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannazza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Presti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistutta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Probing an Allosteric Pocket of CDK2 with Small Molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcmdc.201600474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27860401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSlsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=33-41&author=M.+S.+Christodoulouauthor=F.+Caporuscioauthor=V.+Restelliauthor=L.+Carlinoauthor=G.+Cannazzaauthor=E.+Costanziauthor=C.+Cittiauthor=L.+Lo+Prestiauthor=P.+Pisaniauthor=R.+Battistuttaauthor=M.+Brogginiauthor=D.+Passarellaauthor=G.+Rastelli&title=Probing+an+Allosteric+Pocket+of+CDK2+with+Small+Molecules&doi=10.1002%2Fcmdc.201600474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Probing an allosteric pocket of CDK2 with small molecules</span></div><div class="casAuthors">Christodoulou, Michael S.; Caporuscio, Fabiana; Restelli, Valentina; Carlino, Luca; Cannazza, Giuseppe; Costanzi, Elisa; Citti, Cinzia; Lo Presti, Leonardo; Pisani, Pasquale; Battistutta, Roberto; Broggini, Massimo; Passarella, Daniele; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The availability of well-characterized allosteric modulators is crucial for investigating the allosteric regulation of protein function.  In a recently identified inactive conformation of cyclin-dependent kinase 2 (CDK2), an open allosteric pocket was detected and proposed as a site to accommodate allosteric inhibitors.  Previous structure-based approaches allowed the identification of a hit compd. expected to bind to this pocket.  Here, the authors report the characterization of this compd. by x-ray crystallog., which surprisingly provided a chem. structure different from that previously reported.  Therefore, the compd. was synthesized and completely characterized.  X-ray structures of the synthesized and purchased compds. were found to be superimposable.  A reaction mechanism was proposed to explain the formation of the structure indicated by crystallog.  Moreover, a stereoselective synthesis was developed to evaluate the biol. activity of the pure stereoisomers.  Modeling studies were performed to unveil the details of the interaction with CDK2.  The activity of the obtained compds. was evaluated with various biol. assays.  Mutagenesis expts. confirmed the binding to the allosteric pocket.  Finally, the allosteric ligands were shown to inhibit the growth of lung (A549) and ovarian (SKOV3) cancer cell lines.  Therefore, this report presents a thorough chem. and biol. characterization of the 1st small-mol. ligands to be used as probes to study the allosteric modulation of CDK2 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosBWAU8ms0C7Vg90H21EOLACvtfcHk0lgjW--kR-bYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSlsr3I&md5=eaf5aeb25d9e1fee9bb129d39200d424</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600474%26sid%3Dliteratum%253Aachs%26aulast%3DChristodoulou%26aufirst%3DM.%2BS.%26aulast%3DCaporuscio%26aufirst%3DF.%26aulast%3DRestelli%26aufirst%3DV.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DCannazza%26aufirst%3DG.%26aulast%3DCostanzi%26aufirst%3DE.%26aulast%3DCitti%26aufirst%3DC.%26aulast%3DLo%2BPresti%26aufirst%3DL.%26aulast%3DPisani%26aufirst%3DP.%26aulast%3DBattistutta%26aufirst%3DR.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DPassarella%26aufirst%3DD.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DProbing%2520an%2520Allosteric%2520Pocket%2520of%2520CDK2%2520with%2520Small%2520Molecules%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D33%26epage%3D41%26doi%3D10.1002%2Fcmdc.201600474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 54 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Adeeb Al Sheikh Ali, Daoud Khan, Arshi Naqvi, Fawzia Faleh Al-blewi, Nadjet Rezki, Mohamed Reda Aouad, <span class="NLM_string-name hlFld-ContribAuthor">Mohamed Hagar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Molecular Modeling, Anticancer Studies, and Density Functional Theory Calculations of 4-(1,2,4-Triazol-3-ylsulfanylmethyl)-1,2,3-triazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     , 301-316. <a href="https://doi.org/10.1021/acsomega.0c04595" title="DOI URL">https://doi.org/10.1021/acsomega.0c04595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04595%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BMolecular%252BModeling%25252C%252BAnticancer%252BStudies%25252C%252Band%252BDensity%252BFunctional%252BTheory%252BCalculations%252Bof%252B4-%2525281%25252C2%25252C4-Triazol-3-ylsulfanylmethyl%252529-1%25252C2%25252C3-triazole%252BDerivatives%26aulast%3DAl%2BSheikh%2BAli%26aufirst%3DAdeeb%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18092020%26date%3D09122020%26date%3D31122020%26volume%3D6%26issue%3D1%26spage%3D301%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paing  Linn</span>, <span class="hlFld-ContribAuthor ">Susumu  Kohno</span>, <span class="hlFld-ContribAuthor ">Jindan  Sheng</span>, <span class="hlFld-ContribAuthor ">Nilakshi  Kulathunga</span>, <span class="hlFld-ContribAuthor ">Hai  Yu</span>, <span class="hlFld-ContribAuthor ">Zhiheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Dominic  Voon</span>, <span class="hlFld-ContribAuthor ">Yoshihiro  Watanabe</span>, <span class="hlFld-ContribAuthor ">Chiaki  Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting RB1 Loss in Cancers. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3737. <a href="https://doi.org/10.3390/cancers13153737" title="DOI URL">https://doi.org/10.3390/cancers13153737</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153737%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BRB1%252BLoss%252Bin%252BCancers%26aulast%3DLinn%26aufirst%3DPaing%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Wenxing  Lv</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.685106" title="DOI URL">https://doi.org/10.3389/fcell.2021.685106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.685106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.685106%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DOpportunities%252Band%252BChallenges%252Bof%252BSmall%252BMolecule%252BInduced%252BTargeted%252BProtein%252BDegradation%26aulast%3DHe%26aufirst%3DMing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junjun  Li</span>, <span class="hlFld-ContribAuthor ">Yuan  Qian</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Yisheng  Qiao</span>, <span class="hlFld-ContribAuthor ">Hao  Song</span>, <span class="hlFld-ContribAuthor ">Liyan  Li</span>, <span class="hlFld-ContribAuthor ">Jiazhi  Guo</span>, <span class="hlFld-ContribAuthor ">Di  Lu</span>, <span class="hlFld-ContribAuthor ">Xingli  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">LncRNA LINC00473 is involved in the progression of invasive pituitary adenoma by upregulating KMT5A via ceRNA-mediated miR-502-3p evasion. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     <a href="https://doi.org/10.1038/s41419-021-03861-y" title="DOI URL">https://doi.org/10.1038/s41419-021-03861-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-03861-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-03861-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DLncRNA%252BLINC00473%252Bis%252Binvolved%252Bin%252Bthe%252Bprogression%252Bof%252Binvasive%252Bpituitary%252Badenoma%252Bby%252Bupregulating%252BKMT5A%252Bvia%252BceRNA-mediated%252BmiR-502-3p%252Bevasion%26aulast%3DLi%26aufirst%3DJunjun%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y. Sheena  Mary</span>, <span class="hlFld-ContribAuthor ">Y. Shyma  Mary</span>, <span class="hlFld-ContribAuthor ">K. S.  Resmi</span>, <span class="hlFld-ContribAuthor ">S.  Sarala</span>, <span class="hlFld-ContribAuthor ">Rohitash  Yadav</span>, <span class="hlFld-ContribAuthor ">Ismail  Celik</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling the structural and reactivity properties of hydrazono methyl-4H-chromen-4-one derivatives—wavefunction-dependent properties, molecular docking, and dynamics simulation studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2021,</strong> <em>27 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s00894-021-04800-6" title="DOI URL">https://doi.org/10.1007/s00894-021-04800-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-021-04800-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-021-04800-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DModeling%252Bthe%252Bstructural%252Band%252Breactivity%252Bproperties%252Bof%252Bhydrazono%252Bmethyl-4H-chromen-4-one%252Bderivatives%2525E2%252580%252594wavefunction-dependent%252Bproperties%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bdynamics%252Bsimulation%252Bstudies%26aulast%3DMary%26aufirst%3DY.%2BSheena%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ghaneya S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hanan H.  Georgey</span>, <span class="hlFld-ContribAuthor ">Esraa Z.  Mohammed</span>, <span class="hlFld-ContribAuthor ">Riham F.  George</span>, <span class="hlFld-ContribAuthor ">Walaa R.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Farghaly A.  Omar</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113389. <a href="https://doi.org/10.1016/j.ejmech.2021.113389" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113389%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMechanistic%252Bselectivity%252Binvestigation%252Band%252B2D-QSAR%252Bstudy%252Bof%252Bsome%252Bnew%252Bantiproliferative%252Bpyrazoles%252Band%252Bpyrazolopyridines%252Bas%252Bpotential%252BCDK2%252Binhibitors%26aulast%3DHassan%26aufirst%3DGhaneya%2BS.%26date%3D2021%26volume%3D218%26spage%3D113389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaowen  Wu</span>, <span class="hlFld-ContribAuthor ">Junya  Yan</span>, <span class="hlFld-ContribAuthor ">Jiayi  Yu</span>, <span class="hlFld-ContribAuthor ">Zhiyuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Qian  Guo</span>, <span class="hlFld-ContribAuthor ">Yan  Kong</span>, <span class="hlFld-ContribAuthor ">Jun  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical significance of CCNE1 copy number gain in acral melanoma patients. </span><span class="cited-content_cbyCitation_journal-name">Melanoma Research</span><span> <strong>2021,</strong> <em>Publish Ahead of Print </em><a href="https://doi.org/10.1097/CMR.0000000000000742" title="DOI URL">https://doi.org/10.1097/CMR.0000000000000742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CMR.0000000000000742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCMR.0000000000000742%26sid%3Dliteratum%253Aachs%26jtitle%3DMelanoma%2520Research%26atitle%3DClinical%252Bsignificance%252Bof%252BCCNE1%252Bcopy%252Bnumber%252Bgain%252Bin%252Bacral%252Bmelanoma%252Bpatients%26aulast%3DWu%26aufirst%3DXiaowen%26date%3D2021%26volume%3DPublish%2520Ahead%2520of%2520Print" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liguo  Wang</span>, <span class="hlFld-ContribAuthor ">Xuejing  Shao</span>, <span class="hlFld-ContribAuthor ">Tianbai  Zhong</span>, <span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Aixiao  Xu</span>, <span class="hlFld-ContribAuthor ">Xiuyun  Sun</span>, <span class="hlFld-ContribAuthor ">Hongying  Gao</span>, <span class="hlFld-ContribAuthor ">Yongbo  Liu</span>, <span class="hlFld-ContribAuthor ">Tianlong  Lan</span>, <span class="hlFld-ContribAuthor ">Yan  Tong</span>, <span class="hlFld-ContribAuthor ">Xue  Tao</span>, <span class="hlFld-ContribAuthor ">Wenxin  Du</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Yingqian  Chen</span>, <span class="hlFld-ContribAuthor ">Ting  Li</span>, <span class="hlFld-ContribAuthor ">Xianbin  Meng</span>, <span class="hlFld-ContribAuthor ">Haiteng  Deng</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Qiaojun  He</span>, <span class="hlFld-ContribAuthor ">Meidan  Ying</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (5)
                                     , 567-575. <a href="https://doi.org/10.1038/s41589-021-00742-5" title="DOI URL">https://doi.org/10.1038/s41589-021-00742-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-021-00742-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-021-00742-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252Bfirst-in-class%252BCDK2%252Bselective%252Bdegrader%252Bfor%252BAML%252Bdifferentiation%252Btherapy%26aulast%3DWang%26aufirst%3DLiguo%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D5%26spage%3D567%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Basharat  Ahmed</span>, <span class="hlFld-ContribAuthor ">Sara  Khan</span>, <span class="hlFld-ContribAuthor ">Faisal  Nouroz</span>, <span class="hlFld-ContribAuthor ">Umar  Farooq</span>, <span class="hlFld-ContribAuthor ">Saba  Khalid</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring multi-target inhibitors using
              in silico
              approach targeting cell cycle dysregulator–CDK proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>280 </em>, 1-15. <a href="https://doi.org/10.1080/07391102.2021.1918253" title="DOI URL">https://doi.org/10.1080/07391102.2021.1918253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1918253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1918253%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DExploring%252Bmulti-target%252Binhibitors%252Busing%252Bin%252Bsilico%252Bapproach%252Btargeting%252Bcell%252Bcycle%252Bdysregulator%2525E2%252580%252593CDK%252Bproteins%26aulast%3DAhmed%26aufirst%3DBasharat%26date%3D2021%26date%3D2021%26volume%3D280%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tae  Nakano-Tateno</span>, <span class="hlFld-ContribAuthor ">Kheng Joe  Lau</span>, <span class="hlFld-ContribAuthor ">Justin  Wang</span>, <span class="hlFld-ContribAuthor ">Cailin  McMahon</span>, <span class="hlFld-ContribAuthor ">Yasuhiko  Kawakami</span>, <span class="hlFld-ContribAuthor ">Toru  Tateno</span>, <span class="hlFld-ContribAuthor ">Takako  Araki</span>. </span><span class="cited-content_cbyCitation_article-title">Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fendo.2021.624686" title="DOI URL">https://doi.org/10.3389/fendo.2021.624686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2021.624686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2021.624686%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DMultimodal%252BNon-Surgical%252BTreatments%252Bof%252BAggressive%252BPituitary%252BTumors%26aulast%3DNakano-Tateno%26aufirst%3DTae%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guan Zhen  He</span>, <span class="hlFld-ContribAuthor ">Wen Jen  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Nanomaterials</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 772. <a href="https://doi.org/10.3390/nano11030772" title="DOI URL">https://doi.org/10.3390/nano11030772</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nano11030772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnano11030772%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomaterials%26atitle%3DPeptide-Functionalized%252BNanoparticles-Encapsulated%252BCyclin-Dependent%252BKinases%252BInhibitor%252BSeliciclib%252Bin%252BTransferrin%252BReceptor%252BOverexpressed%252BCancer%252BCells%26aulast%3DHe%26aufirst%3DGuan%2BZhen%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yihua  Ye</span>, <span class="hlFld-ContribAuthor ">Yuqi  Wen</span>, <span class="hlFld-ContribAuthor ">Zhongnan  Zhang</span>, <span class="hlFld-ContribAuthor ">Song  He</span>, <span class="hlFld-ContribAuthor ">Xiaochen  Bo</span>, . </span><span class="cited-content_cbyCitation_article-title">Drug-Target Interaction Prediction Based on Adversarial Bayesian Personalized Ranking. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2021,</strong> <em>2021 </em>, 1-16. <a href="https://doi.org/10.1155/2021/6690154" title="DOI URL">https://doi.org/10.1155/2021/6690154</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2021/6690154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2021%2F6690154%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DDrug-Target%252BInteraction%252BPrediction%252BBased%252Bon%252BAdversarial%252BBayesian%252BPersonalized%252BRanking%26aulast%3DYe%26aufirst%3DYihua%26date%3D2021%26volume%3D2021%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Szymanowska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Gornowicz</span>, <span class="hlFld-ContribAuthor ">Anna  Bielawska</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Bielawski</span>. </span><span class="cited-content_cbyCitation_article-title">[1,2,4]triazines – as potential drugs in cancer chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Postępy Higieny i Medycyny Doświadczalnej</span><span> <strong>2021,</strong> <em>75 </em>, 64-84. <a href="https://doi.org/10.5604/01.3001.0014.7145" title="DOI URL">https://doi.org/10.5604/01.3001.0014.7145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5604/01.3001.0014.7145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5604%2F01.3001.0014.7145%26sid%3Dliteratum%253Aachs%26jtitle%3DPost%25C4%2599py%2520Higieny%2520i%2520Medycyny%2520Do%25C5%259Bwiadczalnej%26atitle%3D%25255B1%25252C2%25252C4%25255Dtriazines%252B%2525E2%252580%252593%252Bas%252Bpotential%252Bdrugs%252Bin%252Bcancer%252Bchemotherapy%26aulast%3DSzymanowska%26aufirst%3DAnna%26date%3D2021%26volume%3D75%26spage%3D64%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y. Sheena  Mary</span>, <span class="hlFld-ContribAuthor ">Y. Shyma  Mary</span>, <span class="hlFld-ContribAuthor ">K. S.  Resmi</span>, <span class="hlFld-ContribAuthor ">Ali Shokuhi  Rad</span>. </span><span class="cited-content_cbyCitation_article-title">Spectroscopic and computational study of chromone derivatives with antitumor activity: detailed DFT, QTAIM and docking investigations. </span><span class="cited-content_cbyCitation_journal-name">SN Applied Sciences</span><span> <strong>2021,</strong> <em>3 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s42452-021-04188-1" title="DOI URL">https://doi.org/10.1007/s42452-021-04188-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s42452-021-04188-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs42452-021-04188-1%26sid%3Dliteratum%253Aachs%26jtitle%3DSN%2520Applied%2520Sciences%26atitle%3DSpectroscopic%252Band%252Bcomputational%252Bstudy%252Bof%252Bchromone%252Bderivatives%252Bwith%252Bantitumor%252Bactivity%25253A%252Bdetailed%252BDFT%25252C%252BQTAIM%252Band%252Bdocking%252Binvestigations%26aulast%3DMary%26aufirst%3DY.%2BSheena%26date%3D2021%26date%3D2021%26volume%3D3%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nidhi  Deswal</span>, <span class="hlFld-ContribAuthor ">Ankita  Shrivastava</span>, <span class="hlFld-ContribAuthor ">Md.  Summon Hossain</span>, <span class="hlFld-ContribAuthor ">Parveen  Gahlyan</span>, <span class="hlFld-ContribAuthor ">Rashim  Bawa</span>, <span class="hlFld-ContribAuthor ">Rinkoo Devi  Gupta</span>, <span class="hlFld-ContribAuthor ">Rakesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Evaluation and Molecular Docking Studies of Novel Triazole Linked 1,4‐Dihydropyridine‐isatin Scaffolds as Potent Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (4)
                                     , 717-725. <a href="https://doi.org/10.1002/slct.202003948" title="DOI URL">https://doi.org/10.1002/slct.202003948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202003948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202003948%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BEvaluation%252Band%252BMolecular%252BDocking%252BStudies%252Bof%252BNovel%252BTriazole%252BLinked%252B1%25252C4%2525E2%252580%252590Dihydropyridine%2525E2%252580%252590isatin%252BScaffolds%252Bas%252BPotent%252BAnticancer%252BAgents%26aulast%3DDeswal%26aufirst%3DNidhi%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D4%26spage%3D717%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew J  Locke</span>, <span class="hlFld-ContribAuthor ">Lazina  Hossain</span>, <span class="hlFld-ContribAuthor ">Glynnis  McCrostie</span>, <span class="hlFld-ContribAuthor ">Daryl A  Ronato</span>, <span class="hlFld-ContribAuthor ">Amira  Fitieh</span>, <span class="hlFld-ContribAuthor ">Tanzeem Ahmed  Rafique</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Mashayekhi</span>, <span class="hlFld-ContribAuthor ">Mobina  Motamedi</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Masson</span>, <span class="hlFld-ContribAuthor ">Ismail Hassan  Ismail</span>. </span><span class="cited-content_cbyCitation_article-title">SUMOylation mediates CtIP’s functions in DNA end resection and replication fork protection. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2021,</strong> <em>49 </em>
                                    (2)
                                     , 928-953. <a href="https://doi.org/10.1093/nar/gkaa1232" title="DOI URL">https://doi.org/10.1093/nar/gkaa1232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa1232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa1232%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DSUMOylation%252Bmediates%252BCtIP%2525E2%252580%252599s%252Bfunctions%252Bin%252BDNA%252Bend%252Bresection%252Band%252Breplication%252Bfork%252Bprotection%26aulast%3DLocke%26aufirst%3DAndrew%2BJ%26date%3D2021%26date%3D2021%26volume%3D49%26issue%3D2%26spage%3D928%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tina  Blažević</span>, <span class="hlFld-ContribAuthor ">Gottfried  Reznicek</span>, <span class="hlFld-ContribAuthor ">Limin  Ding</span>, <span class="hlFld-ContribAuthor ">Gangqiang  Yang</span>, <span class="hlFld-ContribAuthor ">Patricia  Haiss</span>, <span class="hlFld-ContribAuthor ">Elke H.  Heiss</span>, <span class="hlFld-ContribAuthor ">Verena M.  Dirsch</span>, <span class="hlFld-ContribAuthor ">Rongxia  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Short Chain (≤C4) Esterification Increases Bioavailability of Rosmarinic Acid and Its Potency to Inhibit Vascular Smooth Muscle Cell Proliferation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.609756" title="DOI URL">https://doi.org/10.3389/fphar.2020.609756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.609756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.609756%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DShort%252BChain%252B%252528%2525E2%252589%2525A4C4%252529%252BEsterification%252BIncreases%252BBioavailability%252Bof%252BRosmarinic%252BAcid%252Band%252BIts%252BPotency%252Bto%252BInhibit%252BVascular%252BSmooth%252BMuscle%252BCell%252BProliferation%26aulast%3DBla%25C5%25BEevi%25C4%2587%26aufirst%3DTina%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanzhi  Liang</span>, <span class="hlFld-ContribAuthor ">Jintong  Du</span>, <span class="hlFld-ContribAuthor ">Reham M.  Elhassan</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2021,</strong> <em>30 </em>
                                    (1)
                                     , 61-76. <a href="https://doi.org/10.1080/13543784.2021.1850693" title="DOI URL">https://doi.org/10.1080/13543784.2021.1850693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2021.1850693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2021.1850693%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DRecent%252Bprogress%252Bin%252Bdevelopment%252Bof%252Bcyclin-dependent%252Bkinase%252B7%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DLiang%26aufirst%3DHanzhi%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D1%26spage%3D61%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed M.  Shawky</span>, <span class="hlFld-ContribAuthor ">Nashwa A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Mohammed A. S.  Abourehab</span>, <span class="hlFld-ContribAuthor ">Ashraf N.  Abdalla</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Gouda</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 15-33. <a href="https://doi.org/10.1080/14756366.2020.1837124" title="DOI URL">https://doi.org/10.1080/14756366.2020.1837124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1837124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1837124%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DPharmacophore-based%252Bvirtual%252Bscreening%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%25252C%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnovel%252Bpyrrolizines%252Bbearing%252Burea%25252Fthiourea%252Bmoieties%252Bwith%252Bpotential%252Bcytotoxicity%252Band%252BCDK%252Binhibitory%252Bactivities%26aulast%3DShawky%26aufirst%3DAhmed%2BM.%26date%3D2021%26date%3D2020%26volume%3D36%26issue%3D1%26spage%3D15%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel  Hume</span>, <span class="hlFld-ContribAuthor ">Grigory L  Dianov</span>, <span class="hlFld-ContribAuthor ">Kristijan  Ramadan</span>. </span><span class="cited-content_cbyCitation_article-title">A unified model for the G1/S cell cycle transition. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2020,</strong> <em>48 </em>
                                    (22)
                                     , 12483-12501. <a href="https://doi.org/10.1093/nar/gkaa1002" title="DOI URL">https://doi.org/10.1093/nar/gkaa1002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa1002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa1002%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DA%252Bunified%252Bmodel%252Bfor%252Bthe%252BG1%25252FS%252Bcell%252Bcycle%252Btransition%26aulast%3DHume%26aufirst%3DSamuel%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D22%26spage%3D12483%26epage%3D12501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rachel  Bayley</span>, <span class="hlFld-ContribAuthor ">Ciara  Ward</span>, <span class="hlFld-ContribAuthor ">Paloma  Garcia</span>. </span><span class="cited-content_cbyCitation_article-title">MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2020,</strong> <em>1874 </em>
                                    (2)
                                     , 188407. <a href="https://doi.org/10.1016/j.bbcan.2020.188407" title="DOI URL">https://doi.org/10.1016/j.bbcan.2020.188407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2020.188407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2020.188407%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DMYBL2%252Bamplification%252Bin%252Bbreast%252Bcancer%25253A%252BMolecular%252Bmechanisms%252Band%252Btherapeutic%252Bpotential%26aulast%3DBayley%26aufirst%3DRachel%26date%3D2020%26volume%3D1874%26issue%3D2%26spage%3D188407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md Gulam Musawwir  Khan</span>, <span class="hlFld-ContribAuthor ">Amit  Ghosh</span>, <span class="hlFld-ContribAuthor ">Bhavesh  Variya</span>, <span class="hlFld-ContribAuthor ">Madanraj Appiya  Santharam</span>, <span class="hlFld-ContribAuthor ">Awais Ullah  Ihsan</span>, <span class="hlFld-ContribAuthor ">Sheela  Ramanathan</span>, <span class="hlFld-ContribAuthor ">Subburaj  Ilangumaran</span>. </span><span class="cited-content_cbyCitation_article-title">Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">BMC Cancer</span><span> <strong>2020,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12885-020-07285-3" title="DOI URL">https://doi.org/10.1186/s12885-020-07285-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12885-020-07285-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12885-020-07285-3%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Cancer%26atitle%3DPrognostic%252Bsignificance%252Bof%252BSOCS1%252Band%252BSOCS3%252Btumor%252Bsuppressors%252Band%252Boncogenic%252Bsignaling%252Bpathway%252Bgenes%252Bin%252Bhepatocellular%252Bcarcinoma%26aulast%3DKhan%26aufirst%3DMd%2BGulam%2BMusawwir%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian Adakole  Ikwu</span>, <span class="hlFld-ContribAuthor ">Yusuf  Isyaku</span>, <span class="hlFld-ContribAuthor ">Babatunde Samuel  Obadawo</span>, <span class="hlFld-ContribAuthor ">Hadiza Abdulrahman  Lawal</span>, <span class="hlFld-ContribAuthor ">Samuel Akolade  Ajibowu</span>. </span><span class="cited-content_cbyCitation_article-title">In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line. </span><span class="cited-content_cbyCitation_journal-name">Journal of Genetic Engineering and Biotechnology</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s43141-020-00066-2" title="DOI URL">https://doi.org/10.1186/s43141-020-00066-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s43141-020-00066-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs43141-020-00066-2%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Genetic%2520Engineering%2520and%2520Biotechnology%26atitle%3DIn%252Bsilico%252Bdesign%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252BCDK2%252Binhibitors%252Bwith%252Bpotent%252Bcytotoxic%252Bactivity%252Bagainst%252BHCT116%252Bcolorectal%252Bcancer%252Bcell%252Bline%26aulast%3DIkwu%26aufirst%3DFabian%2BAdakole%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carrow I.  Wells</span>, <span class="hlFld-ContribAuthor ">James D.  Vasta</span>, <span class="hlFld-ContribAuthor ">Cesear R.  Corona</span>, <span class="hlFld-ContribAuthor ">Jennifer  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Chad A.  Zimprich</span>, <span class="hlFld-ContribAuthor ">Morgan R.  Ingold</span>, <span class="hlFld-ContribAuthor ">Julie E.  Pickett</span>, <span class="hlFld-ContribAuthor ">David H.  Drewry</span>, <span class="hlFld-ContribAuthor ">Kathryn M.  Pugh</span>, <span class="hlFld-ContribAuthor ">Marie K.  Schwinn</span>, <span class="hlFld-ContribAuthor ">Byounghoon  Hwang</span>, <span class="hlFld-ContribAuthor ">Hicham  Zegzouti</span>, <span class="hlFld-ContribAuthor ">Kilian V. M.  Huber</span>, <span class="hlFld-ContribAuthor ">Mei  Cong</span>, <span class="hlFld-ContribAuthor ">Poncho L.  Meisenheimer</span>, <span class="hlFld-ContribAuthor ">Timothy M.  Willson</span>, <span class="hlFld-ContribAuthor ">Matthew B.  Robers</span>. </span><span class="cited-content_cbyCitation_article-title">Quantifying CDK inhibitor selectivity in live cells. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-16559-0" title="DOI URL">https://doi.org/10.1038/s41467-020-16559-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-16559-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-16559-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DQuantifying%252BCDK%252Binhibitor%252Bselectivity%252Bin%252Blive%252Bcells%26aulast%3DWells%26aufirst%3DCarrow%2BI.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinhua  Qu</span>, <span class="hlFld-ContribAuthor ">Liumei  Zhu</span>, <span class="hlFld-ContribAuthor ">Linlin  Song</span>, <span class="hlFld-ContribAuthor ">Shaohua  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">circ_0084927 promotes cervical carcinogenesis by sponging miR-1179 that suppresses CDK2, a cell cycle-related gene. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell International</span><span> <strong>2020,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12935-020-01417-2" title="DOI URL">https://doi.org/10.1186/s12935-020-01417-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12935-020-01417-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12935-020-01417-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%2520International%26atitle%3Dcirc_0084927%252Bpromotes%252Bcervical%252Bcarcinogenesis%252Bby%252Bsponging%252BmiR-1179%252Bthat%252Bsuppresses%252BCDK2%25252C%252Ba%252Bcell%252Bcycle-related%252Bgene%26aulast%3DQu%26aufirst%3DXinhua%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lo  Lai</span>, <span class="hlFld-ContribAuthor ">Ga Yoon  Shin</span>, <span class="hlFld-ContribAuthor ">Hongyu  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Cell Cycle Regulators in Cell Survival—Dual Functions of Cyclin-Dependent Kinase 20 and p21Cip1/Waf1. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (22)
                                     , 8504. <a href="https://doi.org/10.3390/ijms21228504" title="DOI URL">https://doi.org/10.3390/ijms21228504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21228504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21228504%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BRole%252Bof%252BCell%252BCycle%252BRegulators%252Bin%252BCell%252BSurvival%2525E2%252580%252594Dual%252BFunctions%252Bof%252BCyclin-Dependent%252BKinase%252B20%252Band%252Bp21Cip1%25252FWaf1%26aulast%3DLai%26aufirst%3DLo%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D22%26spage%3D8504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Fan</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoshuang  Wang</span>, <span class="hlFld-ContribAuthor ">Yakun  Ma</span>, <span class="hlFld-ContribAuthor ">Yongtao  Li</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 12O—A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (21)
                                     , 5199. <a href="https://doi.org/10.3390/molecules25215199" title="DOI URL">https://doi.org/10.3390/molecules25215199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25215199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25215199%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252B12O%2525E2%252580%252594A%252BNovel%252BOral%252BMulti-Kinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumor%26aulast%3DFan%26aufirst%3DYan%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D21%26spage%3D5199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Theo  Rodat</span>, <span class="hlFld-ContribAuthor ">Melanie  Krebs</span>, <span class="hlFld-ContribAuthor ">Alexander  Döbber</span>, <span class="hlFld-ContribAuthor ">Björn  Jansen</span>, <span class="hlFld-ContribAuthor ">Anja  Steffen-Heins</span>, <span class="hlFld-ContribAuthor ">Karin  Schwarz</span>, <span class="hlFld-ContribAuthor ">Christian  Peifer</span>. </span><span class="cited-content_cbyCitation_article-title">Restricted suitability of BODIPY for caging in biological applications based on singlet oxygen generation. </span><span class="cited-content_cbyCitation_journal-name">Photochemical & Photobiological Sciences</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 1319-1325. <a href="https://doi.org/10.1039/D0PP00097C" title="DOI URL">https://doi.org/10.1039/D0PP00097C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0PP00097C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0PP00097C%26sid%3Dliteratum%253Aachs%26jtitle%3DPhotochemical%2520%2526%2520Photobiological%2520Sciences%26atitle%3DRestricted%252Bsuitability%252Bof%252BBODIPY%252Bfor%252Bcaging%252Bin%252Bbiological%252Bapplications%252Bbased%252Bon%252Bsinglet%252Boxygen%252Bgeneration%26aulast%3DRodat%26aufirst%3DTheo%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D1319%26epage%3D1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinjia  Yan</span>, <span class="hlFld-ContribAuthor ">Jing  Wen</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (21)
                                     , 1916-1937. <a href="https://doi.org/10.2174/1568026620666200624161151" title="DOI URL">https://doi.org/10.2174/1568026620666200624161151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200624161151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200624161151%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BScenario%252Bof%252B1%25252C3-oxazole%252BDerivatives%252Bfor%252BAnticancer%252BActivity%26aulast%3DYan%26aufirst%3DXinjia%26date%3D2020%26volume%3D20%26issue%3D21%26spage%3D1916%26epage%3D1937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junpei  Matsuoka</span>, <span class="hlFld-ContribAuthor ">Shinsuke  Inuki</span>, <span class="hlFld-ContribAuthor ">Yuka  Matsuda</span>, <span class="hlFld-ContribAuthor ">Yoichi  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Mayumi  Otani</span>, <span class="hlFld-ContribAuthor ">Masahiro  Oka</span>, <span class="hlFld-ContribAuthor ">Shinya  Oishi</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Ohno</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of Dictyodendrins A–F by the Gold‐Catalyzed Cascade Cyclization of Conjugated Diyne with Pyrrole. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (49)
                                     , 11150-11157. <a href="https://doi.org/10.1002/chem.202001950" title="DOI URL">https://doi.org/10.1002/chem.202001950</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202001950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202001950%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DTotal%252BSynthesis%252Bof%252BDictyodendrins%252BA%2525E2%252580%252593F%252Bby%252Bthe%252BGold%2525E2%252580%252590Catalyzed%252BCascade%252BCyclization%252Bof%252BConjugated%252BDiyne%252Bwith%252BPyrrole%26aulast%3DMatsuoka%26aufirst%3DJunpei%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D49%26spage%3D11150%26epage%3D11157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saleh  Bagheri</span>, <span class="hlFld-ContribAuthor ">Hassan  Behnejad</span>, <span class="hlFld-ContribAuthor ">Rohoullah  Firouzi</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Karimi‐Jafari</span>. </span><span class="cited-content_cbyCitation_article-title">Using the Semiempirical Quantum Mechanics in Improving the Molecular Docking: A Case Study with CDK2. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2020,</strong> <em>39 </em>
                                    (9)
                                     , 2000036. <a href="https://doi.org/10.1002/minf.202000036" title="DOI URL">https://doi.org/10.1002/minf.202000036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.202000036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.202000036%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DUsing%252Bthe%252BSemiempirical%252BQuantum%252BMechanics%252Bin%252BImproving%252Bthe%252BMolecular%252BDocking%25253A%252BA%252BCase%252BStudy%252Bwith%252BCDK2%26aulast%3DBagheri%26aufirst%3DSaleh%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D9%26spage%3D2000036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shovonlal  Bhowmick</span>, <span class="hlFld-ContribAuthor ">Nora Abdullah  AlFaris</span>, <span class="hlFld-ContribAuthor ">Jozaa Zaidan  ALTamimi</span>, <span class="hlFld-ContribAuthor ">Zeid A.  ALOthman</span>, <span class="hlFld-ContribAuthor ">Tahany Saleh  Aldayel</span>, <span class="hlFld-ContribAuthor ">Saikh Mohammad  Wabaidur</span>, <span class="hlFld-ContribAuthor ">Md Ataul  Islam</span>. </span><span class="cited-content_cbyCitation_article-title">Screening and analysis of bioactive food compounds for modulating the CDK2 protein for cell cycle arrest: Multi-cheminformatics approaches for anticancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1216 </em>, 128316. <a href="https://doi.org/10.1016/j.molstruc.2020.128316" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128316%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DScreening%252Band%252Banalysis%252Bof%252Bbioactive%252Bfood%252Bcompounds%252Bfor%252Bmodulating%252Bthe%252BCDK2%252Bprotein%252Bfor%252Bcell%252Bcycle%252Barrest%25253A%252BMulti-cheminformatics%252Bapproaches%252Bfor%252Banticancer%252Btherapeutics%26aulast%3DBhowmick%26aufirst%3DShovonlal%26date%3D2020%26volume%3D1216%26spage%3D128316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Guglielmo</span>, <span class="hlFld-ContribAuthor ">Daniela  Cortese</span>, <span class="hlFld-ContribAuthor ">Celine  Cano</span>, <span class="hlFld-ContribAuthor ">Roberta  Fruttero</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (13)
                                     , 4016-4024. <a href="https://doi.org/10.1080/07391102.2019.1666032" title="DOI URL">https://doi.org/10.1080/07391102.2019.1666032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1666032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1666032%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bdynamics%252Bsimulations%252Breveal%252Bthe%252Bdeterminants%252Bof%252Bcyclin-dependent%252Bkinase%252B2%252Binhibition%252Bby%252B5-nitrosopyrimidine%252Bderivatives%26aulast%3DGuglielmo%26aufirst%3DStefano%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D13%26spage%3D4016%26epage%3D4024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bharat  Goel</span>, <span class="hlFld-ContribAuthor ">Nancy  Tripathi</span>, <span class="hlFld-ContribAuthor ">Nivedita  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">Shreyans K.  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (17)
                                     , 1535-1563. <a href="https://doi.org/10.2174/1568026620666200516152756" title="DOI URL">https://doi.org/10.2174/1568026620666200516152756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200516152756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200516152756%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BCDK%252BInhibitors%252Bfor%252Bthe%252BTherapeutic%252BManagement%252Bof%252BCancer%26aulast%3DGoel%26aufirst%3DBharat%26date%3D2020%26volume%3D20%26issue%3D17%26spage%3D1535%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingxing  Teng</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhixiang  He</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Kwiatkowski</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Caitlin E.  Mills</span>, <span class="hlFld-ContribAuthor ">Chiara  Victor</span>, <span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Peter K.  Sorger</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Development of CDK2 and CDK5 Dual Degrader TMX‐2172. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (33)
                                     , 13969-13974. <a href="https://doi.org/10.1002/ange.202004087" title="DOI URL">https://doi.org/10.1002/ange.202004087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202004087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202004087%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDevelopment%252Bof%252BCDK2%252Band%252BCDK5%252BDual%252BDegrader%252BTMX%2525E2%252580%2525902172%26aulast%3DTeng%26aufirst%3DMingxing%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D33%26spage%3D13969%26epage%3D13974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingxing  Teng</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhixiang  He</span>, <span class="hlFld-ContribAuthor ">Nicholas P.  Kwiatkowski</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Caitlin E.  Mills</span>, <span class="hlFld-ContribAuthor ">Chiara  Victor</span>, <span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Peter K.  Sorger</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Development of CDK2 and CDK5 Dual Degrader TMX‐2172. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (33)
                                     , 13865-13870. <a href="https://doi.org/10.1002/anie.202004087" title="DOI URL">https://doi.org/10.1002/anie.202004087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202004087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202004087%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDevelopment%252Bof%252BCDK2%252Band%252BCDK5%252BDual%252BDegrader%252BTMX%2525E2%252580%2525902172%26aulast%3DTeng%26aufirst%3DMingxing%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D33%26spage%3D13865%26epage%3D13870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hrvoje  Rimac</span>, <span class="hlFld-ContribAuthor ">Maria A  Grishina</span>, <span class="hlFld-ContribAuthor ">Vladimir A  Potemkin</span>. </span><span class="cited-content_cbyCitation_article-title">Electron density analysis of CDK complexes using the AlteQ method. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (15)
                                     , 1387-1397. <a href="https://doi.org/10.4155/fmc-2020-0076" title="DOI URL">https://doi.org/10.4155/fmc-2020-0076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0076%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DElectron%252Bdensity%252Banalysis%252Bof%252BCDK%252Bcomplexes%252Busing%252Bthe%252BAlteQ%252Bmethod%26aulast%3DRimac%26aufirst%3DHrvoje%26date%3D2020%26volume%3D12%26issue%3D15%26spage%3D1387%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher J  Lord</span>, <span class="hlFld-ContribAuthor ">Niall  Quinn</span>, <span class="hlFld-ContribAuthor ">Colm J  Ryan</span>. </span><span class="cited-content_cbyCitation_article-title">Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2020,</strong> <em>9 </em><a href="https://doi.org/10.7554/eLife.58925" title="DOI URL">https://doi.org/10.7554/eLife.58925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.58925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.58925%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DIntegrative%252Banalysis%252Bof%252Blarge-scale%252Bloss-of-function%252Bscreens%252Bidentifies%252Brobust%252Bcancer-associated%252Bgenetic%252Binteractions%26aulast%3DLord%26aufirst%3DChristopher%2BJ%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sherif T. S.  Hassan</span>. </span><span class="cited-content_cbyCitation_article-title">Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2020,</strong> <em>8 </em>
                                    (5)
                                     , 132. <a href="https://doi.org/10.3390/biomedicines8050132" title="DOI URL">https://doi.org/10.3390/biomedicines8050132</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines8050132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines8050132%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DBrassicasterol%252Bwith%252BDual%252BAnti-Infective%252BProperties%252Bagainst%252BHSV-1%252Band%252BMycobacterium%252Btuberculosis%25252C%252Band%252BCardiovascular%252BProtective%252BEffect%25253A%252BNonclinical%252BIn%252BVitro%252Band%252BIn%252BSilico%252BAssessments%26aulast%3DHassan%26aufirst%3DSherif%2BT.%2BS.%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D5%26spage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin W.  Gorski</span>, <span class="hlFld-ContribAuthor ">Frederick R.  Ueland</span>, <span class="hlFld-ContribAuthor ">Jill M.  Kolesar</span>. </span><span class="cited-content_cbyCitation_article-title">CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. </span><span class="cited-content_cbyCitation_journal-name">Diagnostics</span><span> <strong>2020,</strong> <em>10 </em>
                                    (5)
                                     , 279. <a href="https://doi.org/10.3390/diagnostics10050279" title="DOI URL">https://doi.org/10.3390/diagnostics10050279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/diagnostics10050279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fdiagnostics10050279%26sid%3Dliteratum%253Aachs%26jtitle%3DDiagnostics%26atitle%3DCCNE1%252BAmplification%252Bas%252Ba%252BPredictive%252BBiomarker%252Bof%252BChemotherapy%252BResistance%252Bin%252BEpithelial%252BOvarian%252BCancer%26aulast%3DGorski%26aufirst%3DJustin%2BW.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D5%26spage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112073. <a href="https://doi.org/10.1016/j.ejmech.2020.112073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bcyclin-dependent%252Bkinase%252B%252528CDK%252529%252Band%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Bdual%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Banticancer%252Bactivity%26aulast%3DCheng%26aufirst%3DChunhui%26date%3D2020%26volume%3D189%26spage%3D112073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Abel T.  Anshabo</span>, <span class="hlFld-ContribAuthor ">Neil  Portman</span>, <span class="hlFld-ContribAuthor ">Elgene  Lim</span>, <span class="hlFld-ContribAuthor ">Wayne  Tilley</span>, <span class="hlFld-ContribAuthor ">C. Elizabeth  Caldon</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CDK2 in cancer: challenges and opportunities for therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 406-413. <a href="https://doi.org/10.1016/j.drudis.2019.12.001" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTargeting%252BCDK2%252Bin%252Bcancer%25253A%252Bchallenges%252Band%252Bopportunities%252Bfor%252Btherapy%26aulast%3DTadesse%26aufirst%3DSolomon%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D406%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Garczyk</span>, <span class="hlFld-ContribAuthor ">Nadina  Ortiz-Brüchle</span>, <span class="hlFld-ContribAuthor ">Ursula  Schneider</span>, <span class="hlFld-ContribAuthor ">Isabella  Lurje</span>, <span class="hlFld-ContribAuthor ">Karolina  Guricova</span>, <span class="hlFld-ContribAuthor ">Nadine T.  Gaisa</span>, <span class="hlFld-ContribAuthor ">Eva  Lorsy</span>, <span class="hlFld-ContribAuthor ">Katharina  Lindemann-Docter</span>, <span class="hlFld-ContribAuthor ">Axel  Heidenreich</span>, <span class="hlFld-ContribAuthor ">Ruth  Knüchel</span>. </span><span class="cited-content_cbyCitation_article-title">Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. </span><span class="cited-content_cbyCitation_journal-name">The American Journal of Pathology</span><span> <strong>2020,</strong> <em>190 </em>
                                    (2)
                                     , 323-332. <a href="https://doi.org/10.1016/j.ajpath.2019.10.004" title="DOI URL">https://doi.org/10.1016/j.ajpath.2019.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ajpath.2019.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ajpath.2019.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520American%2520Journal%2520of%2520Pathology%26atitle%3DNext-Generation%252BSequencing%252BReveals%252BPotential%252BPredictive%252BBiomarkers%252Band%252BTargets%252Bof%252BTherapy%252Bfor%252BUrothelial%252BCarcinoma%252Bin%252BSitu%252Bof%252Bthe%252BUrinary%252BBladder%26aulast%3DGarczyk%26aufirst%3DStefan%26date%3D2020%26volume%3D190%26issue%3D2%26spage%3D323%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David J.  Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Modern traditional Chinese medicine: Identifying, defining and usage of TCM components. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 113-158. <a href="https://doi.org/10.1016/bs.apha.2019.07.001" title="DOI URL">https://doi.org/10.1016/bs.apha.2019.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apha.2019.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apha.2019.07.001%26sid%3Dliteratum%253Aachs%26atitle%3DModern%252Btraditional%252BChinese%252Bmedicine%25253A%252BIdentifying%25252C%252Bdefining%252Band%252Busage%252Bof%252BTCM%252Bcomponents%26aulast%3DNewman%26aufirst%3DDavid%2BJ.%26date%3D2020%26spage%3D113%26epage%3D158%26pub%3DElsevier%26atitle%3DPharmacological%252BAdvances%252Bin%252BNatural%252BProduct%252BDrug%252BDiscovery%26date%3D2020%26volume%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Liu</span>, <span class="hlFld-ContribAuthor ">Jinlan  Gao</span>, <span class="hlFld-ContribAuthor ">Chenyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yingying  Guo</span>, <span class="hlFld-ContribAuthor ">Shiquan  Wang</span>, <span class="hlFld-ContribAuthor ">Fei  Shen</span>, <span class="hlFld-ContribAuthor ">Xuesha  Xing</span>, <span class="hlFld-ContribAuthor ">Yang  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. </span><span class="cited-content_cbyCitation_journal-name">DNA Repair</span><span> <strong>2020,</strong> <em>85 </em>, 102702. <a href="https://doi.org/10.1016/j.dnarep.2019.102702" title="DOI URL">https://doi.org/10.1016/j.dnarep.2019.102702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dnarep.2019.102702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dnarep.2019.102702%26sid%3Dliteratum%253Aachs%26jtitle%3DDNA%2520Repair%26atitle%3DTo%252Bcontrol%252Bor%252Bto%252Bbe%252Bcontrolled%25253F%252BDual%252Broles%252Bof%252BCDK2%252Bin%252BDNA%252Bdamage%252Band%252BDNA%252Bdamage%252Bresponse%26aulast%3DLiu%26aufirst%3DQi%26date%3D2020%26volume%3D85%26spage%3D102702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Somi  Jeong</span>, <span class="hlFld-ContribAuthor ">Seunghwa  Jung</span>, <span class="hlFld-ContribAuthor ">Gyun-Seok  Park</span>, <span class="hlFld-ContribAuthor ">Juhyun  Shin</span>, <span class="hlFld-ContribAuthor ">Jae-Wook  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioengineered</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 791-800. <a href="https://doi.org/10.1080/21655979.2020.1794100" title="DOI URL">https://doi.org/10.1080/21655979.2020.1794100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/21655979.2020.1794100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F21655979.2020.1794100%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineered%26atitle%3DPiperine%252Bsynergistically%252Benhances%252Bthe%252Beffect%252Bof%252Btemozolomide%252Bagainst%252Btemozolomide-resistant%252Bhuman%252Bglioma%252Bcell%252Blines%26aulast%3DJeong%26aufirst%3DSomi%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1%26spage%3D791%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmet  Alptekin</span>, <span class="hlFld-ContribAuthor ">Bingwei  Ye</span>, <span class="hlFld-ContribAuthor ">Yajie  Yu</span>, <span class="hlFld-ContribAuthor ">Candace J.  Poole</span>, <span class="hlFld-ContribAuthor ">Jan  van Riggelen</span>, <span class="hlFld-ContribAuthor ">Yunhong  Zha</span>, <span class="hlFld-ContribAuthor ">Han-Fei  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2019,</strong> <em>38 </em>
                                    (50)
                                     , 7504-7520. <a href="https://doi.org/10.1038/s41388-019-0967-3" title="DOI URL">https://doi.org/10.1038/s41388-019-0967-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-019-0967-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-019-0967-3%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DGlycine%252Bdecarboxylase%252Bis%252Ba%252Btranscriptional%252Btarget%252Bof%252BMYCN%252Brequired%252Bfor%252Bneuroblastoma%252Bcell%252Bproliferation%252Band%252Btumorigenicity%26aulast%3DAlptekin%26aufirst%3DAhmet%26date%3D2019%26date%3D2019%26volume%3D38%26issue%3D50%26spage%3D7504%26epage%3D7520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taj  Mohammad</span>, <span class="hlFld-ContribAuthor ">Sagar  Batra</span>, <span class="hlFld-ContribAuthor ">Rashmi  Dahiya</span>, <span class="hlFld-ContribAuthor ">Mohammad Hassan  Baig</span>, <span class="hlFld-ContribAuthor ">Irfan Ahmad  Rather</span>, <span class="hlFld-ContribAuthor ">Jae-June  Dong</span>, <span class="hlFld-ContribAuthor ">Imtaiyaz  Hassan</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (24)
                                     , 4589. <a href="https://doi.org/10.3390/molecules24244589" title="DOI URL">https://doi.org/10.3390/molecules24244589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24244589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24244589%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIdentification%252Bof%252BHigh-Affinity%252BInhibitors%252Bof%252BCyclin-Dependent%252BKinase%252B2%252BTowards%252BAnticancer%252BTherapy%26aulast%3DMohammad%26aufirst%3DTaj%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D24%26spage%3D4589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Concepción  Sánchez-Martínez</span>, <span class="hlFld-ContribAuthor ">María José  Lallena</span>, <span class="hlFld-ContribAuthor ">Sonia Gutiérrez  Sanfeliciano</span>, <span class="hlFld-ContribAuthor ">Alfonso  de Dios</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126637. <a href="https://doi.org/10.1016/j.bmcl.2019.126637" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCyclin%252Bdependent%252Bkinase%252B%252528CDK%252529%252Binhibitors%252Bas%252Banticancer%252Bdrugs%25253A%252BRecent%252Badvances%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DConcepci%25C3%25B3n%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Diao</span>, <span class="hlFld-ContribAuthor ">Wei-Yuan  Lin</span>, <span class="hlFld-ContribAuthor ">Xie-Er  Jian</span>, <span class="hlFld-ContribAuthor ">Yan-Hong  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Wei  You</span>, <span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 196-207. <a href="https://doi.org/10.1016/j.ejmech.2019.06.055" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.055%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrimidine-based%252Bbenzothiazole%252Bderivatives%252Bas%252Bpotent%252Bcyclin-dependent%252Bkinase%252B2%252Binhibitors%252Bwith%252Banticancer%252Bactivity%26aulast%3DDiao%26aufirst%3DPeng-Cheng%26date%3D2019%26volume%3D179%26spage%3D196%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. P. Shyam  Shankar</span>, <span class="hlFld-ContribAuthor ">Damodaran  Bahulayan</span>. </span><span class="cited-content_cbyCitation_article-title">Chemistry, chemical biology and photophysics of certain new chromene–triazole–coumarin triads as fluorescent inhibitors of CDK2 and CDK4 induced cancers. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2019,</strong> <em>43 </em>
                                    (35)
                                     , 13863-13872. <a href="https://doi.org/10.1039/C9NJ02924A" title="DOI URL">https://doi.org/10.1039/C9NJ02924A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ02924A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ02924A%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DChemistry%25252C%252Bchemical%252Bbiology%252Band%252Bphotophysics%252Bof%252Bcertain%252Bnew%252Bchromene%2525E2%252580%252593triazole%2525E2%252580%252593coumarin%252Btriads%252Bas%252Bfluorescent%252Binhibitors%252Bof%252BCDK2%252Band%252BCDK4%252Binduced%252Bcancers%26aulast%3DShankar%26aufirst%3DE.%2BP.%2BShyam%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D35%26spage%3D13863%26epage%3D13872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Hou</span>, <span class="hlFld-ContribAuthor ">Qiuju  Fan</span>, <span class="hlFld-ContribAuthor ">Lin  Su</span>, <span class="hlFld-ContribAuthor ">Hongtao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Oridonin Derivatives via Mizoroki-Heck Reaction and Click Chemistry for Cytotoxic Activity. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 935-947. <a href="https://doi.org/10.2174/1871520619666190118121439" title="DOI URL">https://doi.org/10.2174/1871520619666190118121439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118121439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118121439%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BOridonin%252BDerivatives%252Bvia%252BMizoroki-Heck%252BReaction%252Band%252BClick%252BChemistry%252Bfor%252BCytotoxic%252BActivity%26aulast%3DHou%26aufirst%3DWei%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D935%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillaume  Guignard</span>, <span class="hlFld-ContribAuthor ">Núria  Llor</span>, <span class="hlFld-ContribAuthor ">David  Pubill</span>, <span class="hlFld-ContribAuthor ">Joan  Bosch</span>, <span class="hlFld-ContribAuthor ">Mercedes  Amat</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of the Ethyl Analog of the Marine Alkaloid Haliclorensin C. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (6)
                                     , 1069. <a href="https://doi.org/10.3390/molecules24061069" title="DOI URL">https://doi.org/10.3390/molecules24061069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24061069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24061069%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DEnantioselective%252BSynthesis%252Bof%252Bthe%252BEthyl%252BAnalog%252Bof%252Bthe%252BMarine%252BAlkaloid%252BHaliclorensin%252BC%26aulast%3DGuignard%26aufirst%3DGuillaume%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Alexandrou</span>, <span class="hlFld-ContribAuthor ">Sandra  George</span>, <span class="hlFld-ContribAuthor ">Christopher  Ormandy</span>, <span class="hlFld-ContribAuthor ">Elgene  Lim</span>, <span class="hlFld-ContribAuthor ">Samantha  Oakes</span>, <span class="hlFld-ContribAuthor ">C.  Caldon</span>. </span><span class="cited-content_cbyCitation_article-title">The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (3)
                                     , 667. <a href="https://doi.org/10.3390/ijms20030667" title="DOI URL">https://doi.org/10.3390/ijms20030667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20030667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20030667%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BProliferative%252Band%252BApoptotic%252BLandscape%252Bof%252BBasal-like%252BBreast%252BCancer%26aulast%3DAlexandrou%26aufirst%3DSarah%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D3%26spage%3D667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. An overview of the cell division cycle, and the role of CDKs and checkpoints. In cells, DNA replicates in the S-phase, and chromosome segregation occurs at the M-phase. Two gap phases separate the S-phase and M-phase: G1, when cells grow and synthesize proteins, and G2, when cells prepare for mitosis. CDK3–cyclin C stimulates Rb phosphorylation to affect the G0/G1 transition. CDK4/6–cyclin D and CDK2–cyclin-E-mediated sequential phosphorylation of Rb relieves suppression of the activity of the E2Fs allowing the G1/S transition through the restriction point. As cells prepare to exit from the S-phase, CDK2–cyclin A directly phosphorylates E2F to deactivate its function, preventing apoptosis that might be triggered by persistent E2F activity. CDK1 in complex with cyclin A or B has defined roles in regulating the G2/M checkpoint and progression through mitosis. The cell cycle is controlled by checkpoints. The integrity of the DNA is assessed at the G1/S checkpoint. Proper chromosome replication is checked at the S and G2/M checkpoints. Attachment of each sister chromatid to a spindle fiber is evaluated at the spindle assembly checkpoint (SAC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural basis of CDK2 activation and inhibition. (A) Nonactivated monomeric CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EK3">4EK3</a>). The N-lobe β-sheets and the αC-helix (PSTAIRE) are shown in pink and blue, respectively; the C-lobe is indicated in purple, and the hinge region and the T-loop are indicated in green. (B) Fully active (phosphorylated CDK2–cyclin A complex, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JST">1JST</a>). Cyclin A and the activating phosphorylation site Thr160 are depicted in cyan and yellow, respectively; ATP is displayed in orange sticks bound in the deep cleft between the two domains. CDK2 apoenzyme is inactive, and full activation entails complex formation with cyclins E or A and phosphorylation of the Thr160 residue. During the activation, the T-loop moves toward the C-terminal domain, where it forms a binding area for the substrate protein, and the αC-helix moves into the binding cleft and is rotated. (C) Inhibited p27-Thr160 phosphorylated CDK2–cyclin A complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JSU">1JSU</a>). The N-terminal of p27-peptide (shown in yellow) binds with cyclin A, and its C-terminal binds to the N-terminal domain of CDK2 to induce structural changes rendering the CDK2–cyclin complex inactive. (D) Mechanisms of CDK2 regulation. The activity of CDK2 is regulated by four mechanisms. The first level of regulation involves the binding of CDK2 to cyclin E or A, resulting in partially activated CDK2–cyclin E or CDK2–cyclin A complex. Second, the full activation of CDK2–cyclin E or A complexes necessitates the phosphorylation of Thr160 by CAK. The third mechanism includes inhibitory phosphorylation of Thr14 and Tyr15 by Wee1 and Myt1 kinases, respectively. Dephosphorylation of these residues by members of the Cdc25 family of protein phosphatases reactivates CDK2. Fourth, CDK2 is deactivated by the binding of CDK inhibitory protein families Cip and Kip. Cyclins E and A are destroyed by the Skp/Cullin/F-box-containing complex (SCF) and the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligases. (E) During the S-phase, CDK2 can follow a distinct path to activation, in which T-loop phosphorylation precedes cyclin binding. Dephosphorylation of CDK2 Thr160 by the cyclin-dependent kinase-interacting phosphatase (KAP) occurs in the absence of cyclin A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of ATP and CDK2 inhibitors to CDK2 structure. (A) ATP (PDB = 1JST), (B) roscovitine (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DDQ">3DDQ</a>), (C) NU2058 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIP">1HIP</a>), (D) NU6102 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIS">1HIS</a>), (E) compound <b>4</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LQE">5LQE</a>). (F) The allosteric inhibitor ANS (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PYL">3PYL</a>). Hydrogen bonds are shown in red dashed lines. The figures were prepared using PyMOL1.3 (Schrödinger Inc., 2013).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Identification and optimization of 2-amino-6-oxypurine core as CDK2 inhibitors. * represents inhibition at 100 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Development of CDK2 inhibitors using purine bioisosters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Optimization of indole based natural products as CDK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Identification and optimization of the thiazole core as CDK2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/medium/jm-2018-01469x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. ATP and allosteric binding sites of CDK2. (A) The catalytic ATP binding site, the two noncatalytic pockets, and the cyclin binding groove are circled and labeled. (B) Type II inhibitor K03861 bound to CDK2 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A14">5A14</a>) and the four core structural components of type II inhibitors: a heterocyclic hinge binding core, a linker, hydrogen bonding structure, and a hydrophobic moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01469/20190502/images/large/jm-2018-01469x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01469&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 179 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norbury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurse, P.</span></span> <span> </span><span class="NLM_article-title">Animal Cell Cycles and Their Control</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1146/annurev.bi.61.070192.002301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1146%2Fannurev.bi.61.070192.002301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1497317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK38XlsVOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1992&pages=441-468&author=C.+Norburyauthor=P.+Nurse&title=Animal+Cell+Cycles+and+Their+Control&doi=10.1146%2Fannurev.bi.61.070192.002301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Animal cell cycles and their control</span></div><div class="casAuthors">Norbury, Chris; Nurse, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">441-70</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review, with 261 refs., of the following aspects of the regulation of the animal cell cycle: the onset of M phase and control of the cycle in G1 phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcub5v_XAKwLVg90H21EOLACvtfcHk0liP3iohyQXa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVOlsLg%253D&md5=f385da1a83b4593191b2a68b893ee48e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.61.070192.002301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.61.070192.002301%26sid%3Dliteratum%253Aachs%26aulast%3DNorbury%26aufirst%3DC.%26aulast%3DNurse%26aufirst%3DP.%26atitle%3DAnimal%2520Cell%2520Cycles%2520and%2520Their%2520Control%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1992%26volume%3D61%26spage%3D441%26epage%3D468%26doi%3D10.1146%2Fannurev.bi.61.070192.002301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartwell, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, T. A.</span></span> <span> </span><span class="NLM_article-title">Checkpoints: Controls that Ensure the Order of Cell Cycle Events</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>246</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1126/science.2683079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.2683079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=2683079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK3cXis12k" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=1989&pages=629-634&author=L.+H.+Hartwellauthor=T.+A.+Weinert&title=Checkpoints%3A+Controls+that+Ensure+the+Order+of+Cell+Cycle+Events&doi=10.1126%2Fscience.2683079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Checkpoints:  controls that ensure the order of cell cycle events</span></div><div class="casAuthors">Hartwell, Leland H.; Weinert, Ted A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">4930</span>),
    <span class="NLM_cas:pages">629-34</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review, with 69 refs., on the cell cycle ordering into dependent pathways in which the initiation of late events is dependent on the completion of early events.  Eliminating control mechanisms enforcing dependency in the cell cycle may result in cell death, infidelity in the distribution of chromosomes or other organelles, or increased susceptibility to environmental perturbations such as DNA damaging agents.  Checkpoints elimination during the early embryonic development is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EHhxKuk-g7Vg90H21EOLACvtfcHk0li9KCNIimzlpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXis12k&md5=e542c8dec21bd8df3b814da86236b2f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.2683079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2683079%26sid%3Dliteratum%253Aachs%26aulast%3DHartwell%26aufirst%3DL.%2BH.%26aulast%3DWeinert%26aufirst%3DT.%2BA.%26atitle%3DCheckpoints%253A%2520Controls%2520that%2520Ensure%2520the%2520Order%2520of%2520Cell%2520Cycle%2520Events%26jtitle%3DScience%26date%3D1989%26volume%3D246%26spage%3D629%26epage%3D634%26doi%3D10.1126%2Fscience.2683079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cell Cycle: A New Approach to Cancer Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9408</span>– <span class="NLM_lpage">9421</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.01.5594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1200%2FJCO.2005.01.5594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16361640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=9408-9421&author=G.+K.+Schwartzauthor=M.+A.+Shah&title=Targeting+the+Cell+Cycle%3A+A+New+Approach+to+Cancer+Therapy&doi=10.1200%2FJCO.2005.01.5594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell cycle: a new approach to cancer therapy</span></div><div class="casAuthors">Schwartz, Gary K.; Shah, Manish A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9408-9421</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate.  Crit. parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next.  The CDKs are regulated pos. by cyclins and regulated neg. by naturally occurring CDK inhibitors (CDKIs).  Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth.  The cell cycle also serves to protect the cell from DNA damage.  Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA.  Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death.  Now in clin. trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest.  Recent attention has also focused on these drugs as inhibitors of transcription.  In addn., there are now agents that abrogate the cell cycle checkpoints at crit. time points that make the tumor cell susceptible to apoptosis.  An understanding of the cell cycle is crit. to understanding how best to clin. develop these agents, both as single agents and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAmpAkG9yEhLVg90H21EOLACvtfcHk0li9KCNIimzlpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ymtA%253D%253D&md5=e3085a43360bfd59b1be9cbd30d581fa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.5594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.5594%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DShah%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520Cell%2520Cycle%253A%2520A%2520New%2520Approach%2520to%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D9408%26epage%3D9421%26doi%3D10.1200%2FJCO.2005.01.5594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Milestones in Cell Division: To Cycle or Not To Cycle: A Critical Decision in Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+Cell+Division%3A+To+Cycle+or+Not+To+Cycle%3A+A+Critical+Decision+in+Cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0li9KCNIimzlpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520Cell%2520Division%253A%2520To%2520Cycle%2520or%2520Not%2520To%2520Cycle%253A%2520A%2520Critical%2520Decision%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Physiological Relevance of Cell Cycle Kinases</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">1007</span>, <span class="refDoi"> DOI: 10.1152/physrev.00025.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1152%2Fphysrev.00025.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=973-1007&author=M.+Malumbres&title=Physiological+Relevance+of+Cell+Cycle+Kinases&doi=10.1152%2Fphysrev.00025.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00025.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00025.2010%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DPhysiological%2520Relevance%2520of%2520Cell%2520Cycle%2520Kinases%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26spage%3D973%26epage%3D1007%26doi%3D10.1152%2Fphysrev.00025.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Kinases as Therapeutic Targets for Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+Cycle+Kinases+as+Therapeutic+Targets+for+Cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0ljZydVCWYcIjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520Cycle%2520Kinases%2520as%2520Therapeutic%2520Targets%2520for%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollins, B. J.</span></span> <span> </span><span class="NLM_article-title">Cyclin C/cdk3 Promotes Rb-dependent G0 Exit</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00300-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0092-8674%2804%2900300-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15084261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=239-251&author=S.+Renauthor=B.+J.+Rollins&title=Cyclin+C%2Fcdk3+Promotes+Rb-dependent+G0+Exit&doi=10.1016%2FS0092-8674%2804%2900300-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin C/Cdk3 promotes Rb-dependent G0 exit</span></div><div class="casAuthors">Ren, Shengjun; Rollins, Barrett J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-251</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">G0 is a physiol. state occupied by resting or terminally differentiated cells that have exited the cell cycle.  In contrast to the well-characterized cyclin/cdk-mediated inactivation of pRb that controls the G1/S transition, little is known about regulation of the G0/G1 transition.  However, pRb is likely to participate in this process because its acute somatic inactivation is sufficient for G0-arrested cells to reenter the cell cycle.  One physiol. regulator of this event may be cyclin C because its highest mRNA levels occur during G0 exit.  Here we show that a non-cdk8-assocd. cellular pool of cyclin C combines with cdk3 to stimulate pRb phosphorylation at S807/811 during the G0/G1 transition, and that this phosphorylation is required for cells to exit G0 efficiently.  Thus, G1 entry is regulated in an analogous fashion to S phase entry, but involves a distinct cyclin/cdk combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrTpjovsiErVg90H21EOLACvtfcHk0ljZydVCWYcIjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFyru78%253D&md5=9bac0bd41fb681e82789589f342b8330</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900300-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900300-9%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRollins%26aufirst%3DB.%2BJ.%26atitle%3DCyclin%2520C%252Fcdk3%2520Promotes%2520Rb-dependent%2520G0%2520Exit%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D239%26epage%3D251%26doi%3D10.1016%2FS0092-8674%2804%2900300-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolupaeva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssens, V.</span></span> <span> </span><span class="NLM_article-title">PP1 and PP2A Phosphatases-cooperating Partners in Modulating Retinoblastoma Protein Activation</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2012.08511.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1111%2Fj.1742-4658.2012.08511.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=627-643&author=V.+Kolupaevaauthor=V.+Janssens&title=PP1+and+PP2A+Phosphatases-cooperating+Partners+in+Modulating+Retinoblastoma+Protein+Activation&doi=10.1111%2Fj.1742-4658.2012.08511.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2012.08511.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2012.08511.x%26sid%3Dliteratum%253Aachs%26aulast%3DKolupaeva%26aufirst%3DV.%26aulast%3DJanssens%26aufirst%3DV.%26atitle%3DPP1%2520and%2520PP2A%2520Phosphatases-cooperating%2520Partners%2520in%2520Modulating%2520Retinoblastoma%2520Protein%2520Activation%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D627%26epage%3D643%26doi%3D10.1111%2Fj.1742-4658.2012.08511.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrière, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cdk1 is Sufficient to Drive the Mammalian Cell Cycle</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1038/nature06046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnature06046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17700700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=811-815&author=D.+Santamar%C3%ADaauthor=C.+Barri%C3%A8reauthor=A.+Cerqueiraauthor=S.+Huntauthor=C.+Tardyauthor=K.+Newtonauthor=J.+F.+C%C3%A1ceresauthor=P.+Dubusauthor=M.+Malumbresauthor=M.+Barbacid&title=Cdk1+is+Sufficient+to+Drive+the+Mammalian+Cell+Cycle&doi=10.1038%2Fnature06046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk1 is sufficient to drive the mammalian cell cycle</span></div><div class="casAuthors">Santamaria, David; Barriere, Cedric; Cerqueira, Antonio; Hunt, Sarah; Tardy, Claudine; Newton, Kathryn; Caceres, Javier F.; Dubus, Pierre; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7155</span>),
    <span class="NLM_cas:pages">811-815</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Unicellular organisms such as yeasts require a single cyclin-dependent kinase, Cdk1, to drive cell division.  In contrast, mammalian cells are thought to require the sequential activation of at least four different cyclin-dependent kinases, Cdk2, Cdk3, Cdk4 and Cdk6, to drive cells through interphase, as well as Cdk1 to proceed through mitosis.  This model has been challenged by recent genetic evidence that mice survive in the absence of individual interphase Cdks.  Moreover, most mouse cell types proliferate in the absence of two or even three interphase Cdks.  Similar results have been obtained on ablation of some of the activating subunits of Cdks, such as the D-type and E-type cyclins.  Here we show that mouse embryos lacking all interphase Cdks (Cdk2, Cdk3, Cdk4 and Cdk6) undergo organogenesis and develop to midgestation.  In these embryos, Cdk1 binds to all cyclins, resulting in the phosphorylation of the retinoblastoma protein pRb and the expression of genes that are regulated by E2F transcription factors.  Mouse embryonic fibroblasts derived from these embryos proliferate in vitro, albeit with an extended cell cycle due to inefficient inactivation of Rb proteins.  However, they become immortal on continuous passage.  We also report that embryos fail to develop to the morula and blastocyst stages in the absence of Cdk1.  These results indicate that Cdk1 is the only essential cell cycle Cdk.  Moreover, they show that in the absence of interphase Cdks, Cdk1 can execute all the events that are required to drive cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEdshMg-kRLVg90H21EOLACvtfcHk0ljZydVCWYcIjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGrsL8%253D&md5=d427cb68fc6c8758df24423761a89264</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature06046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06046%26sid%3Dliteratum%253Aachs%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarri%25C3%25A8re%26aufirst%3DC.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DHunt%26aufirst%3DS.%26aulast%3DTardy%26aufirst%3DC.%26aulast%3DNewton%26aufirst%3DK.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DJ.%2BF.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCdk1%2520is%2520Sufficient%2520to%2520Drive%2520the%2520Mammalian%2520Cell%2520Cycle%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D811%26epage%3D815%26doi%3D10.1038%2Fnature06046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle, Cdks and Cancer: A Changing Paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+Cycle%2C+Cdks+and+Cancer%3A+A+Changing+Paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0liDeEdmglSvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520Cycle%252C%2520Cdks%2520and%2520Cancer%253A%2520A%2520Changing%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Cell Cycle Proteins as Promising Targets in Cancer Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrc.2016.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28127048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=93-115&author=T.+Ottoauthor=P.+Sicinski&title=Cell+Cycle+Proteins+as+Promising+Targets+in+Cancer+Therapy&doi=10.1038%2Fnrc.2016.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle proteins as promising targets in cancer therapy</span></div><div class="casAuthors">Otto, Tobias; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-115</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer is characterized by uncontrolled tumor cell proliferation resulting from aberrant activity of various cell cycle proteins.  Therefore, cell cycle regulators are considered attractive targets in cancer therapy.  Intriguingly, animal models demonstrate that some of these proteins are not essential for proliferation of non-transformed cells and development of most tissues.  By contrast, many cancers are uniquely dependent on these proteins and hence are selectively sensitive to their inhibition.  After decades of research on the physiol. functions of cell cycle proteins and their relevance for cancer, this knowledge recently translated into the first approved cancer therapeutic targeting of a direct regulator of the cell cycle.  In this review, we focus on proteins that directly regulate cell cycle progression (such as cyclin-dependent kinases (CDKs)), as well as checkpoint kinases, Aurora kinases and Polo-like kinases (PLKs).  We discuss the role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment and results of clin. trials, as well as the future therapeutic potential of various cell cycle inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLDKWC7de8OLVg90H21EOLACvtfcHk0liDeEdmglSvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GqsrY%253D&md5=42d0185e537bebbe203be6bae0595376</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.138%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DT.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DCell%2520Cycle%2520Proteins%2520as%2520Promising%2520Targets%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D93%26epage%3D115%26doi%3D10.1038%2Fnrc.2016.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laderian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1053%2Fj.seminoncol.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29935901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=395-403&author=B.+Laderianauthor=T.+Fojo&title=CDK4%2F6+Inhibition+as+a+Therapeutic+Strategy+in+Breast+Cancer%3A+Palbociclib%2C+Ribociclib%2C+and+Abemaciclib&doi=10.1053%2Fj.seminoncol.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition as a Therapeutic Strategy in Breast Cancer: Palbociclib, Ribociclib, and Abemaciclib</span></div><div class="casAuthors">Laderian, Bahar; Fojo, Tito</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">395-403</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">With 40,920 American women expected to die from breast cancer in 2018 and global health ests. that more than 508,000 women died in 2011 from this disease, the identification of novel therapeutic strategies for the treatment of breast cancer cannot be ignored.  A breakthrough class of cancer drugs that has emerged in recent years and has had an impact in the treatment of breast cancer are the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, with palbociclib the first in class to have received regulatory approval for breast cancer.  In this article we will compare and contrast three CDK4/6 inhibitors - palbociclib, ribociclib and abemaciclib - that have received regulatory approval for the treatment of metastatic breast cancer.  Ribociclib and abemaciclib developed after the success of palbociclib represent examples of "me-too" therapies increasingly being deployed in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThrkaFQi4NbVg90H21EOLACvtfcHk0liDeEdmglSvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCns7rK&md5=9e8dd8a2354559a98c90178c12fdffd8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLaderian%26aufirst%3DB.%26aulast%3DFojo%26aufirst%3DT.%26atitle%3DCDK4%252F6%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520in%2520Breast%2520Cancer%253A%2520Palbociclib%252C%2520Ribociclib%252C%2520and%2520Abemaciclib%26jtitle%3DSemin.%2520Oncol.%26date%3D2017%26volume%3D44%26spage%3D395%26epage%3D403%26doi%3D10.1053%2Fj.seminoncol.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0liDeEdmglSvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malinkova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vylicil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase Inhibitors for Cancer Therapy: a Patent Review (2009 - 2014)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1517/13543776.2015.1045414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1517%2F13543776.2015.1045414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26161698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=953-970&author=V.+Malinkovaauthor=J.+Vylicilauthor=V.+Krystof&title=Cyclin-dependent+Kinase+Inhibitors+for+Cancer+Therapy%3A+a+Patent+Review+%282009+-+2014%29&doi=10.1517%2F13543776.2015.1045414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014)</span></div><div class="casAuthors">Malinkova, Veronika; Vylicil, Jakub; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">953-970</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell cycle deregulation is a common characteristic of cancer cells.  Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of mol. mechanisms.  Based on these observations, small mol. CDK inhibitors are being developed as potential cancer therapeutics.  Some of these compds. have entered Phase III clin. trials and one of them, palbociclib, recently received accelerated approval from the FDA.  However, the complexity of CDK biol. and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues.  This article reviews patent applications related to small mol. CDK inhibitors published between 2009 and 2014.  Clin. trials with pan-specific inhibitors have generally yielded unambiguously pos. outcomes.  However, better results have been achieved with highly specific inhibitors of CDK4/CDK6.  This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors.  The development of such compds. is challenging because all CDKs have very similar active sites.  Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPDLi65wpHSrVg90H21EOLACvtfcHk0ljI3ef_LWQNJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrjK&md5=b0fbe03411a8f0aea9775a16683f2b2c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543776.2015.1045414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2015.1045414%26sid%3Dliteratum%253Aachs%26aulast%3DMalinkova%26aufirst%3DV.%26aulast%3DVylicil%26aufirst%3DJ.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DCyclin-dependent%2520Kinase%2520Inhibitors%2520for%2520Cancer%2520Therapy%253A%2520a%2520Patent%2520Review%2520%25282009%2520-%25202014%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26spage%3D953%26epage%3D970%26doi%3D10.1517%2F13543776.2015.1045414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+Sanchez-Martinezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadler, S.</span></span> <span> </span><span class="NLM_article-title">Perspectives for Cancer Therapies with Cdk2 Inhibitors</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1054/drup.2001.0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1054%2Fdrup.2001.0224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12030783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlsl2hsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2001&pages=347-367&author=S.+Wadler&title=Perspectives+for+Cancer+Therapies+with+Cdk2+Inhibitors&doi=10.1054%2Fdrup.2001.0224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives for cancer therapies with cdk2 inhibitors</span></div><div class="casAuthors">Wadler, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">347-367</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern anticancer strategies are designed against specific mol. targets with the goal of sparing normal, non-neoplastic tissues.  Choosing specific mol. targets, however, is problematic.  Cdk2 (cyclin dependent kinase 2, cell division kinase 2, p33) is an important candidate target for therapeutic intervention.  Phosphorylation of retinoblastoma protein (pRb) by Cdk2 is the penultimate step in the transition from G1 to S phase.  Inhibition of this step could potentially result in inhibition of proliferation, cytostasis, and possibly apoptosis in human tumors.  Cdk2 also plays a crit. role in the transition through S phase and the S to G2 transition as well.  Inhibitors of the cyclin dependent kinases, such as Flavopiridol and UCN-01, are currently in clin. trials.  While demonstrating clin. activity, neither acts specifically against Cdk2.  Other more specific Cdk2 inhibitors are currently in preclin. development.  Further studies to explore the therapeutic worth of such agents are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopsjFO8cg8-LVg90H21EOLACvtfcHk0ljI3ef_LWQNJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlsl2hsbk%253D&md5=429a5960a1117919f2700b68238de3a1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1054%2Fdrup.2001.0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.2001.0224%26sid%3Dliteratum%253Aachs%26aulast%3DWadler%26aufirst%3DS.%26atitle%3DPerspectives%2520for%2520Cancer%2520Therapies%2520with%2520Cdk2%2520Inhibitors%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2001%26volume%3D4%26spage%3D347%26epage%3D367%26doi%3D10.1054%2Fdrup.2001.0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shchemelinin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sefc, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Necas, E.</span></span> <span> </span><span class="NLM_article-title">Protein Kinases, Their Function and Implication in Cancer and Other Diseases</span>. <i>Folia Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17089919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BD28nls1GgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=81-100&author=I.+Shchemelininauthor=L.+Sefcauthor=E.+Necas&title=Protein+Kinases%2C+Their+Function+and+Implication+in+Cancer+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases, their function and implication in cancer and other diseases</span></div><div class="casAuthors">Shchemelinin I; Sefc L; Necas E</div><div class="citationInfo"><span class="NLM_cas:title">Folia biologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">81-100</span>
        ISSN:<span class="NLM_cas:issn">0015-5500</span>.
    </div><div class="casAbstract">Protein phosphorylation is known to play an important role in various cellular processes such as cell division, metabolism, survival and apoptosis.  It is driven by specific enzymes, tyrosine and serine-threonine protein kinases.  Human protein kinases constitute a complicated system with intricate internal and external interactions.  The complexity and sophistication of the system implies its vulnerability.  Alterations in functions of these enzymes may launch series of pathological changes within the cell and as a result cause diseases.  Protein kinases have been shown to be involved in various pathological processes, first of all malignancies.  Deregulation of different protein kinases has been found in chronic myelogenous leukaemia, gastrointestinal stromal tumours, various other sarcomas and cancers as well as non-malignant disorders.  Therefore, they are regarded as important effectors in human pathology and represent prospective therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzDhllLp8mfv3jf77P2BG3fW6udTcc2eZZttqtFZ2w9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nls1GgtA%253D%253D&md5=e5262093a6dc1d589c614afdeccd9c2b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShchemelinin%26aufirst%3DI.%26aulast%3DSefc%26aufirst%3DL.%26aulast%3DNecas%26aufirst%3DE.%26atitle%3DProtein%2520Kinases%252C%2520Their%2520Function%2520and%2520Implication%2520in%2520Cancer%2520and%2520Other%2520Diseases%26jtitle%3DFolia%2520Biol.%26date%3D2006%26volume%3D52%26spage%3D81%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Cyclin-Dependent Kinase Regulation: Structures of Cdks, Their Cyclin Activators, and Cip and INK4 Inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1999.2640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1006%2Fjmbi.1999.2640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1999&pages=821-828&author=N.+P.+Pavletich&title=Mechanisms+of+Cyclin-Dependent+Kinase+Regulation%3A+Structures+of+Cdks%2C+Their+Cyclin+Activators%2C+and+Cip+and+INK4+Inhibitors&doi=10.1006%2Fjmbi.1999.2640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.2640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.2640%26sid%3Dliteratum%253Aachs%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DMechanisms%2520of%2520Cyclin-Dependent%2520Kinase%2520Regulation%253A%2520Structures%2520of%2520Cdks%252C%2520Their%2520Cyclin%2520Activators%252C%2520and%2520Cip%2520and%2520INK4%2520Inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D287%26spage%3D821%26epage%3D828%26doi%3D10.1006%2Fjmbi.1999.2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-Dependent+Kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2eYbliVEkD156Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewald, J. C.</span></span> <span> </span><span class="NLM_article-title">Fueling the Cycle: CDKs in Carbon and Energy Metabolism</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">93</span>, <span class="refDoi"> DOI: 10.3389/fcell.2018.00093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3389%2Ffcell.2018.00093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=30175098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BB3c3kvVWgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=93&author=M.+Solakiauthor=J.+C.+Ewald&title=Fueling+the+Cycle%3A+CDKs+in+Carbon+and+Energy+Metabolism&doi=10.3389%2Ffcell.2018.00093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fueling the Cycle: CDKs in Carbon and Energy Metabolism</span></div><div class="casAuthors">Solaki Maria; Ewald Jennifer C</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are the central regulators of the eukaryotic cell cycle, and are conserved across eukaryotes.  Their main and well-studied function lies in the regulation and the time-keeping of cell cycle entry and progression.  Additionally, more and more non canonical functions of CDKs are being uncovered.  One fairly recently discovered role of CDKs is the coordination of carbon and energy metabolism with proliferation.  Evidence from different model organisms is accumulating that CDKs can directly and indirectly control fluxes through metabolism, for example by phosphorylating metabolic enzymes.  In this mini-review, we summarize the emerging role of CDKs in regulating carbon and energy metabolism and discuss examples in different models from yeast to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSlxeUlx0N0y6e0F5ixvZgXfW6udTcc2eYbliVEkD156Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3kvVWgsw%253D%253D&md5=570222933abd3202fe868ce94ed9e63b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2018.00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2018.00093%26sid%3Dliteratum%253Aachs%26aulast%3DSolaki%26aufirst%3DM.%26aulast%3DEwald%26aufirst%3DJ.%2BC.%26atitle%3DFueling%2520the%2520Cycle%253A%2520CDKs%2520in%2520Carbon%2520and%2520Energy%2520Metabolism%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2018%26volume%3D6%26spage%3D93%26doi%3D10.3389%2Ffcell.2018.00093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hydbring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Non-canonical Functions of Cell Cycle Cyclins and Cyclin-dependent Kinases</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1038/nrm.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrm.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27033256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlOksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=280-292&author=P.+Hydbringauthor=M.+Malumbresauthor=P.+Sicinski&title=Non-canonical+Functions+of+Cell+Cycle+Cyclins+and+Cyclin-dependent+Kinases&doi=10.1038%2Fnrm.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases</span></div><div class="casAuthors">Hydbring, Per; Malumbres, Marcos; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">280-292</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The roles of cyclins and their catalytic partners, the cyclin-dependent kinases (CDKs), as core components of the machinery that drives cell cycle progression are well established.  Increasing evidence indicates that mammalian cyclins and CDKs also carry out important functions in other cellular processes, such as transcription, DNA damage repair, control of cell death, differentiation, the immune response and metab.  Some of these non-canonical functions are performed by cyclins or CDKs, independently of their resp. cell cycle partners, suggesting that there was a substantial divergence in the functions of these proteins during evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqltFQjJuMXrbVg90H21EOLACvtfcHk0lhtbjrBcZQUEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlOksLw%253D&md5=4d8aaf10c0542828112c561f5311f7da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DHydbring%26aufirst%3DP.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DNon-canonical%2520Functions%2520of%2520Cell%2520Cycle%2520Cyclins%2520and%2520Cyclin-dependent%2520Kinases%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26spage%3D280%26epage%3D292%26doi%3D10.1038%2Fnrm.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhavan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L. H.</span></span> <span> </span><span class="NLM_article-title">A Decade of CDK5</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/35096019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2F35096019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=11584302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVajsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=749-759&author=R.+Dhavanauthor=L.+H.+Tsai&title=A+Decade+of+CDK5&doi=10.1038%2F35096019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of CDK5</span></div><div class="casAuthors">Dhavan, Rani; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-759</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since it was identified a decade ago, cyclin-dependent kinase 5 (CDK5) has emerged as a crucial regulator of neuronal migration in the developing central nervous system, CDK5 phosphorylates a diverse list of substrates, implicating it in the regulation of a range of cellular processes - from adhesion and motility, to synaptic plasticity and drug addiction.  Recent evidence indicates that deregulation of this kinase is involved in the pathol. of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJjFohRrOz2LVg90H21EOLACvtfcHk0ljv6occVODZuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVajsLg%253D&md5=e1f256de5c9fb733c3b28ccb060fe2ad</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2F35096019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35096019%26sid%3Dliteratum%253Aachs%26aulast%3DDhavan%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.%2BH.%26atitle%3DA%2520Decade%2520of%2520CDK5%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D749%26epage%3D759%26doi%3D10.1038%2F35096019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X. F.</span></span> <span> </span><span class="NLM_article-title">In a Nongenomic Action, Steroid Hormone 20-Hydroxyecdysone Induces Phosphorylation of Cyclin-dependent Kinase 10 to Promote Gene Transcription</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1750</span>, <span class="refDoi"> DOI: 10.1210/en.2013-2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1210%2Fen.2013-2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24517229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFensL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2014&pages=1738-1750&author=W.+Liuauthor=M.+J.+Caiauthor=J.+X.+Wangauthor=X.+F.+Zhao&title=In+a+Nongenomic+Action%2C+Steroid+Hormone+20-Hydroxyecdysone+Induces+Phosphorylation+of+Cyclin-dependent+Kinase+10+to+Promote+Gene+Transcription&doi=10.1210%2Fen.2013-2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">In a nongenomic action, steroid hormone 20-hydroxyecdysone induces phosphorylation of cyclin-dependent kinase 10 to promote gene transcription</span></div><div class="casAuthors">Liu, Wen; Cai, Mei-Juan; Wang, Jin-Xing; Zhao, Xiao-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1738-1750, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The insect steroid hormone 20-hydroxyecdysone (20E) regulates gene transcription via a genomic pathway by forming a transcription complex that binds to DNA with the help of the chaperone proteins, heat shock proteins (Hsps) Hsc70 and Hsp90.  However, the nongenomic mechanisms by which 20E regulates gene expression remain unclear.  In this study, we found that 20E regulated the phosphorylation of serine/threonine protein kinase cyclin-dependent kinase 10 (CDK10) through a nongenomic pathway to mediate gene transcription in the lepidopteran Helicoverpa armigera.  The down-regulation of CDK10 by RNA interference in larvae and the epidermal cell line delayed development and suppressed 20E-induced gene transcription.  CDK10 was localized to the nucleus via its KKRR motif, and this nuclear localization and the ATPase motif were necessary for the efficient expression of the 20E-inducible gene.  The rapid phosphorylation of CDK10 was induced by 20E, whereas it was repressed by the inhibitors of G-protein-coupled receptors, phospholipase C, and Ca2+ channels.  Phosphorylated CDK10 exhibited increased interactions with Hsps Hsc70 and Hsp90 and then promoted the interactions between Hsps and ecdysone receptor EcRB1 and the binding of the Hsps-EcRB1 complex to the 20E response element for the regulation of gene transcription.  CDK10 depletion suppressed the formation of the Hsps-EcRB1 complex at the hormone receptor 3 promoter.  These results suggest that 20E induces CDK10 phosphorylation via a nongenomic pathway to regulate gene transcription in the nucleus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-VhfqbCrtS7Vg90H21EOLACvtfcHk0ljv6occVODZuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFensL%252FP&md5=33cdc1721c715a3357d80ae8bf2707a9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1210%2Fen.2013-2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2013-2020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BX.%26aulast%3DZhao%26aufirst%3DX.%2BF.%26atitle%3DIn%2520a%2520Nongenomic%2520Action%252C%2520Steroid%2520Hormone%252020-Hydroxyecdysone%2520Induces%2520Phosphorylation%2520of%2520Cyclin-dependent%2520Kinase%252010%2520to%2520Promote%2520Gene%2520Transcription%26jtitle%3DEndocrinology%26date%3D2014%26volume%3D155%26spage%3D1738%26epage%3D1750%26doi%3D10.1210%2Fen.2013-2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, V. J.</span></span> <span> </span><span class="NLM_article-title">CDK11 Complexes Promote pre-mRNA Splicing</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">8623</span>– <span class="NLM_lpage">8629</span>, <span class="refDoi"> DOI: 10.1074/jbc.M210057200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M210057200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=8623-8629&author=D.+Huauthor=A.+Mayedaauthor=J.+H.+Trembleyauthor=J.+M.+Lahtiauthor=V.+J.+Kidd&title=CDK11+Complexes+Promote+pre-mRNA+Splicing&doi=10.1074%2Fjbc.M210057200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M210057200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M210057200%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DD.%26aulast%3DMayeda%26aufirst%3DA.%26aulast%3DTrembley%26aufirst%3DJ.%2BH.%26aulast%3DLahti%26aufirst%3DJ.%2BM.%26aulast%3DKidd%26aufirst%3DV.%2BJ.%26atitle%3DCDK11%2520Complexes%2520Promote%2520pre-mRNA%2520Splicing%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D8623%26epage%3D8629%26doi%3D10.1074%2Fjbc.M210057200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span> <span> </span><span class="NLM_article-title">Structural Dissection of Cyclin Dependent Kinases Regulation and Protein Recognition Properties</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.4161/cc.9.8.11195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.9.8.11195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20372077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1551-1561&author=G.+Lolli&title=Structural+Dissection+of+Cyclin+Dependent+Kinases+Regulation+and+Protein+Recognition+Properties&doi=10.4161%2Fcc.9.8.11195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dissection of cyclin dependent kinases regulation and protein recognition properties</span></div><div class="casAuthors">Lolli, Graziano</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1561</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  They are regulated by their cyclin partners and by a variety of addnl. protein effectors (inhibitors, kinases, phosphatases).  Each CDK serves its function by means of specific protein recognition properties.  These are also responsible for the differential regulation of CDKs/Cyclin couples involved in processes as different as cell cycle and transcription.  The structural features detg. general and specific properties for CDKs/Cyclin complexes are analyzed.  They reside in an overall conserved architecture with divergent spots used by the complexes to present themselves to specific substrates or other protein effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28MAQ6SOxDLVg90H21EOLACvtfcHk0ljv6occVODZuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP&md5=34d193f3e930ba5043f152a252063f36</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.8.11195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.8.11195%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26atitle%3DStructural%2520Dissection%2520of%2520Cyclin%2520Dependent%2520Kinases%2520Regulation%2520and%2520Protein%2520Recognition%2520Properties%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D1551%26epage%3D1561%26doi%3D10.4161%2Fcc.9.8.11195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor’s-eye View of the ATP-binding Site of CDKs in Different Regulatory States</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1021/cb500135f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500135f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1251-1256&author=A.+Echalierauthor=A.+J.+Holeauthor=G.+Lolliauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=An+Inhibitor%E2%80%99s-eye+View+of+the+ATP-binding+Site+of+CDKs+in+Different+Regulatory+States&doi=10.1021%2Fcb500135f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States</span></div><div class="casAuthors">Echalier, Aude; Hole, Alison J.; Lolli, Graziano; Endicott, Jane A.; Noble, Martin E. M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1251-1256</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have used a chem. diverse panel of kinase inhibitors to assess the chem. similarity of the ATP-binding sites of cyclin-dependent kinase (CDK) subfamily members in a range of activation states.  Using this approach, we find that different activation states of a particular CDK may differ from each other as much as different CDKs in the same activation state.  We also find that inhibitors discriminate more effectively among CDK family members in their monomeric state than in their cyclin-bound state, providing direct evidence for the belief that selective binding to inactive kinase states might be more readily achieved than selective binding to active states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokueQs6w8YR7Vg90H21EOLACvtfcHk0li4z-xB67Ga1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrtr0%253D&md5=4419c60fe22d593aa23c8136030535f6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb500135f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500135f%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DAn%2520Inhibitor%25E2%2580%2599s-eye%2520View%2520of%2520the%2520ATP-binding%2520Site%2520of%2520CDKs%2520in%2520Different%2520Regulatory%2520States%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1251%26epage%3D1256%26doi%3D10.1021%2Fcb500135f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Discovery of Cyclin-Dependent Protein Kinase Inhibitors</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1042/EBC20170040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1042%2FEBC20170040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29118092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=439-452&author=M.+P.+Martinauthor=J.+A.+Endicottauthor=M.+E.+M.+Noble&title=Structure-based+Discovery+of+Cyclin-Dependent+Protein+Kinase+Inhibitors&doi=10.1042%2FEBC20170040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of cyclin-dependent protein kinase inhibitors</span></div><div class="casAuthors">Martin Mathew P; Endicott Jane A; Noble Martin E M</div><div class="citationInfo"><span class="NLM_cas:title">Essays in biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-452</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond.  After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer.  Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings.  Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members.  We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor-target interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqZGQ3bfUY0XELvajU9pjPfW6udTcc2eZbHchtnQIndrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7pt1Gmtg%253D%253D&md5=7795a97e063f43e77499e9a03020d6cb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1042%2FEBC20170040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20170040%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26atitle%3DStructure-based%2520Discovery%2520of%2520Cyclin-Dependent%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DEssays%2520Biochem.%26date%3D2017%26volume%3D61%26spage%3D439%26epage%3D452%26doi%3D10.1042%2FEBC20170040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skamnaki, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The Structure of Cyclin E1/CDK2: Implications for CDK2 Activation and CDK2-Independent Roles</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7600554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsj.emboj.7600554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=452-463&author=R.+Hondaauthor=E.+D.+Loweauthor=E.+Dubininaauthor=V.+Skamnakiauthor=A.+Cookauthor=N.+R.+Brownauthor=L.+N.+Johnson&title=The+Structure+of+Cyclin+E1%2FCDK2%3A+Implications+for+CDK2+Activation+and+CDK2-Independent+Roles&doi=10.1038%2Fsj.emboj.7600554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600554%26sid%3Dliteratum%253Aachs%26aulast%3DHonda%26aufirst%3DR.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DDubinina%26aufirst%3DE.%26aulast%3DSkamnaki%26aufirst%3DV.%26aulast%3DCook%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520Structure%2520of%2520Cyclin%2520E1%252FCDK2%253A%2520Implications%2520for%2520CDK2%2520Activation%2520and%2520CDK2-Independent%2520Roles%26jtitle%3DEMBO%2520J.%26date%3D2005%26volume%3D24%26spage%3D452%26epage%3D463%26doi%3D10.1038%2Fsj.emboj.7600554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Cyclin-Dependent Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(02)00182-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0163-7258%2802%2900182-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12191605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=125-133&author=T.+G.+Daviesauthor=D.+J.+Prattauthor=J.+A.+Endicottauthor=L.+N.+Johnsonauthor=M.+E.+Noble&title=Structure-Based+Design+of+Cyclin-Dependent+Kinase+Inhibitors&doi=10.1016%2FS0163-7258%2802%2900182-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Davies, Thomas G.; Pratt, David J.; Endicott, Jane A.; Johnson, Louise N.; Noble, Martin E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 44 refs.  The eukaryotic cell cycle is tightly regulated by the sequential activation and deactivation of the cyclin-dependent kinases (CDKs).  Aberrant CDK activity is a common defect in human tumors, and clin., it often confers a poor prognosis.  The strong genetic link between CDKs and the mol. pathol. of cancer has provided the rationale for developing small-mol. inhibitors of these kinases.  X-ray crystallog. recently has revealed the mol. details of CDK regulation by cyclin binding and phosphorylation, and by complex formation with endogenous inhibitors.  Knowledge of the structure of CDK2 has been key in driving the design and development of a large no. of ATP competitive inhibitors.  Crystallog. has revealed that the ATP-binding site of CDK2 can accommodate a no. of diverse mol. frameworks, exploiting various sites of interaction.  In addn., residues outside the main ATP-binding cleft have been identified that could be targeted to increase specificity and potency.  These results suggest that it may be possible to design pharmacol. relevant ligands that act as specific and potent inhibitors of CDK activity.  The authors provide a review of the current state of the field, along with an overview of their current inhibitor design studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3hEq4qfNuH7Vg90H21EOLACvtfcHk0li4z-xB67Ga1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShtbs%253D&md5=30c6073dccb49ef417ca0130b00756a9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900182-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900182-1%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DStructure-Based%2520Design%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D125%26epage%3D133%26doi%3D10.1016%2FS0163-7258%2802%2900182-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span> <span> </span><span class="NLM_article-title">Dephosphorylation of Cdk2 Thr160 by the Cyclin-dependent Kinase-interacting Phosphatase KAP in the Absence of Cyclin</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1126/science.270.5233.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.270.5233.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=7569954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2MXosFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=90-93&author=R.+Y.+Poonauthor=T.+Hunter&title=Dephosphorylation+of+Cdk2+Thr160+by+the+Cyclin-dependent+Kinase-interacting+Phosphatase+KAP+in+the+Absence+of+Cyclin&doi=10.1126%2Fscience.270.5233.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin</span></div><div class="casAuthors">Poon, Randy Y. C.; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5233</span>),
    <span class="NLM_cas:pages">90-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The activation of cyclin-dependent kinases (CDKs) requires the phosphorylation of a conserved Thr residue (Thr-160 in Cdk2) by CDK-activating kinase (CAK).  Human KAP (also called Cdi1), a CDK-assocd. phosphoprotein phosphatase, was shown to dephosphorylate Thr-160 in human Cdk2.  KAP was unable to dephosphorylate Tyr-15 and only dephosphorylated Thr-160 in native monomeric Cdk2.  The binding of cyclin A to Cdk2 inhibited the dephosphorylation of Thr-160 by KAP but did not preclude the binding of KAP to the cyclin A-Cdk2 complex.  Moreover, the dephosphorylation of Thr-160 by KAP prevented Cdk2 kinase activity upon subsequent assocn. with cyclin A.  These results suggest that KAP binds to Cdk2 and dephosphorylates Thr-160 when the assocd. cyclin subunit is degraded or dissocs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZeoyQxRXcOLVg90H21EOLACvtfcHk0lhBaVeYlnzhHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosFOmsLY%253D&md5=a74ab260ad484d166c9ed02ad420f8a3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5233.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5233.90%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DR.%2BY.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DDephosphorylation%2520of%2520Cdk2%2520Thr160%2520by%2520the%2520Cyclin-dependent%2520Kinase-interacting%2520Phosphatase%2520KAP%2520in%2520the%2520Absence%2520of%2520Cyclin%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D90%26epage%3D93%26doi%3D10.1126%2Fscience.270.5233.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Putting One Step Before the Other: Distinct Activation Pathways for Cdk1 and Cdk2 Bring Order to the Mammalian Cell Cycle</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.4161/cc.9.4.10732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.9.4.10732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20139727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=706-714&author=K.+A.+Merrickauthor=R.+P.+Fisher&title=Putting+One+Step+Before+the+Other%3A+Distinct+Activation+Pathways+for+Cdk1+and+Cdk2+Bring+Order+to+the+Mammalian+Cell+Cycle&doi=10.4161%2Fcc.9.4.10732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle</span></div><div class="casAuthors">Merrick, Karl A.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">706-714</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Eukaryotic cell division is controlled by the activity of cyclin-dependent kinases (CDKs).  Cdk1 and Cdk2, which function at different stages of the mammalian cell cycle, both require cyclin-binding and phosphorylation of the activation (T-) loop for full activity, but differ with respect to the order in which the two steps occur in vivo.  To form stable complexes with either of its partners-cyclins A and B-Cdk1 must be phosphorylated on its T-loop, but that phosphorylation in turn depends on the presence of cyclin.  Cdk2 can follow a kinetically distinct path to activation in which T-loop phosphorylation precedes cyclin-binding, and thereby out-compete the more abundant Cdk1 for limiting amts. of cyclin A.  Math. modeling suggests this could be a principal basis for the temporal ordering of CDK activation during S phase, which may dictate the sequence in which replication origins fire.  Still to be detd. are how: (1) the activation machinery discriminates between closely related CDKs, and (2) coordination of the cell cycle is affected when this mechanism of pathway insulation breaks down.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuode7wYph7Vg90H21EOLACvtfcHk0lhBaVeYlnzhHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cju7k%253D&md5=ddd15a097eb40d1b728f688c44dd2347</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.4.10732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.4.10732%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DPutting%2520One%2520Step%2520Before%2520the%2520Other%253A%2520Distinct%2520Activation%2520Pathways%2520for%2520Cdk1%2520and%2520Cdk2%2520Bring%2520Order%2520to%2520the%2520Mammalian%2520Cell%2520Cycle%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D706%26epage%3D714%26doi%3D10.4161%2Fcc.9.4.10732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Distinct Activation Pathways Confer Cyclin-binding Specificity on Cdk1 and Cdk2 in Human Cells</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2008.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molcel.2008.10.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=662-672&author=K.+A.+Merrickauthor=S.+Larochelleauthor=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=R.+P.+Fisher&title=Distinct+Activation+Pathways+Confer+Cyclin-binding+Specificity+on+Cdk1+and+Cdk2+in+Human+Cells&doi=10.1016%2Fj.molcel.2008.10.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2008.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2008.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DDistinct%2520Activation%2520Pathways%2520Confer%2520Cyclin-binding%2520Specificity%2520on%2520Cdk1%2520and%2520Cdk2%2520in%2520Human%2520Cells%26jtitle%3DMol.%2520Cell%26date%3D2008%26volume%3D32%26spage%3D662%26epage%3D672%26doi%3D10.1016%2Fj.molcel.2008.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremner, R.</span></span> <span> </span><span class="NLM_article-title">A CDK2 Activity Signature Predicts Outcome in CDK2-low Cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2491</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1038/onc.2016.409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2016.409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27819669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2gtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=2491-2502&author=S.+R.+McCurdyauthor=M.+Pacalauthor=M.+Ahmadauthor=R.+Bremner&title=A+CDK2+Activity+Signature+Predicts+Outcome+in+CDK2-low+Cancers&doi=10.1038%2Fonc.2016.409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A CDK2 activity signature predicts outcome in CDK2-low cancers</span></div><div class="casAuthors">McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2491-2502</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The role of cyclin-dependent kinase 2 (CDK2) in cancer is controversial.  A major hurdle is the availability of tools to easily assess its activity across many samples.  Here, we introduce a transcriptional signature to specifically track CDK2 activity.  It responds to genetic and chem. perturbations in the CDK-RB-E2F axis, correlates with mitotic rate in vitro and in vivo and reacts rapidly to changes in CDK2 activity during cell cycle progression.  We find that CDK2 activity is specifically elevated in human testes, mirroring its crit. function in mice, and report very distinct profiles across human cancers.  Increased CDK2 activity decreases risk in colon cancer, but elevates poor outcome two- to fivefold in specific tumors, including low grade glioma, kidney, thyroid, adrenocortical and prostate cancer.  These are typically 'CDK2-low' cancers, suggesting that above a certain threshold CDK2 promotes progression, but further increases do not influence outcome.  Multivariate anal. revealed that the CDK2 signature is the most important predictive feature in these cancers vs. dozens of other clin. parameters, such as tumor grade or mitotic index.  Thus, transcriptome data provides a novel, straightforward method to monitor CDK2 activity, implicates key roles for the kinase in a subset of human tissues and tumors and enhances cancer risk prediction.  The strategy used here for CDK2 could be applied to other kinases that influence transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkkYovR0LeFrVg90H21EOLACvtfcHk0lhBaVeYlnzhHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2gtbzF&md5=0836de84a5e04824d9e2c1c48da3469a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fonc.2016.409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2016.409%26sid%3Dliteratum%253Aachs%26aulast%3DMcCurdy%26aufirst%3DS.%2BR.%26aulast%3DPacal%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DM.%26aulast%3DBremner%26aufirst%3DR.%26atitle%3DA%2520CDK2%2520Activity%2520Signature%2520Predicts%2520Outcome%2520in%2520CDK2-low%2520Cancers%26jtitle%3DOncogene%26date%3D2017%26volume%3D36%26spage%3D2491%26epage%3D2502%26doi%3D10.1038%2Fonc.2016.409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diril, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisteau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnacaram, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janela, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noffke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginhoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldis, P.</span></span> <span> </span><span class="NLM_article-title">Cdk2 Catalytic Activity is Essential for Meiotic Cell Division <i>In vivo</i></span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>473</i></span>,  <span class="NLM_fpage">2783</span>– <span class="NLM_lpage">2798</span>, <span class="refDoi"> DOI: 10.1042/BCJ20160607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1042%2FBCJ20160607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=473&publication_year=2016&pages=2783-2798&author=S.+Chauhanauthor=M.+K.+Dirilauthor=J.+H.+Leeauthor=X.+Bisteauauthor=V.+Manoharanauthor=D.+Adhikariauthor=C.+K.+Ratnacaramauthor=B.+Janelaauthor=J.+Noffkeauthor=F.+Ginhouxauthor=V.+Coppolaauthor=K.+Liuauthor=L.+Tessarolloauthor=P.+Kaldis&title=Cdk2+Catalytic+Activity+is+Essential+for+Meiotic+Cell+Division+In+vivo&doi=10.1042%2FBCJ20160607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1042%2FBCJ20160607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20160607%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DS.%26aulast%3DDiril%26aufirst%3DM.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DBisteau%26aufirst%3DX.%26aulast%3DManoharan%26aufirst%3DV.%26aulast%3DAdhikari%26aufirst%3DD.%26aulast%3DRatnacaram%26aufirst%3DC.%2BK.%26aulast%3DJanela%26aufirst%3DB.%26aulast%3DNoffke%26aufirst%3DJ.%26aulast%3DGinhoux%26aufirst%3DF.%26aulast%3DCoppola%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DKaldis%26aufirst%3DP.%26atitle%3DCdk2%2520Catalytic%2520Activity%2520is%2520Essential%2520for%2520Meiotic%2520Cell%2520Division%2520In%2520vivo%26jtitle%3DBiochem.%2520J.%26date%3D2016%26volume%3D473%26spage%3D2783%26epage%3D2798%26doi%3D10.1042%2FBCJ20160607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narasimha, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaulich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, S. F.</span></span> <span> </span><span class="NLM_article-title">Cyclin D Activates the Rb Tumor Suppressor by Mono-phosphorylation</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e02872</span>, <span class="refDoi"> DOI: 10.7554/eLife.02872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.7554%2FeLife.02872" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e02872&author=A.+M.+Narasimhaauthor=M.+Kaulichauthor=G.+S.+Shapiroauthor=Y.+J.+Choiauthor=P.+Sicinskiauthor=S.+F.+Dowdy&title=Cyclin+D+Activates+the+Rb+Tumor+Suppressor+by+Mono-phosphorylation&doi=10.7554%2FeLife.02872"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.7554%2FeLife.02872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.02872%26sid%3Dliteratum%253Aachs%26aulast%3DNarasimha%26aufirst%3DA.%2BM.%26aulast%3DKaulich%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DG.%2BS.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DDowdy%26aufirst%3DS.%2BF.%26atitle%3DCyclin%2520D%2520Activates%2520the%2520Rb%2520Tumor%2520Suppressor%2520by%2520Mono-phosphorylation%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De02872%26doi%3D10.7554%2FeLife.02872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denissova, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinases Regulate the Antiproliferative Function of Smads</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nature02650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnature02650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15241418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2004&pages=226-231&author=I.+Matsuuraauthor=N.+G.+Denissovaauthor=G.+Wangauthor=D.+Heauthor=J.+Longauthor=F.+Liu&title=Cyclin-Dependent+Kinases+Regulate+the+Antiproliferative+Function+of+Smads&doi=10.1038%2Fnature02650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases regulate the antiproliferative function of Smads</span></div><div class="casAuthors">Matsuura, Isao; Denissova, Natalia G.; Wang, Guannan; He, Dongming; Long, Jianyin; Liu, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">6996</span>),
    <span class="NLM_cas:pages">226-231</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transforming growth factor-β (TGF-β) potently inhibits cell cycle progression at the G1 phase.  Smad3 has a key function in mediating the TGF-β growth-inhibitory response.  Here we show that Smad3 is a major physiol. substrate of the G1 cyclin-dependent kinases CDK4 and CDK2.  Except for the retinoblastoma protein family, Smad3 is the only CDK4 substrate demonstrated so far.  We have mapped CDK4 and CDK2 phosphorylation sites to Thr 8, Thr 178 and Ser 212 in Smad3.  Mutation of the CDK phosphorylation sites increases Smad3 transcriptional activity, leading to higher expression of the CDK inhibitor p15.  Mutation of the CDK phosphorylation sites of Smad3 also increases its ability to downregulate the expression of c-myc.  Using Smad3-/- mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability.  Taken together, these findings indicate that CDK phosphorylation of Smad3 inhibits its transcriptional activity and antiproliferative function.  Because cancer cells often contain high levels of CDK activity, diminishing Smad3 activity by CDK phosphorylation may contribute to tumorigenesis and TGF-β resistance in cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCSqptmYD0rVg90H21EOLACvtfcHk0ljD1PYOgbJgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVGjsr0%253D&md5=f129c1f8e2748a9aac36adebd937e704</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature02650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02650%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuura%26aufirst%3DI.%26aulast%3DDenissova%26aufirst%3DN.%2BG.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DCyclin-Dependent%2520Kinases%2520Regulate%2520the%2520Antiproliferative%2520Function%2520of%2520Smads%26jtitle%3DNature%26date%3D2004%26volume%3D430%26spage%3D226%26epage%3D231%26doi%3D10.1038%2Fnature02650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Major, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, R. H.</span></span> <span> </span><span class="NLM_article-title">Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-cyclin Complexes for Phosphorylation-Dependent Recruitment of P300/CBP Coactivators</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2661</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.7.2649-2661.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1128%2FMCB.24.7.2649-2661.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15024056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1emsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=2649-2661&author=M.+L.+Majorauthor=R.+Lepeauthor=R.+H.+Costa&title=Forkhead+Box+M1B+Transcriptional+Activity+Requires+Binding+of+Cdk-cyclin+Complexes+for+Phosphorylation-Dependent+Recruitment+of+P300%2FCBP+Coactivators&doi=10.1128%2FMCB.24.7.2649-2661.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators</span></div><div class="casAuthors">Major, Michael L.; Lepe, Rita; Costa, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2649-2661</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Previous liver regeneration studies demonstrated that the mouse forkhead box M1B (FoxM1B) transcription factor regulates hepatocyte proliferation through expression of cell cycle genes that stimulate cyclin-dependent kinase 2 (Cdk2) and Cdk1 activity.  In this study, the authors demonstrated that disruption of the FoxM1B Cdk1/2 phosphorylation site at Thr residue 596 significantly reduced both FoxM1B transcriptional activity and Cdk phosphorylation of the FoxM1B T596A mutant protein in vivo.  Retention of this FoxM1B 596 Cdk phosphorylation site was found to be essential for recruiting the histone acetyltransferase CREB binding protein (CBP) to the FoxM1B transcriptional activation domain.  Consistent with these findings, dominant neg. Cdk1 protein significantly reduced FoxM1B transcriptional activity and inhibited FoxM1B recruitment of the CBP coactivator protein.  Likewise, Cdc25B-mediated stimulation of Cdk activity together with elevated levels of the CBP coactivator protein provided a 6.2-fold synergistic increase in FoxM1B transcriptional activity.  Furthermore, mutation of the FoxM1B Leu-641 residue within an LXL motif (residues 639 to 641) inhibited recruitment of Cdk-cyclin complexes and caused significant redn. in both FoxM1B transcriptional activity and in vivo Cdk phosphorylation of the FoxM1B Thr-596 residue.  The authors demonstrated that FoxM1B transcriptional activity requires binding of either S-phase or M-phase Cdk-cyclin complexes to mediate efficient Cdk phosphorylation of the FoxM1B Thr-596 residue, which is essential for recruitment of p300/CBP coactivator proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtw_ZOkr-5orVg90H21EOLACvtfcHk0ljD1PYOgbJgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1emsL4%253D&md5=357b671b9d86d5cdeaa0ce2d7c70082f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.7.2649-2661.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.7.2649-2661.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMajor%26aufirst%3DM.%2BL.%26aulast%3DLepe%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DR.%2BH.%26atitle%3DForkhead%2520Box%2520M1B%2520Transcriptional%2520Activity%2520Requires%2520Binding%2520of%2520Cdk-cyclin%2520Complexes%2520for%2520Phosphorylation-Dependent%2520Recruitment%2520of%2520P300%252FCBP%2520Coactivators%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D2649%26epage%3D2661%26doi%3D10.1128%2FMCB.24.7.2649-2661.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tindall, D. J.</span></span> <span> </span><span class="NLM_article-title">CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1126/science.1130512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.1130512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17038621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOgtrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2006&pages=294-297&author=H.+Huangauthor=K.+M.+Reganauthor=Z.+Louauthor=J.+Chenauthor=D.+J.+Tindall&title=CDK2-Dependent+Phosphorylation+of+FOXO1+as+an+Apoptotic+Response+to+DNA+Damage&doi=10.1126%2Fscience.1130512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage</span></div><div class="casAuthors">Huang, Haojie; Regan, Kevin M.; Lou, Zhenkun; Chen, Junjie; Tindall, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">5797</span>),
    <span class="NLM_cas:pages">294-297</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The function of cyclin-dependent kinase 2 (CDK2) is often abolished after DNA damage.  The inhibition of CDK2 plays a central role in DNA damage-induced cell cycle arrest and DNA repair.  However, whether CDK2 also influences the survival of cells under genotoxic stress is unknown.  Forkhead box O (FOXO) transcription factors are emerging as key regulators of cell survival.  CDK2 specifically phosphorylated FOXO1 at serine-249 (Ser249) in vitro and in vivo.  Phosphorylation of Ser249 resulted in cytoplasmic localization and inhibition of FOXO1.  This phosphorylation was abrogated upon DNA damage through the cell cycle checkpoint pathway that is dependent on the protein kinases Chk1 and Chk2.  Moreover, silencing of FOXO1 by small interfering RNA diminished DNA damage-induced death in both p53-deficient and p53-proficient cells.  This effect was reversed by restored expression of FOXO1 in a manner depending on phosphorylation of Ser249.  Functional interaction between CDK2 and FOXO1 provides a mechanism that regulates apoptotic cell death after DNA strand breakage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD9appoowtV7Vg90H21EOLACvtfcHk0ljD1PYOgbJgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOgtrvI&md5=e3011ebb7cbc313b277e7c1be2f3f5a2</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1130512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1130512%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DRegan%26aufirst%3DK.%2BM.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTindall%26aufirst%3DD.%2BJ.%26atitle%3DCDK2-Dependent%2520Phosphorylation%2520of%2520FOXO1%2520as%2520an%2520Apoptotic%2520Response%2520to%2520DNA%2520Damage%26jtitle%3DScience%26date%3D2006%26volume%3D314%26spage%3D294%26epage%3D297%26doi%3D10.1126%2Fscience.1130512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G.</span></span> <span> </span><span class="NLM_article-title">Cdk2-Dependent Phosphorylation of Id2 Modulates Activity of E2A-Related Transcription Factors</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1093/emboj/16.2.332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Femboj%2F16.2.332" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=332-342&author=E.+Haraauthor=M.+Hallauthor=G.+Peters&title=Cdk2-Dependent+Phosphorylation+of+Id2+Modulates+Activity+of+E2A-Related+Transcription+Factors&doi=10.1093%2Femboj%2F16.2.332"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.2.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.2.332%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DE.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DCdk2-Dependent%2520Phosphorylation%2520of%2520Id2%2520Modulates%2520Activity%2520of%2520E2A-Related%2520Transcription%2520Factors%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D332%26epage%3D342%26doi%3D10.1093%2Femboj%2F16.2.332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voit, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grummt, I.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of UBF at Serine 388 is Required for Interaction with RNA Polymerase I and Activation of Rdna Transcription</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">13631</span>– <span class="NLM_lpage">13636</span>, <span class="refDoi"> DOI: 10.1073/pnas.231071698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.231071698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=13631-13636&author=R.+Voitauthor=I.+Grummt&title=Phosphorylation+of+UBF+at+Serine+388+is+Required+for+Interaction+with+RNA+Polymerase+I+and+Activation+of+Rdna+Transcription&doi=10.1073%2Fpnas.231071698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.231071698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.231071698%26sid%3Dliteratum%253Aachs%26aulast%3DVoit%26aufirst%3DR.%26aulast%3DGrummt%26aufirst%3DI.%26atitle%3DPhosphorylation%2520of%2520UBF%2520at%2520Serine%2520388%2520is%2520Required%2520for%2520Interaction%2520with%2520RNA%2520Polymerase%2520I%2520and%2520Activation%2520of%2520Rdna%2520Transcription%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D13631%26epage%3D13636%26doi%3D10.1073%2Fpnas.231071698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. Y.</span></span> <span> </span><span class="NLM_article-title">Cdk2-Dependent Phosphorylation of the NF-Y Transcription Factor and Its Involvement in the P<sup>53</sup>-P<sup>21</sup> Signaling Pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">36966</span>– <span class="NLM_lpage">36972</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305178200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M305178200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=36966-36972&author=J.+Yunauthor=H.+D.+Chaeauthor=T.+S.+Choiauthor=E.+H.+Kimauthor=Y.+J.+Bangauthor=J.+Chungauthor=K.+S.+Choiauthor=R.+Mantovaniauthor=D.+Y.+Shin&title=Cdk2-Dependent+Phosphorylation+of+the+NF-Y+Transcription+Factor+and+Its+Involvement+in+the+P53-P21+Signaling+Pathway&doi=10.1074%2Fjbc.M305178200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305178200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305178200%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DH.%2BD.%26aulast%3DChoi%26aufirst%3DT.%2BS.%26aulast%3DKim%26aufirst%3DE.%2BH.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DK.%2BS.%26aulast%3DMantovani%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DD.%2BY.%26atitle%3DCdk2-Dependent%2520Phosphorylation%2520of%2520the%2520NF-Y%2520Transcription%2520Factor%2520and%2520Its%2520Involvement%2520in%2520the%2520P53-P21%2520Signaling%2520Pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D36966%26epage%3D36972%26doi%3D10.1074%2Fjbc.M305178200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebold, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempnauer, K. H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and Activation of B-Myb by Cyclin A-Cdk2</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(06)00121-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-9822%2806%2900121-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9094315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=253-260&author=U.+Zieboldauthor=O.+Bartschauthor=R.+Maraisauthor=S.+Ferrariauthor=K.+H.+Klempnauer&title=Phosphorylation+and+Activation+of+B-Myb+by+Cyclin+A-Cdk2&doi=10.1016%2FS0960-9822%2806%2900121-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and activation of B-Myb by cyclin A-Cdk2</span></div><div class="casAuthors">Ziebold, Ulrike; Bartsch, Olaf; Marais, Richard; Ferrari, Stefano; Klempnauer, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-260</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Background: Cyclins and their catalytic partners, the cyclin-dependent kinases (Cdks), function as key regulators of the eukaryotic cell cycle.  Specific cyclin-Cdk complexes are active at successive stages during the cell cycle and control cell-cycle progression by phosphorylating specific target proteins, most of which have not yet been identified.  B-Myb, a conserved member of the Myb oncoprotein family, is a sequence-specific DNA-binding protein expressed in virtually all proliferating mammalian cells.  Increasing evidence suggests that B-Myb lays an important role during the late G1 and early S phases of the cell cycle.  In this study, we have examd. the regulation of B-Myb activity by cyclin-Cdks.  Results: We found that the transcriptional transactivation potential of B-Myb was repressed by a regulatory domain located at the carboxyl terminus of the protein.  Coexpression of B-Myb and cyclin A relieved this repression by phosphorylation of B-Myb in its carboxy-terminal region.  Tryptic phosphopeptide mapping revealed that endogenous B-Myb was phosphorylated in cells undergoing S phase.  Conclusions: This work provides evidence for a link between the Myb oncoprotein family and the cell-cycle machinery.  We have shown that the carboxyl terminus of B-Myb acts as a cell-cycle sensor that regulates the transactivation function of B-Myb.  Moreover, our studies have identified B-Myb as a target of cyclin A-Cdk2 and have indicated that B-Myb activity is regulated by phosphorylation mediated by cyclin A-Cdk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpspxO-Ly3L1bVg90H21EOLACvtfcHk0lg95Q-D561HlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOjtLc%253D&md5=b5a3d1ab5812c76a0a21454c5aa79b22</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2806%2900121-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252806%252900121-7%26sid%3Dliteratum%253Aachs%26aulast%3DZiebold%26aufirst%3DU.%26aulast%3DBartsch%26aufirst%3DO.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DKlempnauer%26aufirst%3DK.%2BH.%26atitle%3DPhosphorylation%2520and%2520Activation%2520of%2520B-Myb%2520by%2520Cyclin%2520A-Cdk2%26jtitle%3DCurr.%2520Biol.%26date%3D1997%26volume%3D7%26spage%3D253%26epage%3D260%26doi%3D10.1016%2FS0960-9822%2806%2900121-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hydbring, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahram, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tronnersjo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogstrand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Lehr, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilischkis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vervoorts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, L. G.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation by Cdk2 is Required for Myc to Repress Ras-induced Senescence in Cotransformation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1073/pnas.0900121106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0900121106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=58-63&author=P.+Hydbringauthor=F.+Bahramauthor=Y.+Suauthor=S.+Tronnersjoauthor=K.+Hogstrandauthor=N.+von+der+Lehrauthor=H.+R.+Sharifiauthor=R.+Lilischkisauthor=N.+Heinauthor=S.+Wuauthor=J.+Vervoortsauthor=M.+Henrikssonauthor=A.+Grandienauthor=B.+Luscherauthor=L.+G.+Larsson&title=Phosphorylation+by+Cdk2+is+Required+for+Myc+to+Repress+Ras-induced+Senescence+in+Cotransformation&doi=10.1073%2Fpnas.0900121106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0900121106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0900121106%26sid%3Dliteratum%253Aachs%26aulast%3DHydbring%26aufirst%3DP.%26aulast%3DBahram%26aufirst%3DF.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DTronnersjo%26aufirst%3DS.%26aulast%3DHogstrand%26aufirst%3DK.%26aulast%3Dvon%2Bder%2BLehr%26aufirst%3DN.%26aulast%3DSharifi%26aufirst%3DH.%2BR.%26aulast%3DLilischkis%26aufirst%3DR.%26aulast%3DHein%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DVervoorts%26aufirst%3DJ.%26aulast%3DHenriksson%26aufirst%3DM.%26aulast%3DGrandien%26aufirst%3DA.%26aulast%3DLuscher%26aufirst%3DB.%26aulast%3DLarsson%26aufirst%3DL.%2BG.%26atitle%3DPhosphorylation%2520by%2520Cdk2%2520is%2520Required%2520for%2520Myc%2520to%2520Repress%2520Ras-induced%2520Senescence%2520in%2520Cotransformation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D58%26epage%3D63%26doi%3D10.1073%2Fpnas.0900121106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattes, B.</span></span> <span> </span><span class="NLM_article-title">A Novel Cdk2 Interactor is Phosphorylated by Cdc7 and Associates with Components of the Replication Complexes</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">4120</span>– <span class="NLM_lpage">4126</span>, <span class="refDoi"> DOI: 10.4161/cc.4.8.1918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.4.8.1918" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=4120-4126&author=I.+Grishinaauthor=B.+Lattes&title=A+Novel+Cdk2+Interactor+is+Phosphorylated+by+Cdc7+and+Associates+with+Components+of+the+Replication+Complexes&doi=10.4161%2Fcc.4.8.1918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.4161%2Fcc.4.8.1918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.4.8.1918%26sid%3Dliteratum%253Aachs%26aulast%3DGrishina%26aufirst%3DI.%26aulast%3DLattes%26aufirst%3DB.%26atitle%3DA%2520Novel%2520Cdk2%2520Interactor%2520is%2520Phosphorylated%2520by%2520Cdc7%2520and%2520Associates%2520with%2520Components%2520of%2520the%2520Replication%2520Complexes%26jtitle%3DCell%2520Cycle%26date%3D2005%26volume%3D4%26spage%3D4120%26epage%3D4126%26doi%3D10.4161%2Fcc.4.8.1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chunder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A. D.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Controls Peripheral Immune Tolerance</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">5659</span>– <span class="NLM_lpage">5666</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4049%2Fjimmunol.1202313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=5659-5666&author=N.+Chunderauthor=L.+Wangauthor=C.+Chenauthor=W.+W.+Hancockauthor=A.+D.+Wells&title=Cyclin-dependent+Kinase+2+Controls+Peripheral+Immune+Tolerance&doi=10.4049%2Fjimmunol.1202313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202313%26sid%3Dliteratum%253Aachs%26aulast%3DChunder%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BD.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Controls%2520Peripheral%2520Immune%2520Tolerance%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D5659%26epage%3D5666%26doi%3D10.4049%2Fjimmunol.1202313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2698</span>– <span class="NLM_lpage">2711</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-10-813139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1182%2Fblood-2017-10-813139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29720484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=2698-2711&author=M.+Yingauthor=X.+Shaoauthor=H.+Jingauthor=Y.+Liuauthor=X.+Qiauthor=J.+Caoauthor=Y.+Chenauthor=S.+Xiangauthor=H.+Songauthor=R.+Huauthor=G.+Weiauthor=B.+Yangauthor=Q.+He&title=Ubiquitin-dependent+Degradation+of+CDK2+Drives+the+Therapeutic+Differentiation+of+AML+by+Targeting+PRDX2&doi=10.1182%2Fblood-2017-10-813139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent degradation of cdk2 drives the therapeutic differentiation of aml by targeting prdx2</span></div><div class="casAuthors">Ying, Meidan; Shao, Xuejing; Jing, Hui; Liu, Yujia; Qi, Xiaotian; Cao, Ji; Chen, Yingqian; Xiang, Senfeng; Song, Hua; Hu, Ronggui; Wei, Guoqing; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2698-2711</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A distinct hallmark of acute myeloid leukemia (AML) is the arrest of leukemic myeloblasts at an immature stage of development.  Therapies that overcome differentiation arrest have emerged as a powerful strategy for treating AML, but targeting leukemia differentiation remains challenging, mainly because of an incomplete mechanistic understanding of the process.  Here, we unveil a new role for cyclin-dependent kinase 2 (CDK2) in blocking myeloid differentiation in AML.  We show that among several interphase CDK, only CDK2 undergoes ubiquitin-dependent proteasome degrdn., which is accompanied by AML cell differentiation.  By using the yeast 2-hybrid system and functional analyses, KLHL6 was identified as a specific E3 ubiquitin ligase regulating the degrdn. of CDK2.  Importantly, inhibiting CDK2, but not other cyclin-dependent kinases CDK1/4/6, effectively induced granulocytic differentiation in AML cell lines and 5 major subtypes of primary patientderived AML samples.  Mechanistically, CDK2 depletion led to the reactivation of differentiation pathway translation, and the differentiation blockade function of CDK2 may be achieved directly by maintaining the activity of PRDX2.  Finally, CDK2 depletion arrested tumor growth of AML cells in nude mice and extended survival in both AML cell line and PDX-AML cells derived xenograft mouse models.  Thus, our work not only provides exptl. evidence for validating CDK2 as a potential therapeutic target for differentiation, but also uncovers the biol. function of the CDK2-PRDX2 axis in blocking AML differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-1GnzdaOHrVg90H21EOLACvtfcHk0ljZGpXkk8Ajvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOiu77M&md5=0f3345fd7dba32cf4809bfb302a037dd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-10-813139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-10-813139%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DUbiquitin-dependent%2520Degradation%2520of%2520CDK2%2520Drives%2520the%2520Therapeutic%2520Differentiation%2520of%2520AML%2520by%2520Targeting%2520PRDX2%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D2698%26epage%3D2711%26doi%3D10.1182%2Fblood-2017-10-813139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saurus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtonen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogarty, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassenius, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsblom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groop, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtonen, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Protects Podocytes from Apoptosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21664</span>, <span class="refDoi"> DOI: 10.1038/srep21664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsrep21664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26876672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFKht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21664&author=P.+Saurusauthor=S.+Kuuselaauthor=V.+Dumontauthor=E.+Lehtonenauthor=C.+L.+Fogartyauthor=M.+I.+Lasseniusauthor=C.+Forsblomauthor=M.+Lehtoauthor=M.+A.+Saleemauthor=P.+H.+Groopauthor=S.+Lehtonen&title=Cyclin-dependent+Kinase+2+Protects+Podocytes+from+Apoptosis&doi=10.1038%2Fsrep21664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 2 protects podocytes from apoptosis</span></div><div class="casAuthors">Saurus, Pauliina; Kuusela, Sara; Dumont, Vincent; Lehtonen, Eero; Fogarty, Christopher L.; Lassenius, Mariann I.; Forsblom, Carol; Lehto, Markku; Saleem, Moin A.; Groop, Per-Henrik; Lehtonen, Sanna</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21664</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Loss of podocytes is an early feature of diabetic nephropathy (DN) and predicts its progression.  We found that treatment of podocytes with sera from normoalbuminuric type 1 diabetes patients with high lipopolysaccharide (LPS) activity, known to predict progression of DN, downregulated CDK2 (cyclin-dependent kinase 2).  LPS-treatment of mice also reduced CDK2 expression.  LPS-induced downregulation of CDK2 was prevented in vitro and in vivo by inhibiting the Toll-like receptor (TLR) pathway using immunomodulatory agent GIT27.  We also obsd. that CDK2 is downregulated in the glomeruli of obese Zucker rats before the onset of proteinuria.  Knockdown of CDK2, or inhibiting its activity with roscovitine in podocytes increased apoptosis.  CDK2 knockdown also reduced expression of PDK1, an activator of the cell survival kinase Akt, and reduced Akt phosphorylation.  This suggests that CDK2 regulates the activity of the cell survival pathway via PDK1.  Furthermore, PDK1 knockdown reduced the expression of CDK2 suggesting a regulatory loop between CDK2 and PDK1.  Collectively, our data show that CDK2 protects podocytes from apoptosis and that reduced expression of CDK2 assocs. with the development of DN.  Preventing downregulation of CDK2 by blocking the TLR pathway with GIT27 may provide a means to prevent podocyte apoptosis and progression of DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpggm0ysr1PyrVg90H21EOLACvtfcHk0ljZGpXkk8Ajvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFKht70%253D&md5=7fd91e429810792d76430fe90e62367c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fsrep21664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21664%26sid%3Dliteratum%253Aachs%26aulast%3DSaurus%26aufirst%3DP.%26aulast%3DKuusela%26aufirst%3DS.%26aulast%3DDumont%26aufirst%3DV.%26aulast%3DLehtonen%26aufirst%3DE.%26aulast%3DFogarty%26aufirst%3DC.%2BL.%26aulast%3DLassenius%26aufirst%3DM.%2BI.%26aulast%3DForsblom%26aufirst%3DC.%26aulast%3DLehto%26aufirst%3DM.%26aulast%3DSaleem%26aufirst%3DM.%2BA.%26aulast%3DGroop%26aufirst%3DP.%2BH.%26aulast%3DLehtonen%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Protects%2520Podocytes%2520from%2520Apoptosis%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21664%26doi%3D10.1038%2Fsrep21664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roig, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Gomez, G.</span></span> <span> </span><span class="NLM_article-title">Cdk2 Activation Acts Upstream of the Mitochondrion During Glucocorticoid Induced Thymocyte Apoptosis</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2790</span>, <span class="refDoi"> DOI: 10.1002/eji.200425154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Feji.200425154" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2004&pages=2781-2790&author=F.+Granesauthor=M.+B.+Roigauthor=H.+J.+Bradyauthor=G.+Gil-Gomez&title=Cdk2+Activation+Acts+Upstream+of+the+Mitochondrion+During+Glucocorticoid+Induced+Thymocyte+Apoptosis&doi=10.1002%2Feji.200425154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Feji.200425154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.200425154%26sid%3Dliteratum%253Aachs%26aulast%3DGranes%26aufirst%3DF.%26aulast%3DRoig%26aufirst%3DM.%2BB.%26aulast%3DBrady%26aufirst%3DH.%2BJ.%26aulast%3DGil-Gomez%26aufirst%3DG.%26atitle%3DCdk2%2520Activation%2520Acts%2520Upstream%2520of%2520the%2520Mitochondrion%2520During%2520Glucocorticoid%2520Induced%2520Thymocyte%2520Apoptosis%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2004%26volume%3D34%26spage%3D2781%26epage%3D2790%26doi%3D10.1002%2Feji.200425154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huskey, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusdra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlbold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goga, A.</span></span> <span> </span><span class="NLM_article-title">Chemical-genetic Analysis of Cyclin Dependent Kinase 2 Function Reveals an Important Role in Cellular Transformation by Multiple Oncogenic Pathways</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">E1019</span>– <span class="NLM_lpage">E1027</span>, <span class="refDoi"> DOI: 10.1073/pnas.1111317109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.1111317109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22474407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslGmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=E1019-E1027&author=D.+Horiuchiauthor=N.+E.+Huskeyauthor=L.+Kusdraauthor=L.+Wohlboldauthor=K.+A.+Merrickauthor=C.+Zhangauthor=K.+J.+Creasmanauthor=K.+M.+Shokatauthor=R.+P.+Fisherauthor=A.+Goga&title=Chemical-genetic+Analysis+of+Cyclin+Dependent+Kinase+2+Function+Reveals+an+Important+Role+in+Cellular+Transformation+by+Multiple+Oncogenic+Pathways&doi=10.1073%2Fpnas.1111317109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways</span></div><div class="casAuthors">Horiuchi, Dai; Huskey, Noelle E.; Kusdra, Leonard; Wohlbold, Lara; Merrick, Karl A.; Zhang, Chao; Creasman, Katelyn J.; Shokat, Kevan M.; Fisher, Robert P.; Goga, Andrei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">E1019-E1027, SE1019/1-SE1019/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A family of conserved serine/threonine kinases known as cyclin-dependent kinases (CDKs) drives orderly cell cycle progression in mammalian cells.  Prior studies have suggested that CDK2 regulates S-phase entry and progression, and frequently shows increased activity in a wide spectrum of human tumors.  Genetic KO/knockdown approaches, however, have suggested that lack of CDK2 protein does not prevent cellular proliferation, both during somatic development in mice as well as in human cancer cell lines.  Here, we use an alternative, chem.-genetic approach to achieve specific inhibition of CDK2 kinase activity in cells.  We directly compare small-mol. inhibition of CDK2 kinase activity with siRNA knockdown and show that small-mol. inhibition results in marked defects in proliferation of nontransformed cells, whereas siRNA knockdown does not, highlighting the differences between these two approaches.  In addn., CDK2 inhibition drastically diminishes anchorage-independent growth of human cancer cells and cells transformed with various oncogenes.  Our results establish that CDK2 activity is necessary for normal mammalian cell cycle progression and suggest that it might be a useful therapeutic target for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr38-RTvuFoa7Vg90H21EOLACvtfcHk0lgcN1LzTNWPGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslGmtLk%253D&md5=dcb463a6fc2696712617034313e8960a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1111317109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1111317109%26sid%3Dliteratum%253Aachs%26aulast%3DHoriuchi%26aufirst%3DD.%26aulast%3DHuskey%26aufirst%3DN.%2BE.%26aulast%3DKusdra%26aufirst%3DL.%26aulast%3DWohlbold%26aufirst%3DL.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DCreasman%26aufirst%3DK.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26aulast%3DGoga%26aufirst%3DA.%26atitle%3DChemical-genetic%2520Analysis%2520of%2520Cyclin%2520Dependent%2520Kinase%25202%2520Function%2520Reveals%2520an%2520Important%2520Role%2520in%2520Cellular%2520Transformation%2520by%2520Multiple%2520Oncogenic%2520Pathways%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3DE1019%26epage%3DE1027%26doi%3D10.1073%2Fpnas.1111317109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Pelt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Cdk2 is Required for Breast Cancer Mediated by the Low-molecular-weight Isoform of Cyclin E</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3377</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-10-4086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3377-3386&author=S.+Akliauthor=C.+S.+Van+Peltauthor=T.+Buiauthor=L.+Meijerauthor=K.+Keyomarsi&title=Cdk2+is+Required+for+Breast+Cancer+Mediated+by+the+Low-molecular-weight+Isoform+of+Cyclin+E&doi=10.1158%2F0008-5472.CAN-10-4086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4086%26sid%3Dliteratum%253Aachs%26aulast%3DAkli%26aufirst%3DS.%26aulast%3DVan%2BPelt%26aufirst%3DC.%2BS.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DCdk2%2520is%2520Required%2520for%2520Breast%2520Cancer%2520Mediated%2520by%2520the%2520Low-molecular-weight%2520Isoform%2520of%2520Cyclin%2520E%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3377%26epage%3D3386%26doi%3D10.1158%2F0008-5472.CAN-10-4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 is an Ideal Target for Ovary Tumors with Elevated Cyclin E1 Expression</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20801</span>– <span class="NLM_lpage">20812</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.18632%2Foncotarget.4600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=20801-20812&author=L.+Yangauthor=D.+Fangauthor=H.+Chenauthor=Y.+Luauthor=Z.+Dongauthor=H.+F.+Dingauthor=Q.+Jingauthor=S.+B.+Suauthor=S.+Huang&title=Cyclin-dependent+Kinase+2+is+an+Ideal+Target+for+Ovary+Tumors+with+Elevated+Cyclin+E1+Expression&doi=10.18632%2Foncotarget.4600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4600%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DH.%2BF.%26aulast%3DJing%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DS.%2BB.%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520is%2520an%2520Ideal%2520Target%2520for%2520Ovary%2520Tumors%2520with%2520Elevated%2520Cyclin%2520E1%2520Expression%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D20801%26epage%3D20812%26doi%3D10.18632%2Foncotarget.4600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">Cyclin E Ablation in the Mouse</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(03)00645-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0092-8674%2803%2900645-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12941272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2003&pages=431-443&author=Y.+Gengauthor=Q.+Yuauthor=E.+Sicinskaauthor=M.+Dasauthor=J.+E.+Schneiderauthor=S.+Bhattacharyaauthor=W.+M.+Rideoutauthor=R.+T.+Bronsonauthor=H.+Gardnerauthor=P.+Sicinski&title=Cyclin+E+Ablation+in+the+Mouse&doi=10.1016%2FS0092-8674%2803%2900645-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E ablation in the mouse</span></div><div class="casAuthors">Geng, Yan; Yu, Qunyan; Sicinska, Ewa; Das, Manjusri; Schneider, Juergen E.; Bhattacharya, Shoumo; Rideout, William M., III; Bronson, Roderick T.; Gardner, Humphrey; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-443</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">E type cyclins-(E1 and E2) are believed to drive cell entry into the S phase.  It is widely assumed that the two E type cyclins are critically required for proliferation of all cell types.  Here, we demonstrate that E type cyclins are largely dispensable for mouse development.  However, endoreplication of trophoblast giant cells and megakaryocytes is severely impaired in the absence of cyclin E.  Cyclin E-deficient cells proliferate actively under conditions of continuous cell cycling but are unable to reenter the cell cycle from the quiescent G0 state.  Mol. analyses revealed that cells lacking cyclin E fail to normally incorporate MCM proteins into DNA replication origins during G0→S progression.  We also found that cyclin E-deficient cells are relatively resistant to oncogenic transformation.  These findings define a mol. function for E type cyclins in cell cycle reentry and reveal a differential requirement for cyclin E in normal vs. oncogenic proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5aUZi6Q1drVg90H21EOLACvtfcHk0lgcN1LzTNWPGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFahtbo%253D&md5=00c88c0b39e844628c8fc78bfb894755</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900645-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900645-7%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DSicinska%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%2BE.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DRideout%26aufirst%3DW.%2BM.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DCyclin%2520E%2520Ablation%2520in%2520the%2520Mouse%26jtitle%3DCell%26date%3D2003%26volume%3D114%26spage%3D431%26epage%3D443%26doi%3D10.1016%2FS0092-8674%2803%2900645-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callister, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedrosian, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knickerbocker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyofuku, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herliczek, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacus, S. S.</span></span> <span> </span><span class="NLM_article-title">Cyclin E and Survival in Patients with Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa021153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1056%2FNEJMoa021153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12432043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1KhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=1566-1575&author=K.+Keyomarsiauthor=S.+L.+Tuckerauthor=T.+A.+Buchholzauthor=M.+Callisterauthor=Y.+Dingauthor=G.+N.+Hortobagyiauthor=I.+Bedrosianauthor=C.+Knickerbockerauthor=W.+Toyofukuauthor=M.+Loweauthor=T.+W.+Herliczekauthor=S.+S.+Bacus&title=Cyclin+E+and+Survival+in+Patients+with+Breast+Cancer&doi=10.1056%2FNEJMoa021153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E and survival in patients with breast cancer</span></div><div class="casAuthors">Keyomarsi, Khandan; Tucker, Susan L.; Buchholz, Thomas A.; Callister, Matthew; Ding, Ye; Hortobagyi, Gabriel N.; Bedrosian, Isabelle; Knickerbocker, Christopher; Toyofuku, Wendy; Lowe, Michael; Herliczek, Thaddues W.; Bacus, Sarah S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1566-1575</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cyclin E, a regulator of the cell cycle, affects the behavior of breast-cancer cells.  We investigated whether levels of cyclin E in the tumor correlated with survival among patients with breast cancer.  Tumor tissue from 395 patients with breast cancer was assayed for cyclin E, cyclin D1, cyclin D3, and the HER-2/neu oncogene with the use of Western blot anal.  Full-length, low-mol.-wt., and total cyclin E were measured.  Immunohistochem. assessments of cyclin E were also made of 256 tumors.  We sought correlations between levels of these mol. markers and disease-specific and overall survival.  The median follow-up was 6.4 yr.  A high level of the low-mol.-wt. isoforms of cyclin E, as detected by Western blotting, correlated strongly with disease-specific survival whether axillary lymph nodes were neg. or pos. for metastases (P< 0.001).  Among 114 patients with stage 1 breast cancer, none of the 102 patients with low levels of cyclin E in the tumor had died of breast cancer by five years after diagnosis, whereas all 12 patients with a high level of low-mol.-wt. cyclin E had died of breast cancer within that period.  In multivariate anal., a high total cyclin E level or high levels of the low-mol.-wt. forms of cyclin E were significantly correlated with poor outcome.  The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 - about eight times as high as the hazard ratios assocd. with other independent clin. and pathol. risk factors.  Levels of total cyclin E and low-mol.-wt. cyclin E in tumor tissue, as measured by Western blot assay, correlate strongly with survival in patients with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTvbHMGyGsi7Vg90H21EOLACvtfcHk0lifY24_AoPFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1KhsLo%253D&md5=472d2c057c9d73ab386ada5c910662b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa021153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa021153%26sid%3Dliteratum%253Aachs%26aulast%3DKeyomarsi%26aufirst%3DK.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DBuchholz%26aufirst%3DT.%2BA.%26aulast%3DCallister%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DBedrosian%26aufirst%3DI.%26aulast%3DKnickerbocker%26aufirst%3DC.%26aulast%3DToyofuku%26aufirst%3DW.%26aulast%3DLowe%26aufirst%3DM.%26aulast%3DHerliczek%26aufirst%3DT.%2BW.%26aulast%3DBacus%26aufirst%3DS.%2BS.%26atitle%3DCyclin%2520E%2520and%2520Survival%2520in%2520Patients%2520with%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D1566%26epage%3D1575%26doi%3D10.1056%2FNEJMoa021153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiering, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memoli, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsongalis, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Transgenic Cyclin E Triggers Dysplasia and Multiple Pulmonary Adenocarcinomas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1073/pnas.0606537104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0606537104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=4089-4094&author=Y.+Maauthor=S.+Fieringauthor=C.+Blackauthor=X.+Liuauthor=Z.+Yuanauthor=V.+A.+Memoliauthor=D.+J.+Robbinsauthor=H.+A.+Bentleyauthor=G.+J.+Tsongalisauthor=E.+Demidenkoauthor=S.+J.+Freemantleauthor=E.+Dmitrovsky&title=Transgenic+Cyclin+E+Triggers+Dysplasia+and+Multiple+Pulmonary+Adenocarcinomas&doi=10.1073%2Fpnas.0606537104"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0606537104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0606537104%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DFiering%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DMemoli%26aufirst%3DV.%2BA.%26aulast%3DRobbins%26aufirst%3DD.%2BJ.%26aulast%3DBentley%26aufirst%3DH.%2BA.%26aulast%3DTsongalis%26aufirst%3DG.%2BJ.%26aulast%3DDemidenko%26aufirst%3DE.%26aulast%3DFreemantle%26aufirst%3DS.%2BJ.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DTransgenic%2520Cyclin%2520E%2520Triggers%2520Dysplasia%2520and%2520Multiple%2520Pulmonary%2520Adenocarcinomas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D4089%26epage%3D4094%26doi%3D10.1073%2Fpnas.0606537104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tetsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">Proliferation of Cancer Cells Despite CDK2 Inhibition</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/S1535-6108(03)00053-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS1535-6108%2803%2900053-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=12676582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislOrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=233-245&author=O.+Tetsuauthor=F.+McCormick&title=Proliferation+of+Cancer+Cells+Despite+CDK2+Inhibition&doi=10.1016%2FS1535-6108%2803%2900053-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Proliferation of cancer cells despite CDK2 inhibition</span></div><div class="casAuthors">Tetsu, Osamu; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-245</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The authors have investigated the contribution of CDK4 and CDK2 inhibition to G1 arrest in colon cancers following inhibition of the MEK/MAP kinase pathway.  CDK4 inhibition is sufficient to cause arrest, but inhibition of CDK2 by p27 Kip1 redistribution or ectopic expression has no effect on proliferation.  Likewise, inhibition of CDK2 through expression of dominant-neg. (DN) CDK2 or antisense oligonucleotides did not prevent cell proliferation in these cells.  The authors therefore tested whether CDK2 activity is dispensable in other cells.  Surprisingly, osteosarcomas and Rb-neg. cervical cancers continued to proliferate after depletion of CDK2 through antisense oligonucleotides or small interfering (si) RNA.  Here the authors report sustained cell proliferation in the absence of CDK2, and the authors suggest that CDK2 is not a suitable target for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlrtla8E307Vg90H21EOLACvtfcHk0lifY24_AoPFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislOrtb0%253D&md5=a4c67cbe660ff486912ab5113cfe53bb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2803%2900053-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252803%252900053-9%26sid%3Dliteratum%253Aachs%26aulast%3DTetsu%26aufirst%3DO.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DProliferation%2520of%2520Cancer%2520Cells%2520Despite%2520CDK2%2520Inhibition%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D233%26epage%3D245%26doi%3D10.1016%2FS1535-6108%2803%2900053-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molenaar, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentijn, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhout, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versteeg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span> <span> </span><span class="NLM_article-title">Inactivation of CDK2 is Synthetically Lethal to MYCN Over-expressing Cancer Cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">12968</span>– <span class="NLM_lpage">12973</span>, <span class="refDoi"> DOI: 10.1073/pnas.0901418106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.0901418106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19525400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=12968-12973&author=J.+J.+Molenaarauthor=M.+E.+Ebusauthor=D.+Geertsauthor=J.+Kosterauthor=F.+Lamersauthor=L.+J.+Valentijnauthor=E.+M.+Westerhoutauthor=R.+Versteegauthor=H.+N.+Caron&title=Inactivation+of+CDK2+is+Synthetically+Lethal+to+MYCN+Over-expressing+Cancer+Cells&doi=10.1073%2Fpnas.0901418106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells</span></div><div class="casAuthors">Molenaar, Jan J.; Ebus, Marli E.; Geerts, Dirk; Koster, Jan; Lamers, Fieke; Valentijn, Linda J.; Westerhout, Ellen M.; Versteeg, Rogier; Caron, Huib N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">12968-12973</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two genes have a synthetically lethal relationship when the silencing or inhibiting of 1 gene is only lethal in the context of a mutation or activation of the second gene.  This situation offers an attractive therapeutic strategy, as inhibition of such a gene will only trigger cell death in tumor cells with an activated second oncogene but spare normal cells without activation of the second oncogene.  Here we present evidence that CDK2 is synthetically lethal to neuroblastoma cells with MYCN amplification and over-expression.  Neuroblastomas are childhood tumors with an often lethal outcome.  Twenty percent of the tumors have MYCN amplification, and these tumors are ultimately refractory to any therapy.  Targeted silencing of CDK2 by 3 RNA interference techniques induced apoptosis in MYCN-amplified neuroblastoma cell lines, but not in MYCN single copy cells.  Silencing of MYCN abrogated this apoptotic response in MYCN-amplified cells.  Inversely, silencing of CDK2 in MYCN single copy cells did not trigger apoptosis, unless a MYCN transgene was activated.  The MYCN induced apoptosis after CDK2 silencing was accompanied by nuclear stabilization of P53, and mRNA profiling showed up-regulation of P53 target genes.  Silencing of P53 rescued the cells from MYCN-driven apoptosis.  The synthetic lethality of CDK2 silencing in MYCN activated neuroblastoma cells can also be triggered by inhibition of CDK2 with a small mol. drug.  Treatment of neuroblastoma cells with roscovitine, a CDK inhibitor, at clin. achievable concns. induced MYCN-dependent apoptosis.  The synthetically lethal relationship between CDK2 and MYCN indicates CDK2 inhibitors as potential MYCN-selective cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr48u4K0MeszLVg90H21EOLACvtfcHk0lifY24_AoPFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVKru77P&md5=016ebf4ccc1f5c6e3b965e999cca58c7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0901418106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0901418106%26sid%3Dliteratum%253Aachs%26aulast%3DMolenaar%26aufirst%3DJ.%2BJ.%26aulast%3DEbus%26aufirst%3DM.%2BE.%26aulast%3DGeerts%26aufirst%3DD.%26aulast%3DKoster%26aufirst%3DJ.%26aulast%3DLamers%26aufirst%3DF.%26aulast%3DValentijn%26aufirst%3DL.%2BJ.%26aulast%3DWesterhout%26aufirst%3DE.%2BM.%26aulast%3DVersteeg%26aufirst%3DR.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26atitle%3DInactivation%2520of%2520CDK2%2520is%2520Synthetically%2520Lethal%2520to%2520MYCN%2520Over-expressing%2520Cancer%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D12968%26epage%3D12973%26doi%3D10.1073%2Fpnas.0901418106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dmitrovsky, E.</span></span> <span> </span><span class="NLM_article-title">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-15-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26304236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2576-2585&author=S.+Huauthor=Y.+Luauthor=B.+Orrauthor=K.+Godekauthor=L.+M.+Mustachioauthor=M.+Kawakamiauthor=D.+Sekulaauthor=D.+A.+Comptonauthor=S.+Freemantleauthor=E.+Dmitrovsky&title=Specific+CP110+Phosphorylation+Sites+Mediate+Anaphase+Catastrophe+after+CDK2+Inhibition%3A+Evidence+for+Cooperation+with+USP33+Knockdown&doi=10.1158%2F1535-7163.MCT-15-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown</span></div><div class="casAuthors">Hu, Shanhu; Lu, Yun; Orr, Bernardo; Godek, Kristina; Mustachio, Lisa Maria; Kawakami, Masanori; Sekula, David; Compton, Duane A.; Freemantle, Sarah; Dmitrovsky, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal instability (CIN) is a hallmark of solid tumor biol. and is implicated in carcinogenesis.  Preferentially eliminating malignant cells by targeting CIN and aneuploidy is an attractive antineoplastic strategy.  We previously reported that CDK2 antagonism causes lung cancer cells to undergo anaphase catastrophe and apoptosis through inhibition of phosphorylation of the centrosomal protein CP110.  Cells with activating KRAS mutations were particularly sensitive to CDK2 inhibition due to downregulation of CP110 protein levels.  This study investigated mechanisms of CDK2 antagonism that mediate anaphase catastrophe via changes in CP110 protein expression and how activated KRAS affects CP110 levels in lung cancers.  Site-directed mutagenesis revealed candidate CDK phosphorylation sites of CP110 (residues Ser 170 and Thr 194) crit. for conferring anaphase catastrophe by altering centrosome clustering in mitosis.  Intriguingly, KRAS mutation can promote CP110 protein degrdn. by upregulating the ubiquitin ligase SCFcyclinF, which targets CP110 protein for destabilization.  Finally, CDK2 inhibitor response was enhanced when combined with knockdown of the deubiquitinase USP33 that in turn accelerates CP110 protein degrdn.  Thus, this study provides mol. pharmacol. insights into how CP110 expression regulates response to CDK2 inhibition.  An improved understanding of in vitro antineoplastic mechanisms of combining CDK2 antagonism with induced CP110 repression provides a rationale for exploring clin. consequences of this strategy.  Taken together, preclin. findings obtained from combining CDK2 inhibition with USP33 repression have implications for treating patients with non-small cell lung cancers.  Mol Cancer Ther; 14(11); 2576-85. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWB2T3vMoX87Vg90H21EOLACvtfcHk0li60fMRXaRo0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7zJ&md5=3426ae1dcbdd54def483fb95afda5eaa</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0443%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DOrr%26aufirst%3DB.%26aulast%3DGodek%26aufirst%3DK.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DSekula%26aufirst%3DD.%26aulast%3DCompton%26aufirst%3DD.%2BA.%26aulast%3DFreemantle%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26atitle%3DSpecific%2520CP110%2520Phosphorylation%2520Sites%2520Mediate%2520Anaphase%2520Catastrophe%2520after%2520CDK2%2520Inhibition%253A%2520Evidence%2520for%2520Cooperation%2520with%2520USP33%2520Knockdown%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2576%26epage%3D2585%26doi%3D10.1158%2F1535-7163.MCT-15-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuzuka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, G. H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis <i>via</i> Cyclin E1/CDK2-Mediated Phosphorylation of CENP-A</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4881</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-17-1240" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4881-4893&author=M.+Takadaauthor=W.+Zhangauthor=A.+Suzukiauthor=T.+S.+Kurodaauthor=Z.+Yuauthor=H.+Inuzukaauthor=D.+Gaoauthor=L.+Wanauthor=M.+Zhuangauthor=L.+Huauthor=B.+Zhaiauthor=C.+J.+Fryauthor=K.+Bloomauthor=G.+Liauthor=G.+H.+Karpen&title=FBW7+Loss+Promotes+Chromosomal+Instability+and+Tumorigenesis+via+Cyclin+E1%2FCDK2-Mediated+Phosphorylation+of+CENP-A&doi=10.1158%2F0008-5472.CAN-17-1240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1240%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DKuroda%26aufirst%3DT.%2BS.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DInuzuka%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DZhuang%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DFry%26aufirst%3DC.%2BJ.%26aulast%3DBloom%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKarpen%26aufirst%3DG.%2BH.%26atitle%3DFBW7%2520Loss%2520Promotes%2520Chromosomal%2520Instability%2520and%2520Tumorigenesis%2520via%2520Cyclin%2520E1%252FCDK2-Mediated%2520Phosphorylation%2520of%2520CENP-A%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4881%26epage%3D4893%26doi%3D10.1158%2F0008-5472.CAN-17-1240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2016.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.tranon.2016.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27863310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=548-556&author=J.+Wangauthor=T.+Yangauthor=G.+Xuauthor=H.+Liuauthor=C.+Renauthor=W.+Xieauthor=M.+Wang&title=Cyclin-Dependent+Kinase+2+Promotes+Tumor+Proliferation+and+Induces+Radio+Resistance+in+Glioblastoma&doi=10.1016%2Fj.tranon.2016.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma</span></div><div class="casAuthors">Wang Jia; Yang Tong; Xu Gaofeng; Liu Hao; Ren Chunying; Xie Wanfu; Wang Maode</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">548-556</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Accumulating evidence indicates that CDK2 promotes hyperproliferation and is associated to poor prognosis in multiple cancer cells.  However, the physiological role of CDK2 in GBM and the biological mechanism still remains unclear.  In this study, we identified that CDK2 expression was significantly enriched in GBM tumors compared with normal brain.  Additionally, CDK2 was functionally required for tumor proliferation and its expression was associated to poor prognosis in GBM patients.  Mechanically, CDK2 induced radio resistance in GBM cells and CDK2 knock down increased cell apoptosis when combined with radiotherapy.  Therapeutically, we found that CDK2 inhibitor attenuated tumor growth both in vitro and in vivo.  Collectively, CDK2 promotes proliferation, induces radio resistance in GBM, and could become a therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9a1Ej-CIqi7mQt-ICR3qNfW6udTcc2eb--_fiHFloIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snotVWqsQ%253D%253D&md5=e994dad0c2785ed5a8d7ca0fe87f98d7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2016.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%25202%2520Promotes%2520Tumor%2520Proliferation%2520and%2520Induces%2520Radio%2520Resistance%2520in%2520Glioblastoma%26jtitle%3DTransl.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D548%26epage%3D556%26doi%3D10.1016%2Fj.tranon.2016.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiles, T. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell Lymphomas</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2982</span>– <span class="NLM_lpage">2989</span>, <span class="refDoi"> DOI: 10.4161/cc.6.23.4994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.6.23.4994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18156799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2982-2989&author=A.+C.+Faberauthor=T.+C.+Chiles&title=Inhibition+of+Cyclin-dependent+Kinase-2+Induces+Apoptosis+in+Human+Diffuse+Large+B-cell+Lymphomas&doi=10.4161%2Fcc.6.23.4994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas</span></div><div class="casAuthors">Faber, Anthony C.; Chiles, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2982-2989</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (cdk) inhibitors have the potential to induce growth arrest and apoptosis in cancer cells.  The genes encoding cdks involved in G1-S progression are often amplified in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).  Here, we evaluated the in vitro cytotoxic activity of the cdk2 inhibitor CVT-313 against several human DLBCL cells.  Treatment of DLBCL cells with CVT-313 resulted in apoptosis.  CVT-313 treatment reduced cdk2-mediated phosphorylation of the retinoblastoma gene product (Rb) on T821, but did not affect cyclin D-cdk4/6-mediated Rb phosphorylation on S807/811.  Depletion of endogenous cdk2 by short interfering (si)RNA also resulted in apoptosis in human LY3, LY8 and LY18 DLBCL cells.  Importantly, inhibition of cdk2 with CVT-313 or knockdown of endogenous cdk2 with siRNA resulted in downregulation of the anti-apoptotic factor Myeloid cell leukemia-1 (Mcl-1), suggesting that decreased levels of cellular Mcl-1 contribute to apoptosis.  In support of this, siRNA-mediated knockdown of Mcl-1 was sufficient to induce apoptosis in all 3 DLBCL.  Further, cdk2 inhibition led to decreased Mcl-1 mRNA levels, which was proceeded by reduced phosphorylation of serine 2 on the carboxyl terminal domain (CTD) of RNA polymerase II.  Taken together, these data suggest that cdk2 activity is necessary for the survival of human DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB15Y3Mu-wf7Vg90H21EOLACvtfcHk0lj95TPvSk_qXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOlur4%253D&md5=7240ad70e193d385ae41269e469c54fd</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.4161%2Fcc.6.23.4994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.6.23.4994%26sid%3Dliteratum%253Aachs%26aulast%3DFaber%26aufirst%3DA.%2BC.%26aulast%3DChiles%26aufirst%3DT.%2BC.%26atitle%3DInhibition%2520of%2520Cyclin-dependent%2520Kinase-2%2520Induces%2520Apoptosis%2520in%2520Human%2520Diffuse%2520Large%2520B-cell%2520Lymphomas%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D2982%26epage%3D2989%26doi%3D10.4161%2Fcc.6.23.4994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Identification of CDK2 as a Novel Target in Treatment of Prostate Cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.2217/fon-2017-0561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.2217%2Ffon-2017-0561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29323532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=709-718&author=X.+Yinauthor=J.+Yuauthor=Y.+Zhouauthor=C.+Wangauthor=Z.+Jiaoauthor=Z.+Qianauthor=H.+Sunauthor=B.+Chen&title=Identification+of+CDK2+as+a+Novel+Target+in+Treatment+of+Prostate+Cancer&doi=10.2217%2Ffon-2017-0561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CDK2 as a novel target in treatment of prostate cancer</span></div><div class="casAuthors">Yin, Xifeng; Yu, Jun; Zhou, Yang; Wang, Chengyue; Jiao, Zhimin; Qian, Zhounan; Sun, Hao; Chen, Binghai</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">709-718</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study aims the potential gene involved in the metastasis of prostate cancer (Pca).  PubMed GEO datasets (GSE6605 and GSE6606) were downloaded.  It used multiple bioinformatics methods to screen differentially expressed genes in Pca.  Gene network was built by STRING and visualized by Cytoscape.  All of the hub genes were analyzed by cBioPortal.  Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay.  Downstream genes of CDK2 were analyzed by western blot.  Sequencing data were analyzed to screen the genes with expression alterations.  The top genes were validated in our samples.  11 Hub genes were screened out.  Among these genes, STAT3 and CDK2 were significantly assocd. with recurrence.  Further study suggested that inhibition of CDK2 reduced invasion of Pca cell lines.  The invasion ability was rescued after reintroduction of CDK2.  These data indicated that CDK2 was a crucial factor in metastasis of Pca and might be a novel therapy target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo42ZzW6tNPUbVg90H21EOLACvtfcHk0lj95TPvSk_qXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlegurk%253D&md5=c91131983f10d0ef4458d1bcec32b2d4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2217%2Ffon-2017-0561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2017-0561%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DZ.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520CDK2%2520as%2520a%2520Novel%2520Target%2520in%2520Treatment%2520of%2520Prostate%2520Cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2018%26volume%3D14%26spage%3D709%26epage%3D718%26doi%3D10.2217%2Ffon-2017-0561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Potentiation of Human Estrogen Receptor Alpha Transcriptional Activation through Phosphorylation of Serines 104 and 106 by the Cyclin A-CDK2 Complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">22296</span>– <span class="NLM_lpage">22302</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.32.22296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.274.32.22296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=22296-22302&author=I.+Rogatskyauthor=J.+M.+Trowbridgeauthor=M.+J.+Garabedian&title=Potentiation+of+Human+Estrogen+Receptor+Alpha+Transcriptional+Activation+through+Phosphorylation+of+Serines+104+and+106+by+the+Cyclin+A-CDK2+Complex&doi=10.1074%2Fjbc.274.32.22296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.32.22296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.32.22296%26sid%3Dliteratum%253Aachs%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DPotentiation%2520of%2520Human%2520Estrogen%2520Receptor%2520Alpha%2520Transcriptional%2520Activation%2520through%2520Phosphorylation%2520of%2520Serines%2520104%2520and%2520106%2520by%2520the%2520Cyclin%2520A-CDK2%2520Complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D22296%26epage%3D22302%26doi%3D10.1074%2Fjbc.274.32.22296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trowbridge, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogatsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garabedian, M. J.</span></span> <span> </span><span class="NLM_article-title">Regulation of Estrogen Receptor Transcriptional Enhancement by the Cyclin A/Cdk2 Complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10137</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.94.19.10132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9294175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10132-10137&author=J.+M.+Trowbridgeauthor=I.+Rogatskyauthor=M.+J.+Garabedian&title=Regulation+of+Estrogen+Receptor+Transcriptional+Enhancement+by+the+Cyclin+A%2FCdk2+Complex&doi=10.1073%2Fpnas.94.19.10132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex</span></div><div class="casAuthors">Trowbridge, Janet M.; Rogatsky, Inez; Garabedian, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10132-10137</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have found that ectopic expression of cyclin A increases hormone-dependent and hormone-independent transcriptional activation by the estrogen receptor in vivo in a no. of cell lines, including HeLa cells, U-2 OS osteosarcoma cells and Hs 578Bst breast epithelial cells.  This effect can be further enhanced in HeLa cells by the concurrent expression of the cyclin-dependent kinase activator, cyclin H, and cdk7, and abolished by expression of the cdk inhibitor, p27KIPI, or by the expression of a dominant neg. catalytically inactive cdk2 mutant.  ER is phosphorylated between amino acids 82 and 121 in vitro by the cyclin A/cdk2 complex and incorporation of phosphate into ER is stimulated by ectopic expression of cyclin A in vivo.  Together, these results strongly suggest a direct role for the cyclin A/cdk2 complex in phosphorylating ER and regulating its transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpi2Mjjhy1LVg90H21EOLACvtfcHk0lj95TPvSk_qXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Cqu7k%253D&md5=b8a8e2916b409988346b8decb8973d77</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10132%26sid%3Dliteratum%253Aachs%26aulast%3DTrowbridge%26aufirst%3DJ.%2BM.%26aulast%3DRogatsky%26aufirst%3DI.%26aulast%3DGarabedian%26aufirst%3DM.%2BJ.%26atitle%3DRegulation%2520of%2520Estrogen%2520Receptor%2520Transcriptional%2520Enhancement%2520by%2520the%2520Cyclin%2520A%252FCdk2%2520Complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D10132%26epage%3D10137%26doi%3D10.1073%2Fpnas.94.19.10132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierson-Mullany, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">10542</span>– <span class="NLM_lpage">10557</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.24.10542-10557.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1128%2FMCB.24.24.10542-10557.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15572662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=10542-10557&author=L.+K.+Pierson-Mullanyauthor=C.+A.+Lange&title=Phosphorylation+of+Progesterone+Receptor+Serine+400+Mediates+Ligand-independent+Transcriptional+Activity+in+Response+to+Activation+of+Cyclin-Dependent+Protein+Kinase+2&doi=10.1128%2FMCB.24.24.10542-10557.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2</span></div><div class="casAuthors">Pierson-Mullany, Lisa K.; Lange, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10542-10557</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human progesterone receptors (PR) are phosphorylated by cyclin-dependent protein kinase 2 (CDK2) at multiple sites, including Ser400.  Herein, we have addressed the significance of phosphorylation of this residue.  PR phospho-Ser400-specific antibodies revealed regulated phosphorylation of Ser400 in response to progestins and mitogens, and this correlated with increased CDK2 levels and activity.  Expression of cyclin E elevated CDK2 activity and downregulated PR independently of ligand.  Similarly, overexpression of activated mutant CDK2 increased PR transcriptional activity in the absence and presence of progestin.  Mutation of PR Ser400 to alanine (S400A) blocked CDK2-induced PR activity in the absence, but not in the presence, of progestin.  PR was unresponsive to activated CDK2 in breast cancer cells with elevated p27, and RNA interference knock-down of p27 partially restored CDK2-induced ligand-independent PR activation.  Similarly, in p27-/- mouse embryonic fibroblasts, elevated CDK2 activity increased wild-type (wt) but not S400A PR transcriptional activity in the absence of progestin.  CDK2 induced nuclear localization of unliganded wt but not S400A PR; liganded S400A PR exhibited delayed nuclear accumulation.  These studies demonstrate that CDK2 regulates PR in the absence of progestins via phosphorylation of Ser400, thus revealing a novel mechanism for upregulated PR transcriptional activity in human breast cancer cells expressing altered cell cycle regulatory mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFBJTUucg5LVg90H21EOLACvtfcHk0lju0YoK9yrxqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFShu7bI&md5=9389bfbb80fcf468cc99194a9a6afb25</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.24.10542-10557.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.24.10542-10557.2004%26sid%3Dliteratum%253Aachs%26aulast%3DPierson-Mullany%26aufirst%3DL.%2BK.%26aulast%3DLange%26aufirst%3DC.%2BA.%26atitle%3DPhosphorylation%2520of%2520Progesterone%2520Receptor%2520Serine%2520400%2520Mediates%2520Ligand-independent%2520Transcriptional%2520Activity%2520in%2520Response%2520to%2520Activation%2520of%2520Cyclin-Dependent%2520Protein%2520Kinase%25202%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D10542%26epage%3D10557%26doi%3D10.1128%2FMCB.24.24.10542-10557.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">HOXA7 stimulates Human Hepatocellular Carcinoma Proliferation through Cyclin E1/CDK2</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.3892/or.2014.3668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3892%2For.2014.3668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25501982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=990-996&author=Y.+Liauthor=X.+H.+Yangauthor=S.+J.+Fangauthor=C.+F.+Qinauthor=R.+L.+Sunauthor=Z.+Y.+Liuauthor=B.+Y.+Jiangauthor=X.+Wuauthor=G.+Li&title=HOXA7+stimulates+Human+Hepatocellular+Carcinoma+Proliferation+through+Cyclin+E1%2FCDK2&doi=10.3892%2For.2014.3668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2</span></div><div class="casAuthors">Li, Yuehui; Yang, Xiao Hui; Fang, Shu Juang; Qin, Chang Fei; Sun, Rui Li; Liu, Zhao Yang; Jiang, Bin Yuan; Wu, Xiang; Li, Guancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">990-996</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">HOX genes are transcription factors that control morphogenesis, organogenesis and differentiation.  Increasing evidence suggests that HOX genes play a role in hepatocellular carcinoma (HCC) progression; however few studies have defined the functional roles and mechanisms of action.  In the present study, we used siRNA and forced-expression in multiple cell lines to define the role of HOXA7 in the regulation of proliferation of HCC in vitro and in vivo.  Knockdown of endogenous HOXA7 decreased the proliferation of HepG2 and QGY-7703 cells.  These changes were not assocd. with significant changes in cyclin D1 and CDK4.  However, down-regulation of HOXA7 significantly reduced cyclin E1 and CDK2 protein levels.  Conversely, overexpression of HOXA7 in QSG-7701 cells stimulated proliferation and increased cyclin E1 and CDK2 protein levels.  Our results confirmed that HOXA7 promoted cell proliferation, and these changes were mediated by cyclin E1/CDK2.  These observations contribute to our understanding of the important roles of HOXA7 in HCC development and progression and HOXA7 could be a promising mol. target for the development of new diagnostic and therapeutic strategies for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0l6a-l8_-GrVg90H21EOLACvtfcHk0lju0YoK9yrxqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVyiu78%253D&md5=d5d441e42812540323143f763b5e2520</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3892%2For.2014.3668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2014.3668%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%2BH.%26aulast%3DFang%26aufirst%3DS.%2BJ.%26aulast%3DQin%26aufirst%3DC.%2BF.%26aulast%3DSun%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DJiang%26aufirst%3DB.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DHOXA7%2520stimulates%2520Human%2520Hepatocellular%2520Carcinoma%2520Proliferation%2520through%2520Cyclin%2520E1%252FCDK2%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D33%26spage%3D990%26epage%3D996%26doi%3D10.3892%2For.2014.3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlund, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horstmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span> <span> </span><span class="NLM_article-title">Critical Role of CDK2 for Melanoma Growth Linked to its Melanocyte-specific Transcriptional Regulation by MITF</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2004.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.ccr.2004.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15607961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=565-576&author=J.+Duauthor=H.+R.+Widlundauthor=M.+A.+Horstmannauthor=S.+Ramaswamyauthor=K.+Rossauthor=W.+E.+Huberauthor=E.+K.+Nishimuraauthor=T.+R.+Golubauthor=D.+E.+Fisher&title=Critical+Role+of+CDK2+for+Melanoma+Growth+Linked+to+its+Melanocyte-specific+Transcriptional+Regulation+by+MITF&doi=10.1016%2Fj.ccr.2004.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF</span></div><div class="casAuthors">Du, Jinyan; Widlund, Hans R.; Horstmann, Martin A.; Ramaswamy, Sridhar; Ross, Ken; Huber, Wade E.; Nishimura, Emi K.; Golub, Todd R.; Fisher, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-576</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The genomic organization of the CDK2 gene, which overlaps the melanocyte-specific gene SILV/PMEL17, poses an interesting regulatory challenge.  The authors show that, despite its ubiquitous expression, CDK2 exhibits tissue-specific regulation by the essential melanocyte lineage transcription factor MITF.  In addn., functional studies revealed this regulation to be crit. for maintaining CDK2 kinase activity and growth of melanoma cells.  Expression levels of MITF and CDK2 are tightly correlated in primary melanoma specimens and predict susceptibility to the CDK2 inhibitor roscovitine.  CDK2 depletion suppressed growth and cell cycle progression in melanoma, but not other cancers, corroborating previous results.  Collectively, these data indicate that CDK2 activity in melanoma is largely maintained at the transcriptional level by MITF, and unlike other malignancies, it may be a suitable drug target in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzGPfKfEQmWLVg90H21EOLACvtfcHk0lju0YoK9yrxqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktVantA%253D%253D&md5=0fdd6a6f788af5fb429c464358782881</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2004.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2004.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWidlund%26aufirst%3DH.%2BR.%26aulast%3DHorstmann%26aufirst%3DM.%2BA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DK.%26aulast%3DHuber%26aufirst%3DW.%2BE.%26aulast%3DNishimura%26aufirst%3DE.%2BK.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26atitle%3DCritical%2520Role%2520of%2520CDK2%2520for%2520Melanoma%2520Growth%2520Linked%2520to%2520its%2520Melanocyte-specific%2520Transcriptional%2520Regulation%2520by%2520MITF%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D565%26epage%3D576%26doi%3D10.1016%2Fj.ccr.2004.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barriere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerqueira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Mice Thrive Without Cdk4 and Cdk2</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molonc.2007.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19383288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=72-83&author=C.+Barriereauthor=D.+Santamariaauthor=A.+Cerqueiraauthor=J.+Galanauthor=A.+Martinauthor=S.+Ortegaauthor=M.+Malumbresauthor=P.+Dubusauthor=M.+Barbacid&title=Mice+Thrive+Without+Cdk4+and+Cdk2&doi=10.1016%2Fj.molonc.2007.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Mice thrive without Cdk4 and Cdk2</span></div><div class="casAuthors">Barriere, Cedric; Santamaria, David; Cerqueira, Antonio; Galan, Javier; Martin, Alberto; Ortega, Sagrario; Malumbres, Marcos; Dubus, Pierre; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mammalian cell division is thought to be driven by sequential activation of several Cyclin-dependent kinases (Cdk), mainly Cdk4, Cdk6, Cdk2 and Cdk1.  Since mice lacking Cdk4, Cdk6 or Cdk2 are viable, it has been proposed that they play compensatory roles.  We report here that mice lacking Cdk4 and Cdk2 complete embryonic development to die shortly thereafter presumably due to heart failure.  However, conditional ablation of Cdk2 in adult mice lacking Cdk4 does not result in obvious abnormalities.  Moreover, these double mutant mice recover normally after partial hepatectomy.  In culture, Cdk4-/-; Cdk2-/- embryonic fibroblasts become immortal, display robust pRb phosphorylation and have normal S phase kinetics.  These observations indicate that Cdk4 and Cdk2 are dispensable for the mammalian cell cycle and for adult homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpa46WnMjB7Vg90H21EOLACvtfcHk0ljmu8PfhJfHvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbbM&md5=360c62de1a9209a076add5d1e6d896fb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarriere%26aufirst%3DC.%26aulast%3DSantamaria%26aufirst%3DD.%26aulast%3DCerqueira%26aufirst%3DA.%26aulast%3DGalan%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMice%2520Thrive%2520Without%2520Cdk4%2520and%2520Cdk2%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D72%26epage%3D83%26doi%3D10.1016%2Fj.molonc.2007.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haagensen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span> <span> </span><span class="NLM_article-title">Combined PI3K and CDK2 Inhibition Induces Cell Death and Enhances <i>In vivo</i> Antitumour Activity in Colorectal Cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fbjc.2016.238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27529512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGmtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=682-690&author=G.+Bealeauthor=E.+J.+Haagensenauthor=H.+D.+Thomasauthor=L.+Z.+Wangauthor=C.+H.+Revillauthor=S.+L.+Payneauthor=B.+T.+Goldingauthor=I.+R.+Hardcastleauthor=D.+R.+Newellauthor=R.+J.+Griffinauthor=C.+Cano&title=Combined+PI3K+and+CDK2+Inhibition+Induces+Cell+Death+and+Enhances+In+vivo+Antitumour+Activity+in+Colorectal+Cancer&doi=10.1038%2Fbjc.2016.238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer</span></div><div class="casAuthors">Beale, Gary; Haagensen, Emma J.; Thomas, Huw D.; Wang, Lan-Zhen; Revill, Charlotte H.; Payne, Sara L.; Golding, Bernard T.; Hardcastle, Ian R.; Newell, David R.; Griffin, Roger J.; Cano, Celine</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clin. trials.  Similarly, CDKs have been investigated as cancer drug targets.  We have synthesized and characterized a series of 6-aminopyrimidines identified from a kinase screen that inhibit PI3K and/or mTOR and/or CDK2.  Kinase inhibition, tumor cell growth, cell cycle distribution, cytotoxicity and signalling expts. were undertaken in HCT116 and HT29 colorectal cancer cell lines, and in vivo HT29 efficacy studies.  2,6-Diaminopyrimidines with an O4-cyclohexylmethyl substituent and a C-5-nitroso or cyano group (1,2,5) induced cell cycle phase alterations and were growth inhibitory (GI50<20 μM).  Compd. 1, but not 2 or 5, potently inhibits CDK2 (IC50=0.1 nM) as well as PI3K, and was cytotoxic at growth inhibitory concns.  Consistent with kinase inhibition data, compd. 1 reduced phospho-Rb and phospho-rS6 at GI50 concns.  Combination of NU6102 (CDK2 inhibitor) and pictilisib (GDC-0941; pan-PI3K inhibitor) resulted in synergistic growth inhibition, and enhanced cytotoxicity in HT29 cells in vitro and HT29 tumor growth inhibition in vivo.  These studies identified a novel series of mixed CDK2/PI3K inhibitors and demonstrate that dual targeting of CDK2 and PI3K can result in enhanced antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpketwbgW-9zLVg90H21EOLACvtfcHk0ljmu8PfhJfHvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGmtrfM&md5=dfd21e42c0a173c476cc9619c677682e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.238%26sid%3Dliteratum%253Aachs%26aulast%3DBeale%26aufirst%3DG.%26aulast%3DHaagensen%26aufirst%3DE.%2BJ.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DRevill%26aufirst%3DC.%2BH.%26aulast%3DPayne%26aufirst%3DS.%2BL.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26atitle%3DCombined%2520PI3K%2520and%2520CDK2%2520Inhibition%2520Induces%2520Cell%2520Death%2520and%2520Enhances%2520In%2520vivo%2520Antitumour%2520Activity%2520in%2520Colorectal%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D115%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fbjc.2016.238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgenvik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weishaupt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartling, F. J.</span></span> <span> </span><span class="NLM_article-title">Combined BET Bromodomain and CDK2 Inhibition in MYC-driven Medulloblastoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2850</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0135-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fs41388-018-0135-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29511348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslGgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=2850-2862&author=S.+Bolinauthor=A.+Borgenvikauthor=C.+U.+Perssonauthor=A.+Sundstromauthor=J.+Qiauthor=J.+E.+Bradnerauthor=W.+A.+Weissauthor=Y.+J.+Choauthor=H.+Weishauptauthor=F.+J.+Swartling&title=Combined+BET+Bromodomain+and+CDK2+Inhibition+in+MYC-driven+Medulloblastoma&doi=10.1038%2Fs41388-018-0135-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma</span></div><div class="casAuthors">Bolin, Sara; Borgenvik, Anna; Persson, Camilla U.; Sundstroem, Anders; Qi, Jun; Bradner, James E.; Weiss, William A.; Cho, Yoon-Jae; Weishaupt, Holger; Swartling, Fredrik J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2850-2862</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Medulloblastoma (MB) is the most common malignant brain tumor in children.  MYC genes are frequently amplified and correlate with poor prognosis in MB.  BET bromodomains recognize acetylated lysine residues and often promote and maintain MYC transcription.  Certain cyclin-dependent kinases (CDKs) are further known to support MYC stabilization in tumor cells.  In this report, MB cells were suppressed by combined targeting of MYC expression and MYC stabilization using BET bromodomain inhibition and CDK2 inhibition, resp.  Such combination treatment worked synergistically and caused cell cycle arrest as well as massive apoptosis.  Immediate transcriptional changes from this combined MYC blockade were found using RNA-Seq profiling and showed remarkable similarities to changes in MYC target gene expression when MYCN was turned off with doxycycline in our MYCN-inducible animal model for Group 3 MB.  In addn., the combination treatment significantly prolonged survival as compared to single-agent therapy in orthotopically transplanted human Group 3 MB with MYC amplifications.  Our data suggest that dual inhibition of CDK2 and BET bromodomains can be a novel treatment approach for suppressing MYC-driven cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ooD_WtfsW7Vg90H21EOLACvtfcHk0ljmu8PfhJfHvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslGgsbo%253D&md5=a5e5ba828ddb5796d90e08deb4c2f936</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0135-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0135-1%26sid%3Dliteratum%253Aachs%26aulast%3DBolin%26aufirst%3DS.%26aulast%3DBorgenvik%26aufirst%3DA.%26aulast%3DPersson%26aufirst%3DC.%2BU.%26aulast%3DSundstrom%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DWeishaupt%26aufirst%3DH.%26aulast%3DSwartling%26aufirst%3DF.%2BJ.%26atitle%3DCombined%2520BET%2520Bromodomain%2520and%2520CDK2%2520Inhibition%2520in%2520MYC-driven%2520Medulloblastoma%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D2850%26epage%3D2862%26doi%3D10.1038%2Fs41388-018-0135-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefanikova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klacanova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilchova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racay, P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Inhibitor SU9516 Increases Sensitivity of Colorectal Carcinoma Cells Caco-2 but not HT29 to BH3Mimetic ABT-737</span>. <i>Gen. Physiol. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.4149/gpb_2017030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4149%2Fgpb_2017030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29372687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGntL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=539-547&author=A.+Stefanikovaauthor=K.+Klacanovaauthor=I.+Pilchovaauthor=J.+Hatokauthor=P.+Racay&title=Cyclin-dependent+Kinase+2+Inhibitor+SU9516+Increases+Sensitivity+of+Colorectal+Carcinoma+Cells+Caco-2+but+not+HT29+to+BH3Mimetic+ABT-737&doi=10.4149%2Fgpb_2017030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737</span></div><div class="casAuthors">Stefanikova, Andrea; Klacanova, Katarina; Pilchova, Ivana; Hatok, Jozef; Racay, Peter</div><div class="citationInfo"><span class="NLM_cas:title">General Physiology and Biophysics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">GPBIE2</span>;
        ISSN:<span class="NLM_cas:issn">0231-5882</span>.
    
            (<span class="NLM_cas:orgname">Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) that represents one of the major causes for cancer related death in humans is often assocd. with over-expression of anti-apoptotic proteins of Bcl-2 family.  The aim of presented study was to det. the effect of ABT-737 inhibitor of anti-apoptotic pro- teins Bcl-2, Bcl-XL and Bcl-w as well as cyclin-dependent kinase 2 (CDK2) inhibitor SU9516 alone and in combination with ABT-737 on survival of colorectal cell lines HT29 and Caco-2.  We have shown that both Caco-2 and HT29 cells that are relatively resistant to ABT-737 are also partially sensitive to SU9516, which increased sensitivity of Caco-2 but not HT29 cells to ABT-737.  Increased sensitivity of Caco-2 cells to ABT-737 after addn. of SU9516 correlated well with SU9516-induced decrease of Mcl-l expression while we have not obsd. downregiilation of Mcl-1 after the treat- ment of HT29 cells with SU9516.  Instead of this, we have shown that treatment of HT29 cells with SU9516 is assocd. with decreased expression of tumor suppressor protein p53.  Our findings provide a rationale for clin. use of Bcl-2 family inhibitors in combination with CDK2 inhibitors for treatment of Mcl-1-dependent colorectal tumors assocd. with expression of Bcl-2, Bcl-XL and Bcl-w proteins.  In addn., we have shown potential of CDK2 inhibitors for treatment of tumors expressing R273H mutant p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpopRluv-W8m7Vg90H21EOLACvtfcHk0lgzgJv6kFQfyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGntL4%253D&md5=a90466a8e776a5647afaeb938c52b058</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.4149%2Fgpb_2017030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4149%252Fgpb_2017030%26sid%3Dliteratum%253Aachs%26aulast%3DStefanikova%26aufirst%3DA.%26aulast%3DKlacanova%26aufirst%3DK.%26aulast%3DPilchova%26aufirst%3DI.%26aulast%3DHatok%26aufirst%3DJ.%26aulast%3DRacay%26aufirst%3DP.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Inhibitor%2520SU9516%2520Increases%2520Sensitivity%2520of%2520Colorectal%2520Carcinoma%2520Cells%2520Caco-2%2520but%2520not%2520HT29%2520to%2520BH3Mimetic%2520ABT-737%26jtitle%3DGen.%2520Physiol.%2520Biophys.%26date%3D2017%26volume%3D36%26spage%3D539%26epage%3D547%26doi%3D10.4149%2Fgpb_2017030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancusi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Self, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Poele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Molecular Profiling and Combinatorial Activity of CCT068127: A Potent CDK2 and CDK9 Inhibitor</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2F1878-0261.12148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29063678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=287-304&author=S.+R.+Whittakerauthor=C.+Barlowauthor=M.+P.+Martinauthor=C.+Mancusiauthor=S.+Wagnerauthor=A.+Selfauthor=E.+Barrieauthor=R.+Te+Poeleauthor=S.+Sharpauthor=N.+Brownauthor=S.+Wilsonauthor=W.+Jacksonauthor=P.+M.+Fischerauthor=P.+A.+Clarkeauthor=M.+I.+Waltonauthor=E.+McDonaldauthor=J.+Blaggauthor=M.+Nobleauthor=M.+D.+Garrettauthor=P.+Workman&title=Molecular+Profiling+and+Combinatorial+Activity+of+CCT068127%3A+A+Potent+CDK2+and+CDK9+Inhibitor&doi=10.1002%2F1878-0261.12148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor</span></div><div class="casAuthors">Whittaker, Steven R.; Barlow, Clare; Martin, Mathew P.; Mancusi, Caterina; Wagner, Steve; Self, Annette; Barrie, Elaine; Te Poele, Robert; Sharp, Swee; Brown, Nathan; Wilson, Stuart; Jackson, Wayne; Fischer, Peter M.; Clarke, Paul A.; Walton, Michael I.; McDonald, Edward; Blagg, Julian; Noble, Martin; Garrett, Michelle D.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">287-304</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Deregulation of the cyclin-dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types.  Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer.  We describe herein the mol. and cellular effects of CCT068127, a novel inhibitor of CDK2 and CDK9.  Optimized from the purine template of seliciclib, CCT068127 exhibits greater potency and selectivity against purified CDK2 and CDK9 and superior antiproliferative activity against human colon cancer and melanoma cell lines.  X-ray crystallog. studies reveal that hydrogen bonding with the DFG motif of CDK2 is the likely mechanism of greater enzymic potency.  Commensurate with inhibition of CDK activity, CCT068127 treatment results in decreased retinoblastoma protein (RB) phosphorylation, reduced phosphorylation of RNA polymerase II, and induction of cell cycle arrest and apoptosis.  The transcriptional signature of CCT068127 shows greatest similarity to other small-mol. CDK and also HDAC inhibitors.  CCT068127 caused a dramatic loss in expression of DUSP6 phosphatase, alongside elevated ERK phosphorylation and activation of MAPK pathway target genes.  MCL1 protein levels are rapidly decreased by CCT068127 treatment and this assocs. with synergistic antiproliferative activity after combined treatment with CCT068127 and ABT263, a BCL2 family inhibitor.  These findings support the rational combination of this series of CDK2/9 inhibitors and BCL2 family inhibitors for the treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAsEQ-SIktWbVg90H21EOLACvtfcHk0lgzgJv6kFQfyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslylur4%253D&md5=8af4ee8d1ac372e854891dc73025364f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12148%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DMancusi%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DSelf%26aufirst%3DA.%26aulast%3DBarrie%26aufirst%3DE.%26aulast%3DTe%2BPoele%26aufirst%3DR.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DMolecular%2520Profiling%2520and%2520Combinatorial%2520Activity%2520of%2520CCT068127%253A%2520A%2520Potent%2520CDK2%2520and%2520CDK9%2520Inhibitor%26jtitle%3DMol.%2520Oncol.%26date%3D2018%26volume%3D12%26spage%3D287%26epage%3D304%26doi%3D10.1002%2F1878-0261.12148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramuta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seashore-Ludlow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edfors, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuominen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krijgsman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeper, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyhazi
Brage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddalo, G.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK2 Overcomes Melanoma Resistance Against BRAF and Hsp90 Inhibitors</span>. <i>Mol. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e7858</span>, <span class="refDoi"> DOI: 10.15252/msb.20177858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.15252%2Fmsb.20177858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29507054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e7858&author=A.+Azimiauthor=S.+Caramutaauthor=B.+Seashore-Ludlowauthor=J.+Bostromauthor=J.+L.+Robinsonauthor=F.+Edforsauthor=R.+Tuominenauthor=K.+Kemperauthor=O.+Krijgsmanauthor=D.+S.+Peeperauthor=J.+Nielsenauthor=J.+Hanssonauthor=S.+Egyhazi%0ABrageauthor=M.+Altunauthor=M.+Uhlenauthor=G.+Maddalo&title=Targeting+CDK2+Overcomes+Melanoma+Resistance+Against+BRAF+and+Hsp90+Inhibitors&doi=10.15252%2Fmsb.20177858"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.15252%2Fmsb.20177858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Fmsb.20177858%26sid%3Dliteratum%253Aachs%26aulast%3DAzimi%26aufirst%3DA.%26aulast%3DCaramuta%26aufirst%3DS.%26aulast%3DSeashore-Ludlow%26aufirst%3DB.%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26aulast%3DEdfors%26aufirst%3DF.%26aulast%3DTuominen%26aufirst%3DR.%26aulast%3DKemper%26aufirst%3DK.%26aulast%3DKrijgsman%26aufirst%3DO.%26aulast%3DPeeper%26aufirst%3DD.%2BS.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DEgyhazi%2BBrage%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DMaddalo%26aufirst%3DG.%26atitle%3DTargeting%2520CDK2%2520Overcomes%2520Melanoma%2520Resistance%2520Against%2520BRAF%2520and%2520Hsp90%2520Inhibitors%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3De7858%26doi%3D10.15252%2Fmsb.20177858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Abreu, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palafox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Murillas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=2301-2313&author=M.+T.+Herrera-Abreuauthor=M.+Palafoxauthor=U.+Asgharauthor=M.+A.+Rivasauthor=R.+J.+Cuttsauthor=I.+Garcia-Murillasauthor=A.+Pearsonauthor=M.+Guzmanauthor=O.+Rodriguezauthor=J.+Gruesoauthor=M.+Belletauthor=J.+Cortesauthor=R.+Elliottauthor=S.+Pancholiauthor=C.+J.+Lord&title=Early+Adaptation+and+Acquired+Resistance+to+CDK4%2F6+Inhibition+in+Estrogen+Receptor-Positive+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera-Abreu%26aufirst%3DM.%2BT.%26aulast%3DPalafox%26aufirst%3DM.%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DRivas%26aufirst%3DM.%2BA.%26aulast%3DCutts%26aufirst%3DR.%2BJ.%26aulast%3DGarcia-Murillas%26aufirst%3DI.%26aulast%3DPearson%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DBellet%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26atitle%3DEarly%2520Adaptation%2520and%2520Acquired%2520Resistance%2520to%2520CDK4%252F6%2520Inhibition%2520in%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D2301%26epage%3D2313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span> <span> </span><span class="NLM_article-title">CDK4/6 Inhibition in Breast Cancer: Current Practice and Future Directions</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1177/1758835918786451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1177%2F1758835918786451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1-15&author=S.+Pernasauthor=S.+M.+Tolaneyauthor=E.+P.+Winerauthor=S.+Goel&title=CDK4%2F6+Inhibition+in+Breast+Cancer%3A+Current+Practice+and+Future+Directions&doi=10.1177%2F1758835918786451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1177%2F1758835918786451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835918786451%26sid%3Dliteratum%253Aachs%26aulast%3DPernas%26aufirst%3DS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DCDK4%252F6%2520Inhibition%2520in%2520Breast%2520Cancer%253A%2520Current%2520Practice%2520and%2520Future%2520Directions%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2018%26volume%3D10%26spage%3D1%26epage%3D15%26doi%3D10.1177%2F1758835918786451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoehr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeruss, J. S.</span></span> <span> </span><span class="NLM_article-title">Synergistic Effect of Eribulin and CDK Inhibition for the Treatment of Triple Negative Breast Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">83925</span>– <span class="NLM_lpage">83939</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.18632%2Foncotarget.20202" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=83925-83939&author=S.+S.+Raoauthor=J.+Stoehrauthor=D.+Dokicauthor=L.+Wanauthor=J.+T.+Deckerauthor=K.+Konopkaauthor=A.+L.+Thomasauthor=J.+Wuauthor=V.+G.+Kaklamaniauthor=L.+D.+Sheaauthor=J.+S.+Jeruss&title=Synergistic+Effect+of+Eribulin+and+CDK+Inhibition+for+the+Treatment+of+Triple+Negative+Breast+Cancer&doi=10.18632%2Foncotarget.20202"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20202%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%2BS.%26aulast%3DStoehr%26aufirst%3DJ.%26aulast%3DDokic%26aufirst%3DD.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DDecker%26aufirst%3DJ.%2BT.%26aulast%3DKonopka%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKaklamani%26aufirst%3DV.%2BG.%26aulast%3DShea%26aufirst%3DL.%2BD.%26aulast%3DJeruss%26aufirst%3DJ.%2BS.%26atitle%3DSynergistic%2520Effect%2520of%2520Eribulin%2520and%2520CDK%2520Inhibition%2520for%2520the%2520Treatment%2520of%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D83925%26epage%3D83939%26doi%3D10.18632%2Foncotarget.20202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deans, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNees, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heierhorst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase 2 Functions in Normal DNA Repair and is a Therapeutic Target in BRCA1-deficient Cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8219</span>– <span class="NLM_lpage">8226</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-3945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-05-3945" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8219-8226&author=A.+J.+Deansauthor=K.+K.+Khannaauthor=C.+J.+McNeesauthor=C.+Mercurioauthor=J.+Heierhorstauthor=G.+A.+McArthur&title=Cyclin-dependent+Kinase+2+Functions+in+Normal+DNA+Repair+and+is+a+Therapeutic+Target+in+BRCA1-deficient+Cancers&doi=10.1158%2F0008-5472.CAN-05-3945"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-3945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-3945%26sid%3Dliteratum%253Aachs%26aulast%3DDeans%26aufirst%3DA.%2BJ.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26aulast%3DMcNees%26aufirst%3DC.%2BJ.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DHeierhorst%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DCyclin-dependent%2520Kinase%25202%2520Functions%2520in%2520Normal%2520DNA%2520Repair%2520and%2520is%2520a%2520Therapeutic%2520Target%2520in%2520BRCA1-deficient%2520Cancers%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8219%26epage%3D8226%26doi%3D10.1158%2F0008-5472.CAN-05-3945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Cyclin E Amplification/overexpression is a Mechanism of Trastuzumab Resistance in HER2<sup>+</sup> Breast Cancer Patients</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">3761</span>– <span class="NLM_lpage">3766</span>, <span class="refDoi"> DOI: 10.1073/pnas.1014835108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1073%2Fpnas.1014835108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21321214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFOltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=3761-3766&author=M.+Scaltritiauthor=P.+J.+Eichhornauthor=J.+Cortesauthor=L.+Prudkinauthor=C.+Auraauthor=J.+Jimenezauthor=S.+Chandarlapatyauthor=V.+Serraauthor=A.+Pratauthor=Y.+H.+Ibrahimauthor=M.+Guzmanauthor=M.+Giliauthor=O.+Rodriguezauthor=S.+Rodriguezauthor=J.+Perezauthor=S.+R.+Greenauthor=S.+Maiauthor=N.+Rosenauthor=C.+Hudisauthor=J.+Baselga&title=Cyclin+E+Amplification%2Foverexpression+is+a+Mechanism+of+Trastuzumab+Resistance+in+HER2%2B+Breast+Cancer+Patients&doi=10.1073%2Fpnas.1014835108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in her2+ breast cancer patients</span></div><div class="casAuthors">Scaltriti, Maurizio; Eichhorn, Pieter J.; Cortes, Javier; Prudkin, Ludmila; Aura, Claudia; Jimenez, Jose; Chandarlapaty, Sarat; Serra, Violeta; Prat, Aleix; Ibrahim, Yasir H.; Guzman, Marta; Gili, Magui; Rodriguez, Olga; Rodriguez, Sonia; Perez, Jose; Green, Simon R.; Mai, Sabine; Rosen, Neal; Hudis, Clifford; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3761-3766, S3761/1-S3761/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Clin. benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified-breast cancer remain limited by primary or acquired resistance.  To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells by chronic exposure to trastuzumab treatment.  Genome-wide copy-no. variation analyses of.the resistant cells compared with parental cells revealed a focal amplification of genomic DNA contg. the cyclin E gene.  In a cohort of 34 HER2+ patients treated with trastuzumab-based therapy, we found that cyclin E amplification/overexpression was assocd. with a worse clin. benefit (33.3% compared with 87.5%, P < 0.02) and a lower progression-free survival (6 mo vs. 14 mo, P < 0.002) compared with nonoverexpressing cyclin E tumors.  To dissect the potential role of cyclin E in trastuzumab resistance, we studied the effects of cyclin E overexpression and cyclin E suppression.  Cyclin E overexpression resulted in resistance to trastuzumab both in vitro and in vivo.  Inhibition of cyclin E activity in cyclin E-amplified trastuzumab resistant clones, either by knockdown of cyclin E expression or treatment with cyclin-dependent kinase 2 (CDK2) inhibitors, led to a dramatic decrease in proliferation and enhanced apoptosis.  In vivo, CDK2 inhibition significantly reduced tumor growth of trastuzumab-resistant xenografts.  Our findings point to a causative role for cyclin E overexpression and the consequent increase in CDK2 activity in trastuzumab resistance and suggest that treatment with CDK2 inhibitors may be a valid strategy in patients with breast tumors with HER2 and cyclin E coamplification/overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxcdApAmM38rVg90H21EOLACvtfcHk0lgiIeKnj1AxiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFOltLY%253D&md5=548c62757110e5caa86ae588af0a27f4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1014835108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1014835108%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DP.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DPrudkin%26aufirst%3DL.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DGili%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DO.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26aulast%3DMai%26aufirst%3DS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DCyclin%2520E%2520Amplification%252Foverexpression%2520is%2520a%2520Mechanism%2520of%2520Trastuzumab%2520Resistance%2520in%2520HER2%252B%2520Breast%2520Cancer%2520Patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D3761%26epage%3D3766%26doi%3D10.1073%2Fpnas.1014835108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span> <span> </span><span class="NLM_article-title">Pre-clinical Evaluation of Cyclin-dependent Kinase 2 and 1 Inhibition in Anti-estrogen-Sensitive and Resistant Breast Cancer Cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsj.bjc.6605479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20010939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=342-350&author=N.+Johnsonauthor=J.+Bentleyauthor=L.+Z.+Wangauthor=D.+R.+Newellauthor=C.+N.+Robsonauthor=G.+I.+Shapiroauthor=N.+J.+Curtin&title=Pre-clinical+Evaluation+of+Cyclin-dependent+Kinase+2+and+1+Inhibition+in+Anti-estrogen-Sensitive+and+Resistant+Breast+Cancer+Cells&doi=10.1038%2Fsj.bjc.6605479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells</span></div><div class="casAuthors">Johnson, N.; Bentley, J.; Wang, L.-Z.; Newell, D. R.; Robson, C. N.; Shapiro, G. I.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) and their cyclin partners, is deregulated in cancer.  Anti-estrogens, such as tamoxifen, antagonize estrogen-induced ERα transactivation of cyclin D1, resulting in reduced CDK4/6 activity, p27Kip1-mediated inhibition of CDK2 and growth arrest.  We hypothesised that direct inhibition of CDK2 and CDK1 may overcome the major clin. problem of anti-estrogen resistance.  Methods: The cellular effects of CDK2/1 siRNA knockdown and purine-based CDK2/1 inhibitors, NU2058 and NU6102, were measured in anti-estrogen-sensitive and resistant breast cancer cell lines.  Results: CDK2 knockdown caused G1 accumulation, whereas CDK1 depletion caused G2/M slowing, and dual CDK1/2 depletion resulted in further G2/M accumulation and cell death in both anti-estrogen-sensitive and resistant cells, confirming CDK2 and CDK1 as targets for breast cancer therapy.  In contrast to tamoxifen, which only affected hormone-sensitive cells, NU2058 and NU6102 reduced CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and proliferation, ultimately resulting in cell death, in both anti-estrogen-sensitive and resistant cells.  Both drugs caused G2/M arrest, reflective of combined CDK2/1 knockdown, with a variable degree of G1 accumulation.  Conclusion: These studies confirm the therapeutic potential of CDK2 and CDK1 inhibitors for cancer therapy, and support their use as an alternative treatment for endocrine-resistant breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOsy7PhpambVg90H21EOLACvtfcHk0ljfV7WmNzbclg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKiuw%253D%253D&md5=832cf69fc4b80a85e01f6d0bdf6233c7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605479%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DRobson%26aufirst%3DC.%2BN.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPre-clinical%2520Evaluation%2520of%2520Cyclin-dependent%2520Kinase%25202%2520and%25201%2520Inhibition%2520in%2520Anti-estrogen-Sensitive%2520and%2520Resistant%2520Breast%2520Cancer%2520Cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D342%26epage%3D350%26doi%3D10.1038%2Fsj.bjc.6605479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goktug, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonga, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlitt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iconaru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morfouace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umans, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span> <span> </span><span class="NLM_article-title">CDK2 Inhibitors as Candidate Therapeutics for Cisplatin- and Noise-induced Hearing Loss</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1084/jem.20172246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1084%2Fjem.20172246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2018&pages=1187-1203&author=T.+Teitzauthor=J.+Fangauthor=A.+N.+Goktugauthor=J.+D.+Bongaauthor=S.+Diaoauthor=R.+A.+Hazlittauthor=L.+Iconaruauthor=M.+Morfouaceauthor=D.+Currierauthor=Y.+Zhouauthor=R.+A.+Umansauthor=M.+R.+Taylorauthor=C.+Chengauthor=J.+Minauthor=B.+Freemanauthor=J.+Pengauthor=M.+F.+Rousselauthor=R.+Kriwackiauthor=R.+K.+Guyauthor=T.+Chenauthor=J.+Zuo&title=CDK2+Inhibitors+as+Candidate+Therapeutics+for+Cisplatin-+and+Noise-induced+Hearing+Loss&doi=10.1084%2Fjem.20172246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1084%2Fjem.20172246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20172246%26sid%3Dliteratum%253Aachs%26aulast%3DTeitz%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DGoktug%26aufirst%3DA.%2BN.%26aulast%3DBonga%26aufirst%3DJ.%2BD.%26aulast%3DDiao%26aufirst%3DS.%26aulast%3DHazlitt%26aufirst%3DR.%2BA.%26aulast%3DIconaru%26aufirst%3DL.%26aulast%3DMorfouace%26aufirst%3DM.%26aulast%3DCurrier%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DUmans%26aufirst%3DR.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZuo%26aufirst%3DJ.%26atitle%3DCDK2%2520Inhibitors%2520as%2520Candidate%2520Therapeutics%2520for%2520Cisplatin-%2520and%2520Noise-induced%2520Hearing%2520Loss%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2018%26volume%3D215%26spage%3D1187%26epage%3D1203%26doi%3D10.1084%2Fjem.20172246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabr, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. J.</span></span> <span> </span><span class="NLM_article-title">Amyloid beta1–42 (Abeta1–42) Induces the CDK2-Mediated Phosphorylation of Tau through the Activation of the mTORC1 Signaling Pathway While Promoting Neuronal Cell Death</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">229</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2017.00229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.3389%2Ffnmol.2017.00229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28790888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVOksLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=229&author=K.+H.+Leeauthor=S.+J.+Leeauthor=H.+J.+Leeauthor=G.+E.+Choiauthor=Y.+H.+Jungauthor=D.+I.+Kimauthor=A.+A.+Gabrauthor=J.+M.+Ryuauthor=H.+J.+Han&title=Amyloid+beta1%E2%80%9342+%28Abeta1%E2%80%9342%29+Induces+the+CDK2-Mediated+Phosphorylation+of+Tau+through+the+Activation+of+the+mTORC1+Signaling+Pathway+While+Promoting+Neuronal+Cell+Death&doi=10.3389%2Ffnmol.2017.00229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid β1-42 (Aβ1-42) induces the CDK2-mediated phosphorylation of tau through the activation of the mTORC1 Signaling pathway while promoting neuronal cell death</span></div><div class="casAuthors">Lee, Ki Hoon; Lee, Sei-Jung; Lee, Hyun Jik; Choi, Gee Euhn; Jung, Young Hyun; Kim, Dah Ihm; Gabr, Amr Ahmed; Ryu, Jung Min; Han, Ho Jae</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">229/1-229/15</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by cognitive impairment and memory loss.  Amyloid β1-42 (Aβ) and hyper-phosphorylation of microtubule-assocd. protein tau have been considered as major histol. features in AD.  However, the mechanism of how Aβ induces the hyper-phosphorylation of tau remains to be clarified.  In the present study, we investigated the underlying cellular mechanisms of Aβ with regard to the cell cycle regulatory protein-mediated phosphorylation of tau in promoting neuronal cell death.  The oligomer Aβ (5 μM) significantly increased the level of caspase 3 cleavage and has the ability to induce cytotoxicity in human neuroblastoma SK-N-MC cells.  Aβ induced the degree of extracellular calcium influx via the L-type channel to facilitate the prodn. of reactive oxygen species (ROS).  Aβ signaling through ROS prodn. is uniquely mediated by the activation of PI3K/Akt, which is in turn required for mammalian target of rapamycin complex 1 (mTORC1) phosphorylation. mTORC1 activated by Aβ further increased the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), a binding protein (4E-BP1) and p70S6K1 to stimulate the HIF1α synthesis responsible for the induction of cyclinD1/cyclin-dependent kinase 4 (CDK4) and cyclinE/CDK2, whereas it significantly attenuated the activation of autophagy.  Aβ distinctively induced the CDK2-mediated phosphorylation of tau, which is responsible for microtubule destabilization in promoting neuronal apoptosis.  In mouse hippocampal primary neurons, the apoptotic cell death induced by Aβ is highly susceptible to the mTORC1 signaling pathway.  These results demonstrate that Aβ efficiently stimulates the mTORC1 signaling pathway to facilitate HIF1α synthesis and autophagy inhibition to promote the expression of cell cycle regulatory proteins, during which CDK2 uniquely stimulates tau phosphorylation for microtubule destabilization-mediated neuronal apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrH1nGss8wRbVg90H21EOLACvtfcHk0ljfV7WmNzbclg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVOksLjF&md5=0740a4e0ab23a83cc090895886180a20</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00229%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DG.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BI.%26aulast%3DGabr%26aufirst%3DA.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BM.%26aulast%3DHan%26aufirst%3DH.%2BJ.%26atitle%3DAmyloid%2520beta1%25E2%2580%259342%2520%2528Abeta1%25E2%2580%259342%2529%2520Induces%2520the%2520CDK2-Mediated%2520Phosphorylation%2520of%2520Tau%2520through%2520the%2520Activation%2520of%2520the%2520mTORC1%2520Signaling%2520Pathway%2520While%2520Promoting%2520Neuronal%2520Cell%2520Death%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26spage%3D229%26doi%3D10.3389%2Ffnmol.2017.00229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+Cyclin-dependent+Kinases+%28CDKs%29+as+Novel+Targets+for+Antiviral+Drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0ljDbPhBrfxYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520Cyclin-dependent%2520Kinases%2520%2528CDKs%2529%2520as%2520Novel%2520Targets%2520for%2520Antiviral%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prigge, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. C.</span></span> <span> </span><span class="NLM_article-title">Targeting Malaria with Specific CDK Inhibitors</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bbapap.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16185941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=160-170&author=J.+A.+Geyerauthor=S.+T.+Priggeauthor=N.+C.+Waters&title=Targeting+Malaria+with+Specific+CDK+Inhibitors&doi=10.1016%2Fj.bbapap.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting malaria with specific CDK inhibitors</span></div><div class="casAuthors">Geyer, Jeanne A.; Prigge, Sean T.; Waters, Norman C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">160-170</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent protein kinases (CDKs) are attractive targets for drug discovery and efforts have led to the identification of novel CDK selective inhibitors in the development of treatments for cancers, neurol. disorders, and infectious diseases.  More recently, they have become the focus of rational drug design programs for the development of new antimalarial agents.  CDKs are valid targets as they function as essential regulators of cell growth and differentiation.  To date, several CDKs have been characterized from the genome of the malaria-causing protozoan Plasmodium falciparum.  Our approach employs exptl. and virtual screening methodologies to identify and refine chem. inhibitors of the parasite CDK Pfmrk, a sequence homolog of human CDK7.  Chemotypes of Pfmrk inhibitors include the purines, quinolinones, oxindoles, and chalcones, which have sub-micromolar IC50 values against the parasite enzyme, but not the human CDKs.  Addnl., we have developed and validated a pharmacophore, based on Pfmrk inhibitors, which contains two hydrogen bond acceptor functions and two hydrophobic sites, including one arom. ring hydrophobic site.  This pharmacophore has been exploited to identify addnl. compds. that demonstrate significant inhibitory activity against Pfmrk.  A mol. model of Pfmrk designed using the crystal structure of human CDK7 highlights key amino acid substitutions in the ATP binding pocket.  Mol. modeling and docking of the active site pocket with selective inhibitors has identified possible receptor-ligand interactions that may be responsible for inhibitor specificity.  Overall, the unique biochem. characteristics assocd. with this protein, to include distinctive active site amino acid residues and variable inhibitor profiles, distinguishes the Pfmrk drug screen as a paradigm for CDK inhibitor anal. in the parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqme2F3kHlrt7Vg90H21EOLACvtfcHk0ljDbPhBrfxYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7nK&md5=fcc6769d81111c242cff806abc75e0ac</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DJ.%2BA.%26aulast%3DPrigge%26aufirst%3DS.%2BT.%26aulast%3DWaters%26aufirst%3DN.%2BC.%26atitle%3DTargeting%2520Malaria%2520with%2520Specific%2520CDK%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D160%26epage%3D170%26doi%3D10.1016%2Fj.bbapap.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholkar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, J. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical Dissection of the Cell Cycle: Probes for Cell Biology and Anti-cancer Drug Development</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1462</span>, <span class="refDoi"> DOI: 10.1038/cddis.2014.420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fcddis.2014.420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25321469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2htbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=e1462&author=S.+Seneseauthor=Y.+C.+Loauthor=D.+Huangauthor=T.+A.+Zangleauthor=A.+A.+Gholkarauthor=L.+Robertauthor=B.+Hometauthor=A.+Ribasauthor=M.+K.+Summersauthor=M.+A.+Teitellauthor=R.+Damoiseauxauthor=J.+Z.+Torres&title=Chemical+Dissection+of+the+Cell+Cycle%3A+Probes+for+Cell+Biology+and+Anti-cancer+Drug+Development&doi=10.1038%2Fcddis.2014.420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development</span></div><div class="casAuthors">Senese, S.; Lo, Y. C.; Huang, D.; Zangle, T. A.; Gholkar, A. A.; Robert, L.; Homet, B.; Ribas, A.; Summers, M. K.; Teitell, M. A.; Damoiseaux, R.; Torres, J. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1462</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cell proliferation relies on the ability of cancer cells to grow, transition through the cell cycle, and divide.  To identify novel chem. probes for dissecting the mechanisms governing cell cycle progression and cell division, and for developing new anti-cancer therapeutics, we developed and performed a novel cancer cell-based high-throughput chem. screen for cell cycle modulators.  This approach identified novel G1, S, G2, and M-phase specific inhibitors with drug-like properties and diverse chemotypes likely targeting a broad array of processes.  We further characterized the M-phase inhibitors and highlight the most potent M-phase inhibitor MI-181, which targets tubulin, inhibits tubulin polymn., activates the spindle assembly checkpoint, arrests cells in mitosis, and triggers a fast apoptotic cell death.  Importantly, MI-181 has broad anti-cancer activity, esp. against BRAFV600E melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUCZpnsdcB_7Vg90H21EOLACvtfcHk0ljDbPhBrfxYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2htbbK&md5=951a258769bdb3dbaa008ec59bb30a47</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2014.420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2014.420%26sid%3Dliteratum%253Aachs%26aulast%3DSenese%26aufirst%3DS.%26aulast%3DLo%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZangle%26aufirst%3DT.%2BA.%26aulast%3DGholkar%26aufirst%3DA.%2BA.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DHomet%26aufirst%3DB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DSummers%26aufirst%3DM.%2BK.%26aulast%3DTeitell%26aufirst%3DM.%2BA.%26aulast%3DDamoiseaux%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DJ.%2BZ.%26atitle%3DChemical%2520Dissection%2520of%2520the%2520Cell%2520Cycle%253A%2520Probes%2520for%2520Cell%2520Biology%2520and%2520Anti-cancer%2520Drug%2520Development%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2014%26volume%3D5%26spage%3De1462%26doi%3D10.1038%2Fcddis.2014.420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Razga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemethova, V.</span></span> <span> </span><span class="NLM_article-title">Selective Therapeutic Intervention: A Challenge Against Off-Target Effects</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2017.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.molmed.2017.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=671-674&author=F.+Razgaauthor=V.+Nemethova&title=Selective+Therapeutic+Intervention%3A+A+Challenge+Against+Off-Target+Effects&doi=10.1016%2Fj.molmed.2017.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2017.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2017.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DRazga%26aufirst%3DF.%26aulast%3DNemethova%26aufirst%3DV.%26atitle%3DSelective%2520Therapeutic%2520Intervention%253A%2520A%2520Challenge%2520Against%2520Off-Target%2520Effects%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D671%26epage%3D674%26doi%3D10.1016%2Fj.molmed.2017.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0lhFv46hVKZbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Preclinical and Clinical Development of the Cyclin-dependent Kinase Inhibitor Flavopiridol</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4270S</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-040020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1078-0432.CCR-040020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15217973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFWls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=4270S&author=G.+I.+Shapiro&title=Preclinical+and+Clinical+Development+of+the+Cyclin-dependent+Kinase+Inhibitor+Flavopiridol&doi=10.1158%2F1078-0432.CCR-040020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12, Pt. 2</span>),
    <span class="NLM_cas:pages">4270s-4275s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (cdks) to reach clin. trial.  In the majority of solid tumor cell lines and xenografts, flavopiridol induces cell cycle arrest and tumor growth inhibition.  This is reflected in clin. outcomes: across multiple Phase II trials there are subsets of patients with prolonged stable disease, although few responses have been obsd.  Flavopiridol displays sequence-dependent cytotoxic synergy with chemotherapy agents.  These effects are most marked when chemotherapy precedes flavopiridol.  In the case of DNA-damaging agents that impose S-phase delay, flavopiridol-mediated cdk inhibition disrupts the phosphorylation of E2F-1, leading to inappropriate persistence of its activity, inducing apoptotic pathways.  This mechanism has been exploited in a Phase I trial of sequential gemcitabine and flavopiridol that has produced promising results.  Flavopiridol is also synergistic with taxanes.  Inhibition of cyclin B-cdk1 by flavopiridol accelerates exit from an abnormal mitosis assocd. with taxane-induced cell death and reduces the phosphorylation of survivin, preventing its stabilization and the cellular protection it affords after taxane exposure.  The sequential combination of docetaxel and flavopiridol has been investigated in a Phase I trial in patients with advanced non-small cell lung cancer, and a randomized Phase II study is under way.  Initial schedules of flavopiridol used prolonged continuous infusions that produced nanomolar levels of drug thought to be capable of achieving cdk inhibition based on results in tumor cell lines.  Recently, it has been discovered that micromolar concns. are likely to be more effective, and shorter infusions that achieve a higher Cmax have now been adopted.  Loading followed by maintenance infusions are also under development, designed to achieve sustained micromolar drug levels.  Clin. trials remain complicated by the absence of pharmacodynamic end points to confirm target inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2TCVhblpcLVg90H21EOLACvtfcHk0lhFv46hVKZbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFWls7o%253D&md5=4b1d241a5fa7b8183d36e87e54f99e62</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-040020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-040020%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPreclinical%2520and%2520Clinical%2520Development%2520of%2520the%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520Flavopiridol%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D4270S%26doi%3D10.1158%2F1078-0432.CCR-040020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClue, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S. R.</span></span> <span> </span><span class="NLM_article-title">Seliciclib, A Cell-Cycle Modulator that Acts through the Inhibition of Cyclin-Dependent Kinases</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.1.131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1517%2F17460441.3.1.131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=131-143&author=R.+C.+Jacksonauthor=A.+L.+Barnettauthor=S.+J.+McClueauthor=S.+R.+Green&title=Seliciclib%2C+A+Cell-Cycle+Modulator+that+Acts+through+the+Inhibition+of+Cyclin-Dependent+Kinases&doi=10.1517%2F17460441.3.1.131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.1.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.1.131%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DGreen%26aufirst%3DS.%2BR.%26atitle%3DSeliciclib%252C%2520A%2520Cell-Cycle%2520Modulator%2520that%2520Acts%2520through%2520the%2520Inhibition%2520of%2520Cyclin-Dependent%2520Kinases%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D131%26epage%3D143%26doi%3D10.1517%2F17460441.3.1.131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulstridge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devine, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Early, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seavers, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), A Novel Cyclin Dependent Kinase Inhibitor Using Fragment-based X-ray Crystallography and Structure Based Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4986</span>– <span class="NLM_lpage">4999</span>, <span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-Piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+A+Novel+Cyclin+Dependent+Kinase+Inhibitor+Using+Fragment-based+X-ray+Crystallography+and+Structure+Based+Drug+Design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-Piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520A%2520Novel%2520Cyclin%2520Dependent%2520Kinase%2520Inhibitor%2520Using%2520Fragment-based%2520X-ray%2520Crystallography%2520and%2520Structure%2520Based%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boccadoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">AT7519, A Novel Small Molecule Multi-cyclin-dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma <i>via</i> GSK-3beta Activation and RNA Polymerase II Inhibition</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2325</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1038/onc.2009.510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2009.510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20101221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2325-2336&author=L.+Santoauthor=S.+Valletauthor=T.+Hideshimaauthor=D.+Cirsteaauthor=H.+Ikedaauthor=S.+Pozziauthor=K.+Patelauthor=Y.+Okawaauthor=G.+Gorgunauthor=G.+Perroneauthor=E.+Calabreseauthor=M.+Yuleauthor=M.+Squiresauthor=M.+Ladettoauthor=M.+Boccadoroauthor=P.+G.+Richardsonauthor=N.+C.+Munshiauthor=K.+C.+Andersonauthor=N.+Raje&title=AT7519%2C+A+Novel+Small+Molecule+Multi-cyclin-dependent+Kinase+Inhibitor%2C+Induces+Apoptosis+in+Multiple+Myeloma+via+GSK-3beta+Activation+and+RNA+Polymerase+II+Inhibition&doi=10.1038%2Fonc.2009.510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition</span></div><div class="casAuthors">Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Yule, M.; Squires, M.; Ladetto, M.; Boccadoro, M.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2325-2336</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent kinases (CDKs) and their cyclin partners.  Overexpression of individual complexes are reported in multiple myeloma (MM), making them attractive therapeutic targets.  In this study, we investigate the preclin. activity of a novel small-mol. multi-CDK inhibitor, AT7519, in MM.  We show the anti-MM activity of AT7519 displaying potent cytotoxicity and apoptosis; assocd. with in vivo tumor growth inhibition and prolonged survival.  At the mol. level, AT7519 inhibited RNA polymerase II (RNA pol II) phosphorylation, a CDK9, 7 substrate, assocd. with decreased RNA synthesis confirmed by [3H] Uridine incorporation.  In addn., AT7519 inhibited glycogen synthase kinase 3β (GSK-3β) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3β knockdown restored MM survival, suggesting the involvement of GSK-3β in AT7519-induced apoptosis.  GSK-3β activation was independent of RNA pol II dephosphorylation confirmed by α-amanitin, a specific RNA pol II inhibitor, showing potent inhibition of RNA pol II phosphorylation without corresponding effects on GSK-3β phosphorylation.  These results offer new insights into the crucial, yet controversial role of GSK-3β in MM and show significant anti-MM activity of AT7519, providing the rationale for its clin. evaluation in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ02d-731b97Vg90H21EOLACvtfcHk0lil8Ps8_sE0Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbY%253D&md5=0b2e88ad2fb5bd776607465c308423f5</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.510%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DPerrone%26aufirst%3DG.%26aulast%3DCalabrese%26aufirst%3DE.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DLadetto%26aufirst%3DM.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DAT7519%252C%2520A%2520Novel%2520Small%2520Molecule%2520Multi-cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520via%2520GSK-3beta%2520Activation%2520and%2520RNA%2520Polymerase%2520II%2520Inhibition%26jtitle%3DOncogene%26date%3D2010%26volume%3D29%26spage%3D2325%26epage%3D2336%26doi%3D10.1038%2Fonc.2009.510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span> <span> </span><span class="NLM_article-title">Biological Characterization of AT7519, A Small-Molecule Inhibitor of Cyclin-Dependent Kinases, in Human Tumor Cell Lines</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-08-0890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19174555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFamsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=324-332&author=M.+S.+Squiresauthor=R.+E.+Feltellauthor=N.+G.+Wallisauthor=E.+J.+Lewisauthor=D.+M.+Smithauthor=D.+M.+Crossauthor=J.+F.+Lyonsauthor=N.+T.+Thompson&title=Biological+Characterization+of+AT7519%2C+A+Small-Molecule+Inhibitor+of+Cyclin-Dependent+Kinases%2C+in+Human+Tumor+Cell+Lines&doi=10.1158%2F1535-7163.MCT-08-0890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines</span></div><div class="casAuthors">Squires, Matthew S.; Feltell, Ruth E.; Wallis, Nicola G.; Lewis, E. Jonathan; Smith, Donna-Michelle; Cross, David M.; Lyons, John F.; Thompson, Neil T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-332</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK), and their regulatory cyclin partners, play a central role in eukaryotic cell growth, division, and death.  This key role in cell cycle progression, as well as their de-regulation in several human cancers, makes them attractive therapeutic targets in oncol.  A series of CDK inhibitors was developed using Astex's fragment-based medicinal chem. approach, linked to high-throughput X-ray crystallog.  A compd. from this series, designated AT7519, is currently in early-phase clin. development.  We describe here the biol. characterization of AT7519, a potent inhibitor of several CDK family members.  AT7519 showed potent anti-proliferative activity (40-940 nmol/L) in a panel of human tumor cell lines, and the mechanism of action was shown here to be consistent with the inhibition of CDK1 and CDK2 in solid tumor cell lines.  AT7519 caused cell cycle arrest followed by apoptosis in human tumor cells and inhibited tumor growth in human tumor xenograft models.  Tumor regression was obsd. following twice daily dosing of AT7519 in the HCT116 and HT29 colon cancer xenograft models.  We show that these biol. effects are linked to inhibition of CDKs in vivo and that AT7519 induces tumor cell apoptosis in these xenograft models.  AT7519 has an attractive biol. profile for development as a clin. candidate, and the tolerability and efficacy in animal models compare favorably with other CDK inhibitors in clin. development.  Studies described here formed the biol. rationale for investigating the potential therapeutic benefit of AT7519 in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7VBX-MzHDbVg90H21EOLACvtfcHk0lil8Ps8_sE0Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFamsL0%253D&md5=55ab6736e850d3acfb3c6095554eb006</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0890%26sid%3Dliteratum%253Aachs%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26atitle%3DBiological%2520Characterization%2520of%2520AT7519%252C%2520A%2520Small-Molecule%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Kinases%252C%2520in%2520Human%2520Tumor%2520Cell%2520Lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D324%26epage%3D332%26doi%3D10.1158%2F1535-7163.MCT-08-0890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seftel, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouroukis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalchal, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laister, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sederias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, A. E.</span></span> <span> </span><span class="NLM_article-title">The CDK Inhibitor AT7519M in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma. A Phase II study of the Canadian Cancer Trials Group</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1358</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1239259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1080%2F10428194.2016.1239259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27750483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1358-1365&author=M.+D.+Seftelauthor=J.+Kuruvillaauthor=T.+Kouroukisauthor=V.+Banerjiauthor=G.+Fraserauthor=M.+Crumpauthor=R.+Kumarauthor=H.+I.+Chalchalauthor=M.+Salimauthor=R.+C.+Laisterauthor=S.+Crockerauthor=S.+B.+Gibsonauthor=M.+Toguchiauthor=J.+F.+Lyonsauthor=H.+Xuauthor=J.+Powersauthor=J.+Sederiasauthor=L.+Seymourauthor=A.+E.+Hay&title=The+CDK+Inhibitor+AT7519M+in+Patients+with+Relapsed+or+Refractory+Chronic+Lymphocytic+Leukemia+%28CLL%29+and+Mantle+Cell+Lymphoma.+A+Phase+II+study+of+the+Canadian+Cancer+Trials+Group&doi=10.1080%2F10428194.2016.1239259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group</span></div><div class="casAuthors">Seftel, Matthew D.; Kuruvilla, John; Kouroukis, Tom; Banerji, Versha; Fraser, Graeme; Crump, Michael; Kumar, Rajat; Chalchal, Haji I.; Salim, Muhammad; Laister, Rob C.; Crocker, Susan; Gibson, Spencer B.; Toguchi, Marcia; Lyons, John F.; Xu, Hao; Powers, Jean; Sederias, Joana; Seymour, Lesley; Hay, Annette E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1358-1365</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">AT7519M is a small mol. inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies.  In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m2 twice weekly for 2 of every 3 wk.  Primary objective was objective response rate (ORR).  Nineteen patients were accrued (7 CLL, 12 MCL).  Four CLL patients achieved stable disease (SD).  Two MCL patients achieved partial response (PR), and 6 had SD.  One addnl. MCL patient with SD subsequently achieved PR 9 mo after completion of AT7519M.  Tumor lysis syndrome was not reported.  In conclusion, AT7519M was safely administered to patients with relapsed/refractory CLL and MCL.  In CLL, some patients had tumor redns., but the ORR was low.  In MCL, activity was noted with ORR of 27%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZUMQXDw67bVg90H21EOLACvtfcHk0libkbdtbtBcvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsLvM&md5=4a63e3a5cb34a9e8eb22826f76ffe113</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1239259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1239259%26sid%3Dliteratum%253Aachs%26aulast%3DSeftel%26aufirst%3DM.%2BD.%26aulast%3DKuruvilla%26aufirst%3DJ.%26aulast%3DKouroukis%26aufirst%3DT.%26aulast%3DBanerji%26aufirst%3DV.%26aulast%3DFraser%26aufirst%3DG.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DChalchal%26aufirst%3DH.%2BI.%26aulast%3DSalim%26aufirst%3DM.%26aulast%3DLaister%26aufirst%3DR.%2BC.%26aulast%3DCrocker%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DS.%2BB.%26aulast%3DToguchi%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSederias%26aufirst%3DJ.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DHay%26aufirst%3DA.%2BE.%26atitle%3DThe%2520CDK%2520Inhibitor%2520AT7519M%2520in%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%2520and%2520Mantle%2520Cell%2520Lymphoma.%2520A%2520Phase%2520II%2520study%2520of%2520the%2520Canadian%2520Cancer%2520Trials%2520Group%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1358%26epage%3D1365%26doi%3D10.1080%2F10428194.2016.1239259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirte, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Cyclin-dependent Kinase Inhibitor, AT7519, in Patients with Advanced Cancer: NCIC Clinical Trials Group IND 177</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2262</span>– <span class="NLM_lpage">2267</span>, <span class="refDoi"> DOI: 10.1038/bjc.2014.565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fbjc.2014.565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25393368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKksr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=2262-2267&author=E.+X.+Chenauthor=S.+Hotteauthor=H.+Hirteauthor=L.+L.+Siuauthor=J.+Lyonsauthor=M.+Squiresauthor=S.+Lovellauthor=S.+Turnerauthor=L.+McIntoshauthor=L.+Seymour&title=A+Phase+I+Study+of+Cyclin-dependent+Kinase+Inhibitor%2C+AT7519%2C+in+Patients+with+Advanced+Cancer%3A+NCIC+Clinical+Trials+Group+IND+177&doi=10.1038%2Fbjc.2014.565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177</span></div><div class="casAuthors">Chen, E. X.; Hotte, S.; Hirte, H.; Siu, L. L.; Lyons, J.; Squires, M.; Lovell, S.; Turner, S.; McIntosh, L.; Seymour, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2262-2267</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: AT7519 is a small-mol. inhibitor of multiple cyclin-dependent kinases (CDKs).  It shows encouraging anti-cancer activity against multiple cell lines and in tumor xenografts.  This phase I study was conducted to evaluate the safety and tolerability of AT7519 given as 1-h i.v. infusion on days 1, 4, 8 and 11 every 3 wk.  Methods: Patients with advanced refractory solid tumors or non-Hodgkin's lymphoma were enrolled.  Dose escalation occurred in a 3+3 manner based on toxicity assessment.  Pharmacokinetic samples were collected after first AT7519 infusion, whereas pharmacodynamics (PD) samples were obtained in selected patients.  Results: Thirty-four patients were enrolled, and 32 received study treatments over 4 dose levels.  Dose-limiting toxicities included mucositis, febrile neutropenia, rash, fatigue and hypokalemia.  The recommended phase II dose (RP2D) was 27.0 mg m-2.  Ten of 19 patients evaluable for efficacy had stable disease as the best response (median duration: 3.3 mo; range: 2.5 to 11.1 mo).  There was no clin. significant QTc prolongation.  There was an apparent dose proportional increase in AT7519 exposure.  The PD studies showed redn. in markers of CDK activity in selected patients' skin biopsies post treatment.  Conclusions: AT7519, when administered as an i.v. infusion on days 1, 4, 8 and 11, was well tolerated.  The RP2D is 27.0 mg m-2.  At this dose level, plasma AT7519 concns. were above the biol. active concns., and preliminary anti-cancer activity was obsd. in patients.  This dosing schedule is being further evaluated in multiple phase II studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdHgaphfp-7Vg90H21EOLACvtfcHk0libkbdtbtBcvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKksr3I&md5=666089cc20121c9903e22e297125882c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.565%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DHotte%26aufirst%3DS.%26aulast%3DHirte%26aufirst%3DH.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DTurner%26aufirst%3DS.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520AT7519%252C%2520in%2520Patients%2520with%2520Advanced%2520Cancer%253A%2520NCIC%2520Clinical%2520Trials%2520Group%2520IND%2520177%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D111%26spage%3D2262%26epage%3D2267%26doi%3D10.1038%2Fbjc.2014.565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rensvold, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretzinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, H.</span></span> <span> </span><span class="NLM_article-title">A Phase I Pharmacokinetic and Pharmacodynamic Study of AT7519, A Cyclin-dependent Kinase Inhibitor in Patients with Refractory Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdq734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fannonc%2Fmdq734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21325451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2137-2143&author=D.+Mahadevanauthor=R.+Plummerauthor=M.+S.+Squiresauthor=D.+Rensvoldauthor=S.+Kurtinauthor=C.+Pretzingerauthor=T.+Dragovichauthor=J.+Adamsauthor=V.+Lockauthor=D.+M.+Smithauthor=D.+Von+Hoffauthor=H.+Calvert&title=A+Phase+I+Pharmacokinetic+and+Pharmacodynamic+Study+of+AT7519%2C+A+Cyclin-dependent+Kinase+Inhibitor+in+Patients+with+Refractory+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdq734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors</span></div><div class="casAuthors">Mahadevan D; Plummer R; Squires M S; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith D M; Von Hoff D; Calvert H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2137-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs).  Based on potent antitumor activity in preclinical models, a first-in-human clinical trial in refractory solid tumors investigated its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD).  PATIENTS AND METHODS:  AT7519 was administered in a '3 + 3' dose- escalation scheme on 5 consecutive days every 3 weeks to patients with advanced, refractory solid tumors.  Samples to monitor AT7519 PK and PD were obtained.  RESULTS:  Twenty-eight patients were treated at seven dose levels (1.8-40 mg/m(2)/day).  At 40 mg/m(2)/day, one patient developed hypotension and ST segment elevation.  At 34 mg/m(2)/day, dose-limiting toxic effects (DLTs) were QTc prolongation with one death (grade 5), fatigue (grade 4) and mucositis (grade 3).  Electrocardiogram review suggested a dose-dependent increase in QTc and recruitment was discontinued without establishing a maximum tolerated dose.  Four patients exhibited stable disease for >6 months and one had a prolonged partial response.  PK profile revealed modest interpatient variation with linear exposure at increasing doses.  Inhibition of markers of CDK activity was observed across the dose range and manifested in antiproliferative activity at a dose of 28 mg/m(2).  CONCLUSION:  AT7519 elicited clinical and PD activity resulting from CDK inhibition at doses below the appearance of DLT of QTc prolongation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7SqqcneEtCi92fW6udTcc2eYTEvNCBrXlV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVWjug%253D%253D&md5=1ea32b63b87ca82732bf0fbf1f182f0c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq734%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DRensvold%26aufirst%3DD.%26aulast%3DKurtin%26aufirst%3DS.%26aulast%3DPretzinger%26aufirst%3DC.%26aulast%3DDragovich%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCalvert%26aufirst%3DH.%26atitle%3DA%2520Phase%2520I%2520Pharmacokinetic%2520and%2520Pharmacodynamic%2520Study%2520of%2520AT7519%252C%2520A%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520in%2520Patients%2520with%2520Refractory%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2137%26epage%3D2143%26doi%3D10.1093%2Fannonc%2Fmdq734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. J.</span></span> <span> </span><span class="NLM_article-title">Peripheral White Blood Cell Toxicity Induced by Broad Spectrum Cyclin-dependent Kinase Inhibitors</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1002/jat.1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fjat.1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17211896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=133-142&author=B.+A.+Jessenauthor=L.+Leeauthor=T.+Koudriakovaauthor=M.+Hainesauthor=K.+Lundgrenauthor=S.+Priceauthor=J.+Nonomiyaauthor=C.+Lewisauthor=G.+J.+Stevens&title=Peripheral+White+Blood+Cell+Toxicity+Induced+by+Broad+Spectrum+Cyclin-dependent+Kinase+Inhibitors&doi=10.1002%2Fjat.1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Jessen, Bart A.; Lee, Leo; Koudriakova, Tatiana; Haines, Morgan; Lundgren, Karen; Price, Sharon; Nonomiya, Jim; Lewis, Cristina; Stevens, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) were pursued for more than a decade for the treatment of cancer.  CDK inhibitors are expected to slow the rate of cell division and potentially increase the apoptotic fraction of rapidly dividing cells.  Although CDK activity is often increased in tumors, normal dividing tissues are also susceptible to the cytostatic and cytotoxic effects of CDK inhibitor action.  Therefore the typical toxicity profile assocd. with cytotoxic anti-cancer therapy, bone marrow suppression and gastrointestinal toxicity, is expected with CDK inhibitors.  Bone marrow toxicity and the ensuing delayed peripheral leukocyte suppression often limit the therapeutic application of cytotoxic anticancer drugs.  Here we characterize an unusual bone marrow-independent acute toxicity toward leukocytes from broad spectrum CDK inhibitors in monkeys and rodents.  The potential combination of both acute and delayed immunosuppression would likely further restrict the application of these particular compds.  Since the cells targeted were non-proliferating, it was assumed that the toxicity was not driven by the intended pharmacol. mechanism thereby facilitating the development of a testing strategy to identify compds. with a reduced potential for acute leukocyte toxicity.  This testing strategy resulted in a CDK inhibitor void of bone marrow-independent leukocyte toxicity that is currently undergoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiTrhjO_2vsbVg90H21EOLACvtfcHk0lhIlU3mVodyoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksF2nt70%253D&md5=d8d707eaa40d555e176c15336c8e885b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fjat.1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1177%26sid%3Dliteratum%253Aachs%26aulast%3DJessen%26aufirst%3DB.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DHaines%26aufirst%3DM.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DG.%2BJ.%26atitle%3DPeripheral%2520White%2520Blood%2520Cell%2520Toxicity%2520Induced%2520by%2520Broad%2520Spectrum%2520Cyclin-dependent%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2007%26volume%3D27%26spage%3D133%26epage%3D142%26doi%3D10.1002%2Fjat.1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troche, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlpine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikhe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkhivker, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AG-024322 is a Multi-Targeted CDK Inhibitor with Potent Antitumor Activity <i>In vivo</i></span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1044</span>– <span class="NLM_lpage">1045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1044-1045&author=C.+C.+Zhangauthor=G.+Trocheauthor=Z.+Yanauthor=M.+E.+Arangoauthor=J.+Higginsauthor=D.+Romeroauthor=S.+Kephartauthor=I.+McAlpineauthor=T.+Koudriakovaauthor=J.+Skaptasonauthor=J.+Nonomiyaauthor=D.+Knightonauthor=R.+A.+Ferreauthor=J.+Tikheauthor=G.+Verkhivker&title=AG-024322+is+a+Multi-Targeted+CDK+Inhibitor+with+Potent+Antitumor+Activity+In+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BC.%26aulast%3DTroche%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DRomero%26aufirst%3DD.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DMcAlpine%26aufirst%3DI.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DTikhe%26aufirst%3DJ.%26aulast%3DVerkhivker%26aufirst%3DG.%26atitle%3DAG-024322%2520is%2520a%2520Multi-Targeted%2520CDK%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activity%2520In%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D1044%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhavalkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oft, M.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib (SCH 727965), A Novel and Potent Cyclin-dependent Kinase Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-10-0324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20663931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2344-2353&author=D.+Parryauthor=T.+Guziauthor=F.+Shanahanauthor=N.+Davisauthor=D.+Prabhavalkarauthor=D.+Wiswellauthor=W.+Seghezziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=R.+Dollauthor=A.+Nomeirauthor=W.+Windsorauthor=T.+Fischmannauthor=Y.+Wangauthor=M.+Oft&title=Dinaciclib+%28SCH+727965%29%2C+A+Novel+and+Potent+Cyclin-dependent+Kinase+Inhibitor&doi=10.1158%2F1535-7163.MCT-10-0324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor</span></div><div class="casAuthors">Parry, David; Guzi, Timothy; Shanahan, Frances; Davis, Nicole; Prabhavalkar, Deepa; Wiswell, Derek; Seghezzi, Wolfgang; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Nomeir, Amin; Windsor, William; Fischmann, Thierry; Wang, Yaolin; Oft, Martin; Chen, Taiying; Kirschmeier, Paul; Lees, Emma M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDK) are key pos. regulators of cell cycle progression and attractive targets in oncol.  SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, resp.  SCH 727965 was selected as a clin. candidate using a functional screen in vivo that integrated both efficacy and safety parameters.  Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index.  In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background.  Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects.  SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.  This was assocd. with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematol. parameters.  These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent.  Mol Cancer Ther; 9(8); 2344-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxn1NtmEAh7LVg90H21EOLACvtfcHk0lhIlU3mVodyoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjtrw%253D&md5=bd2d30fdfdca0f2bceb3f5c0b44b8630</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0324%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DPrabhavalkar%26aufirst%3DD.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DNomeir%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DOft%26aufirst%3DM.%26atitle%3DDinaciclib%2520%2528SCH%2520727965%2529%252C%2520A%2520Novel%2520and%2520Potent%2520Cyclin-dependent%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2344%26epage%3D2353%26doi%3D10.1158%2F1535-7163.MCT-10-0324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karikari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido-Laguna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasheed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenhof, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeshkumar, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B. D.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent Kinase Inhibitor Dinaciclib (SCH727965) Inhibits Pancreatic Cancer Growth and Progression in Murine Xenograft Models</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.4161/cbt.12.7.16475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcbt.12.7.16475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21768779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1yitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=598-609&author=G.+Feldmannauthor=A.+Mishraauthor=S.+Bishtauthor=C.+Karikariauthor=I.+Garrido-Lagunaauthor=Z.+Rasheedauthor=N.+A.+Ottenhofauthor=T.+Dadonauthor=H.+Alvarezauthor=V.+Fendrichauthor=N.+V.+Rajeshkumarauthor=W.+Matsuiauthor=P.+Brossartauthor=M.+Hidalgoauthor=R.+Bannerjiauthor=A.+Maitraauthor=B.+D.+Nelkin&title=Cyclin-dependent+Kinase+Inhibitor+Dinaciclib+%28SCH727965%29+Inhibits+Pancreatic+Cancer+Growth+and+Progression+in+Murine+Xenograft+Models&doi=10.4161%2Fcbt.12.7.16475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models</span></div><div class="casAuthors">Feldmann, Georg; Mishra, Anjali; Bisht, Savita; Karikari, Collins; Garrido-Laguna, Ignacio; Rasheed, Zeshaan; Ottenhof, Niki A.; Dadon, Tikva; Alvarez, Hector; Fendrich, Volker; Rajeshkumar, N. V.; Matsui, William; Brossart, Peter; Hidalgo, Manuel; Bannedi, Rajat; Maitra, Anirban; Nelkin, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">598-609</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Pancreatic cancer is one of the most lethal of human malignancies, and potent therapeutic options are lacking.  Inhibition of cell cycle progression through pharmacol. blockade of cyclin-dependent kinases (CDK) has been suggested as a potential treatment option for human cancers with deregulated cell cycle control.  Dinaciclib (SCH727965) is a novel small mol. multi-CDK inhibitor with low nanomolar potency against CDK1, CDK2, CDK5 and CDK9 that has shown favorable toxicity and efficacy in preliminary mouse expts., and has been well tolerated in phase I clin. trials.  In the current study, the therapeutic efficacy of SCH727965 on human pancreatic cancer cells was tested using in vitro and in vivo model systems.  Treatment with SCH727965 significantly reduced in vitro cell growth, motility and colony formation in soft agar of MIAPaCa-2 and Pa20C cells.  These phenotypic changes were accompanied by marked redn. of phosphorylation of Retinoblastoma (Rb) and reduced activation of RalA.  Single agent therapy with SCH727965 (40 mg/kg i.p. twice weekly) for 4 wk significantly reduced s.c. tumor growth in 10/10 (100%) of tested low-passage human pancreatic cancer xenografts.  Treatment of low passage pancreatic cancer xenografts with a combination of SCH727965 and gemcitabine was significantly more effective than either agent alone.  Gene Set Enrichment Anal. identified overrepresentation of the Notch and Transforming Growth Factor-β (TGFβ) signaling pathways in the xenografts least responsive to SCH727965 treatment.  Treatment with the cyclin-dependent kinase inhibitor SCH727965 alone or in combination is a highly promising novel exptl. therapeutic strategy against pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKxXezCaUs9bVg90H21EOLACvtfcHk0lh__NOyNwHAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1yitro%253D&md5=1edbe3fd0d2e95a362cf30cc41230293</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.4161%2Fcbt.12.7.16475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.12.7.16475%26sid%3Dliteratum%253Aachs%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DMishra%26aufirst%3DA.%26aulast%3DBisht%26aufirst%3DS.%26aulast%3DKarikari%26aufirst%3DC.%26aulast%3DGarrido-Laguna%26aufirst%3DI.%26aulast%3DRasheed%26aufirst%3DZ.%26aulast%3DOttenhof%26aufirst%3DN.%2BA.%26aulast%3DDadon%26aufirst%3DT.%26aulast%3DAlvarez%26aufirst%3DH.%26aulast%3DFendrich%26aufirst%3DV.%26aulast%3DRajeshkumar%26aufirst%3DN.%2BV.%26aulast%3DMatsui%26aufirst%3DW.%26aulast%3DBrossart%26aufirst%3DP.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBannerji%26aufirst%3DR.%26aulast%3DMaitra%26aufirst%3DA.%26aulast%3DNelkin%26aufirst%3DB.%2BD.%26atitle%3DCyclin-dependent%2520Kinase%2520Inhibitor%2520Dinaciclib%2520%2528SCH727965%2529%2520Inhibits%2520Pancreatic%2520Cancer%2520Growth%2520and%2520Progression%2520in%2520Murine%2520Xenograft%2520Models%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2011%26volume%3D12%26spage%3D598%26epage%3D609%26doi%3D10.4161%2Fcbt.12.7.16475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-dependent Kinases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1021/ml100051d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100051d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFWis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=204-208&author=K.+Paruchauthor=M.+P.+Dwyerauthor=C.+Alvarezauthor=C.+Brownauthor=T.-Y.+Chanauthor=R.+J.+Dollauthor=K.+Keertikarauthor=C.+Knutsonauthor=B.+McKittrickauthor=J.+Riveraauthor=R.+Rossmanauthor=G.+Tuckerauthor=T.+Fischmannauthor=A.+Hruzaauthor=V.+Madison&title=Discovery+of+Dinaciclib+%28SCH+727965%29%3A+A+Potent+and+Selective+Inhibitor+of+Cyclin-dependent+Kinases&doi=10.1021%2Fml100051d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Paruch, Kamil; Dwyer, Michael P.; Alvarez, Carmen; Brown, Courtney; Chan, Tin-Yau; Doll, Ronald J.; Keertikar, Kerry; Knutson, Chad; McKittrick, Brian; Rivera, Jocelyn; Rossman, Randall; Tucker, Greg; Fischmann, Thierry; Hruza, Alan; Madison, Vincent; Nomeir, Amin A.; Wang, Yaolin; Kirschmeier, Paul; Lees, Emma; Parry, David; Sgambellone, Nicole; Seghezzi, Wolfgang; Schultz, Lesley; Shanahan, Frances; Wiswell, Derek; Xu, Xiaoying; Zhou, Quiao; James, Ray A.; Paradkar, Vidyadhar M.; Park, Haengsoon; Rokosz, Laura R.; Stauffer, Tara M.; Guzi, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncol. therapeutics.  Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability.  This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorrwrMq6CW6rVg90H21EOLACvtfcHk0lh__NOyNwHAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFWis78%253D&md5=3b982547e064f658748fe4887a208659</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fml100051d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100051d%26sid%3Dliteratum%253Aachs%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DT.-Y.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DKnutson%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DFischmann%26aufirst%3DT.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520Dinaciclib%2520%2528SCH%2520727965%2529%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D204%26epage%3D208%26doi%3D10.1021%2Fml100051d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">A cyclin-dependent Kinase Inhibitor, Dinaciclib in Preclinical Treatment Models of Thyroid Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0172315</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0172315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1371%2Fjournal.pone.0172315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28207834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvV2js70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0172315&author=S.+F.+Linauthor=J.+D.+Linauthor=C.+Hsuehauthor=T.+C.+Chouauthor=R.+J.+Wong&title=A+cyclin-dependent+Kinase+Inhibitor%2C+Dinaciclib+in+Preclinical+Treatment+Models+of+Thyroid+Cancer&doi=10.1371%2Fjournal.pone.0172315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer</span></div><div class="casAuthors">Lin, Shu-Fu; Lin, Jen-Der; Hsueh, Chuen; Chou, Ting-Chao; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0172315/1-e0172315/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer.  Materials and methods: Seven cell lines originating from three pathol. types of thyroid cancer (papillary, follicular and anaplastic) were studied.  The cytotoxicity of dinaciclib was measured using a lactate dehydrogenase assay.  The expression of proteins assocd. with cell cycle and apoptosis was assessed using Western blot anal. and immunofluorescence microscopy.  Cell cycle distribution was measured by flow cytometry and immunofluorescence microscopy.  Apoptosis and caspase-3 activity were measured by flow cytometry and fluorometric assay.  Mice bearing flank anaplastic thyroid cancer (ATC) were treated with i.p. injections of dinaciclib.  Results: Dinaciclib inhibited thyroid cancer cell proliferation in a dose-dependent manner.  Dinaciclib had a low median-effect dose (≤ 16.0 nM) to inhibit cell proliferation in seven thyroid cancer cell lines.  Dinaciclib decreased CDK1, cyclin B1, and Aurora A expression, induced cell cycle arrest in the G2/M phase, and induced accumulation of prophase mitotic cells.  Dinaciclib decreased Mcl-1, Bcl-xL and survivin expression, activated caspase-3 and induced apoptosis.  In vivo, the growth of ATC xenograft tumors was retarded in a dose-dependent fashion with daily dinaciclib treatment.  Higher-dose dinaciclib (50 mg/kg) caused slight, but significant wt. loss, which was absent with lower-dose dinaciclib (40 mg/kg) treatment.  Conclusions: Dinaciclib inhibited thyroid cancer proliferation both in vitro and in vivo.  These findings support dinaciclib as a potential drug for further studies in clin. trials for the treatment of patients with refractory thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEykCdurzeXrVg90H21EOLACvtfcHk0lh__NOyNwHAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvV2js70%253D&md5=a849ddd6669c23b1c966a469ce810fb9</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0172315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0172315%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BF.%26aulast%3DLin%26aufirst%3DJ.%2BD.%26aulast%3DHsueh%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DT.%2BC.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DA%2520cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520Dinaciclib%2520in%2520Preclinical%2520Treatment%2520Models%2520of%2520Thyroid%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0172315%26doi%3D10.1371%2Fjournal.pone.0172315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieerkehazhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiple CDK Inhibitor Dinaciclib Suppresses Neuroblastoma Growth <i>via</i> Inhibiting CDK2 and CDK9 Activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29090</span>, <span class="refDoi"> DOI: 10.1038/srep29090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fsrep29090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27378523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=29090&author=Z.+Chenauthor=Z.+Wangauthor=J.+C.+Pangauthor=Y.+Yuauthor=S.+Bieerkehazhiauthor=J.+Luauthor=T.+Huauthor=Y.+Zhaoauthor=X.+Xuauthor=H.+Zhangauthor=J.+S.+Yiauthor=S.+Liuauthor=J.+Yang&title=Multiple+CDK+Inhibitor+Dinaciclib+Suppresses+Neuroblastoma+Growth+via+Inhibiting+CDK2+and+CDK9+Activity&doi=10.1038%2Fsrep29090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity</span></div><div class="casAuthors">Chen, Zhenghu; Wang, Zhenyu; Pang, Jonathan C.; Yu, Yang; Bieerkehazhi, Shayahati; Lu, Jiaxiong; Hu, Ting; Zhao, Yanling; Xu, Xin; Zhang, Hong; Yi, Joanna S.; Liu, Shangfeng; Yang, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29090</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approx. 15% of cancer-related mortality in children.  Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contribute to tumor cell progression in many cancers including NB.  Therefore, small mol. inhibitors of CDKs comprise a strategic option in cancer therapy.  Here we show that a novel multiple-CDK inhibitor, dinaciclib (SCH727965, MK-7965), exhibits potent anti-proliferative effects on a panel of NB cell lines by blocking the activity of CDK2 and CDK9.  Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16).  Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse model of two NB cell lines and blocked tumor development in the TH-MYCN transgenic NB mouse model.  Taken together, this study suggests that CDK2 and CDK9 are potential therapeutic targets in NB and that abrogating CDK2 and CDK9 activity by small mols. like dinaciclib is a promising strategy and a treatment option for NB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpobqy7FGRmgLVg90H21EOLACvtfcHk0lhdPVJCiY6VoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFahtL7M&md5=056d13b71230bd6cbe127371ea5ca3f3</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fsrep29090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29090%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPang%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DBieerkehazhi%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYi%26aufirst%3DJ.%2BS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiple%2520CDK%2520Inhibitor%2520Dinaciclib%2520Suppresses%2520Neuroblastoma%2520Growth%2520via%2520Inhibiting%2520CDK2%2520and%2520CDK9%2520Activity%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D29090%26doi%3D10.1038%2Fsrep29090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moharram, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marhall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, J. U.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the CDK Inhibitor Dinaciclib <i>in vitro</i> and <i>in vivo</i> in T-cell Acute Lymphoblastic Leukemia</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.canlet.2017.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28756008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1CkurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2017&pages=73-78&author=S.+A.+Moharramauthor=K.+Shahauthor=F.+Khanumauthor=A.+Marhallauthor=M.+Gaziauthor=J.+U.+Kazi&title=Efficacy+of+the+CDK+Inhibitor+Dinaciclib+in+vitro+and+in+vivo+in+T-cell+Acute+Lymphoblastic+Leukemia&doi=10.1016%2Fj.canlet.2017.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Moharram, Sausan A.; Shah, Kinjal; Khanum, Fatima; Marhaell, Alissa; Gazi, Mohiuddin; Kazi, Julhash U.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease of the blood affecting children, adolescents and adults.  Although current treatment protocols for T-ALL have improved overall survival, a portion of T-ALL patients still experiences treatment failure.  Thus, the development of novel therapies is needed.  In this study, we used several patient-derived T-ALL cell lines to screen for an effective drug for T-ALL.  Using a panel of 378 inhibitors against different kinases, we identified the CDK inhibitor dinaciclib as a potential drug for T-ALL.  Dinaciclib treatment significantly reduced cell viability and completely blocked colony formation.  Furthermore, cells treated with dinaciclib showed decreased expression of several pro-survival proteins including survivin, cyclin T1 and c-MYC.  Dinaciclib treatment also increased accumulation of cells in G2/M phase and significantly induced apoptosis.  Finally, dinaciclib extended survival of mice in a T-ALL cell xenograft model.  Collectively, these data suggest that the CDK inhibitor dinaciclib is an active drug for T-ALL in the preclin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptsRZLPpSpE7Vg90H21EOLACvtfcHk0lhdPVJCiY6VoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1CkurbF&md5=873f899cd70d91a1afe2bec1b7c8b1d5</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DMoharram%26aufirst%3DS.%2BA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DKhanum%26aufirst%3DF.%26aulast%3DMarhall%26aufirst%3DA.%26aulast%3DGazi%26aufirst%3DM.%26aulast%3DKazi%26aufirst%3DJ.%2BU.%26atitle%3DEfficacy%2520of%2520the%2520CDK%2520Inhibitor%2520Dinaciclib%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520T-cell%2520Acute%2520Lymphoblastic%2520Leukemia%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D405%26spage%3D73%26epage%3D78%26doi%3D10.1016%2Fj.canlet.2017.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarfo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathiraja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derosier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrary
Sisk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Dinaciclib <i>vs</i> Ofatumumab in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1876</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-748210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1182%2Fblood-2016-10-748210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=28126927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1876-1878&author=P.+Ghiaauthor=L.+Scarfoauthor=S.+Perezauthor=K.+Pathirajaauthor=M.+Derosierauthor=K.+Smallauthor=C.+McCrary%0ASiskauthor=N.+Patton&title=Efficacy+and+Safety+of+Dinaciclib+vs+Ofatumumab+in+Patients+with+Relapsed%2Frefractory+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fblood-2016-10-748210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Ghia, Paolo; Scarfo, Lydia; Perez, Susan; Pathiraja, Kumudu; Derosier, Martha; Small, Karen; Sisk, Christine McCrary; Patton, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1876-1878</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">This article relates to results of a randomized, open-label, phase 3 trial designed to compare the efficacy and tolerability of dinaciclib with ofatumumab in patients with relapsed/refractory CLL.  This article relates to potential antileukemic activity and signals an acceptable safety and tolerability profile of dinaciclib compared with ofatumumab in patients with relapsed/refractory CLL, even among high-risk subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBDG-gJoqKebVg90H21EOLACvtfcHk0lhdPVJCiY6VoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7vL&md5=aa30f64f5458fb0def0ad959ab58d666</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-748210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-748210%26sid%3Dliteratum%253Aachs%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DScarfo%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPathiraja%26aufirst%3DK.%26aulast%3DDerosier%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DK.%26aulast%3DMcCrary%2BSisk%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DN.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Dinaciclib%2520vs%2520Ofatumumab%2520in%2520Patients%2520with%2520Relapsed%252Frefractory%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1876%26epage%3D1878%26doi%3D10.1182%2Fblood-2016-10-748210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saladino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D.</span></span> <span> </span><span class="NLM_article-title">CYC065, Potential Therapeutic Agent for AML and MLL Leukaemia</span>. <i>Clin. Lymphoma Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">S183</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2015.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.clml.2015.04.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=S183&author=S.+Frameauthor=C.+Saladinoauthor=S.+Davisauthor=D.+Blakeauthor=D.+Zheleva&title=CYC065%2C+Potential+Therapeutic+Agent+for+AML+and+MLL+Leukaemia&doi=10.1016%2Fj.clml.2015.04.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DS.%26aulast%3DSaladino%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DD.%26aulast%3DZheleva%26aufirst%3DD.%26atitle%3DCYC065%252C%2520Potential%2520Therapeutic%2520Agent%2520for%2520AML%2520and%2520MLL%2520Leukaemia%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26spage%3DS183%26doi%3D10.1016%2Fj.clml.2015.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustachio, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, P. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">djw297</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fjnci%2Fdjw297" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=djw297&author=M.+Kawakamiauthor=L.+M.+Mustachioauthor=J.+Rodriguez-Canalesauthor=B.+Minoauthor=J.+Roszikauthor=P.+Tongauthor=J.+Wangauthor=J.+J.+Leeauthor=J.+H.+Myungauthor=J.+V.+Heymachauthor=F.+M.+Johnsonauthor=S.+Hongauthor=L.+Zhengauthor=S.+Huauthor=P.+A.+Villalobos&title=Next-Generation+CDK2%2F9+Inhibitors+and+Anaphase+Catastrophe+in+Lung+Cancer&doi=10.1093%2Fjnci%2Fdjw297"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw297%26sid%3Dliteratum%253Aachs%26aulast%3DKawakami%26aufirst%3DM.%26aulast%3DMustachio%26aufirst%3DL.%2BM.%26aulast%3DRodriguez-Canales%26aufirst%3DJ.%26aulast%3DMino%26aufirst%3DB.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DMyung%26aufirst%3DJ.%2BH.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DJohnson%26aufirst%3DF.%2BM.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DVillalobos%26aufirst%3DP.%2BA.%26atitle%3DNext-Generation%2520CDK2%252F9%2520Inhibitors%2520and%2520Anaphase%2520Catastrophe%2520in%2520Lung%2520Cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2017%26volume%3D109%26spage%3Ddjw297%26doi%3D10.1093%2Fjnci%2Fdjw297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1000394, A Novel Cyclin-dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono-and in Combination Treatment upon Oral Application</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-12-0286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22821149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=2265-2273&author=G.+Siemeisterauthor=U.+L%C3%BCckingauthor=A.+M.+Wengnerauthor=P.+Lienauauthor=W.+Steinkeauthor=C.+Schatzauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=BAY+1000394%2C+A+Novel+Cyclin-dependent+Kinase+Inhibitor%2C+with+Potent+Antitumor+Activity+in+Mono-and+in+Combination+Treatment+upon+Oral+Application&doi=10.1158%2F1535-7163.MCT-12-0286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application</span></div><div class="casAuthors">Siemeister, Gerhard; Luecking, Ulrich; Wengner, Antje M.; Lienau, Philip; Steinke, Wolfram; Schatz, Christoph; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2265-2273</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulated activity of cyclin-dependent kinases (CDK) results in loss of cell-cycle checkpoint function and increased expression of antiapoptotic proteins, which has been directly linked to the mol. pathol. of cancer.  BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC50 values in the range between 5 and 25 nmol/L.  Cell proliferation was inhibited at low nanomolar concn. in a broad spectrum of human cancer cell lines.  In cell-based assays, the inhibition of phosphorylation of the CDK substrates retinoblastoma protein, nucleophosmin, and RNA polymerase II was shown.  Cell-cycle profiles were consistent with inhibition of CDK 1, 2, and 4 as shown in cell-cycle block and release expts.  The physicochem. and pharmacokinetic properties of BAY 1000394 facilitate rapid absorption and moderate oral bioavailability.  The compd. potently inhibits growth of various human tumor xenografts on athymic mice including models of chemotherapy resistance upon oral dosing.  Furthermore, BAY 1000394 shows more than additive efficacy when combined with cisplatin and etoposide.  These results suggest that BAY 1000394 is a potent pan-CDK inhibitor and a novel oral cytotoxic agent currently in phase I clin. trials.  Mol Cancer Ther; 11(10); 2265-73. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMnyCrxDjqbVg90H21EOLACvtfcHk0lh-wV0rLx_Bfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyksrvK&md5=c175eacd5440b59b113a78a61a89a4b5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0286%26sid%3Dliteratum%253Aachs%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DSchatz%26aufirst%3DC.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DBAY%25201000394%252C%2520A%2520Novel%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520with%2520Potent%2520Antitumor%2520Activity%2520in%2520Mono-and%2520in%2520Combination%2520Treatment%2520upon%2520Oral%2520Application%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D2265%26epage%3D2273%26doi%3D10.1158%2F1535-7163.MCT-12-0286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, A Novel Oral Multi-kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+A+Novel+Oral+Multi-kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lh-wV0rLx_Bfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520A%2520Novel%2520Oral%2520Multi-kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covaciu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonmassar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Atri, S.</span></span> <span> </span><span class="NLM_article-title">The Cyclin-dependent Kinase Inhibitor PHA-848125 Suppresses the <i>In vitro</i> Growth of Human Melanomas Sensitive or Resistant to Temozolomide, and Shows Synergistic Effects in Combination with this Triazene Compound</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2009.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.phrs.2009.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20026273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=437-448&author=S.+Caporaliauthor=E.+Alvinoauthor=G.+Staraceauthor=M.+Ciomeiauthor=M.+G.+Brascaauthor=L.+Levatiauthor=A.+Garbinauthor=D.+Castigliaauthor=C.+Covaciuauthor=E.+Bonmassarauthor=S.+D%E2%80%99Atri&title=The+Cyclin-dependent+Kinase+Inhibitor+PHA-848125+Suppresses+the+In+vitro+Growth+of+Human+Melanomas+Sensitive+or+Resistant+to+Temozolomide%2C+and+Shows+Synergistic+Effects+in+Combination+with+this+Triazene+Compound&doi=10.1016%2Fj.phrs.2009.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound</span></div><div class="casAuthors">Caporali, Simona; Alvino, Ester; Starace, Giuseppe; Ciomei, Marina; Brasca, Maria Gabriella; Levati, Lauretta; Garbin, Alberto; Castiglia, Daniele; Covaciu, Claudia; Bonmassar, Enzo; D'Atri, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">437-448</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PHA-848125 is a novel cyclin-dependent kinase inhibitor under Phase I/II clin. investigation.  In this study, we describe, for the first time, the effect of PHA-848125 on human melanoma cells in vitro.  Seven melanoma cell lines with different sensitivity to temozolomide (TMZ) were exposed to PHA-848125 for 5 days and then assayed for cell growth.  In all cases, including TMZ-resistant cells, PHA-848125 IC50 values were significantly below the max. plasma concns. achievable in the clinic.  In the most PHA-848125-sensitive cell line, the drug caused a concn.-dependent G1 arrest.  PHA-848125 also impaired phosphorylation of the retinoblastoma protein at CDK2 and CDK4 specific sites, decreased retinoblastoma protein and cyclin A levels, and increased p21Cip1, p27Kip1 and p53 expression.  Combined treatment with fixed ratios of TMZ plus PHA-848125 was studied in three melanoma cell lines.  PHA-848125 was added to the cells 48 h after TMZ and cell growth was evaluated after 3 addnl. days of culture.  Parallel expts. were performed in the presence of O6-benzylguanine (BG), to prevent repair of Me adducts at O6-guanine induced by TMZ.  Drug combination of TMZ plus BG and PHA-848125 produced additive or synergistic effects on cell growth, depending on the cell line.  In the absence of BG, the combination was still more active than the single agents in the cell line moderately sensitive to TMZ, but comparable to PHA-848125 alone in the two TMZ-resistant cell lines.  When TMZ plus BG were used in combination with PHA-848125 against cultured normal melanocytes, neither synergistic nor additive antiproliferative effects were obsd.  Our results indicate that PHA-848125 can have a therapeutic potential in melanoma patients, alone or combined with TMZ.  Moreover this agent appears to be particularly attractive on the bases of its effectiveness against TMZ-resistant melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvf6wmJ-DGabVg90H21EOLACvtfcHk0lhqSngxZj_mPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlCitL8%253D&md5=ecae4f53c2ee5100cfbc79a9742ed7fc</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DCaporali%26aufirst%3DS.%26aulast%3DAlvino%26aufirst%3DE.%26aulast%3DStarace%26aufirst%3DG.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DLevati%26aufirst%3DL.%26aulast%3DGarbin%26aufirst%3DA.%26aulast%3DCastiglia%26aufirst%3DD.%26aulast%3DCovaciu%26aufirst%3DC.%26aulast%3DBonmassar%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Atri%26aufirst%3DS.%26atitle%3DThe%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520PHA-848125%2520Suppresses%2520the%2520In%2520vitro%2520Growth%2520of%2520Human%2520Melanomas%2520Sensitive%2520or%2520Resistant%2520to%2520Temozolomide%252C%2520and%2520Shows%2520Synergistic%2520Effects%2520in%2520Combination%2520with%2520this%2520Triazene%2520Compound%26jtitle%3DPharmacol.%2520Res.%26date%3D2010%26volume%3D61%26spage%3D437%26epage%3D448%26doi%3D10.1016%2Fj.phrs.2009.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amboldi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastori, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pevarello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roletto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traquandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span> <span> </span><span class="NLM_article-title">Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), A Potent, Orally Available Cyclin Dependent Kinase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5152</span>– <span class="NLM_lpage">5163</span>, <span class="refDoi"> DOI: 10.1021/jm9006559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-Tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+A+Potent%2C+Orally+Available+Cyclin+Dependent+Kinase+Inhibitor&doi=10.1021%2Fjm9006559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-Tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520A%2520Potent%252C%2520Orally%2520Available%2520Cyclin%2520Dependent%2520Kinase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163%26doi%3D10.1021%2Fjm9006559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Degrassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giusti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciomei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Texido, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of PHA-848125, A Cyclin-dependent Kinase Inhibitor, on the K-Ras(G12D)LA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-09-0726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=20197397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=673-681&author=A.+Degrassiauthor=M.+Russoauthor=C.+Nanniauthor=V.+Pattonauthor=R.+Alzaniauthor=A.+M.+Giustiauthor=S.+Fantiauthor=M.+Ciomeiauthor=E.+Pesentiauthor=G.+Texido&title=Efficacy+of+PHA-848125%2C+A+Cyclin-dependent+Kinase+Inhibitor%2C+on+the+K-Ras%28G12D%29LA2+Lung+Adenocarcinoma+Transgenic+Mouse+Model%3A+Evaluation+by+Multimodality+Imaging&doi=10.1158%2F1535-7163.MCT-09-0726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging</span></div><div class="casAuthors">Degrassi, Anna; Russo, Micaela; Nanni, Cristina; Patton, Veronica; Alzani, Rachele; Giusti, Anna M.; Fanti, Stefano; Ciomei, Marina; Pesenti, Enrico; Texido, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-681</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">K-ras is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), the most common form of lung cancer.  Recent studies indicate that NSCLC patients with mutant K-ras do not respond to epidermal growth factor receptor inhibitors.  In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clin. trial, on a transgenic mouse model, K-RasG12DLA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.  We used magnetic resonance imaging and positron emission tomog. to follow longitudinally disease progression and evaluate therapeutic efficacy in this model.  Treatment of K-RasG12DLA2 mice with 40 mg/kg twice daily for 10 days with PHA-848125 induced a significant tumor growth inhibition at the end of treatment (P < 0.005) and this was accompanied by a redn. in the cell membrane turnover, as seen by 11C-Choline-positron emission tomog. (P < 0.05).  Magnetic resonance imaging data were validated vs. histol. and the mechanism of action of the compd. was verified by immunohistochem., using cyclin-dependent kinase-related biomarkers phospho-Retinoblastoma and cyclin A.  In this study, multimodality imaging was successfully used for the preclin. assessment of PHA-848125 therapeutic efficacy on a lung adenocarcinoma mouse model.  This compd. induced a volumetric and metabolic anticancer effect and could represent a valid therapeutic approach for NSCLC patients with mutant K-ras.  Mol Cancer Ther; 9(3); 673-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUdhs7i0u7T7Vg90H21EOLACvtfcHk0li1bg8VJ_sd1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFensL8%253D&md5=d3f302a36706c2e6a1f6c28b1cba9962</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0726%26sid%3Dliteratum%253Aachs%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DM.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DPatton%26aufirst%3DV.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DGiusti%26aufirst%3DA.%2BM.%26aulast%3DFanti%26aufirst%3DS.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DTexido%26aufirst%3DG.%26atitle%3DEfficacy%2520of%2520PHA-848125%252C%2520A%2520Cyclin-dependent%2520Kinase%2520Inhibitor%252C%2520on%2520the%2520K-Ras%2528G12D%2529LA2%2520Lung%2520Adenocarcinoma%2520Transgenic%2520Mouse%2520Model%253A%2520Evaluation%2520by%2520Multimodality%2520Imaging%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D673%26epage%3D681%26doi%3D10.1158%2F1535-7163.MCT-09-0726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Serra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancera, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artacho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skylaris, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciacchi, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, M. C.</span></span> <span> </span><span class="NLM_article-title">Novel Structural Features of CDK Inhibition Revealed by <i>an ab Initio</i> Computational Method Combined with Dynamic Simulations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5141</span>– <span class="NLM_lpage">5153</span>, <span class="refDoi"> DOI: 10.1021/jm060190+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060190%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5141-5153&author=L.+Headyauthor=M.+Fernandez-Serraauthor=R.+L.+Manceraauthor=S.+Joyceauthor=A.+R.+Venkitaramanauthor=E.+Artachoauthor=C.+K.+Skylarisauthor=L.+C.+Ciacchiauthor=M.+C.+Payne&title=Novel+Structural+Features+of+CDK+Inhibition+Revealed+by+an+ab+Initio+Computational+Method+Combined+with+Dynamic+Simulations&doi=10.1021%2Fjm060190%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm060190%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060190%252B%26sid%3Dliteratum%253Aachs%26aulast%3DHeady%26aufirst%3DL.%26aulast%3DFernandez-Serra%26aufirst%3DM.%26aulast%3DMancera%26aufirst%3DR.%2BL.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26aulast%3DArtacho%26aufirst%3DE.%26aulast%3DSkylaris%26aufirst%3DC.%2BK.%26aulast%3DCiacchi%26aufirst%3DL.%2BC.%26aulast%3DPayne%26aufirst%3DM.%2BC.%26atitle%3DNovel%2520Structural%2520Features%2520of%2520CDK%2520Inhibition%2520Revealed%2520by%2520an%2520ab%2520Initio%2520Computational%2520Method%2520Combined%2520with%2520Dynamic%2520Simulations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5141%26epage%3D5153%26doi%3D10.1021%2Fjm060190%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvert, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel Purine and Pyrimidine Cyclin-dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2797</span>– <span class="NLM_lpage">2804</span>, <span class="refDoi"> DOI: 10.1021/jm990628o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990628o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2797-2804&author=C.+E.+Arrisauthor=F.+T.+Boyleauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=E.+F.+Garmanauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=S.+Grantauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=A.+M.+Lawrieauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=E.+A.+Sausvilleauthor=R.+Schultzauthor=W.+Yu&title=Identification+of+Novel+Purine+and+Pyrimidine+Cyclin-dependent+Kinase+Inhibitors+with+Distinct+Molecular+Interactions+and+Tumor+Cell+Growth+Inhibition+Profiles&doi=10.1021%2Fjm990628o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Fjm990628o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990628o%26sid%3Dliteratum%253Aachs%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGarman%26aufirst%3DE.%2BF.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520Novel%2520Purine%2520and%2520Pyrimidine%2520Cyclin-dependent%2520Kinase%2520Inhibitors%2520with%2520Distinct%2520Molecular%2520Interactions%2520and%2520Tumor%2520Cell%2520Growth%2520Inhibition%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2797%26epage%3D2804%26doi%3D10.1021%2Fjm990628o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, H. J.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of a Potent Purine-based Cyclin-dependent Kinase Inhibitor</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1038/nsb842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnsb842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=745-749&author=T.+G.+Daviesauthor=J.+Bentleyauthor=C.+E.+Arrisauthor=F.+T.+Boyleauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=I.+R.+Hardcastleauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=J.+A.+Tuckerauthor=L.+Wangauthor=H.+J.+Whitfield&title=Structure-based+Design+of+a+Potent+Purine-based+Cyclin-dependent+Kinase+Inhibitor&doi=10.1038%2Fnsb842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fnsb842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb842%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhitfield%26aufirst%3DH.%2BJ.%26atitle%3DStructure-based%2520Design%2520of%2520a%2520Potent%2520Purine-based%2520Cyclin-dependent%2520Kinase%2520Inhibitor%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D745%26epage%3D749%26doi%3D10.1038%2Fnsb842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span> <span> </span><span class="NLM_article-title">4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00884-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-894X%2802%2900884-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=217-222&author=V.+Mesguicheauthor=R.+J.+Parsonsauthor=C.+E.+Arrisauthor=J.+Bentleyauthor=F.+T.+Boyleauthor=N.+J.+Curtinauthor=T.+G.+Daviesauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=L.+Z.+Wangauthor=I.+R.+Hardcastle&title=4-Alkoxy-2%2C6-diaminopyrimidine+Derivatives%3A+Inhibitors+of+Cyclin+Dependent+Kinases+1+and+2&doi=10.1016%2FS0960-894X%2802%2900884-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900884-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900884-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DParsons%26aufirst%3DR.%2BJ.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26atitle%3D4-Alkoxy-2%252C6-diaminopyrimidine%2520Derivatives%253A%2520Inhibitors%2520of%2520Cyclin%2520Dependent%2520Kinases%25201%2520and%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D217%26epage%3D222%26doi%3D10.1016%2FS0960-894X%2802%2900884-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arris, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyerol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitfield, H. J.</span></span> <span> </span><span class="NLM_article-title">N2-Substituted O6-cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-dependent Kinases 1 and 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3710</span>– <span class="NLM_lpage">3722</span>, <span class="refDoi"> DOI: 10.1021/jm0311442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0311442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3710-3722&author=I.+R.+Hardcastleauthor=C.+E.+Arrisauthor=J.+Bentleyauthor=F.+T.+Boyleauthor=Y.+Chenauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=J.+Menyerolauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=D.+J.+Prattauthor=L.+Z.+Wangauthor=H.+J.+Whitfield&title=N2-Substituted+O6-cyclohexylmethylguanine+Derivatives%3A+Potent+Inhibitors+of+Cyclin-dependent+Kinases+1+and+2&doi=10.1021%2Fjm0311442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2</span></div><div class="casAuthors">Hardcastle, Ian R.; Arris, Christine E.; Bentley, Johanne; Boyle, F. Thomas; Chen, Yuzhu; Curtin, Nicola J.; Endicott, Jane A.; Gibson, Ashleigh E.; Golding, Bernard T.; Griffin, Roger J.; Jewsbury, Philip; Menyerol, Jerome; Mesguiche, Veronique; Newell, David R.; Noble, Martin E. M.; Pratt, David J.; Wang, Lan-Zhen; Whitfield, Hayley J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3710-3722</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ATP competitive cyclin-dependent kinase inhibitor O6-cyclohexylmethylguanine (NU2058, 1) has been employed as the lead in a structure-based drug discovery program resulting in the discovery of the potent CDK1 and -2 inhibitor NU6102 (3, IC50 = 9.5 nM and 5.4 nM vs CDK1/cyclin B and CDK2/cyclin A3, resp.).  The SAR for this series have been explored further by the synthesis and evaluation of 45 N2-substituted analogs of NU2058.  These studies have confirmed the requirement for the hydrogen bonding N2-NH group and the requirement for an arom. N2-substituent to confer potency in the series.  Addnl. potency is conferred by the presence of a group capable of donating a hydrogen bond at the 4'-position, for example, the 4'-hydroxy deriv. (25, IC50 = 94 nM and 69 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.), 4'-monomethylsulfonamide deriv. (28, IC50 = 9 nM and 7.0 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.), and 4'-carboxamide deriv. (34, IC50 = 67 nM and 64 nM vs. CDK1/cyclinB and CDK2/cyclin A3, resp.).  X-ray crystal structures have been obtained for key compds. and have been used to explain the obsd. trends in activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdDB9D6YHzKLVg90H21EOLACvtfcHk0ljad3TvfC4aVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gisbg%253D&md5=305eef50961c3f1ffad033cf9ab18c3f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm0311442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0311442%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DMenyerol%26aufirst%3DJ.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWhitfield%26aufirst%3DH.%2BJ.%26atitle%3DN2-Substituted%2520O6-cyclohexylmethylguanine%2520Derivatives%253A%2520Potent%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%25201%2520and%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3710%26epage%3D3722%26doi%3D10.1021%2Fjm0311442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayle, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggerty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesguiche, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of 2-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1577</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1039/b703241b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1039%2Fb703241b" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=1577-1585&author=F.+Marchettiauthor=K.+L.+Sayleauthor=J.+Bentleyauthor=W.+Cleggauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=K.+Haggertyauthor=R.+W.+Harringtonauthor=V.+Mesguicheauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=R.+J.+Parsonsauthor=D.+J.+Prattauthor=L.+Z.+Wangauthor=I.+R.+Hardcastle&title=Structure-based+Design+of+2-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.1039%2Fb703241b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1039%2Fb703241b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703241b%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti%26aufirst%3DF.%26aulast%3DSayle%26aufirst%3DK.%2BL.%26aulast%3DBentley%26aufirst%3DJ.%26aulast%3DClegg%26aufirst%3DW.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHarrington%26aufirst%3DR.%2BW.%26aulast%3DMesguiche%26aufirst%3DV.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DParsons%26aufirst%3DR.%2BJ.%26aulast%3DPratt%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26atitle%3DStructure-based%2520Design%2520of%25202-Arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2007%26volume%3D5%26spage%3D1577%26epage%3D1585%26doi%3D10.1039%2Fb703241b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaurasia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasco, A.</span></span> <span> </span><span class="NLM_article-title">6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A New Scaffold Endowed with Potent CDK2 Inhibitory Activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.ejmech.2013.07.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=333-338&author=D.+Boschiauthor=P.+Toscoauthor=N.+Chandraauthor=S.+Chaurasiaauthor=R.+Frutteroauthor=R.+Griffinauthor=L.+Z.+Wangauthor=A.+Gasco&title=6-Cyclohexylmethoxy-5-%28cyano-NNO-azoxy%29pyrimidine-4-amine%3A+A+New+Scaffold+Endowed+with+Potent+CDK2+Inhibitory+Activity&doi=10.1016%2Fj.ejmech.2013.07.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DBoschi%26aufirst%3DD.%26aulast%3DTosco%26aufirst%3DP.%26aulast%3DChandra%26aufirst%3DN.%26aulast%3DChaurasia%26aufirst%3DS.%26aulast%3DFruttero%26aufirst%3DR.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGasco%26aufirst%3DA.%26atitle%3D6-Cyclohexylmethoxy-5-%2528cyano-NNO-azoxy%2529pyrimidine-4-amine%253A%2520A%2520New%2520Scaffold%2520Endowed%2520with%2520Potent%2520CDK2%2520Inhibitory%2520Activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D333%26epage%3D338%26doi%3D10.1016%2Fj.ejmech.2013.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carbain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggerty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">8-Substituted O(6)-cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-based Inhibitor Design to Optimize an Alternative Binding Mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1021/jm401555v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401555v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=56-70&author=B.+Carbainauthor=D.+J.+Patersonauthor=E.+Anscombeauthor=A.+J.+Campbellauthor=C.+Canoauthor=A.+Echalierauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=K.+Haggertyauthor=I.+R.+Hardcastleauthor=P.+J.+Jewsburyauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=C.+Rocheauthor=L.+Z.+Wangauthor=R.+J.+Griffin&title=8-Substituted+O%286%29-cyclohexylmethylguanine+CDK2+Inhibitors%3A+Using+Structure-based+Inhibitor+Design+to+Optimize+an+Alternative+Binding+Mode&doi=10.1021%2Fjm401555v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm401555v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401555v%26sid%3Dliteratum%253Aachs%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DD.%2BJ.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3D8-Substituted%2520O%25286%2529-cyclohexylmethylguanine%2520CDK2%2520Inhibitors%253A%2520Using%2520Structure-based%2520Inhibitor%2520Design%2520to%2520Optimize%2520an%2520Alternative%2520Binding%2520Mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D56%26epage%3D70%26doi%3D10.1021%2Fjm401555v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meschini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Vidal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielson, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuillon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of an Irreversible Inhibitor of CDK2</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1159</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2015.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26320860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1159-1164&author=E.+Anscombeauthor=E.+Meschiniauthor=R.+Mora-Vidalauthor=M.+P.+Martinauthor=D.+Stauntonauthor=M.+Geitmannauthor=U.+H.+Danielsonauthor=W.+A.+Stanleyauthor=L.+Z.+Wangauthor=T.+Reuillonauthor=B.+T.+Goldingauthor=C.+Canoauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=S.+R.+Wedgeauthor=J.+A.+Endicottauthor=R.+J.+Griffin&title=Identification+and+Characterization+of+an+Irreversible+Inhibitor+of+CDK2&doi=10.1016%2Fj.chembiol.2015.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of an Irreversible Inhibitor of CDK2</span></div><div class="casAuthors">Anscombe, Elizabeth; Meschini, Elisa; Mora-Vidal, Regina; Martin, Mathew P.; Staunton, David; Geitmann, Matthis; Danielson, U. Helena; Stanley, Will A.; Wang, Lan Z.; Reuillon, Tristan; Golding, Bernard T.; Cano, Celine; Newell, David R.; Noble, Martin E. M.; Wedge, Stephen R.; Endicott, Jane A.; Griffin, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1159-1164</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible inhibitors that modify cysteine or lysine residues within a protein kinase ATP binding site offer, through their distinctive mode of action, an alternative to ATP-competitive agents.  4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)benzenesulfonamide (NU6102) is a potent and selective ATP-competitive inhibitor of CDK2 in which the sulfonamide moiety is positioned close to a pair of lysine residues.  Guided by the CDK2/NU6102 structure, we designed 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300), which binds covalently to CDK2 as shown by a co-complex crystal structure.  Acute incubation with NU6300 produced a durable inhibition of Rb phosphorylation in SKUT-1B cells, consistent with it acting as an irreversible CDK2 inhibitor.  NU6300 is the first covalent CDK2 inhibitor to be described, and illustrates the potential of vinyl sulfones for the design of more potent and selective compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEjfhxiEvjbVg90H21EOLACvtfcHk0liYWjzPhdn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL7M&md5=e6a29b14eb31abd659a48511bb11ed98</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DMeschini%26aufirst%3DE.%26aulast%3DMora-Vidal%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DStaunton%26aufirst%3DD.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DStanley%26aufirst%3DW.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DReuillon%26aufirst%3DT.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520an%2520Irreversible%2520Inhibitor%2520of%2520CDK2%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1159%26epage%3D1164%26doi%3D10.1016%2Fj.chembiol.2015.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chegaev, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruttero, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of N(2)-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcmdc.201600108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27355194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1705-1708&author=D.+Corteseauthor=K.+Chegaevauthor=S.+Guglielmoauthor=L.+Z.+Wangauthor=B.+T.+Goldingauthor=C.+Canoauthor=R.+Fruttero&title=Synthesis+and+Biological+Evaluation+of+N%282%29-Substituted+2%2C4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines+and+Related+5-Cyano-NNO-azoxy+Derivatives+as+Cyclin-Dependent+Kinase+2+%28CDK2%29+Inhibitors&doi=10.1002%2Fcmdc.201600108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors</span></div><div class="casAuthors">Cortese, Daniela; Chegaev, Konstantin; Guglielmo, Stefano; Wang, Lan Z.; Golding, Bernard T.; Cano, Celine; Fruttero, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1705-1708</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor NU6027 (6-cyclohexylmethoxy-5-nitroso-2,4-diaminopyrimidine) was used as the lead for the synthesis of a series of analogs in order to provide further insight into the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.  Aliph. amino substituents were introduced at position 2.  The use of linear or less sterically hindered amines gave rise to compds. endowed with slightly better activity than the lead; on the other hand, the compds. were less active if a bulkier amino substituent was used.  Substitution of the 5-nitroso group with a 5-cyano-NNO-azoxy moiety afforded a new class of inhibitors, the activity of which against CDK2 was found to be similar to that of the nitroso series.  The most active nitroso compd. was (2S)-2-[(4-amino-6-cyclohexylmethoxy-5-nitrosopyrimidin-2-yl)amino]propan-1-ol (IC50=0.16 μm), while in the 5-cyano-NNO-azoxy series the most active compd. was 4-amino-5-[(Z)-cyano-NNO-azoxy]-2-{[(2S)-1-hydroxypropan-2-yl]amino}-6-cyclohexylmethoxypyrimidine (IC50=0.30 μm).  Taken together, these new analogs of NU6027 enhance our understanding of the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc8zFq1q29fLVg90H21EOLACvtfcHk0liYWjzPhdn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyhs7fK&md5=d04c8a4f75b087b79d5eca20afba87cf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600108%26sid%3Dliteratum%253Aachs%26aulast%3DCortese%26aufirst%3DD.%26aulast%3DChegaev%26aufirst%3DK.%26aulast%3DGuglielmo%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DFruttero%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520N%25282%2529-Substituted%25202%252C4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines%2520and%2520Related%25205-Cyano-NNO-azoxy%2520Derivatives%2520as%2520Cyclin-Dependent%2520Kinase%25202%2520%2528CDK2%2529%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1705%26epage%3D1708%26doi%3D10.1002%2Fcmdc.201600108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anscombe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harnor, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korolchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudhope, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedge, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano, C.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1746</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1746-1767&author=C.+R.+Coxonauthor=E.+Anscombeauthor=S.+J.+Harnorauthor=M.+P.+Martinauthor=B.+Carbainauthor=B.+T.+Goldingauthor=I.+R.+Hardcastleauthor=L.+K.+Harlowauthor=S.+Korolchukauthor=C.+J.+Mathesonauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=M.+Sivaprakasamauthor=S.+J.+Tudhopeauthor=D.+M.+Turnerauthor=L.+Z.+Wangauthor=S.+R.+Wedgeauthor=C.+Wongauthor=R.+J.+Griffinauthor=J.+A.+Endicottauthor=C.+Cano&title=Cyclin-Dependent+Kinase+%28CDK%29+Inhibitors%3A+Structure-Activity+Relationships+and+Insights+into+the+CDK-2+Selectivity+of+6-Substituted+2-Arylaminopurines&doi=10.1021%2Facs.jmedchem.6b01254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines</span></div><div class="casAuthors">Coxon, Christopher R.; Anscombe, Elizabeth; Harnor, Suzannah J.; Martin, Mathew P.; Carbain, Benoit; Golding, Bernard T.; Hardcastle, Ian R.; Harlow, Lisa K.; Korolchuk, Svitlana; Matheson, Christopher J.; Newell, David R.; Noble, Martin E. M.; Sivaprakasam, Mangaleswaran; Tudhope, Susan J.; Turner, David M.; Wang, Lan Z.; Wedge, Stephen R.; Wong, Christopher; Griffin, Roger J.; Endicott, Jane A.; Cano, Celine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1746-1767</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Purines and related heterocycles substituted at C-2 with 4'-sulfamoylanilino and at C-6 with a variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1.  6-Substituents that favor competitive inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1.  Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) that exhibited high potency towards CDK2 (IC50 0.044 μM), but was ∼ 2000-fold less active towards CDK1 (IC50 86 μM).  This compd. is therefore a useful tool for studies of cell cycle regulation.  Crystal structures of inhibitor-kinase complexes showed that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket, and that is preferred in CDK2, but has not been obsd. in CDK1.  This aspect of the active site may be exploited for the design of inhibitors that distinguish between CDK1 and CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYzXYCKo7CrVg90H21EOLACvtfcHk0lj6peMrfc44cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7fK&md5=520549b69fec2b2af9758bfcf8708c55</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01254%26sid%3Dliteratum%253Aachs%26aulast%3DCoxon%26aufirst%3DC.%2BR.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DHarnor%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DHarlow%26aufirst%3DL.%2BK.%26aulast%3DKorolchuk%26aufirst%3DS.%26aulast%3DMatheson%26aufirst%3DC.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSivaprakasam%26aufirst%3DM.%26aulast%3DTudhope%26aufirst%3DS.%2BJ.%26aulast%3DTurner%26aufirst%3DD.%2BM.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DCano%26aufirst%3DC.%26atitle%3DCyclin-Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%253A%2520Structure-Activity%2520Relationships%2520and%2520Insights%2520into%2520the%2520CDK-2%2520Selectivity%2520of%25206-Substituted%25202-Arylaminopurines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1746%26epage%3D1767%26doi%3D10.1021%2Facs.jmedchem.6b01254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Gahmen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesely, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">391</span>, <span class="refDoi"> DOI: 10.1002/prot.340220408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fprot.340220408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1995&pages=378-391&author=U.+Schulze-Gahmenauthor=J.+Brandsenauthor=H.+D.+Jonesauthor=D.+O.+Morganauthor=L.+Meijerauthor=J.+Veselyauthor=S.+H.+Kim&title=Multiple+Modes+of+Ligand+Recognition%3A+Crystal+Structures+of+Cyclin-dependent+Protein+Kinase+2+in+Complex+with+ATP+and+Two+Inhibitors%2C+Olomoucine+and+Isopentenyladenine&doi=10.1002%2Fprot.340220408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fprot.340220408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340220408%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26aulast%3DBrandsen%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DVesely%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DMultiple%2520Modes%2520of%2520Ligand%2520Recognition%253A%2520Crystal%2520Structures%2520of%2520Cyclin-dependent%2520Protein%2520Kinase%25202%2520in%2520Complex%2520with%2520ATP%2520and%2520Two%2520Inhibitors%252C%2520Olomoucine%2520and%2520Isopentenyladenine%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1995%26volume%3D22%26spage%3D378%26epage%3D391%26doi%3D10.1002%2Fprot.340220408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oumata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">CR8, A Potent and Selective, Roscovitine-derived Inhibitor of Cyclin-dependent Kinases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5797</span>– <span class="NLM_lpage">5807</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fonc.2008.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18574471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFyqtrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5797-5807&author=K.+Bettayebauthor=N.+Oumataauthor=A.+Echalierauthor=Y.+Ferandinauthor=J.+A.+Endicottauthor=H.+Galonsauthor=L.+Meijer&title=CR8%2C+A+Potent+and+Selective%2C+Roscovitine-derived+Inhibitor+of+Cyclin-dependent+Kinases&doi=10.1038%2Fonc.2008.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases</span></div><div class="casAuthors">Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J. A.; Galons, H.; Meijer, L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">5797-5807</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Among the ten pharmacol. inhibitors of cyclin-dependent kinases (CDKs) currently in clin. trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers.  An extensive medicinal chem. study, designed to generate more potent analogs of roscovitine, led to the identification of an optimal substitution at the N6 position (compd. CR8).  An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9.  CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases.  Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions.  The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells.  CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine.  CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium redn. (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold).  This improved cell death-inducing activity of CR8 over (R)-roscovitine was obsd. in 25 different cell lines.  Altogether these results show that second-generation analogs of (R)-roscovitine can be designed with improved antitumor potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvXAJQBwEMJbVg90H21EOLACvtfcHk0lj6peMrfc44cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFyqtrfI&md5=31e226f8a2f23caf88e6c9422138d2d7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.191%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DOumata%26aufirst%3DN.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGalons%26aufirst%3DH.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DCR8%252C%2520A%2520Potent%2520and%2520Selective%252C%2520Roscovitine-derived%2520Inhibitor%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5797%26epage%3D5807%26doi%3D10.1038%2Fonc.2008.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thunnissen, A.-M. W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinoza, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeClerc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1126/science.281.5376.533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1126%2Fscience.281.5376.533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9677190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=533-538&author=N.+S.+Grayauthor=L.+Wodickaauthor=A.-M.+W.+H.+Thunnissenauthor=T.+C.+Normanauthor=S.+Kwonauthor=F.+H.+Espinozaauthor=D.+O.+Morganauthor=G.+Barnesauthor=S.+LeClercauthor=L.+Meijerauthor=S.-H.+Kimauthor=D.+J.+Lockhartauthor=P.+G.+Schultz&title=Exploiting+Chemical+Libraries%2C+Structure%2C+and+Genomics+in+the+Search+for+Kinase+Inhibitors&doi=10.1126%2Fscience.281.5376.533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span></div><div class="casAuthors">Gray, Nathanael S.; Wodicka, Lisa; Thunnissen, Andy-Mark W. H.; Norman, Thea C.; Kwon, Soojin; Espinoza, F. Hernan; Morgan, David O.; Barnes, Georjana; LeClerc, Sophie; Meijer, Laurent; Kim, Sung-Hou; Lockhart, David J.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5376</span>),
    <span class="NLM_cas:pages">533-538</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP-binding site of the human cyclin-dependent kinase 2 (CDK2).  By iterating chem. library synthesis and biol. screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified.  The structural basis for the binding affinity and selectivity was detd. by anal. of a three-dimensional crystal structure of a CDK2-inhibitor complex.  The cellular effects of these compds. were characterized in mammalian cells and yeast.  In the latter case the effects were characterized on a genome-wide scale by monitoring changes in mRNA levels in treated cells with high-d. oligonucleotide probe arrays.  Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may led to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTOOPjk16tbVg90H21EOLACvtfcHk0lichl1JjfU5mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D&md5=08b8debe4d05c1169c152ccd6676def8</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5376.533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5376.533%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWodicka%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.-M.%2BW.%2BH.%26aulast%3DNorman%26aufirst%3DT.%2BC.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DEspinoza%26aufirst%3DF.%2BH.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DLeClerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DExploiting%2520Chemical%2520Libraries%252C%2520Structure%252C%2520and%2520Genomics%2520in%2520the%2520Search%2520for%2520Kinase%2520Inhibitors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D533%26epage%3D538%26doi%3D10.1126%2Fscience.281.5376.533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camasses, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodimont, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheinerman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasinska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D.</span></span> <span> </span><span class="NLM_article-title">An Integrated Chemical Biology Approach Provides Insight Into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1028</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2012.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22921070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1028-1040&author=A.+Echalierauthor=E.+Cotauthor=A.+Camassesauthor=E.+Hodimontauthor=F.+Hohauthor=P.+Jayauthor=F.+Sheinermanauthor=L.+Krasinskaauthor=D.+Fisher&title=An+Integrated+Chemical+Biology+Approach+Provides+Insight+Into+Cdk2+Functional+Redundancy+and+Inhibitor+Sensitivity&doi=10.1016%2Fj.chembiol.2012.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity</span></div><div class="casAuthors">Echalier, Aude; Cot, Emilie; Camasses, Alain; Hodimont, Elsie; Hoh, Francois; Jay, Philippe; Sheinerman, Felix; Krasinska, Liliana; Fisher, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1028-1040</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cdk2 promotes DNA replication and is a promising cancer therapeutic target, but its functions appear redundant with Cdk1, an essential Cdk affected by most Cdk2 inhibitors.  Here, we present an integrated multidisciplinary approach to address Cdk redundancy.  Math. modeling of enzymol. data predicted conditions allowing selective chem. Cdk2 inhibition.  Together with expts. in Xenopus egg exts., this supports a rate-limiting role for Cdk2 in DNA replication.  To confirm this we designed inhibitor-resistant (ir)-Cdk2 mutants using a novel bioinformatics approach.  Bypassing inhibition with ir-Cdk2 or with Cdk1 shows that Cdk2 is rate-limiting for replication in this system because Cdk1 is insufficiently active.  Addnl., crystal structures and kinetics reveal alternative binding modes of Cdk1-selective and Cdk2-selective inhibitors and mechanisms of Cdk2 inhibitor resistance.  Our approach thus provides insight into structure, functions, and biochem. of a cyclin-dependent kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRa9UiVuPpOLVg90H21EOLACvtfcHk0lichl1JjfU5mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kku7zN&md5=d134c52fd1ad5442e07bec46a3edd9be</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DCot%26aufirst%3DE.%26aulast%3DCamasses%26aufirst%3DA.%26aulast%3DHodimont%26aufirst%3DE.%26aulast%3DHoh%26aufirst%3DF.%26aulast%3DJay%26aufirst%3DP.%26aulast%3DSheinerman%26aufirst%3DF.%26aulast%3DKrasinska%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DD.%26atitle%3DAn%2520Integrated%2520Chemical%2520Biology%2520Approach%2520Provides%2520Insight%2520Into%2520Cdk2%2520Functional%2520Redundancy%2520and%2520Inhibitor%2520Sensitivity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1028%26epage%3D1040%26doi%3D10.1016%2Fj.chembiol.2012.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filgueira De Azevedo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlicek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-dependent Kinases by Purine Analogues: Crystal Structure of Human Cdk2 Complexed with Roscovitine</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1111/j.1432-1033.1997.0518a.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1111%2Fj.1432-1033.1997.0518a.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=9030780" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1997&pages=518-526&author=W.+Filgueira+De+Azevedoauthor=S.+Leclercauthor=L.+Meijerauthor=L.+Havlicekauthor=M.+Strnadauthor=S.+H.+Kim&title=Inhibition+of+Cyclin-dependent+Kinases+by+Purine+Analogues%3A+Crystal+Structure+of+Human+Cdk2+Complexed+with+Roscovitine&doi=10.1111%2Fj.1432-1033.1997.0518a.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1997.0518a.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1997.0518a.x%26sid%3Dliteratum%253Aachs%26aulast%3DFilgueira%2BDe%2BAzevedo%26aufirst%3DW.%26aulast%3DLeclerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DStrnad%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DInhibition%2520of%2520Cyclin-dependent%2520Kinases%2520by%2520Purine%2520Analogues%253A%2520Crystal%2520Structure%2520of%2520Human%2520Cdk2%2520Complexed%2520with%2520Roscovitine%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1997%26volume%3D243%26spage%3D518%26epage%3D526%26doi%3D10.1111%2Fj.1432-1033.1997.0518a.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J.</span></span> <span> </span><span class="NLM_article-title">Probing the Links Between <i>In vitro</i> Potency, ADMET and Physicochemical Parameters</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1038/nrd3367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+Links+Between+In+vitro+Potency%2C+ADMET+and+Physicochemical+Parameters&doi=10.1038%2Fnrd3367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0lhKGfidWrTPMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520Links%2520Between%2520In%2520vitro%2520Potency%252C%2520ADMET%2520and%2520Physicochemical%2520Parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208%26doi%3D10.1038%2Fnrd3367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisinga, W.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based Inhibition: Deriving K<sub>I</sub> and K<sub>inact</sub> Directly from Time-Dependent IC<sub>50</sub> Values</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">923</span>, <span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.-F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-based+Inhibition%3A+Deriving+KI+and+Kinact+Directly+from+Time-Dependent+IC50+Values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0lhKGfidWrTPMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.-F.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-based%2520Inhibition%253A%2520Deriving%2520KI%2520and%2520Kinact%2520Directly%2520from%2520Time-Dependent%2520IC50%2520Values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camarillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span> <span> </span><span class="NLM_article-title">Covalent Modification of CDK2 by 4-Hydroxynonenal as a Mechanism of Inhibition of Cell Cycle Progression</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=323-332&author=J.+M.+Camarilloauthor=K.+L.+Roseauthor=J.+J.+Galliganauthor=S.+Xuauthor=L.+J.+Marnett&title=Covalent+Modification+of+CDK2+by+4-Hydroxynonenal+as+a+Mechanism+of+Inhibition+of+Cell+Cycle+Progression&doi=10.1021%2Facs.chemrestox.5b00485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DCamarillo%26aufirst%3DJ.%2BM.%26aulast%3DRose%26aufirst%3DK.%2BL.%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DCovalent%2520Modification%2520of%2520CDK2%2520by%25204-Hydroxynonenal%2520as%2520a%2520Mechanism%2520of%2520Inhibition%2520of%2520Cell%2520Cycle%2520Progression%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D323%26epage%3D332%26doi%3D10.1021%2Facs.chemrestox.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluations of Pyrazolo[3,4-<i>d</i>]pyrimidines as Cyclin-dependent Kinase 2 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(03)00065-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0223-5234%2803%2900065-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=525-532&author=D.+C.+Kimauthor=Y.+R.+Leeauthor=B.+S.+Yangauthor=K.+J.+Shinauthor=D.+J.+Kimauthor=B.+Y.+Chungauthor=K.+H.+Yoo&title=Synthesis+and+Biological+Evaluations+of+Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Cyclin-dependent+Kinase+2+Inhibitors&doi=10.1016%2FS0223-5234%2803%2900065-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900065-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900065-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DYang%26aufirst%3DB.%2BS.%26aulast%3DShin%26aufirst%3DK.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BJ.%26aulast%3DChung%26aufirst%3DB.%2BY.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluations%2520of%2520Pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Cyclin-dependent%2520Kinase%25202%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D525%26epage%3D532%26doi%3D10.1016%2FS0223-5234%2803%2900065-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayyad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merugu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushwaha, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpoormath, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Some Novel 4,6-disubstituted Pyrazolo[3,4-<i>d</i>]pyrimidines as Cyclin-dependent Kinase 2 (CDK2) Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bioorg.2018.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=29753773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptl2ju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2018&pages=46-59&author=S.+Cherukupalliauthor=B.+Chandrasekaranauthor=V.+Krystofauthor=R.+R.+Aletiauthor=N.+Sayyadauthor=S.+R.+Meruguauthor=N.+D.+Kushwahaauthor=R.+Karpoormath&title=Synthesis%2C+Anticancer+Evaluation%2C+and+Molecular+Docking+Studies+of+Some+Novel+4%2C6-disubstituted+Pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Cyclin-dependent+Kinase+2+%28CDK2%29+Inhibitors&doi=10.1016%2Fj.bioorg.2018.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors</span></div><div class="casAuthors">Cherukupalli, Srinivasulu; Chandrasekaran, Balakumar; Krystof, Vladimir; Aleti, Rajeshwar Reddy; Sayyad, Nisar; Merugu, Srinivas Reddy; Kushwaha, Narva Deshwar; Karpoormath, Rajshekhar</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of 4,6-disubstituted pyrazolo[3,4-d]pyrimidines (7-43) bearing various anilines at C-4 position and thiophenethyl or thiopentane moieties at C-6 position have been designed and synthesized by mol. hybridization approach.  All the synthesized compds. were evaluated for in vitro CDK2/cyclin E and Abl kinase inhibitory activity as well as anti-proliferative activity against K-562 (chronic myelogeneous leukemia), and MCF-7 (breast adenocarcinoma) cell lines.  The structure-activity relationship (SAR) studies revealed that compds. with thiophenethyl group at C-6 with mono-substituted anilines at C-4 exhibited better CDK2 inhibitory activity compared to alkyl group (thiopentane) at C-6 and di-substituted anilines at C-4 of the scaffold.  In particular, compds. having 2-chloro, 3-nitro and 4-methylthio aniline groups at C-4 displayed significant enzymic inhibitory activity against CDK2 with single digit micromolar IC50 values.  The in silico mol. docking studies suggested possible binding orientation and the binding energies were in agreement with the obsd. SAR as well as exptl. results.  In addn., some of the synthesized compds. showed anti-proliferative effects against K-562 and MCF-7 cancer cell lines with IC50 values in a micromolar range.  Thus, the synthesized compds. could be considered as new anticancer hits for further lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2PV0fqijqG7Vg90H21EOLACvtfcHk0liYGPwQBS0Jow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptl2ju78%253D&md5=730e49d92ab8d7f20eab898ef9c29a47</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DChandrasekaran%26aufirst%3DB.%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DSayyad%26aufirst%3DN.%26aulast%3DMerugu%26aufirst%3DS.%2BR.%26aulast%3DKushwaha%26aufirst%3DN.%2BD.%26aulast%3DKarpoormath%26aufirst%3DR.%26atitle%3DSynthesis%252C%2520Anticancer%2520Evaluation%252C%2520and%2520Molecular%2520Docking%2520Studies%2520of%2520Some%2520Novel%25204%252C6-disubstituted%2520Pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Cyclin-dependent%2520Kinase%25202%2520%2528CDK2%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D79%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.bioorg.2018.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alikian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine is a Potent Inhibitor of Cyclin-dependent Protein Kinases 1, 2, and 9, which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8508</span>– <span class="NLM_lpage">8522</span>, <span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+Potent+Inhibitor+of+Cyclin-dependent+Protein+Kinases+1%2C+2%2C+and+9%2C+which+Demonstrates+Antitumor+Effects+in+Human+Tumor+Xenografts+Following+Oral+Administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0liYGPwQBS0Jow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin-dependent%2520Protein%2520Kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520Demonstrates%2520Antitumor%2520Effects%2520in%2520Human%2520Tumor%2520Xenografts%2520Following%2520Oral%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambellone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokosz, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T. J.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]pyrimidines as Orally Available Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6220</span>– <span class="NLM_lpage">6223</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2007.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6220-6223&author=K.+Paruchauthor=M.+P.+Dwyerauthor=C.+Alvarezauthor=C.+Brownauthor=T.+Y.+Chanauthor=R.+J.+Dollauthor=K.+Keertikarauthor=C.+Knutsonauthor=B.+McKittrickauthor=J.+Riveraauthor=R.+Rossmanauthor=G.+Tuckerauthor=T.+O.+Fischmannauthor=A.+Hruzaauthor=V.+Madisonauthor=A.+A.+Nomeirauthor=Y.+Wangauthor=E.+Leesauthor=D.+Parryauthor=N.+Sgambelloneauthor=W.+Seghezziauthor=L.+Schultzauthor=F.+Shanahanauthor=D.+Wiswellauthor=X.+Xuauthor=Q.+Zhouauthor=R.+A.+Jamesauthor=V.+M.+Paradkarauthor=H.+Parkauthor=L.+R.+Rokoszauthor=T.+M.+Staufferauthor=T.+J.+Guzi&title=Pyrazolo%5B1%2C5-a%5Dpyrimidines+as+Orally+Available+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.1016%2Fj.bmcl.2007.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DT.%2BY.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DKnutson%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%26aulast%3DRivera%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DSgambellone%26aufirst%3DN.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DSchultz%26aufirst%3DL.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DJames%26aufirst%3DR.%2BA.%26aulast%3DParadkar%26aufirst%3DV.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DRokosz%26aufirst%3DL.%2BR.%26aulast%3DStauffer%26aufirst%3DT.%2BM.%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520Orally%2520Available%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6220%26epage%3D6223%26doi%3D10.1016%2Fj.bmcl.2007.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popowycz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamigeon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo-Lozano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-dependent Kinase Inhibitor (<i>R</i>)-RoscovitineAnalogue</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1021/jm801340z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801340z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=655-663&author=F.+Popowyczauthor=G.+Fournetauthor=C.+Schneiderauthor=K.+Bettayebauthor=Y.+Ferandinauthor=C.+Lamigeonauthor=O.+M.+Tiradoauthor=S.+Mateo-Lozanoauthor=V.+Notarioauthor=P.+Colasauthor=P.+Bernardauthor=L.+Meijerauthor=B.+Joseph&title=Pyrazolo%5B1%2C5-a%5D-1%2C3%2C5-triazine+as+a+Purine+Bioisostere%3A+Access+to+Potent+Cyclin-dependent+Kinase+Inhibitor+%28R%29-RoscovitineAnalogue&doi=10.1021%2Fjm801340z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm801340z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801340z%26sid%3Dliteratum%253Aachs%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLamigeon%26aufirst%3DC.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DPyrazolo%255B1%252C5-a%255D-1%252C3%252C5-triazine%2520as%2520a%2520Purine%2520Bioisostere%253A%2520Access%2520to%2520Potent%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520%2528R%2529-RoscovitineAnalogue%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D655%26epage%3D663%26doi%3D10.1021%2Fjm801340z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popowycz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">N- & -N, A New Class of Cell Death-inducing Kinase Inhibitors Derived from the Purine Roscovitine</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2724</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F1535-7163.MCT-08-0080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=18790752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2713-2724&author=K.+Bettayebauthor=H.+Sallamauthor=Y.+Ferandinauthor=F.+Popowyczauthor=G.+Fournetauthor=M.+Hassanauthor=A.+Echalierauthor=P.+Bernardauthor=J.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=N-+%26+-N%2C+A+New+Class+of+Cell+Death-inducing+Kinase+Inhibitors+Derived+from+the+Purine+Roscovitine&doi=10.1158%2F1535-7163.MCT-08-0080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine</span></div><div class="casAuthors">Bettayeb, Karima; Sallam, Hatem; Ferandin, Yoan; Popowycz, Florence; Fournet, Guy; Hassan, Moustapha; Echalier, Aude; Bernard, Philippe; Endicott, Jane; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2713-2724</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) and their regulators show frequent abnormalities in tumors.  Ten low mol. wt. pharmacol. inhibitors of CDKs are currently in clin. trials against various cancers, including the 2,6,9-trisubstituted purine (R)-roscovitine (CYC202/Seliciclib).  We here report the characterization of N-&-N1, a bioisoster of roscovitine displaying improved antitumoral properties.  N-&-N1 shows exquisite selectivity for CDKs, with 2- to 3-fold enhanced potency compared with (R)-roscovitine.  Inhibition of retinoblastoma protein phosphorylation and RNA polymerase II Ser2 phosphorylation in neuroblastoma SH-SY5Y cells exposed to N-&-N1 indicates that N-&-N1 is able to inhibit CDKs in a cellular context.  N-&-N1 also down-regulates the expression of RNA polymerase.  Cocrystal structures of N-&-N1 and (R)-roscovitine in complex with CDK2/cyclin A reveal that both inhibitors adopt similar binding modes.  A competitive assay shows that, compared with (R)-roscovitine, N-&-N1 has reduced affinity for Erk2 and pyridoxal kinase.  N-&-N1 triggers cell death in a panel of diverse cell lines.  Cell death is accompanied by events characteristic of apoptosis: cytochrome c release, activation of effector caspases, and poly(ADP-ribose) polymerase cleavage.  Induction of p53 and p21CIP1 and down-regulation of the Mcl-1 antiapoptotic factor were also obsd.  Studies in mice show that N-&-N1 has pharmacokinetics properties similar to those of (R)-roscovitine.  Altogether, these results show that analogs of (R)-roscovitine can be designed with improved antitumor potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAdPDD672MabVg90H21EOLACvtfcHk0lhlxh2t-awTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7nL&md5=a2d1cc3e59c608be45064a2ace6f0426</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0080%26sid%3Dliteratum%253Aachs%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DSallam%26aufirst%3DH.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DEndicott%26aufirst%3DJ.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DN-%2520%2526%2520-N%252C%2520A%2520New%2520Class%2520of%2520Cell%2520Death-inducing%2520Kinase%2520Inhibitors%2520Derived%2520from%2520the%2520Purine%2520Roscovitine%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2713%26epage%3D2724%26doi%3D10.1158%2F1535-7163.MCT-08-0080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridine Inhibitors of Cyclin-dependent Kinases: Highly Potent 2,6-Difluorophenacyl Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2408</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2FS0960-894X%2803%2900381-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2405-2408&author=R.+N.+Misraauthor=H.+Xiaoauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=S.+D.+Kimballauthor=K.+R.+Webster&title=1H-Pyrazolo%5B3%2C4-b%5Dpyridine+Inhibitors+of+Cyclin-dependent+Kinases%3A+Highly+Potent+2%2C6-Difluorophenacyl+Analogues&doi=10.1016%2FS0960-894X%2803%2900381-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900381-0%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3D1H-Pyrazolo%255B3%252C4-b%255Dpyridine%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%253A%2520Highly%2520Potent%25202%252C6-Difluorophenacyl%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2405%26epage%3D2408%26doi%3D10.1016%2FS0960-894X%2803%2900381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keertikar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmann, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seghezzi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgambellone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiswell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T. J.</span></span> <span> </span><span class="NLM_article-title">Versatile Templates for the Development of Novel Kinase Inhibitors: Discovery of Novel CDK Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6216</span>– <span class="NLM_lpage">6219</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2007.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=17904366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6216-6219&author=M.+P.+Dwyerauthor=K.+Paruchauthor=C.+Alvarezauthor=R.+J.+Dollauthor=K.+Keertikarauthor=J.+Ducaauthor=T.+O.+Fischmannauthor=A.+Hruzaauthor=V.+Madisonauthor=E.+Leesauthor=D.+Parryauthor=W.+Seghezziauthor=N.+Sgambelloneauthor=F.+Shanahanauthor=D.+Wiswellauthor=T.+J.+Guzi&title=Versatile+Templates+for+the+Development+of+Novel+Kinase+Inhibitors%3A+Discovery+of+Novel+CDK+Inhibitors&doi=10.1016%2Fj.bmcl.2007.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors</span></div><div class="casAuthors">Dwyer, Michael P.; Paruch, Kamil; Alvarez, Carmen; Doll, Ronald J.; Keertikar, Kerry; Duca, Jose; Fischmann, Thierry O.; Hruza, Alan; Madison, Vincent; Lees, Emma; Parry, David; Seghezzi, Wolfgang; Sgambellone, Nicole; Shanahan, Frances; Wiswell, Derek; Guzi, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6216-6219</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of four bicyclic cores were prepd. and evaluated as cyclin-dependent kinase-2 (CDK2) inhibitors.  From the in-vitro and cell-based anal., the pyrazolo[1,5-a]pyrimidine core I emerged as the superior core for further elaboration in the identification of novel CDK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZXTjUqi5x5LVg90H21EOLACvtfcHk0lhlxh2t-awTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zL&md5=7f9cf88bfa50cc06f6b6235da7835ae9</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DAlvarez%26aufirst%3DC.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DKeertikar%26aufirst%3DK.%26aulast%3DDuca%26aufirst%3DJ.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DParry%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DSgambellone%26aufirst%3DN.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26atitle%3DVersatile%2520Templates%2520for%2520the%2520Development%2520of%2520Novel%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520Novel%2520CDK%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6216%26epage%3D6219%26doi%3D10.1016%2Fj.bmcl.2007.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingipalli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Azabenzimidazole Derivatives as Potent, Selective Inhibitors of TBK1/IKKepsilon Kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2063</span>– <span class="NLM_lpage">2069</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2012.01.018" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2063-2069&author=T.+Wangauthor=M.+A.+Blockauthor=S.+Cowenauthor=A.+M.+Daviesauthor=E.+Devereauxauthor=L.+Gingipalliauthor=J.+Johannesauthor=N.+A.+Larsenauthor=Q.+Suauthor=J.+A.+Tuckerauthor=D.+Whitstonauthor=J.+Wuauthor=H.+J.+Zhangauthor=M.+Zindaauthor=C.+Chuaqui&title=Discovery+of+Azabenzimidazole+Derivatives+as+Potent%2C+Selective+Inhibitors+of+TBK1%2FIKKepsilon+Kinases&doi=10.1016%2Fj.bmcl.2012.01.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBlock%26aufirst%3DM.%2BA.%26aulast%3DCowen%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DDevereaux%26aufirst%3DE.%26aulast%3DGingipalli%26aufirst%3DL.%26aulast%3DJohannes%26aufirst%3DJ.%26aulast%3DLarsen%26aufirst%3DN.%2BA.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWhitston%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DChuaqui%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Azabenzimidazole%2520Derivatives%2520as%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520TBK1%252FIKKepsilon%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2063%26epage%3D2069%26doi%3D10.1016%2Fj.bmcl.2012.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, H. B.</span></span> <span> </span><span class="NLM_article-title">Structure-based Design of a New Class of Highly Selective Aminoimidazo[1,2-<i>a</i>]pyridine-based Inhibitors of Cyclin Dependent Kinases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1943</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2005.01.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1943-1947&author=C.+Hamdouchiauthor=B.+Zhongauthor=J.+Mendozaauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+De+Diegoauthor=D.+Robertsonauthor=C.+D.+Spencerauthor=B.+D.+Andersonauthor=S.+A.+Watkinsauthor=F.+Zhangauthor=H.+B.+Brooks&title=Structure-based+Design+of+a+New+Class+of+Highly+Selective+Aminoimidazo%5B1%2C2-a%5Dpyridine-based+Inhibitors+of+Cyclin+Dependent+Kinases&doi=10.1016%2Fj.bmcl.2005.01.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DMendoza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DDe%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DStructure-based%2520Design%2520of%2520a%2520New%2520Class%2520of%2520Highly%2520Selective%2520Aminoimidazo%255B1%252C2-a%255Dpyridine-based%2520Inhibitors%2520of%2520Cyclin%2520Dependent%2520Kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1943%26epage%3D1947%26doi%3D10.1016%2Fj.bmcl.2005.01.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Prado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span> <span> </span><span class="NLM_article-title">Aminoimidazo[1,2-<i>a</i>]pyridines as a New Structural Class of Cyclin-Dependent Kinase Inhibitors. Part 1: Design, Synthesis, and Biological Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6095</span>– <span class="NLM_lpage">6099</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2004.09.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=6095-6099&author=C.+Jaramilloauthor=J.+E.+de+Diegoauthor=C.+Hamdouchiauthor=E.+Collinsauthor=H.+Keyserauthor=C.+Sanchez-Martinezauthor=M.+del+Pradoauthor=B.+Normanauthor=H.+B.+Brooksauthor=S.+A.+Watkinsauthor=C.+D.+Spencerauthor=J.+A.+Dempseyauthor=B.+D.+Andersonauthor=R.+M.+Campbellauthor=T.+Leggettauthor=B.+Patelauthor=R.+M.+Schultzauthor=J.+Espinosaauthor=M.+Viethauthor=F.+Zhangauthor=D.+E.+Timm&title=Aminoimidazo%5B1%2C2-a%5Dpyridines+as+a+New+Structural+Class+of+Cyclin-Dependent+Kinase+Inhibitors.+Part+1%3A+Design%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1016%2Fj.bmcl.2004.09.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DKeyser%26aufirst%3DH.%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3Ddel%2BPrado%26aufirst%3DM.%26aulast%3DNorman%26aufirst%3DB.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DLeggett%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DEspinosa%26aufirst%3DJ.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTimm%26aufirst%3DD.%2BE.%26atitle%3DAminoimidazo%255B1%252C2-a%255Dpyridines%2520as%2520a%2520New%2520Structural%2520Class%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors.%2520Part%25201%253A%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D6095%26epage%3D6099%26doi%3D10.1016%2Fj.bmcl.2004.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdouchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaramillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Diego, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The Discovery of a New Structural Class of Cyclin-dependent Kinase Inhibitors, Aminoimidazo[1,2-<i>a</i>]pyridines</span>. <i>Mol. Cancer. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=14749470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1-9&author=C.+Hamdouchiauthor=H.+Keyserauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+De+Diegoauthor=C.+D.+Spencerauthor=J.+A.+Dempseyauthor=B.+D.+Andersonauthor=T.+Leggettauthor=N.+B.+Stammauthor=R.+M.+Schultzauthor=S.+A.+Watkinsauthor=K.+Cockeauthor=S.+Lemkeauthor=T.+F.+Burke&title=The+Discovery+of+a+New+Structural+Class+of+Cyclin-dependent+Kinase+Inhibitors%2C+Aminoimidazo%5B1%2C2-a%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines</span></div><div class="casAuthors">Hamdouchi, Chafiq; Keyser, Heather; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Spencer, Charles D.; Dempsey, Jack Alan; Anderson, Bryan D.; Leggett, Tillie; Stamm, Nancy B.; Schultz, Richard M.; Watkins, Scott A.; Cocke, Kim; Lemke, Stephanie; Burke, Teresa F.; Beckmann, Richard P.; Dixon, Jeffrey T.; Gurganus, Thomas M.; Rankl, Nancy B.; Houck, Keith A.; Zhang, Faming; Vieth, Michal; Espinosa, Juan; Timm, David E.; Campbell, Robert M.; Patel, Bharvin K. R.; Brooks, Harold B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The protein kinase family represents an enormous opportunity for drug development.  However, the current limitation in structural diversity of kinase inhibitors has complicated efforts to identify effective treatments of diseases that involve protein kinase signaling pathways.  We have identified a new structural class of protein serine/threonine kinase inhibitors comprising an aminoimidazo[1,2-a]pyridine nucleus.  In this report, we describe the first successful use of this class of aza-heterocycles to generate potent inhibitors of cyclin-dependent kinases that compete with ATP for binding to a catalytic subunit of the protein.  Co-crystal structures of CDK2 in complex with lead compds. reveal a unique mode of binding.  Using this knowledge, a structure-based design approach directed this chem. scaffold toward generating potent and selective CDK2 inhibitors, which selectively inhibited the CDK2-dependent phosphorylation of Rb and induced caspase-3-dependent apoptosis in HCT 116 tumor cells.  The discovery of this new class of ATP-site-directed protein kinase inhibitors, aminoimidazo[1,2-a]pyridines, provides the basis for a new medicinal chem. tool to be used in the search for effective treatments of cancer and other diseases that involve protein kinase signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMw2VkQ5EuPLVg90H21EOLACvtfcHk0lh2TZzQMuObZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFajtg%253D%253D&md5=0d78d757d0deb6089b996765cd189df1</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC.%26aulast%3DKeyser%26aufirst%3DH.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3DDe%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DLeggett%26aufirst%3DT.%26aulast%3DStamm%26aufirst%3DN.%2BB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DCocke%26aufirst%3DK.%26aulast%3DLemke%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26atitle%3DThe%2520Discovery%2520of%2520a%2520New%2520Structural%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%252C%2520Aminoimidazo%255B1%252C2-a%255Dpyridines%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minshull, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauptit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannifer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowsell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanway, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span> <span> </span><span class="NLM_article-title">Imidazo[1,2-<i>b</i>]pyridazines: A Potent and Selective Class of Cyclin-dependent Kinase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2249</span>– <span class="NLM_lpage">2252</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2004.02.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2249-2252&author=K.+F.+Bythauthor=N.+Cooperauthor=J.+D.+Culshawauthor=D.+W.+Heatonauthor=S.+E.+Oakesauthor=C.+A.+Minshullauthor=R.+A.+Normanauthor=R.+A.+Pauptitauthor=J.+A.+Tuckerauthor=J.+Breedauthor=A.+Panniferauthor=S.+Rowsellauthor=J.+J.+Stanwayauthor=A.+L.+Valentineauthor=A.+P.+Thomas&title=Imidazo%5B1%2C2-b%5Dpyridazines%3A+A+Potent+and+Selective+Class+of+Cyclin-dependent+Kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2004.02.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DByth%26aufirst%3DK.%2BF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DOakes%26aufirst%3DS.%2BE.%26aulast%3DMinshull%26aufirst%3DC.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DPannifer%26aufirst%3DA.%26aulast%3DRowsell%26aufirst%3DS.%26aulast%3DStanway%26aufirst%3DJ.%2BJ.%26aulast%3DValentine%26aufirst%3DA.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26atitle%3DImidazo%255B1%252C2-b%255Dpyridazines%253A%2520A%2520Potent%2520and%2520Selective%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2249%26epage%3D2252%26doi%3D10.1016%2Fj.bmcl.2004.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokurno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, C. J.</span></span> <span> </span><span class="NLM_article-title">Triazolo[1,5-<i>a</i>]pyrimidines as Novel CDK2 Inhibitors: Protein Structure-guided Design and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1357</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.11.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2005.11.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1353-1357&author=C.+M.+Richardsonauthor=D.+S.+Williamsonauthor=M.+J.+Parrattauthor=J.+Borgognoniauthor=A.+D.+Cansfieldauthor=P.+Dokurnoauthor=G.+L.+Francisauthor=R.+Howesauthor=J.+D.+Mooreauthor=J.+B.+Murrayauthor=A.+Robertsonauthor=A.+E.+Surgenorauthor=C.+J.+Torrance&title=Triazolo%5B1%2C5-a%5Dpyrimidines+as+Novel+CDK2+Inhibitors%3A+Protein+Structure-guided+Design+and+SAR&doi=10.1016%2Fj.bmcl.2005.11.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.11.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.11.048%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DC.%2BM.%26aulast%3DWilliamson%26aufirst%3DD.%2BS.%26aulast%3DParratt%26aufirst%3DM.%2BJ.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DCansfield%26aufirst%3DA.%2BD.%26aulast%3DDokurno%26aufirst%3DP.%26aulast%3DFrancis%26aufirst%3DG.%2BL.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BB.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DSurgenor%26aufirst%3DA.%2BE.%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26atitle%3DTriazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520Novel%2520CDK2%2520Inhibitors%253A%2520Protein%2520Structure-guided%2520Design%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1353%26epage%3D1357%26doi%3D10.1016%2Fj.bmcl.2005.11.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indirubin-3′-monoxime Derivatives as Potent Inhibitors Against CDK2 and CDK9</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2447</span>– <span class="NLM_lpage">2451</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.03.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25908517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVeksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2447-2451&author=L.+Yanauthor=F.+Laiauthor=X.+Chenauthor=Z.+Xiao&title=Discovery+of+Novel+Indirubin-3%E2%80%B2-monoxime+Derivatives+as+Potent+Inhibitors+Against+CDK2+and+CDK9&doi=10.1016%2Fj.bmcl.2015.03.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9</span></div><div class="casAuthors">Yan, Lei; Lai, Fangfang; Chen, Xiaoguang; Xiao, Zhiyan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2447-2451</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indirubin 3'-monoxime (IM) is a potent cyclin-dependent kinase (CDK) inhibitor.  Twenty novel IM derivs. were prepd. to investigate the structure-activity relationships (SAR) of this compd. class.  Six compds. showed significant inhibition against both CDK2/cyclin E1 and CDK9/cyclin T1.  The most potent compd. exhibited IC50 values at submicromolar level.  Preliminary SAR trends were suggested and cytotoxicity of these compds. was investigated.  Mol. docking studies on two compds. provided conducive clues for further structural optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodx4x7bHuIJLVg90H21EOLACvtfcHk0lh2TZzQMuObZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVeksL4%253D&md5=110a858faa3d296ca3352ffdfc439840</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.066%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Novel%2520Indirubin-3%25E2%2580%25B2-monoxime%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520Against%2520CDK2%2520and%2520CDK9%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2447%26epage%3D2451%26doi%3D10.1016%2Fj.bmcl.2015.03.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-activity Relationships of Novel Indirubin Derivatives as Potent Anti-proliferative Agents with CDK2 Inhibitory Activities</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmc.2005.08.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=237-246&author=M.+J.+Moonauthor=S.+K.+Leeauthor=J.+W.+Leeauthor=W.+K.+Songauthor=S.+W.+Kimauthor=J.+I.+Kimauthor=C.+Choauthor=S.+J.+Choiauthor=Y.+C.+Kim&title=Synthesis+and+Structure-activity+Relationships+of+Novel+Indirubin+Derivatives+as+Potent+Anti-proliferative+Agents+with+CDK2+Inhibitory+Activities&doi=10.1016%2Fj.bmc.2005.08.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DSong%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DCho%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BC.%26atitle%3DSynthesis%2520and%2520Structure-activity%2520Relationships%2520of%2520Novel%2520Indirubin%2520Derivatives%2520as%2520Potent%2520Anti-proliferative%2520Agents%2520with%2520CDK2%2520Inhibitory%2520Activities%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D237%26epage%3D246%26doi%3D10.1016%2Fj.bmc.2005.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brumby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prien, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span> <span> </span><span class="NLM_article-title">From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2-inhibitors</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1002/cbic.200400108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.200400108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=531-540&author=R.+Jautelatauthor=T.+Brumbyauthor=M.+Schaferauthor=H.+Briemauthor=G.+Eisenbrandauthor=S.+Schwahnauthor=M.+Krugerauthor=U.+Luckingauthor=O.+Prienauthor=G.+Siemeister&title=From+the+Insoluble+Dye+Indirubin+towards+Highly+Active%2C+Soluble+CDK2-inhibitors&doi=10.1002%2Fcbic.200400108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400108%26sid%3Dliteratum%253Aachs%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DBrumby%26aufirst%3DT.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DEisenbrand%26aufirst%3DG.%26aulast%3DSchwahn%26aufirst%3DS.%26aulast%3DKruger%26aufirst%3DM.%26aulast%3DLucking%26aufirst%3DU.%26aulast%3DPrien%26aufirst%3DO.%26aulast%3DSiemeister%26aufirst%3DG.%26atitle%3DFrom%2520the%2520Insoluble%2520Dye%2520Indirubin%2520towards%2520Highly%2520Active%252C%2520Soluble%2520CDK2-inhibitors%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D531%26epage%3D540%26doi%3D10.1002%2Fcbic.200400108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlbeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span> <span> </span><span class="NLM_article-title">Novel Indirubin Derivatives, Promising Anti-Tumor Agents Inhibiting Cyclin-Dependent Kinases</span>. <i>Int. J. Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.5414/CPP42656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.5414%2FCPP42656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15598038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BD2cnit1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2004&pages=656-658&author=K.+H.+Merzauthor=S.+Schwahnauthor=F.+Hippeauthor=S.+Muhlbeyerauthor=S.+Jakobsauthor=G.+Eisenbrand&title=Novel+Indirubin+Derivatives%2C+Promising+Anti-Tumor+Agents+Inhibiting+Cyclin-Dependent+Kinases&doi=10.5414%2FCPP42656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases</span></div><div class="casAuthors">Merz K H; Schwahn S; Hippe F; Muhlbeyer S; Jakobs S; Eisenbrand G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">656-8</span>
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAEHro78iunsuCWE5mhx1RfW6udTcc2eZB_u-Y4XNM6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnit1yqtw%253D%253D&md5=a0adc10cdb67538599d3f1bd3c26cadb</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.5414%2FCPP42656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCPP42656%26sid%3Dliteratum%253Aachs%26aulast%3DMerz%26aufirst%3DK.%2BH.%26aulast%3DSchwahn%26aufirst%3DS.%26aulast%3DHippe%26aufirst%3DF.%26aulast%3DMuhlbeyer%26aufirst%3DS.%26aulast%3DJakobs%26aufirst%3DS.%26aulast%3DEisenbrand%26aufirst%3DG.%26atitle%3DNovel%2520Indirubin%2520Derivatives%252C%2520Promising%2520Anti-Tumor%2520Agents%2520Inhibiting%2520Cyclin-Dependent%2520Kinases%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D42%26spage%3D656%26epage%3D658%26doi%3D10.5414%2FCPP42656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polychronopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaltsounis, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myrianthopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarricone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greengard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-dependent Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1021/jm031016d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031016d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=935-946&author=P.+Polychronopoulosauthor=P.+Magiatisauthor=A.+L.+Skaltsounisauthor=V.+Myrianthopoulosauthor=E.+Mikrosauthor=A.+Tarriconeauthor=A.+Musacchioauthor=S.+M.+Roeauthor=L.+Pearlauthor=M.+Leostauthor=P.+Greengardauthor=L.+Meijer&title=Structural+Basis+for+the+Synthesis+of+Indirubins+as+Potent+and+Selective+Inhibitors+of+Glycogen+Synthase+Kinase-3+and+Cyclin-dependent+Kinases&doi=10.1021%2Fjm031016d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases</span></div><div class="casAuthors">Polychronopoulos, Panagiotis; Magiatis, Prokopios; Skaltsounis, Alexios-Leandros; Myrianthopoulos, Vassilios; Mikros, Emmanuel; Tarricone, Aldo; Musacchio, Andrea; Roe, S. Mark; Pearl, Laurence; Leost, Maryse; Greengard, Paul; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">935-946</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pharmacol. inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease.  Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3.  Using the co-crystal structures of various indirubins with GSK-3β, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases.  This modeling approach provided some insight into the mol. basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors.  Predicted mols., including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors.  Control, kinase-inactive indirubins were obtained by introduction of a Me substitution on N1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiBEh_1jE0e7Vg90H21EOLACvtfcHk0lg6ZvkmERQqDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFCjtA%253D%253D&md5=3bfe8cccc4cbe23bffae66bb3569b889</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm031016d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031016d%26sid%3Dliteratum%253Aachs%26aulast%3DPolychronopoulos%26aufirst%3DP.%26aulast%3DMagiatis%26aufirst%3DP.%26aulast%3DSkaltsounis%26aufirst%3DA.%2BL.%26aulast%3DMyrianthopoulos%26aufirst%3DV.%26aulast%3DMikros%26aufirst%3DE.%26aulast%3DTarricone%26aufirst%3DA.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DPearl%26aufirst%3DL.%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DGreengard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Synthesis%2520of%2520Indirubins%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase-3%2520and%2520Cyclin-dependent%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D935%26epage%3D946%26doi%3D10.1021%2Fjm031016d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbrand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muehlbeyer, S.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Indirubin and its Derivatives: Novel Anticancer Molecules with Their Origin in Traditional Chinese Phytomedicine</span>. <i>J. Cancer Res. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1007/s00432-004-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs00432-004-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2004&pages=627-635&author=G.+Eisenbrandauthor=F.+Hippeauthor=S.+Jakobsauthor=S.+Muehlbeyer&title=Molecular+Mechanisms+of+Indirubin+and+its+Derivatives%3A+Novel+Anticancer+Molecules+with+Their+Origin+in+Traditional+Chinese+Phytomedicine&doi=10.1007%2Fs00432-004-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs00432-004-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-004-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DEisenbrand%26aufirst%3DG.%26aulast%3DHippe%26aufirst%3DF.%26aulast%3DJakobs%26aufirst%3DS.%26aulast%3DMuehlbeyer%26aufirst%3DS.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Indirubin%2520and%2520its%2520Derivatives%253A%2520Novel%2520Anticancer%2520Molecules%2520with%2520Their%2520Origin%2520in%2520Traditional%2520Chinese%2520Phytomedicine%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D130%26spage%3D627%26epage%3D635%26doi%3D10.1007%2Fs00432-004-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, R. T.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montana, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocque, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuyper, L. F.</span></span> <span> </span><span class="NLM_article-title">Oxindole-based Inhibitors of Cyclin-dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4339</span>– <span class="NLM_lpage">4358</span>, <span class="refDoi"> DOI: 10.1021/jm010117d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010117d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4339-4358&author=H.+N.+Bramsonauthor=J.+Coronaauthor=S.+T.+Davisauthor=S.+H.+Dickersonauthor=M.+Edelsteinauthor=S.+V.+Fryeauthor=R.+T.+Gampeauthor=P.+A.+Harrisauthor=A.+Hassellauthor=W.+D.+Holmesauthor=R.+N.+Hunterauthor=K.+E.+Lackeyauthor=B.+Lovejoyauthor=M.+J.+Luzzioauthor=V.+Montanaauthor=W.+J.+Rocqueauthor=D.+Rusnakauthor=L.+Shewchukauthor=J.+M.+Vealauthor=D.+H.+Walkerauthor=L.+F.+Kuyper&title=Oxindole-based+Inhibitors+of+Cyclin-dependent+Kinase+2+%28CDK2%29%3A+Design%2C+Synthesis%2C+Enzymatic+Activities%2C+and+X-ray+Crystallographic+Analysis&doi=10.1021%2Fjm010117d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis</span></div><div class="casAuthors">Bramson, H. Neal; Corona, John; Davis, Stephen T.; Dickerson, Scott H.; Edelstein, Mark; Frye, Stephen V.; Gampe, Robert T., Jr.; Harris, Phil A.; Hassell, Anne; Holmes, William D.; Hunter, Robert N.; Lackey, Karen E.; Lovejoy, Brett; Luzzio, Michael J.; Montana, Val; Rocque, Warren J.; Rusnak, David; Shewchuk, Lisa; Veal, James M.; Walker, Duncan H.; Kuyper, Lee F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4339-4358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two closely related classes of oxindole-based compds., 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).  The initial lead compd. was prepd. as a homolog of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor.  Crystallog. anal. of the lead compd. bound to CDK2 provided the basis for analog design.  A semiautomated method of ligand docking was used to select compds. for synthesis, and a no. of compds. with low nanomolar inhibitory activity vs. CDK2 were identified.  Enzyme binding determinants for several analogs were evaluated by X-ray crystallog.  Compds. in this series inhibited CDK2 with a potency ∼10-fold greater than that for CDK1.  Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOmtXxUWKlrVg90H21EOLACvtfcHk0lg6ZvkmERQqDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvFGnt7Y%253D&md5=d628549913ca46f9edf6b4692c82419d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm010117d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010117d%26sid%3Dliteratum%253Aachs%26aulast%3DBramson%26aufirst%3DH.%2BN.%26aulast%3DCorona%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DS.%2BT.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEdelstein%26aufirst%3DM.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DHolmes%26aufirst%3DW.%2BD.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DLovejoy%26aufirst%3DB.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DMontana%26aufirst%3DV.%26aulast%3DRocque%26aufirst%3DW.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DKuyper%26aufirst%3DL.%2BF.%26atitle%3DOxindole-based%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%2520%2528CDK2%2529%253A%2520Design%252C%2520Synthesis%252C%2520Enzymatic%2520Activities%252C%2520and%2520X-ray%2520Crystallographic%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4339%26epage%3D4358%26doi%3D10.1021%2Fjm010117d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecointre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleval, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrues, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouft, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejoncour, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyvinec, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loaec, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honnorat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandolfo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castel, H.</span></span> <span> </span><span class="NLM_article-title">Impact of Meriolins, A New Class of Cyclin-dependent Kinase Inhibitors, on Malignant Glioma Proliferation and Neo-angiogenesis</span>. <i>Neuro. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1498</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nou102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1093%2Fneuonc%2Fnou102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24891448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1484-1498&author=M.+Jarryauthor=C.+Lecointreauthor=C.+Mallevalauthor=L.+Desruesauthor=M.+T.+Schouftauthor=V.+Lejoncourauthor=F.+Ligerauthor=G.+Lyvinecauthor=B.+Josephauthor=N.+Loaecauthor=L.+Meijerauthor=J.+Honnoratauthor=P.+Gandolfoauthor=H.+Castel&title=Impact+of+Meriolins%2C+A+New+Class+of+Cyclin-dependent+Kinase+Inhibitors%2C+on+Malignant+Glioma+Proliferation+and+Neo-angiogenesis&doi=10.1093%2Fneuonc%2Fnou102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis</span></div><div class="casAuthors">Jarry, Marie; Lecointre, Celine; Malleval, Celine; Desrues, Laurence; Schouft, Marie-Therese; Lejoncour, Vadim; Liger, Francois; Lyvinec, Gildas; Joseph, Benoit; Loaec, Nadege; Meijer, Laurent; Honnorat, Jerome; Gandolfo, Pierrick; Castel, Helene</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1484-1498</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Glioblastomas are the most frequent and most aggressive primary brain tumors in adults.  The median overall survival is limited to a few months despite surgery, radiotherapy, and chemotherapy.  It is now clearly established that hyperactivity of cyclin-dependent kinases (CDKs) is one of the processes underlying hyperproliferation and tumoral growth.  The marine natural products meridianins and variolins, characterized as CDK inhibitors, display a kinase-inhibitory activity assocd. with cytotoxic effects.  In order to improve selectivity and efficiency of these CDK inhibitors, a series of hybrid compds. called meriolins have been synthesized.  Methods.  The potential antitumoral activity of meriolins was investigated in vitro on glioma cell lines (SW1088 and U87), native neural cells, and a human endothelial cell line (HUV-EC-C).  The impact of i.p. or intratumoral administrations of meriolin 15 was evaluated in vivo on 2 different nude mice-xenografted glioma models.  Results.  Meriolins 3, 5, and 15 exhibited antiproliferative properties with nanomolar IC50 and induced cell-cycle arrest and CDK inhibition assocd. with apoptotic events in human glioma cell lines.  These meriolins blocked the proliferation rate of HUV-EC-C through cell cycle arrest and apoptosis.  In vivo, meriolin 15 provoked a robust redn. in tumor vol. in spite of toxicity for highest doses, assocd. with inhibition of cell division, activation of caspase 3, redn. of CD133 cells, and modifications of the vascular architecture.  Conclusion.  Meriolins, and meriolin 15 in particular, exhibit antiproliferative and proapoptotic activities on both glioma and intratumoral endothelial cells, constituting key promising therapeutic lead compds. for the treatment of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg3AVyoDsGa7Vg90H21EOLACvtfcHk0li3E7-MXk1ZZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqu7vJ&md5=d915cd825fc5f9d1e23b0cc3a46cbe7b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnou102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnou102%26sid%3Dliteratum%253Aachs%26aulast%3DJarry%26aufirst%3DM.%26aulast%3DLecointre%26aufirst%3DC.%26aulast%3DMalleval%26aufirst%3DC.%26aulast%3DDesrues%26aufirst%3DL.%26aulast%3DSchouft%26aufirst%3DM.%2BT.%26aulast%3DLejoncour%26aufirst%3DV.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DLyvinec%26aufirst%3DG.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DLoaec%26aufirst%3DN.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DHonnorat%26aufirst%3DJ.%26aulast%3DGandolfo%26aufirst%3DP.%26aulast%3DCastel%26aufirst%3DH.%26atitle%3DImpact%2520of%2520Meriolins%252C%2520A%2520New%2520Class%2520of%2520Cyclin-dependent%2520Kinase%2520Inhibitors%252C%2520on%2520Malignant%2520Glioma%2520Proliferation%2520and%2520Neo-angiogenesis%26jtitle%3DNeuro.%2520Oncol.%26date%3D2014%26volume%3D16%26spage%3D1484%26epage%3D1498%26doi%3D10.1093%2Fneuonc%2Fnou102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echalier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettayeb, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferandin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/cyclin A/meriolin Complex</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/jm700940h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700940h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=737-751&author=A.+Echalierauthor=K.+Bettayebauthor=Y.+Ferandinauthor=O.+Lozachauthor=M.+Clementauthor=A.+Valetteauthor=F.+Ligerauthor=B.+Marquetauthor=J.+C.+Morrisauthor=J.+A.+Endicottauthor=B.+Josephauthor=L.+Meijer&title=Meriolins+%283-%28pyrimidin-4-yl%29-7-azaindoles%29%3A+Synthesis%2C+Kinase+Inhibitory+Activity%2C+Cellular+Effects%2C+and+Structure+of+a+CDK2%2Fcyclin+A%2Fmeriolin+Complex&doi=10.1021%2Fjm700940h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex</span></div><div class="casAuthors">Echalier, Aude; Bettayeb, Karima; Ferandin, Yoan; Lozach, Olivier; Clelment, Monique; Valette, Annie; Liger, Francois; Marquet, Bernard; Morris, Jonathan C.; Endicott, Jane A.; Joseph, Benoit; Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">737-751</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. characterization of 3-(pyrimidin-4-yl)-7-azaindoles (meriolins), a chem. hybrid between the natural products meridianins and variolins, derived from marine organisms.  Meriolins display potent inhibitory activities toward cyclin-dependent kinases (CDKs) and, to a lesser extent, other kinases (GSK-3, DYRK1A).  The crystal structures of I (meriolin 5) and variolin B in complex with CDK2/cyclin A reveal that the two inhibitors are oriented in very different ways inside the ATP-binding pocket of the kinase.  A structure-activity relationship provides further insight into the mol. mechanism of action of this family of kinase inhibitors.  Meriolins are also potent antiproliferative and proapoptotic agents in cells cultured either as monolayers or in spheroids.  Proapoptotic efficacy of meriolins correlates best with their CDK2 and CDK9 inhibitory activity.  Meriolins thus constitute a promising class of pharmacol. agents to be further evaluated against the numerous human diseases that imply abnormal regulation of CDKs including cancers, neurodegenerative disorders, and polycystic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJgno3A1_7LVg90H21EOLACvtfcHk0li3E7-MXk1ZZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msL8%253D&md5=1bfb3d02c6894c04237eee27bbccaa5b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm700940h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700940h%26sid%3Dliteratum%253Aachs%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DClement%26aufirst%3DM.%26aulast%3DValette%26aufirst%3DA.%26aulast%3DLiger%26aufirst%3DF.%26aulast%3DMarquet%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DMeriolins%2520%25283-%2528pyrimidin-4-yl%2529-7-azaindoles%2529%253A%2520Synthesis%252C%2520Kinase%2520Inhibitory%2520Activity%252C%2520Cellular%2520Effects%252C%2520and%2520Structure%2520of%2520a%2520CDK2%252Fcyclin%2520A%252Fmeriolin%2520Complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D737%26epage%3D751%26doi%3D10.1021%2Fjm700940h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chashoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargotra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoo, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guru, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aruri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatikonda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madishetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nandi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span> <span> </span><span class="NLM_article-title">Design of Novel 3-Pyrimidinylazaindole based CDK2/9 Inhibitors with Potent <i>In-vitro</i> and <i>In-vivo</i> Antitumor Efficacy in a Triple-Negative Breast Cancer Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9470</span>– <span class="NLM_lpage">9489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9470-9489&author=U.+Singhauthor=G.+Chashooauthor=S.+U.+Khanauthor=P.+Mahajanauthor=A.+Nargotraauthor=G.+Mahajanauthor=A.+Singhauthor=A.+Sharmaauthor=M.+J.+Mintooauthor=S.+K.+Guruauthor=H.+Aruriauthor=T.+Thatikondaauthor=P.+Sahuauthor=P.+Chibberauthor=V.+Kumarauthor=S.+A.+Mirauthor=S.+S.+Bharateauthor=S.+Madishettiauthor=U.+Nandiauthor=G.+Singhauthor=D.+M.+Mondheauthor=S.+Bhushanauthor=F.+Malikauthor=S.+Mignaniauthor=R.+A.+Vishwakarmaauthor=P.+P.+Singh&title=Design+of+Novel+3-Pyrimidinylazaindole+based+CDK2%2F9+Inhibitors+with+Potent+In-vitro+and+In-vivo+Antitumor+Efficacy+in+a+Triple-Negative+Breast+Cancer+Model&doi=10.1021%2Facs.jmedchem.7b00663"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00663%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DU.%26aulast%3DChashoo%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DS.%2BU.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DNargotra%26aufirst%3DA.%26aulast%3DMahajan%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMintoo%26aufirst%3DM.%2BJ.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DAruri%26aufirst%3DH.%26aulast%3DThatikonda%26aufirst%3DT.%26aulast%3DSahu%26aufirst%3DP.%26aulast%3DChibber%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMir%26aufirst%3DS.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DMadishetti%26aufirst%3DS.%26aulast%3DNandi%26aufirst%3DU.%26aulast%3DSingh%26aufirst%3DG.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DMalik%26aufirst%3DF.%26aulast%3DMignani%26aufirst%3DS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26atitle%3DDesign%2520of%2520Novel%25203-Pyrimidinylazaindole%2520based%2520CDK2%252F9%2520Inhibitors%2520with%2520Potent%2520In-vitro%2520and%2520In-vivo%2520Antitumor%2520Efficacy%2520in%2520a%2520Triple-Negative%2520Breast%2520Cancer%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9470%26epage%3D9489%26doi%3D10.1021%2Facs.jmedchem.7b00663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roongta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranadive, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span> <span> </span><span class="NLM_article-title">N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-dependent Kinase 2. <i>N</i>-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), A Highly Efficacious and Selective Antitumor Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1728</span>, <span class="refDoi"> DOI: 10.1021/jm0305568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Y.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+Inhibitors+of+Cyclin-dependent+Kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-+piperidinecarboxamide+%28BMS-387032%29%2C+A+Highly+Efficacious+and+Selective+Antitumor+Agent&doi=10.1021%2Fjm0305568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-%2520piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520A%2520Highly%2520Efficacious%2520and%2520Selective%2520Antitumor%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728%26doi%3D10.1021%2Fjm0305568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursuker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roongta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batorsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulheron, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairchild, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Aminothiazole Inhibitors of Cyclin-dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3905</span>– <span class="NLM_lpage">3927</span>, <span class="refDoi"> DOI: 10.1021/jm0201520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0201520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3905-3927&author=K.+S.+Kimauthor=S.+D.+Kimballauthor=R.+N.+Misraauthor=D.+B.+Rawlinsauthor=J.+T.+Huntauthor=H.+Y.+Xiaoauthor=S.+Luauthor=L.+Qianauthor=W.+C.+Hanauthor=W.+Shanauthor=T.+Mittauthor=Z.+W.+Caiauthor=M.+A.+Possauthor=H.+Zhuauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Y.+Changauthor=N.+Pavletichauthor=A.+Kamathauthor=W.+G.+Humphreysauthor=P.+Maratheauthor=I.+Bursukerauthor=K.+A.+Kellarauthor=U.+Roongtaauthor=R.+Batorskyauthor=J.+G.+Mulheronauthor=D.+Bolauthor=C.+R.+Fairchildauthor=F.+Y.+Leeauthor=K.+R.+Webster&title=Discovery+of+Aminothiazole+Inhibitors+of+Cyclin-dependent+Kinase+2%3A+Synthesis%2C+X-ray+Crystallographic+Analysis%2C+and+Biological+Activities&doi=10.1021%2Fjm0201520"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Fjm0201520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0201520%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPavletich%26aufirst%3DN.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DBursuker%26aufirst%3DI.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBol%26aufirst%3DD.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DDiscovery%2520of%2520Aminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%253A%2520Synthesis%252C%2520X-ray%2520Crystallographic%2520Analysis%252C%2520and%2520Biological%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3905%26epage%3D3927%26doi%3D10.1021%2Fjm0201520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockett, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawtin, R. E.</span></span> <span> </span><span class="NLM_article-title">SNS-032 is a Potent and Selective CDK 2, 7 and 9 Inhibitor that Drives Target Modulation in Patient Samples</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1007/s00280-008-0921-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs00280-008-0921-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=19169685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2009&pages=723-732&author=A.+Conroyauthor=D.+E.+Stockettauthor=D.+Walkerauthor=M.+R.+Arkinauthor=U.+Hochauthor=J.+A.+Foxauthor=R.+E.+Hawtin&title=SNS-032+is+a+Potent+and+Selective+CDK+2%2C+7+and+9+Inhibitor+that+Drives+Target+Modulation+in+Patient+Samples&doi=10.1007%2Fs00280-008-0921-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples</span></div><div class="casAuthors">Conroy, Andrew; Stockett, David E.; Walker, Duncan; Arkin, Michelle R.; Hoch, Ute; Fox, Judith A.; Hawtin, Rachael Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-732</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clin. trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).  We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis.  We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.  Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS anal. to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.  SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9.  Treatment of RPMI-8226 MM cells at 300 nM (IC90) for 6 h was sufficient for commitment to apoptosis.  This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling mols.  SNS-032 activity was unaffected by human serum.  Target modulation was obsd. in PBMC from treated patients.  These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis.  Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clin. study of SNS-032 in MM and CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMlNcab7zzo7Vg90H21EOLACvtfcHk0ljIaSOtWe7mNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCksLY%253D&md5=231b8ddb93821ba00d912ed28dbc1ccb</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs00280-008-0921-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-008-0921-5%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DA.%26aulast%3DStockett%26aufirst%3DD.%2BE.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26atitle%3DSNS-032%2520is%2520a%2520Potent%2520and%2520Selective%2520CDK%25202%252C%25207%2520and%25209%2520Inhibitor%2520that%2520Drives%2520Target%2520Modulation%2520in%2520Patient%2520Samples%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2009%26volume%3D64%26spage%3D723%26epage%3D732%26doi%3D10.1007%2Fs00280-008-0921-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrasali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakkaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubitt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlehurst, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tash, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span> <span> </span><span class="NLM_article-title">Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-dependent Kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3768</span>– <span class="NLM_lpage">3782</span>, <span class="refDoi"> DOI: 10.1021/jm301234k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301234k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtF2jtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3768-3782&author=E.+Schonbrunnauthor=S.+Betziauthor=R.+Alamauthor=M.+P.+Martinauthor=A.+Beckerauthor=H.+Hanauthor=R.+Francisauthor=R.+Chakrasaliauthor=S.+Jakkarajauthor=A.+Kaziauthor=S.+M.+Sebtiauthor=C.+L.+Cubittauthor=A.+W.+Gebhardauthor=L.+A.+Hazlehurstauthor=J.+S.+Tashauthor=G.+I.+Georg&title=Development+of+Highly+Potent+and+Selective+Diaminothiazole+Inhibitors+of+Cyclin-dependent+Kinases&doi=10.1021%2Fjm301234k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases</span></div><div class="casAuthors">Schonbrunn, Ernst; Betzi, Stephane; Alam, Riazul; Martin, Mathew P.; Becker, Andreas; Han, Huijong; Francis, Rawle; Chakrasali, Ramappa; Jakkaraj, Sudhakar; Kazi, Aslamuzzaman; Sebti, Said M.; Cubitt, Christopher L.; Gebhard, Anthony W.; Hazlehurst, Lori A.; Tash, Joseph S.; Georg, Gunda I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3768-3782</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diaminothiazoles such as I were prepd. as inhibitors of cyclin-dependent kinase 2 (CDK2) for potential use as antitumor agents and as male contraceptive agents based on the optimization of a hit compd. with weak inhibitory activity (IC50 = 15 μM) discovered by high-throughput screening.  Using cocrystal structures of 35 diaminothiazoles with CDK2, the structure-activity relations of diaminothiazoles for CDK2 inhibition were detd. and used to find I.  I was tested for inhibition against a panel of 339 kinases; cyclin-dependent kinases were inhibited selectively, particularly CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6.  I inhibited the proliferation of 13 out of 15 cancer cell lines with IC50 values of 0.27-6.9 μM; the antiproliferative activity correlated to complete suppression of retinoblastoma phosphorylation and the onset of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeM-VFFhEenrVg90H21EOLACvtfcHk0lipJU-Wj_ZmLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtF2jtb8%253D&md5=067bdf2349f9cd853b83d19131e0770f</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm301234k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301234k%26sid%3Dliteratum%253Aachs%26aulast%3DSchonbrunn%26aufirst%3DE.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DChakrasali%26aufirst%3DR.%26aulast%3DJakkaraj%26aufirst%3DS.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DCubitt%26aufirst%3DC.%2BL.%26aulast%3DGebhard%26aufirst%3DA.%2BW.%26aulast%3DHazlehurst%26aufirst%3DL.%2BA.%26aulast%3DTash%26aufirst%3DJ.%2BS.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26atitle%3DDevelopment%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Diaminothiazole%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3768%26epage%3D3782%26doi%3D10.1021%2Fjm301234k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osnowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNae, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkinshaw, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR analysis, X-ray Crystallography, and Biological Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1662</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.1021/jm0309957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1662-1675&author=S.+Wangauthor=C.+Meadesauthor=G.+Woodauthor=A.+Osnowskiauthor=S.+Andersonauthor=R.+Yuillauthor=M.+Thomasauthor=M.+Meznaauthor=W.+Jacksonauthor=C.+Midgleyauthor=G.+Griffithsauthor=I.+Flemingauthor=S.+Greenauthor=I.+McNaeauthor=S.+Y.+Wuauthor=C.+McInnesauthor=D.+Zhelevaauthor=M.+D.+Walkinshawauthor=P.+M.+Fischer&title=2-Anilino-4-%28thiazol-5-yl%29pyrimidine+CDK+Inhibitors%3A+Synthesis%2C+SAR+analysis%2C+X-ray+Crystallography%2C+and+Biological+Activity&doi=10.1021%2Fjm0309957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm0309957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DOsnowski%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DYuill%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DMidgley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3D2-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520CDK%2520Inhibitors%253A%2520Synthesis%252C%2520SAR%2520analysis%252C%2520X-ray%2520Crystallography%252C%2520and%2520Biological%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1662%26epage%3D1675%26doi%3D10.1021%2Fjm0309957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of 2-Methyl- and 2-Amino-<i>N</i>-aryl-4,5-dihydrothiazolo[4,5-<i>h</i>]quinazolin-8-amines as Ring-constrained 2-Anilino-4-(thiazol-5-yl)pyrimidine Cyclin-Dependent Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1021/jm901660c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901660c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2136-2145&author=N.+A.+McIntyreauthor=C.+McInnesauthor=G.+Griffithsauthor=A.+L.+Barnettauthor=G.+Kontopidisauthor=A.+M.+Slawinauthor=W.+Jacksonauthor=M.+Thomasauthor=D.+I.+Zhelevaauthor=S.+Wangauthor=D.+G.+Blakeauthor=N.+J.+Westwoodauthor=P.+M.+Fischer&title=Design%2C+Synthesis%2C+and+Evaluation+of+2-Methyl-+and+2-Amino-N-aryl-4%2C5-dihydrothiazolo%5B4%2C5-h%5Dquinazolin-8-amines+as+Ring-constrained+2-Anilino-4-%28thiazol-5-yl%29pyrimidine+Cyclin-Dependent+Kinase+Inhibitors&doi=10.1021%2Fjm901660c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm901660c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901660c%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntyre%26aufirst%3DN.%2BA.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DSlawin%26aufirst%3DA.%2BM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DWestwood%26aufirst%3DN.%2BJ.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%25202-Methyl-%2520and%25202-Amino-N-aryl-4%252C5-dihydrothiazolo%255B4%252C5-h%255Dquinazolin-8-amines%2520as%2520Ring-constrained%25202-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2136%26epage%3D2145%26doi%3D10.1021%2Fjm901660c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakowec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span> <span> </span><span class="NLM_article-title">Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4308</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1158%2F0008-5472.CAN-05-2507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16618755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4299-4308&author=M.+Paytonauthor=G.+Chungauthor=P.+Yakowecauthor=A.+Wongauthor=D.+Powersauthor=L.+Xiongauthor=N.+Zhangauthor=J.+Lealauthor=T.+L.+Bushauthor=V.+Santoraauthor=B.+Askewauthor=A.+Taskerauthor=R.+Radinskyauthor=R.+Kendallauthor=S.+Coats&title=Discovery+and+Evaluation+of+Dual+CDK1+and+CDK2+Inhibitors&doi=10.1158%2F0008-5472.CAN-05-2507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors</span></div><div class="casAuthors">Payton, Marc; Chung, Grace; Yakowec, Peter; Wong, Andrew; Powers, Dave; Xiong, Ling; Zhang, Nancy; Leal, Juan; Bush, Tammy L.; Santora, Vincent; Askew, Ben; Tasker, Andrew; Radinsky, Robert; Kendall, Richard; Coats, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4299-4308</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In eukaryotic cells, cyclin-dependent kinase (CDK) complexes regulate the temporal progression of cells through the cell cycle.  Deregulation in the cell cycle is an essential component in the evolution of cancer.  Here, we validate CDK1 and CDK2 as potential therapeutic targets using novel selective small-mol. inhibitors of cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes (CDKi).  Flow cytometry-based methods were developed to assess intracellular retinoblastoma (Rb) phosphorylation to show inhibition of the CDK pathway.  Tumor cells treated with CDK inhibitors showed an overall decrease in cell proliferation, accumulation of cells in G1 and G2, and apoptosis in a cell line-specific manner.  Although CDK inhibitors activate p53, the inhibitors were equipotent in arresting the cell cycle in isogenic breast and colon tumor cells lacking p53, suggesting the response is independent of p53.  In vivo, the CDK inhibitors prevented the growth of colon and prostate tumors, blocked proliferation of tumor cells, and inhibited Rb phosphorylation.  The discovery and evaluation of novel potent and selective CDK1 and CDK2 inhibitors will help delineate the role that CDK complexes play in regulating tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD-1KHUKXUl7Vg90H21EOLACvtfcHk0lg91Zm06HJNuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSltb8%253D&md5=2f2585ff3af06a4523cc144344d8d08f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2507%26sid%3Dliteratum%253Aachs%26aulast%3DPayton%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DG.%26aulast%3DYakowec%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLeal%26aufirst%3DJ.%26aulast%3DBush%26aufirst%3DT.%2BL.%26aulast%3DSantora%26aufirst%3DV.%26aulast%3DAskew%26aufirst%3DB.%26aulast%3DTasker%26aufirst%3DA.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DCoats%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520Evaluation%2520of%2520Dual%2520CDK1%2520and%2520CDK2%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4299%26epage%3D4308%26doi%3D10.1158%2F0008-5472.CAN-05-2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery and the Human Kinome: Recent Trends</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2011.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=21256157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFyiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=144-156&author=R.+Eglenauthor=T.+Reisine&title=Drug+Discovery+and+the+Human+Kinome%3A+Recent+Trends&doi=10.1016%2Fj.pharmthera.2011.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery and the human kinome: Recent trends</span></div><div class="casAuthors">Eglen, Richard; Reisine, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-156</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major new trend in drugs targeted at protein kinases is the discovery of allosteric modulators.  These compds. differ from ATP-centric drugs in that they do not compete with ATP for binding to the catalytic domain, generally acting by inducing conformational changes to modulate activity.  They could provide a no. of advantages over more classical protein kinase drugs.  For example, they are likely to be more selective, since they bind to unique regions of the kinase and may be useful in overcoming resistance that has developed to drugs that compete with ATP.  They offer the ability of activating the kinases either by removing factors that inhibit kinase activity or by simply producing changes to the enzyme to foster catalytic activity.  Furthermore, they provide more subtle modulation of kinase activity than simply blocking ATP access to inhibit activity.  One hurdle to overcome in discovering these compds. is that allosteric modulators may need to inhibit protein-protein interactions; generally difficult to accomplish with small mols.  Despite the tech. problems of identifying allosteric modulators, major gains have been made in identifying allosteric inhibitors and activators of the growth factor receptors as well as sol. tyrosine and serine/threonine kinases and some of these drugs are now in various stages of clin. trials.  This review will focus on the discovery of novel allosteric modulators of protein kinases and drug discovery approaches that have been employed to identify such compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3aFpUgbPaHrVg90H21EOLACvtfcHk0lg91Zm06HJNuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFyiu78%253D&md5=08edb08d2845b8a51924b46a8546c2bb</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.%26aulast%3DReisine%26aufirst%3DT.%26atitle%3DDrug%2520Discovery%2520and%2520the%2520Human%2520Kinome%253A%2520Recent%2520Trends%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D144%26epage%3D156%26doi%3D10.1016%2Fj.pharmthera.2011.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duyne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span> <span> </span><span class="NLM_article-title">A Novel Binding Pocket of Cyclin-dependent Kinase 2</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1002/prot.22136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fprot.22136" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=122-132&author=H.+Chenauthor=R.+Van+Duyneauthor=N.+Zhangauthor=F.+Kashanchiauthor=C.+Zeng&title=A+Novel+Binding+Pocket+of+Cyclin-dependent+Kinase+2&doi=10.1002%2Fprot.22136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1002%2Fprot.22136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22136%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DVan%2BDuyne%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DKashanchi%26aufirst%3DF.%26aulast%3DZeng%26aufirst%3DC.%26atitle%3DA%2520Novel%2520Binding%2520Pocket%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2009%26volume%3D74%26spage%3D122%26epage%3D132%26doi%3D10.1002%2Fprot.22136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadgar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIV-1 Virus Replication Using Small Soluble Tat Peptides</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2005.09.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.virol.2005.09.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16289656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2006&pages=373-389&author=E.+Agbottahauthor=N.+Zhangauthor=S.+Dadgarauthor=A.+Pumferyauthor=J.+D.+Wadeauthor=C.+Zengauthor=F.+Kashanchi&title=Inhibition+of+HIV-1+Virus+Replication+Using+Small+Soluble+Tat+Peptides&doi=10.1016%2Fj.virol.2005.09.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HIV-1 virus replication using small soluble Tat peptides</span></div><div class="casAuthors">Agbottah, Emmanuel; Zhang, Naigong; Dadgar, Shabnam; Pumfery, Anne; Wade, John D.; Zeng, Chen; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">373-389</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although the introduction of highly active antiretroviral therapy (HAART) has led to a significant redn. in AIDS-related morbidity and mortality, unfortunately, many patients discontinue their initial HAART regimen, resulting in development of viral resistance.  During HIV infection, the viral activator Tat is needed for viral progeny formation, and the basic and core domains of Tat are the most conserved parts of the protein.  Here, the authors show that a Tat 41/44 peptide from the core domain can inhibit HIV-1 gene expression and replication.  The peptides are not toxic to cells and target the Cdk2/Cyclin E complex, inhibiting the phosphorylation of serine 5 of RNAPII.  Using the Cdk2 x-ray crystallog. structure, the authors found that the low-energy wild-type peptides could bind to the ATP binding pocket, whereas the mutant peptide bound to the Cdk2 interface.  Finally, the authors show that these peptides do not allow loading of the catalytic domain of the cdk/cyclin complex onto the HIV-1 promoter in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUzniCAMWU7Vg90H21EOLACvtfcHk0lg91Zm06HJNuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCrsbo%253D&md5=2bebdc565e9cb905dce573ef91877589</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2005.09.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2005.09.062%26sid%3Dliteratum%253Aachs%26aulast%3DAgbottah%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDadgar%26aufirst%3DS.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520HIV-1%2520Virus%2520Replication%2520Using%2520Small%2520Soluble%2520Tat%2520Peptides%26jtitle%3DVirology%26date%3D2006%26volume%3D345%26spage%3D373%26epage%3D389%26doi%3D10.1016%2Fj.virol.2005.09.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubbers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakkaraj, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georg, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potential Allosteric Ligand Binding Site in CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1021/cb100410m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb100410m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=492-501&author=S.+Betziauthor=R.+Alamauthor=M.+Martinauthor=D.+J.+Lubbersauthor=H.+Hanauthor=S.+R.+Jakkarajauthor=G.+I.+Georgauthor=E.+Schonbrunn&title=Discovery+of+a+Potential+Allosteric+Ligand+Binding+Site+in+CDK2&doi=10.1021%2Fcb100410m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potential Allosteric Ligand Binding Site in CDK2</span></div><div class="casAuthors">Betzi, Stephane; Alam, Riazul; Martin, Mathew; Lubbers, Donna J.; Han, Huijong; Jakkaraj, Sudhakar R.; Georg, Gunda I.; Schonbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">492-501</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key regulatory enzymes in cell cycle progression and transcription.  Aberrant activity of CDKs has been implicated in a no. of medical conditions, and numerous small mol. CDK inhibitors have been reported as potential drug leads.  However, these inhibitors exclusively bind to the ATP site, which is largely conserved among protein kinases, and clin. trials have not resulted in viable drug candidates, attributed in part to the lack of target selectivity.  CDKs are unique among protein kinases, as their functionality strictly depends on assocn. with their partner proteins, the cyclins.  In an effort to identify potential target sites for disruption of the CDK-cyclin interaction, we probed the extrinsic fluorophore 8-anilino-1-naphthalene sulfonate (ANS) with human CDK2 and cyclin A using fluorescence spectroscopy and protein crystallog.  ANS interacts with free CDK2 in a satn.-dependent manner with an apparent Kd of 37 μM, and cyclin A displaced ANS from CDK2 with an EC50 value of 0.6 μM.  Co-crystal structures with ANS alone and in ternary complex with ATP site-directed inhibitors revealed two ANS mols. bound adjacent to one another, away from the ATP site, in a large pocket that extends from the DFG region above the C-helix.  Binding of ANS is accompanied by substantial structural changes in CDK2, resulting in a C-helix conformation that is incompatible for cyclin A assocn.  These findings indicate the potential of the ANS binding pocket as a new target site for allosteric inhibitors disrupting the interaction of CDKs and cyclins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlhg8YO4Yl7Vg90H21EOLACvtfcHk0lh3k05nPemSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Gisb4%253D&md5=893aed13b1638f7626fbb4851014fe6e</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fcb100410m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb100410m%26sid%3Dliteratum%253Aachs%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DJakkaraj%26aufirst%3DS.%2BR.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520a%2520Potential%2520Allosteric%2520Ligand%2520Binding%2520Site%2520in%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D492%26epage%3D501%26doi%3D10.1021%2Fcb100410m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingles, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonbrunn, E.</span></span> <span> </span><span class="NLM_article-title">A Novel Approach to the Discovery of Small-molecule Ligands of CDK2</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2136</span>, <span class="refDoi"> DOI: 10.1002/cbic.201200316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.201200316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=22893598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOqt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=2128-2136&author=M.+P.+Martinauthor=R.+Alamauthor=S.+Betziauthor=D.+J.+Inglesauthor=J.+Y.+Zhuauthor=E.+Schonbrunn&title=A+Novel+Approach+to+the+Discovery+of+Small-molecule+Ligands+of+CDK2&doi=10.1002%2Fcbic.201200316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2</span></div><div class="casAuthors">Martin, Mathew P.; Alam, Riazul; Betzi, Stephane; Ingles, Donna J.; Zhu, Jin-Yi; Schoenbrunn, Ernst</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2128-2136, S2128/1-S2128/6</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In an attempt to identify novel small-mol. ligands of cyclin-dependent kinase 2 (CDK2) with potential as allosteric inhibitors, we have devised a robust and cost-effective fluorescence-based high-throughput screening assay.  The assay is based on the specific interaction of CDK2 with the extrinsic fluorophore 8-anilino-1-naphthalene sulfonate (ANS), which binds to a large allosteric pocket adjacent to the ATP site.  Hit compds. that displace ANS directly or indirectly from CDK2 are readily classified as ATP site binders or allosteric ligands through the use of staurosporine, which blocks the ATP site without displacing ANS.  Pilot screening of 1453 compds. led to the discovery of 12 compds. with displacement activities (EC50 values) ranging from 6 to 44 μ, all of which were classified as ATP-site-directed ligands.  Four new type I inhibitor scaffolds were confirmed by x-ray crystallog.  Although this small compd. library contained only ATP-site-directed ligands, the application of this assay to large compd. libraries has the potential to reveal previously unrecognized chem. scaffolds suitable for structure-based design of CDK2 inhibitors with new mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK5zgMh94f7rVg90H21EOLACvtfcHk0lh3k05nPemSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOqt7bK&md5=829eb8234fb945d206cd9324c3a1f845</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200316%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BP.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DBetzi%26aufirst%3DS.%26aulast%3DIngles%26aufirst%3DD.%2BJ.%26aulast%3DZhu%26aufirst%3DJ.%2BY.%26aulast%3DSchonbrunn%26aufirst%3DE.%26atitle%3DA%2520Novel%2520Approach%2520to%2520the%2520Discovery%2520of%2520Small-molecule%2520Ligands%2520of%2520CDK2%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D2128%26epage%3D2136%26doi%3D10.1002%2Fcbic.201200316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chripkova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span> <span> </span><span class="NLM_article-title">Structure-based Discovery of the First Allosteric Inhibitors of Cyclin-dependent Kinase 2</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2296</span>– <span class="NLM_lpage">2305</span>, <span class="refDoi"> DOI: 10.4161/cc.29295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.4161%2Fcc.29295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=24911186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2296-2305&author=G.+Rastelliauthor=A.+Anighoroauthor=M.+Chripkovaauthor=L.+Carrassaauthor=M.+Broggini&title=Structure-based+Discovery+of+the+First+Allosteric+Inhibitors+of+Cyclin-dependent+Kinase+2&doi=10.4161%2Fcc.29295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2</span></div><div class="casAuthors">Rastelli, Giulio; Anighoro, Andrew; Chripkova, Martina; Carrassa, Laura; Broggini, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2296-2305</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is currently gaining a foothold in drug discovery.  Recently, the first crystal structure of CDK2 with an open allosteric pocket adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the structure has not yet been exploited for the structure-based design of type III allosteric inhibitors.  In this work we report the results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2.  Using a combination of docking and post-docking analyses made with our tool BEAR, 7 allosteric ligands (hit rate of 20%) with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the micromolar range.  Competition expts. performed in the presence of the ATP-competitive inhibitor staurosporine confirmed that the 7 ligands are truly allosteric, in agreement with their design.  Of these, compd. 2 bound CDK2 with an EC50 value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75-1 breast cancer cells with IC50 values of approx. 20 μM, while compd. 4 had an EC50 value of 71 μM and IC50 values around 4 μM.  Remarkably, the most potent compd. 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells.  Finally, hit expansion through analog search of the most potent inhibitor 4 revealed an addnl. ligand 4g with similar in vitro potency on breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGYE_h0shsbVg90H21EOLACvtfcHk0lh3k05nPemSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzF&md5=e790fc2920b61e6b85b5097a49cbc7bb</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4161%2Fcc.29295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29295%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DChripkova%26aufirst%3DM.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DBroggini%26aufirst%3DM.%26atitle%3DStructure-based%2520Discovery%2520of%2520the%2520First%2520Allosteric%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%25202%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2296%26epage%3D2305%26doi%3D10.4161%2Fcc.29295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Nonpeptide Allosteric Inhibitors Interrupting the Interaction of CDK2/cyclin A3 by Virtual Screening and Bioassays</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4069</span>– <span class="NLM_lpage">4073</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2015.08.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4069-4073&author=Y.+Huauthor=S.+Liauthor=F.+Liuauthor=L.+Gengauthor=X.+Shuauthor=J.+Zhang&title=Discovery+of+Novel+Nonpeptide+Allosteric+Inhibitors+Interrupting+the+Interaction+of+CDK2%2Fcyclin+A3+by+Virtual+Screening+and+Bioassays&doi=10.1016%2Fj.bmcl.2015.08.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGeng%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Novel%2520Nonpeptide%2520Allosteric%2520Inhibitors%2520Interrupting%2520the%2520Interaction%2520of%2520CDK2%252Fcyclin%2520A3%2520by%2520Virtual%2520Screening%2520and%2520Bioassays%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4069%26epage%3D4073%26doi%3D10.1016%2Fj.bmcl.2015.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karthiga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryanarayanan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cyclin-binding Groove Site to Inhibit the Catalytic Activity of CDK2/cyclin A Complex Using p27(KIP1)-derived Peptidomimetic Inhibitors</span>. <i>J. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1007/s12154-014-0124-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1007%2Fs12154-014-0124-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=25584078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A280%3ADC%252BC2MvlvFSlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=11-24&author=A.+Karthigaauthor=S.+K.+Tripathiauthor=R.+Shanmugamauthor=V.+Suryanarayananauthor=S.+K.+Singh&title=Targeting+the+Cyclin-binding+Groove+Site+to+Inhibit+the+Catalytic+Activity+of+CDK2%2Fcyclin+A+Complex+Using+p27%28KIP1%29-derived+Peptidomimetic+Inhibitors&doi=10.1007%2Fs12154-014-0124-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors</span></div><div class="casAuthors">Karthiga Arumugasamy; Tripathi Sunil Kumar; Suryanarayanan Venkatesan; Singh Sanjeev Kumar; Shanmugam Ramasamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Functionally activated cyclin-dependent kinase 2 (CDK2)/cyclin A complex has been validated as an interesting therapeutic target to develop the efficient antineoplastic drug based on the cell cycle arrest.  Cyclin A binds to CDK2 and activates the kinases as well as recruits the substrate and inhibitors using a hydrophobic cyclin-binding groove (CBG).  Blocking the cyclin substrate recruitment on CBG is an alternative approach to override the specificity hurdle of the currently available ATP site targeting CDK2 inhibitors.  Greater understanding of the interaction of CDK2/cyclin A complex with p27 (negative regulator) reveals that the Leu-Phe-Gly (LFG) motif region of p27 binds with the CBG site of cyclin A to arrest the malignant cell proliferation that induces apoptosis.  In the present study, Replacement with Partial Ligand Alternatives through Computational Enrichment (REPLACE) drug design strategies have been applied to acquire LFG peptide-derived peptidomimetics library.  The peptidomimetics function is equivalent with respect to substrate p27 protein fashion but does not act as an ATP antagonist.  The combined approach of molecular docking, molecular dynamics (MD), and molecular electrostatic potential and ADME/T prediction were carried out to evaluate the peptidomimetics.  Resultant interaction and electrostatic potential maps suggested that smaller substituent is desirable at the position of phenyl ring to interact with Trp217, Arg250, and Gln254 residues in the active site.  The best docked poses were refined by the MD simulations which resulted in conformational changes.  After equilibration, the structure of the peptidomimetic and receptor complex was stable.  The results revealed that the various substrate protein-derived peptidomimetics could serve as perfect leads against CDK2 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLKGDiEiQ4VrHHuJhbyicZfW6udTcc2ebbTzBudioBS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvlvFSlsg%253D%253D&md5=3682b29af420bc71e46b6ab952fd9821</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2Fs12154-014-0124-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-014-0124-y%26sid%3Dliteratum%253Aachs%26aulast%3DKarthiga%26aufirst%3DA.%26aulast%3DTripathi%26aufirst%3DS.%2BK.%26aulast%3DShanmugam%26aufirst%3DR.%26aulast%3DSuryanarayanan%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26atitle%3DTargeting%2520the%2520Cyclin-binding%2520Groove%2520Site%2520to%2520Inhibit%2520the%2520Catalytic%2520Activity%2520of%2520CDK2%252Fcyclin%2520A%2520Complex%2520Using%2520p27%2528KIP1%2529-derived%2520Peptidomimetic%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D8%26spage%3D11%26epage%3D24%26doi%3D10.1007%2Fs12154-014-0124-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premnath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1573</span>– <span class="NLM_lpage">1582</span>, <span class="refDoi"> DOI: 10.1021/jm3013882</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3013882" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1573-1582&author=S.+Liuauthor=P.+N.+Premnathauthor=J.+K.+Bolgerauthor=T.+L.+Perkinsauthor=L.+O.+Kirklandauthor=G.+Kontopidisauthor=C.+McInnes&title=Optimization+of+Non-ATP+Competitive+CDK%2FCyclin+Groove+Inhibitors+through+REPLACE-Mediated+Fragment+Assembly&doi=10.1021%2Fjm3013882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm3013882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3013882%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DPremnath%26aufirst%3DP.%2BN.%26aulast%3DBolger%26aufirst%3DJ.%2BK.%26aulast%3DPerkins%26aufirst%3DT.%2BL.%26aulast%3DKirkland%26aufirst%3DL.%2BO.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DOptimization%2520of%2520Non-ATP%2520Competitive%2520CDK%252FCyclin%2520Groove%2520Inhibitors%2520through%2520REPLACE-Mediated%2520Fragment%2520Assembly%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1573%26epage%3D1582%26doi%3D10.1021%2Fjm3013882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plater, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewsbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">REPLACE: A Strategy for Iterative Design of Cyclin-Binding Groove Inhibitors</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1002/cbic.200600189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcbic.200600189" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=1909-1915&author=M.+J.+Andrewsauthor=G.+Kontopidisauthor=C.+McInnesauthor=A.+Platerauthor=L.+Innesauthor=A.+Cowanauthor=P.+Jewsburyauthor=P.+M.+Fischer&title=REPLACE%3A+A+Strategy+for+Iterative+Design+of+Cyclin-Binding+Groove+Inhibitors&doi=10.1002%2Fcbic.200600189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600189%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BJ.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DPlater%26aufirst%3DA.%26aulast%3DInnes%26aufirst%3DL.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DREPLACE%253A%2520A%2520Strategy%2520for%2520Iterative%2520Design%2520of%2520Cyclin-Binding%2520Groove%2520Inhibitors%26jtitle%3DChemBioChem%26date%3D2006%26volume%3D7%26spage%3D1909%26epage%3D1915%26doi%3D10.1002%2Fcbic.200600189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Premnath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span> <span> </span><span class="NLM_article-title">Benzamide Capped Peptidomimetics as Non-ATP Competitive Inhibitors of CDK2 Using the REPLACE Strategy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3754</span>– <span class="NLM_lpage">3760</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.bmcl.2016.05.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3754-3760&author=P.+N.+Premnathauthor=S.+N.+Craigauthor=S.+Liuauthor=C.+McInnes&title=Benzamide+Capped+Peptidomimetics+as+Non-ATP+Competitive+Inhibitors+of+CDK2+Using+the+REPLACE+Strategy&doi=10.1016%2Fj.bmcl.2016.05.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.067%26sid%3Dliteratum%253Aachs%26aulast%3DPremnath%26aufirst%3DP.%2BN.%26aulast%3DCraig%26aufirst%3DS.%2BN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMcInnes%26aufirst%3DC.%26atitle%3DBenzamide%2520Capped%2520Peptidomimetics%2520as%2520Non-ATP%2520Competitive%2520Inhibitors%2520of%2520CDK2%2520Using%2520the%2520REPLACE%2520Strategy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3754%26epage%3D3760%26doi%3D10.1016%2Fj.bmcl.2016.05.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gondeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbal-Chaloin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrian-Herrada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divita, G.</span></span> <span> </span><span class="NLM_article-title">Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/cyclin Activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">13793</span>– <span class="NLM_lpage">13800</span>, <span class="refDoi"> DOI: 10.1074/jbc.M413690200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1074%2Fjbc.M413690200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=13793-13800&author=C.+Gondeauauthor=S.+Gerbal-Chaloinauthor=P.+Belloauthor=G.+Aldrian-Herradaauthor=M.+C.+Morrisauthor=G.+Divita&title=Design+of+a+Novel+Class+of+Peptide+Inhibitors+of+Cyclin-dependent+Kinase%2Fcyclin+Activation&doi=10.1074%2Fjbc.M413690200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M413690200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M413690200%26sid%3Dliteratum%253Aachs%26aulast%3DGondeau%26aufirst%3DC.%26aulast%3DGerbal-Chaloin%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DP.%26aulast%3DAldrian-Herrada%26aufirst%3DG.%26aulast%3DMorris%26aufirst%3DM.%2BC.%26aulast%3DDivita%26aufirst%3DG.%26atitle%3DDesign%2520of%2520a%2520Novel%2520Class%2520of%2520Peptide%2520Inhibitors%2520of%2520Cyclin-dependent%2520Kinase%252Fcyclin%2520Activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D13793%26epage%3D13800%26doi%3D10.1074%2Fjbc.M413690200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drueckes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Type II Inhibitors Targeting CDK2</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2116</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2116-2125&author=L.+T.+Alexanderauthor=H.+Mobitzauthor=P.+Drueckesauthor=P.+Savitskyauthor=O.+Fedorovauthor=J.+M.+Elkinsauthor=C.+M.+Deaneauthor=S.+W.+Cowan-Jacobauthor=S.+Knapp&title=Type+II+Inhibitors+Targeting+CDK2&doi=10.1021%2Facschembio.5b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Type II Inhibitors Targeting CDK2</span></div><div class="casAuthors">Alexander, Leila T.; Mobitz, Henrik; Drueckes, Peter; Savitsky, Pavel; Fedorov, Oleg; Elkins, Jonathan M.; Deane, Charlotte M.; Cowan-Jacob, Sandra W.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2116-2125</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases can switch between active and inactive conformations of the ATP/Mg2+ binding motif DFG, which has been explored for the development of type I or type II inhibitors.  However, factors modulating DFG conformations remain poorly understood.  We chose CDK2 as a model system to study the DFG in-out transition on a target that was thought to have an inaccessible DFG-out conformation.  We used site-directed mutagenesis of key residues identified in structural comparisons in conjunction with biochem. and biophys. characterization of the generated mutants.  As a result, we identified key residues that facilitate the DFG-out movement, facilitating binding of type II inhibitors.  However, surprisingly, we also found that wild type CDK2 is able to bind type II inhibitors.  Using protein crystallog. structural anal. of the CDK2 complex with an aminopyrimidine-Ph urea inhibitor (K03861) revealed a canonical type II binding mode and the first available type II inhibitor CDK2 cocrystal structure.  We found that the identified type II inhibitors compete with binding of activating cyclins.  In addn., anal. of the binding kinetics of the identified inhibitors revealed slow off-rates.  The study highlights the importance of residues that may be distant to the ATP binding pocket in modulating the energetics of the DFG-out transition and hence inhibitor binding.  The presented data also provide the foundation for a new class of slow off-rate cyclin-competitive CDK2 inhibitors targeting the inactive DFG-out state of this important kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccF5AnJpk-7Vg90H21EOLACvtfcHk0lg490s4O3LNGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCiurfJ&md5=dac10d551827decf3574e04f9f981d98</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00398%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DL.%2BT.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DDrueckes%26aufirst%3DP.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DDeane%26aufirst%3DC.%2BM.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DType%2520II%2520Inhibitors%2520Targeting%2520CDK2%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2116%26epage%3D2125%26doi%3D10.1021%2Facschembio.5b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+Type+II+Binding+Mode%3A+A+Privileged+Approach+for+Kinase+Inhibitor+Focused+Drug+Discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lg490s4O3LNGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520Type%2520II%2520Binding%2520Mode%253A%2520A%2520Privileged%2520Approach%2520for%2520Kinase%2520Inhibitor%2520Focused%2520Drug%2520Discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Inhibitors that Bind to Inactive Kinase Conformations</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+Design+of+Inhibitors+that+Bind+to+Inactive+Kinase+Conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lg490s4O3LNGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520Design%2520of%2520Inhibitors%2520that%2520Bind%2520to%2520Inactive%2520Kinase%2520Conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2004.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=15123247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=525-534&author=C.+McInnesauthor=S.+Wangauthor=S.+Andersonauthor=J.+O%E2%80%99Boyleauthor=W.+Jacksonauthor=G.+Kontopidisauthor=C.+Meadesauthor=M.+Meznaauthor=M.+Thomasauthor=G.+Woodauthor=D.+P.+Laneauthor=P.+M.+Fischer&title=Structural+Determinants+of+CDK4+Inhibition+and+Design+of+Selective+ATP+Competitive+Inhibitors&doi=10.1016%2Fj.chembiol.2004.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span></div><div class="casAuthors">McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice; Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-534</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of selective inhibitors of the CDK4/cyclin D1 complex have been reported recently.  Due to the absence of an exptl. CDK4 structure, the ligand and protein determinants contributing to CDK4 selectivity are poorly understood at present.  Here, we report the use of computational methods to elucidate the characteristics of selectivity and to derive the structural basis for specific, high-affinity binding of inhibitors to the CDK4 active site.  From these data, the hypothesis emerged that appropriate incorporation of an ionizable function into a CDK2 inhibitor results in more favorable binding to CDK4.  This knowledge was applied to the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore that are potent and highly selective ATP antagonists of CDK4/cyclin D1.  The findings of this study also have significant implications in the design of CDK4 mimic structures based on CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU07M2Ugw65bVg90H21EOLACvtfcHk0lgpr4djwJVUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D&md5=94d613c28266a51507bf63d34965d792</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DStructural%2520Determinants%2520of%2520CDK4%2520Inhibition%2520and%2520Design%2520of%2520Selective%2520ATP%2520Competitive%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D525%26epage%3D534%26doi%3D10.1016%2Fj.chembiol.2004.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+Structural+and+Functional+Studies+of+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+Inhibitors+Suggest+the+Basis+for+Isotype+Selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lgpr4djwJVUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520Structural%2520and%2520Functional%2520Studies%2520of%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520Inhibitors%2520Suggest%2520the%2520Basis%2520for%2520Isotype%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A General Strategy for Creating ″Inactive-conformation″ abl Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.chembiol.2006.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=16873026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=779-786&author=B.+Okramauthor=A.+Nagleauthor=F.+J.+Adrianauthor=C.+Leeauthor=P.+Renauthor=X.+Wangauthor=T.+Simauthor=Y.+Xieauthor=X.+Wangauthor=G.+Xiaauthor=G.+Spraggonauthor=M.+Warmuthauthor=Y.+Liuauthor=N.+S.+Gray&title=A+General+Strategy+for+Creating+%E2%80%B3Inactive-conformation%E2%80%B3+abl+Inhibitors&doi=10.1016%2Fj.chembiol.2006.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A General Strategy for Creating "Inactive-Conformation" Abl Inhibitors</span></div><div class="casAuthors">Okram, Barun; Nagle, Advait; Adrian, Francisco J.; Lee, Christian; Ren, Pingda; Wang, Xia; Sim, Taebo; Xie, Yongping; Wang, Xing; Xia, Gang; Spraggon, Glen; Warmuth, Markus; Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Kinase inhibitors that bind to the ATP cleft can be broadly classified into two groups: Those that bind exclusively to the ATP site with the kinase assuming a conformation otherwise conducive to phosphotransfer (type I), and those that exploit a hydrophobic site immediately adjacent to the ATP pocket made accessible by a conformational rearrangement of the activation loop (type II).  To date, all type II inhibitors were discovered by using structure-activity-guided optimization strategies.  Here, we describe a general pharmacophore model of type II inhibition that enables a rational "hybrid-design" approach whereby a 3-trifluoromethylbenzamide functionality is appended to four distinct type I scaffolds in order to convert them into their corresponding type II counterparts.  We demonstrate that the designed compds. function as type II inhibitors by using biochem. and cellular kinase assays and by cocrystallog. with Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEmN-Rh-LxOLVg90H21EOLACvtfcHk0lgpr4djwJVUAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGisL0%253D&md5=84514353c00e20f85225f62d00dc2529</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520General%2520Strategy%2520for%2520Creating%2520%25E2%2580%25B3Inactive-conformation%25E2%2580%25B3%2520abl%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D779%26epage%3D786%26doi%3D10.1016%2Fj.chembiol.2006.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Small-molecule Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0lgM-nLyAxIAZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christodoulou, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannazza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Presti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battistutta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passarella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Probing an Allosteric Pocket of CDK2 with Small Molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=10.1002%2Fcmdc.201600474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=27860401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSlsr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=33-41&author=M.+S.+Christodoulouauthor=F.+Caporuscioauthor=V.+Restelliauthor=L.+Carlinoauthor=G.+Cannazzaauthor=E.+Costanziauthor=C.+Cittiauthor=L.+Lo+Prestiauthor=P.+Pisaniauthor=R.+Battistuttaauthor=M.+Brogginiauthor=D.+Passarellaauthor=G.+Rastelli&title=Probing+an+Allosteric+Pocket+of+CDK2+with+Small+Molecules&doi=10.1002%2Fcmdc.201600474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Probing an allosteric pocket of CDK2 with small molecules</span></div><div class="casAuthors">Christodoulou, Michael S.; Caporuscio, Fabiana; Restelli, Valentina; Carlino, Luca; Cannazza, Giuseppe; Costanzi, Elisa; Citti, Cinzia; Lo Presti, Leonardo; Pisani, Pasquale; Battistutta, Roberto; Broggini, Massimo; Passarella, Daniele; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The availability of well-characterized allosteric modulators is crucial for investigating the allosteric regulation of protein function.  In a recently identified inactive conformation of cyclin-dependent kinase 2 (CDK2), an open allosteric pocket was detected and proposed as a site to accommodate allosteric inhibitors.  Previous structure-based approaches allowed the identification of a hit compd. expected to bind to this pocket.  Here, the authors report the characterization of this compd. by x-ray crystallog., which surprisingly provided a chem. structure different from that previously reported.  Therefore, the compd. was synthesized and completely characterized.  X-ray structures of the synthesized and purchased compds. were found to be superimposable.  A reaction mechanism was proposed to explain the formation of the structure indicated by crystallog.  Moreover, a stereoselective synthesis was developed to evaluate the biol. activity of the pure stereoisomers.  Modeling studies were performed to unveil the details of the interaction with CDK2.  The activity of the obtained compds. was evaluated with various biol. assays.  Mutagenesis expts. confirmed the binding to the allosteric pocket.  Finally, the allosteric ligands were shown to inhibit the growth of lung (A549) and ovarian (SKOV3) cancer cell lines.  Therefore, this report presents a thorough chem. and biol. characterization of the 1st small-mol. ligands to be used as probes to study the allosteric modulation of CDK2 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosBWAU8ms0C7Vg90H21EOLACvtfcHk0lgM-nLyAxIAZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSlsr3I&md5=eaf5aeb25d9e1fee9bb129d39200d424</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600474%26sid%3Dliteratum%253Aachs%26aulast%3DChristodoulou%26aufirst%3DM.%2BS.%26aulast%3DCaporuscio%26aufirst%3DF.%26aulast%3DRestelli%26aufirst%3DV.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DCannazza%26aufirst%3DG.%26aulast%3DCostanzi%26aufirst%3DE.%26aulast%3DCitti%26aufirst%3DC.%26aulast%3DLo%2BPresti%26aufirst%3DL.%26aulast%3DPisani%26aufirst%3DP.%26aulast%3DBattistutta%26aufirst%3DR.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DPassarella%26aufirst%3DD.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DProbing%2520an%2520Allosteric%2520Pocket%2520of%2520CDK2%2520with%2520Small%2520Molecules%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D33%26epage%3D41%26doi%3D10.1002%2Fcmdc.201600474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EK3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EK3','PDB','4EK3'); return false;">PDB: 4EK3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JST" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JST','PDB','1JST'); return false;">PDB: 1JST</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JSU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JSU','PDB','1JSU'); return false;">PDB: 1JSU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DDQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DDQ','PDB','3DDQ'); return false;">PDB: 3DDQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIP','PDB','1HIP'); return false;">PDB: 1HIP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HIS','PDB','1HIS'); return false;">PDB: 1HIS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LQE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LQE','PDB','5LQE'); return false;">PDB: 5LQE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PYL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PYL','PDB','3PYL'); return false;">PDB: 3PYL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A14" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A14','PDB','5A14'); return false;">PDB: 5A14</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01469&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01469%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-9" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01469" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a9ce65b78d93e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
